🧪 #gicancer #pancreaticcancer
Can targeting guanine nucleotide depletion expose a new vulnerability in pancreatic cancer?
Wu et al use integrated screening approaches to investigate guanine nucleotide depletion as a potential strategy against pancreatic cancer. Their work examines the role of IMPDH2 and explores whether this approach could enhance the effects of KRAS inhibition.
📄 “Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition”
Read the paper here: gut.bmj.com/content/75/11/2156
DOI: 10.1136/gutjnl-2025-336235
📖 Gut, November 2026 | GI cancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
Gut (journal)
Gut is a monthly peer-reviewed medical journal on gastroenterology and hepatology. It is the journal of the British Society of Gastroenterology and is published by BMJ. As of 2010, the editor-in-chief is Emad El-Omar. More on Wikipedia
-
Gut Journal
@Gut_BMJ
-
Gut Journal
@Gut_BMJ
📝 #gutblog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #gutblog: blogs.bmj.com/gut/2026/10/24/gutblog-preclinical-stages-o…
🔗 Read the paper in Gut: gut.bmj.com/content/75/11/2225
#crohnsdisease #ibd #faecalcalprotectin #preventionresearch -
Gut Journal reposted
Phil Smith
@PhilSmithIsBack
A great opportunity - if you are interested, please do apply - it would be great to have fantastic GI (adult/Paeds)/GI surgery trainees (from across the globe) as part of the @FrontGastro_BMJ Editorial team #teamfg
Frontline Gastro
@FrontGastro_BMJ
⚠️ 🚨 JOB ADVERT ALERT ⚠️ 🚨
Very excited to announce that Frontline Gastro are inviting applications for a new team of Trainee Editors 🥳 🎉 ! This is a 2-year post aimed at trainees of all levels, with applications from across the globe encouraged 🌎!
Check out the flyer for more details 👇 👇 👇 .
🔈 🗣️ HOW TO APPLY 📣
If you want to apply, please send a CV and covering letter outlining a) your reasons for your interest in the post and b) any ideas and innovations you will bring to the role to our fantastic deputy editors, Dr Aditi Kumar (aditikumar@nhs.net) & Dr Oliver Tavabie (oliver.tavabie@nhs.net).
🤔 💭 ANY QUESTIONS? 🙋
If you want to chat to our current Trainee Editors about the role, then feel free to email Dr Kohilan Gananandan (k.gananandan1@nhs.net) and Dr Benjamin Norton (benjamin.norton@nhs.net).
This is a fantastic role and not an opportunity to miss ‼️
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @DDWMeeting @ESGE_news
#jobadvert #traineeeditor #careeropportunities #editorialjobs #globalapplications -
Gut Journal
@Gut_BMJ
🎯 #gicancer
Could stromal biomarkers help identify colorectal cancers that respond poorly to immunotherapy?
Coma et al present a stromal biomarker-based framework for identifying colorectal cancers with mismatch repair proficiency/microsatellite stability (pMMR/MSS) and mismatch repair deficiency/microsatellite instability (dMMR/MSI). The study focuses on identifying patients with poor outcomes and limited benefit from immunotherapy, potentially helping refine risk assessment and treatment selection.
📄 "Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy"
Read the paper here: gut.bmj.com/content/75/11/2143
DOI: 10.1136/gutjnl-2025-336804
📖 Gut, November 2026 | GI cancer #colorectalcancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🎥 NEW #gutvideo! 🧬
🔬 Could TL1A offer a new therapeutic target for perianal fistulising Crohn's disease?
📖 In their #gut paper, "TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease", Gudiño et al. reveal how TL1A-activated T cells contribute to tissue remodelling, identifying a potential new therapeutic target.
🎙️ Professor Azucena Salas, senior author of the paper, discusses the findings and their implications in our latest #gutvideo!
▶️ WATCH: www.youtube.com/watch?v=23vSCNJpC-U
📄 READ: gut.bmj.com/content/75/10/1922
#crohnsdisease #ibd #gastroenterology #tl1a -
Gut Journal
@Gut_BMJ
🧫 #gutrecentadvancesinbasicscience
How might microbes along the gut–reproductive tract axis influence gynaecological cancer?
In this #gutrecentadvancesinbasicscience paper, Chen et al explore how microbial communities may influence the development and treatment of gynaecological cancers through the gut–reproductive tract axis. The article reviews emerging links between microbial activity, cancer pathogenesis and potential therapeutic approaches.
📄 “Modulating the gut-reproductive tract axis: microbial influence on gynaecological cancer pathogenesis and treatment”
Read the paper here: gut.bmj.com/content/75/11/2278
DOI: 10.1136/gutjnl-2025-337778
📖 Gut, November 2026 | #gutrecentadvancesinbasicscience
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
BSG
@BritSocGastro
📢 Job Opportunity: Trainee Editors
Interested in shaping the future of gastroenterology publishing?
@FrontGastro_BMJ is looking for a Trainee Editor to join its Editorial Board for a two-year term.
📩 Apply now: www.bsg.org.uk/BSG/media/BSG-Media/PDFs/FG-Trainee-AE-Adv…
#gastroenterology -
Gut Journal reposted
Kohilan Gananandan
@KGananandan
Can’t recommend this job enough! It’s been a fantastic 2 years. Please get in touch if you’d like more info! @FrontGastro_BMJ @BSGTrainees @BASLedu @EASLedu
Frontline Gastro
@FrontGastro_BMJ
⚠️ 🚨 JOB ADVERT ALERT ⚠️ 🚨
Very excited to announce that Frontline Gastro are inviting applications for a new team of Trainee Editors 🥳 🎉 ! This is a 2-year post aimed at trainees of all levels, with applications from across the globe encouraged 🌎!
Check out the flyer for more details 👇 👇 👇 .
🔈 🗣️ HOW TO APPLY 📣
If you want to apply, please send a CV and covering letter outlining a) your reasons for your interest in the post and b) any ideas and innovations you will bring to the role to our fantastic deputy editors, Dr Aditi Kumar (aditikumar@nhs.net) & Dr Oliver Tavabie (oliver.tavabie@nhs.net).
🤔 💭 ANY QUESTIONS? 🙋
If you want to chat to our current Trainee Editors about the role, then feel free to email Dr Kohilan Gananandan (k.gananandan1@nhs.net) and Dr Benjamin Norton (benjamin.norton@nhs.net).
This is a fantastic role and not an opportunity to miss ‼️
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @DDWMeeting @ESGE_news
#jobadvert #traineeeditor #careeropportunities #editorialjobs #globalapplications -
Gut Journal
@Gut_BMJ
🌉 #gutfrontcover | #guteditorschoice | #gutpodcast
🦠 Can the gut microbiome help identify precancerous colorectal lesions?
In this #guteditorschoice study, Louca et al analyse stool microbiome data from 1,762 people undergoing colonoscopy to investigate microbial signatures across colorectal neoplasia stages and subtypes.
🔬 The findings reveal that associations between the gut microbiome and precancerous lesions were generally weak and inconsistent, with no robust microbial signature identified. Adding microbiome data to clinical and demographic factors offered only a modest improvement in identifying high-risk neoplasia. These results highlight the need for further longitudinal research to establish how microbial changes relate to colorectal cancer development.
📄 "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" - 🔗 Read the paper: gut.bmj.com/content/75/11/2118
🎧 Listen out for the #gutpodcast discussing this #guteditorschoice paper, coming soon to:
🍎 Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
🟢 Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
🎙️ Podbean: gutbmj.podbean.com
📖 Gut, November 2026 | Gut microbiota
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#gutmicrobiome #colorectalcancer #colorectalneoplasia #microbiomeresearch -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
⚠️ 🚨 JOB ADVERT ALERT ⚠️ 🚨
Very excited to announce that Frontline Gastro are inviting applications for a new team of Trainee Editors 🥳 🎉 ! This is a 2-year post aimed at trainees of all levels, with applications from across the globe encouraged 🌎!
Check out the flyer for more details 👇 👇 👇 .
🔈 🗣️ HOW TO APPLY 📣
If you want to apply, please send a CV and covering letter outlining a) your reasons for your interest in the post and b) any ideas and innovations you will bring to the role to our fantastic deputy editors, Dr Aditi Kumar (aditikumar@nhs.net) & Dr Oliver Tavabie (oliver.tavabie@nhs.net).
🤔 💭 ANY QUESTIONS? 🙋
If you want to chat to our current Trainee Editors about the role, then feel free to email Dr Kohilan Gananandan (k.gananandan1@nhs.net) and Dr Benjamin Norton (benjamin.norton@nhs.net).
This is a fantastic role and not an opportunity to miss ‼️
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @DDWMeeting @ESGE_news
#jobadvert #traineeeditor #careeropportunities #editorialjobs #globalapplications -
Gut Journal
@Gut_BMJ
🎙️🦠 NEW #gutpodcast | November 2026 #guteditorschoice!
Can the gut microbiome help detect precancerous colorectal lesions? 🔬
🎧 Dr Philip Smith talks to Professor Colin Rees about the study by Louca et al:
📄 “Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes”
🔎 Analysing stool microbiomes from 1,762 participants undergoing colonoscopy, the researchers found:
🔹 Weak and inconsistent microbial associations with precancerous lesions
🔹 No robust microbiome signatures for early detection
🔹 Only marginal improvements in predicting high-risk neoplasia when microbiome data were added to clinical factors
💡 Could major microbiome changes emerge later in colorectal cancer development?
🎧 Listen to the discussion on #gutpodcast!
▶️ Apple: podcasts.apple.com/us/podcast/gut-microbiome-signatures-i…
▶️ Spotify: open.spotify.com/episode/2uJkYxOtaZtv3LMtW4eqQ2
▶️ Web: gutbmj.podbean.com/e/gut-microbiome-signatures-in-colorec…
📖 Read the paper: gut.bmj.com/content/75/11/2118
#guteditorschoice #gutmicrobiome #colorectalcancer #gastroenterology @BottProf -
Gut Journal reposted
Gloria Alvarez Sola @galvarezsola
Excited to share our work in @Gut_BMJ !👏We found that alcohol rewires the hepatic secretome, leading us to identify the FSTL3–Activin A–ActRII axis as a druggable target in alcohol-associated liver disease.
@russpgoodman
#liverdisease #ald
gut.bmj.com/content/gutjnl/early/2026/11/11/gutjnl-2026-3… -
Gut Journal reposted
Russell Goodman @russpgoodman
Excited to share our new work in Gut, led by @galvarezsola from our lab! We asked: could the ethanol-induced hepatic secretome reveal therapeutic targets for alcohol-associated liver disease?
#livertwitter #ald @Gut_BMJ
gut.bmj.com/cgi/rapidpdf/gutjnl-2026-340224?ijkey=HaqkjjD…
We combined human proteomics with mouse liver transcriptomics to identify secreted proteins that were induced by alcohol. FSTL3 stood out as a top hit, and with no prior link to ALD.
We then used multiple complementary approaches, including human liver spatial transcriptomics, to identify FSTL3 as a protective factor secreted by hepatic stellate cells, acting through neutralization of hepatocyte secreted Activin A.
What’s most exciting for us is that drugs targeting Activin A and its receptors are already being developed or are FDA approved for other diseases. Our next goal is to test whether we can repurpose these drugs as a potential treatments for ALD.
Thanks to @galvarezsola and all our collaborators for the work that brought this story together! -
Gut Journal reposted
BSG Trainees
@BSGTrainees
📢 Job Opportunity: Trainee Editors
Interested in shaping the future of gastroenterology publishing?
@FrontGastro_BMJ is looking for a Trainee Editor to join its Editorial Board for a two-year term.
📩 Apply now: www.bsg.org.uk/BSG/media/BSG-Media/PDFs/FG-Trainee-AE-Adv…
#gastroenterology -
Gut Journal
@Gut_BMJ
🧬 #gutrecentadvancesinclinicalpractice
Could genetic testing help explain adult cholestatic liver disease when standard investigations leave questions unanswered?
In this #gutrecentadvancesinclinicalpractice paper, Liebe et al discuss the use of genetic analysis in adult cholestatic liver disease, drawing lessons from progressive paediatric syndromes and cohort studies. The article considers how genetic insights can improve understanding of disease and support clinical assessment.
📄 “Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies”
Read the paper here: gut.bmj.com/content/75/11/2267
DOI: 10.1136/gutjnl-2025-337027
📖 Gut, November 2026 | #gutrecentadvancesinclinicalpractice — Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🔬 #gutendoscopynews
Can EUS-guided measurement of portal vein pressure accurately reflect pressure measured during surgery?
Singh et al examine the accuracy of endoscopic ultrasound (EUS)-guided direct portal vein pressure measurement by comparing it with intraoperative measurements. The comparison addresses an important question for the assessment of portal hypertension and the potential clinical role of this technique.
📄 "How accurate is EUS-guided direct portal vein pressure measurement? A comparison with intraoperative measurements" - read the paper here: gut.bmj.com/content/75/11/2088
DOI: 10.1136/gutjnl-2025-335661
📖 Gut, November 2026 | Endoscopy — #gutendoscopynews
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧬 #gutcommentary | Hepatology
How does zinc help determine the fate of liver cells during alcohol-associated liver disease?
Fernandez-Barrena et al discuss zinc-dependent post-transcriptional regulation and its role in hepatocyte fate and liver regeneration in alcohol-associated liver disease. This work highlights the importance of understanding how cellular regulatory mechanisms influence the liver’s response to injury.
📄 "Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease"
Read the paper here: gut.bmj.com/content/75/11/2085
DOI: 10.1136/gutjnl-2025-337941
📖 Gut, November 2026 | Hepatology — #gutcommentary
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#alcohol #liverdisease -
Gut Journal
@Gut_BMJ
🦠 #hepatology #hepatitisc #hcv
What antibody characteristics may help protect against hepatitis C reinfection?
Chumbe et al examine antibody profiles associated with protection against hepatitis C virus (HCV) reinfection in a high-risk cohort. Understanding the features of potentially protective antibody responses may help inform future research into immunity and prevention.
📄 “Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort”
Read the paper here: gut.bmj.com/content/75/11/2256
DOI: 10.1136/gutjnl-2025-336302
📖 Gut, November 2026 | Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
BSG
@BritSocGastro
📢 The November 2026 BSG Gut Highlights are now live!
Read abstract summaries of the best and most interesting articles recently published in Gut in #oesophageal, #neurogastroenterology, #ibd, #hepatology, and gut microbiota 💡
@Gut_BMJ -
Gut Journal
@Gut_BMJ
🫁 #pancreas #acutepancreatitis #pancreatitis #lunginjury
How might a fatty acid contribute to lung injury during hypertriglyceridaemia-associated acute pancreatitis?
Bai et al investigate how oleic acid may contribute to lung injury in hypertriglyceridaemia-associated acute pancreatitis. Their study examines the PIEZO1/NR4A1/CPT1A axis and its role in endothelial fatty acid oxidation, offering insight into a potential mechanism linking metabolic disturbance with organ injury.
📄 “Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation”
Read the paper here: gut.bmj.com/content/75/11/2199
DOI: 10.1136/gutjnl-2025-336441
📖 Gut, November 2026 | Pancreas
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
This month’s @Gut_BMJ features research spanning colorectal cancer and the gut microbiome, liver disease, pancreatic cancer, autoimmune gastritis, endoscopy and the gut–reproductive tract axis. Explore the studies and clinical insights shaping our understanding of gastrointestinal disease.
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
The November issue of @Gut_BMJ has the #gutfrontcover showing the beautiful Gateshead Millennium Bridge, Newcastle-upon-Tyne, UK. This is to celebrate the #guteditorschoice by Louca et al.
What can the gut microbiome reveal about colorectal neoplasia at different stages and across different subtypes?
In this month’s #guteditorschoice, Louca et al explore gut microbiome signatures across colorectal neoplasia stages and subtypes, investigating how microbial patterns differ as colorectal lesions develop. The findings offer insights into the relationship between the gut microbiome and colorectal neoplasia.
📄 Read the paper "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" via: gut.bmj.com/content/75/11/2118 DOI: 10.1136/gutjnl-2025-337478
🎧 The November #gutpodcast discussing this #guteditorschoice paper will be available on:
• Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
• Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
• Podbean: gutbmj.podbean.com
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
@FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
This week we will be looking back at some of our favourite papers selected by all of you in the FG cup earlier this year 🏆 🏅.
PAPER 1: 🔎 Functional dyspepsia or gastroparesis?
Upper GI symptoms such as early satiety, fullness, pain, bloating & nausea pose a diagnostic challenge.
📊 This high-quality review explores:
• Why symptoms & delayed gastric emptying often don’t align
• The overlap in pathophysiology & management
• How FD & gastroparesis may be best seen as ends of a spectrum of gut-brain interaction disorders
💡 Practical algorithms for assessment & treatment help clinicians avoid over-investigation and focus on tailored management.
👉 Read the review: fg.bmj.com/content/16/5/392
#neurogastroenterology #dyspepsia #gastroparesis #foamed
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @AmCollegeGastro @Aegastro @WAGE_media -
Gut Journal reposted
Blumberg Institute
@BlumbergInstit1
📰 New publication in Gut featuring #bsbi faculty member Dr. Ying-Hsiu Su explores HBV DNA integration patterns in HBeAg-negative chronic hepatitis B, including DNA repair, biological selection and clonal expansion.
Learn more🔗: gut.bmj.com/content/early/2026/09/28/gutjnl-2026-340701
#hbv #hepatitisb #research -
Gut Journal
@Gut_BMJ
🩺 #stomach #gastriccancer #autoimmunegastritis
What does an international study reveal about autoimmune gastritis and the risk of gastric neoplasia?
Lenti et al investigate the clinical characteristics of autoimmune gastritis and its associated gastric neoplastic risk across an international multicentre cohort. The findings contribute to the understanding of this condition and the clinical factors relevant to patient assessment and follow-up.
📄 “Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study”
Read the paper here: gut.bmj.com/content/75/11/2171
DOI: 10.1136/gutjnl-2025-337458
📖 Gut, November 2026 | Stomach
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧪 #gicancer #pancreaticcancer
Can targeting guanine nucleotide depletion expose a new vulnerability in pancreatic cancer?
Wu et al use integrated screening approaches to investigate guanine nucleotide depletion as a potential strategy against pancreatic cancer. Their work examines the role of IMPDH2 and explores whether this approach could enhance the effects of KRAS inhibition.
📄 “Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition”
Read the paper here: gut.bmj.com/content/75/11/2156
DOI: 10.1136/gutjnl-2025-336235
📖 Gut, November 2026 | GI cancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
📝 #gutblog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #gutblog: blogs.bmj.com/gut/2026/10/24/gutblog-preclinical-stages-o…
🔗 Read the paper in Gut: gut.bmj.com/content/75/11/2225
#crohnsdisease #ibd #faecalcalprotectin #preventionresearch -
Gut Journal
@Gut_BMJ
🎯 #gicancer
Could stromal biomarkers help identify colorectal cancers that respond poorly to immunotherapy?
Coma et al present a stromal biomarker-based framework for identifying colorectal cancers with mismatch repair proficiency/microsatellite stability (pMMR/MSS) and mismatch repair deficiency/microsatellite instability (dMMR/MSI). The study focuses on identifying patients with poor outcomes and limited benefit from immunotherapy, potentially helping refine risk assessment and treatment selection.
📄 "Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy"
Read the paper here: gut.bmj.com/content/75/11/2143
DOI: 10.1136/gutjnl-2025-336804
📖 Gut, November 2026 | GI cancer #colorectalcancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🌉 #gutfrontcover | #guteditorschoice | #gutpodcast
🦠 Can the gut microbiome help identify precancerous colorectal lesions?
In this #guteditorschoice study, Louca et al analyse stool microbiome data from 1,762 people undergoing colonoscopy to investigate microbial signatures across colorectal neoplasia stages and subtypes.
🔬 The findings reveal that associations between the gut microbiome and precancerous lesions were generally weak and inconsistent, with no robust microbial signature identified. Adding microbiome data to clinical and demographic factors offered only a modest improvement in identifying high-risk neoplasia. These results highlight the need for further longitudinal research to establish how microbial changes relate to colorectal cancer development.
📄 "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" - 🔗 Read the paper: gut.bmj.com/content/75/11/2118
🎧 Listen out for the #gutpodcast discussing this #guteditorschoice paper, coming soon to:
🍎 Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
🟢 Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
🎙️ Podbean: gutbmj.podbean.com
📖 Gut, November 2026 | Gut microbiota
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#gutmicrobiome #colorectalcancer #colorectalneoplasia #microbiomeresearch -
Gut Journal
@Gut_BMJ
🧫 #gutrecentadvancesinbasicscience
How might microbes along the gut–reproductive tract axis influence gynaecological cancer?
In this #gutrecentadvancesinbasicscience paper, Chen et al explore how microbial communities may influence the development and treatment of gynaecological cancers through the gut–reproductive tract axis. The article reviews emerging links between microbial activity, cancer pathogenesis and potential therapeutic approaches.
📄 “Modulating the gut-reproductive tract axis: microbial influence on gynaecological cancer pathogenesis and treatment”
Read the paper here: gut.bmj.com/content/75/11/2278
DOI: 10.1136/gutjnl-2025-337778
📖 Gut, November 2026 | #gutrecentadvancesinbasicscience
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
Bruno Ramos-Molina, PhD
@Brunorm84
Gut #microbiome profiles associated with simple liver steatosis in #masld @Gut_BMJ gut.bmj.com/content/early/2026/10/27/gutjnl-2025-337572
-
Gut Journal
@Gut_BMJ
🧬 #gutrecentadvancesinclinicalpractice
Could genetic testing help explain adult cholestatic liver disease when standard investigations leave questions unanswered?
In this #gutrecentadvancesinclinicalpractice paper, Liebe et al discuss the use of genetic analysis in adult cholestatic liver disease, drawing lessons from progressive paediatric syndromes and cohort studies. The article considers how genetic insights can improve understanding of disease and support clinical assessment.
📄 “Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies”
Read the paper here: gut.bmj.com/content/75/11/2267
DOI: 10.1136/gutjnl-2025-337027
📖 Gut, November 2026 | #gutrecentadvancesinclinicalpractice — Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🔬 #gutendoscopynews
Can EUS-guided measurement of portal vein pressure accurately reflect pressure measured during surgery?
Singh et al examine the accuracy of endoscopic ultrasound (EUS)-guided direct portal vein pressure measurement by comparing it with intraoperative measurements. The comparison addresses an important question for the assessment of portal hypertension and the potential clinical role of this technique.
📄 "How accurate is EUS-guided direct portal vein pressure measurement? A comparison with intraoperative measurements" - read the paper here: gut.bmj.com/content/75/11/2088
DOI: 10.1136/gutjnl-2025-335661
📖 Gut, November 2026 | Endoscopy — #gutendoscopynews
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal
@Gut_BMJ
🧬 #gutcommentary | Hepatology
How does zinc help determine the fate of liver cells during alcohol-associated liver disease?
Fernandez-Barrena et al discuss zinc-dependent post-transcriptional regulation and its role in hepatocyte fate and liver regeneration in alcohol-associated liver disease. This work highlights the importance of understanding how cellular regulatory mechanisms influence the liver’s response to injury.
📄 "Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease"
Read the paper here: gut.bmj.com/content/75/11/2085
DOI: 10.1136/gutjnl-2025-337941
📖 Gut, November 2026 | Hepatology — #gutcommentary
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#alcohol #liverdisease -
Gut Journal
@Gut_BMJ
🦠 #hepatology #hepatitisc #hcv
What antibody characteristics may help protect against hepatitis C reinfection?
Chumbe et al examine antibody profiles associated with protection against hepatitis C virus (HCV) reinfection in a high-risk cohort. Understanding the features of potentially protective antibody responses may help inform future research into immunity and prevention.
📄 “Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort”
Read the paper here: gut.bmj.com/content/75/11/2256
DOI: 10.1136/gutjnl-2025-336302
📖 Gut, November 2026 | Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
Dr Mark Silverberg
@guthealthmd
Is your doctor still telling you your diet isn’t important when you have IBD??
Congrats to @SunHoLee15 @KenCroitoru @The_GEMProject for another important step on the journey to preventing IBD.
Gut Journal
@Gut_BMJ
📝 #gutblog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #gutblog: blogs.bmj.com/gut/2026/10/24/gutblog-preclinical-stages-o…
🔗 Read the paper in Gut: gut.bmj.com/content/75/11/2225
#crohnsdisease #ibd #faecalcalprotectin #preventionresearch -
Gut Journal
@Gut_BMJ
🫁 #pancreas #acutepancreatitis #pancreatitis #lunginjury
How might a fatty acid contribute to lung injury during hypertriglyceridaemia-associated acute pancreatitis?
Bai et al investigate how oleic acid may contribute to lung injury in hypertriglyceridaemia-associated acute pancreatitis. Their study examines the PIEZO1/NR4A1/CPT1A axis and its role in endothelial fatty acid oxidation, offering insight into a potential mechanism linking metabolic disturbance with organ injury.
📄 “Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation”
Read the paper here: gut.bmj.com/content/75/11/2199
DOI: 10.1136/gutjnl-2025-336441
📖 Gut, November 2026 | Pancreas
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
This month’s @Gut_BMJ features research spanning colorectal cancer and the gut microbiome, liver disease, pancreatic cancer, autoimmune gastritis, endoscopy and the gut–reproductive tract axis. Explore the studies and clinical insights shaping our understanding of gastrointestinal disease.
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
The November issue of @Gut_BMJ has the #gutfrontcover showing the beautiful Gateshead Millennium Bridge, Newcastle-upon-Tyne, UK. This is to celebrate the #guteditorschoice by Louca et al.
What can the gut microbiome reveal about colorectal neoplasia at different stages and across different subtypes?
In this month’s #guteditorschoice, Louca et al explore gut microbiome signatures across colorectal neoplasia stages and subtypes, investigating how microbial patterns differ as colorectal lesions develop. The findings offer insights into the relationship between the gut microbiome and colorectal neoplasia.
📄 Read the paper "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" via: gut.bmj.com/content/75/11/2118 DOI: 10.1136/gutjnl-2025-337478
🎧 The November #gutpodcast discussing this #guteditorschoice paper will be available on:
• Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
• Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
• Podbean: gutbmj.podbean.com
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
@FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🩺 #stomach #gastriccancer #autoimmunegastritis
What does an international study reveal about autoimmune gastritis and the risk of gastric neoplasia?
Lenti et al investigate the clinical characteristics of autoimmune gastritis and its associated gastric neoplastic risk across an international multicentre cohort. The findings contribute to the understanding of this condition and the clinical factors relevant to patient assessment and follow-up.
📄 “Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study”
Read the paper here: gut.bmj.com/content/75/11/2171
DOI: 10.1136/gutjnl-2025-337458
📖 Gut, November 2026 | Stomach
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧪 #gicancer #pancreaticcancer
Can targeting guanine nucleotide depletion expose a new vulnerability in pancreatic cancer?
Wu et al use integrated screening approaches to investigate guanine nucleotide depletion as a potential strategy against pancreatic cancer. Their work examines the role of IMPDH2 and explores whether this approach could enhance the effects of KRAS inhibition.
📄 “Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition”
Read the paper here: gut.bmj.com/content/75/11/2156
DOI: 10.1136/gutjnl-2025-336235
📖 Gut, November 2026 | GI cancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
📝 #gutblog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #gutblog: blogs.bmj.com/gut/2026/10/24/gutblog-preclinical-stages-o…
🔗 Read the paper in Gut: gut.bmj.com/content/75/11/2225
#crohnsdisease #ibd #faecalcalprotectin #preventionresearch -
Gut Journal
@Gut_BMJ
🎯 #gicancer
Could stromal biomarkers help identify colorectal cancers that respond poorly to immunotherapy?
Coma et al present a stromal biomarker-based framework for identifying colorectal cancers with mismatch repair proficiency/microsatellite stability (pMMR/MSS) and mismatch repair deficiency/microsatellite instability (dMMR/MSI). The study focuses on identifying patients with poor outcomes and limited benefit from immunotherapy, potentially helping refine risk assessment and treatment selection.
📄 "Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy"
Read the paper here: gut.bmj.com/content/75/11/2143
DOI: 10.1136/gutjnl-2025-336804
📖 Gut, November 2026 | GI cancer #colorectalcancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
-
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal
@Gut_BMJ
🌉 #gutfrontcover | #guteditorschoice | #gutpodcast
🦠 Can the gut microbiome help identify precancerous colorectal lesions?
In this #guteditorschoice study, Louca et al analyse stool microbiome data from 1,762 people undergoing colonoscopy to investigate microbial signatures across colorectal neoplasia stages and subtypes.
🔬 The findings reveal that associations between the gut microbiome and precancerous lesions were generally weak and inconsistent, with no robust microbial signature identified. Adding microbiome data to clinical and demographic factors offered only a modest improvement in identifying high-risk neoplasia. These results highlight the need for further longitudinal research to establish how microbial changes relate to colorectal cancer development.
📄 "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" - 🔗 Read the paper: gut.bmj.com/content/75/11/2118
🎧 Listen out for the #gutpodcast discussing this #guteditorschoice paper, coming soon to:
🍎 Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
🟢 Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
🎙️ Podbean: gutbmj.podbean.com
📖 Gut, November 2026 | Gut microbiota
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#gutmicrobiome #colorectalcancer #colorectalneoplasia #microbiomeresearch -
Gut Journal
@Gut_BMJ
🧫 #gutrecentadvancesinbasicscience
How might microbes along the gut–reproductive tract axis influence gynaecological cancer?
In this #gutrecentadvancesinbasicscience paper, Chen et al explore how microbial communities may influence the development and treatment of gynaecological cancers through the gut–reproductive tract axis. The article reviews emerging links between microbial activity, cancer pathogenesis and potential therapeutic approaches.
📄 “Modulating the gut-reproductive tract axis: microbial influence on gynaecological cancer pathogenesis and treatment”
Read the paper here: gut.bmj.com/content/75/11/2278
DOI: 10.1136/gutjnl-2025-337778
📖 Gut, November 2026 | #gutrecentadvancesinbasicscience
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
🔬 #gutendoscopynews
Can EUS-guided measurement of portal vein pressure accurately reflect pressure measured during surgery?
Singh et al examine the accuracy of endoscopic ultrasound (EUS)-guided direct portal vein pressure measurement by comparing it with intraoperative measurements. The comparison addresses an important question for the assessment of portal hypertension and the potential clinical role of this technique.
📄 "How accurate is EUS-guided direct portal vein pressure measurement? A comparison with intraoperative measurements" - read the paper here: gut.bmj.com/content/75/11/2088
DOI: 10.1136/gutjnl-2025-335661
📖 Gut, November 2026 | Endoscopy — #gutendoscopynews
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧬 #gutrecentadvancesinclinicalpractice
Could genetic testing help explain adult cholestatic liver disease when standard investigations leave questions unanswered?
In this #gutrecentadvancesinclinicalpractice paper, Liebe et al discuss the use of genetic analysis in adult cholestatic liver disease, drawing lessons from progressive paediatric syndromes and cohort studies. The article considers how genetic insights can improve understanding of disease and support clinical assessment.
📄 “Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies”
Read the paper here: gut.bmj.com/content/75/11/2267
DOI: 10.1136/gutjnl-2025-337027
📖 Gut, November 2026 | #gutrecentadvancesinclinicalpractice — Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
#guteditorschoice
MASLD is increasingly recognised as a multisystem metabolic disorder — but what does this mean for colorectal cancer risk?
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
This international consensus statement addresses the relationship between MASLD and colorectal cancer across epidemiology, pathogenesis and management. A multidisciplinary panel of 35 international experts reached consensus on all 17 statements considered.
The panel concludes that MASLD is associated with increased colorectal cancer risk and that a greater metabolic burden is associated with further risk. More severe MASLD is also associated with worse outcomes among patients with both MASLD and colorectal cancer.
The consensus highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic factors such as leptin and adiponectin. It also discusses potential risk-reduction strategies including lifestyle-associated weight loss, earlier risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists.
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
🎙️ It is also the subject of the October #gutpodcast, coming soon. -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
🦠 #hepatology #hepatitisc #hcv
What antibody characteristics may help protect against hepatitis C reinfection?
Chumbe et al examine antibody profiles associated with protection against hepatitis C virus (HCV) reinfection in a high-risk cohort. Understanding the features of potentially protective antibody responses may help inform future research into immunity and prevention.
📄 “Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort”
Read the paper here: gut.bmj.com/content/75/11/2256
DOI: 10.1136/gutjnl-2025-336302
📖 Gut, November 2026 | Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧬 #gutcommentary | Hepatology
How does zinc help determine the fate of liver cells during alcohol-associated liver disease?
Fernandez-Barrena et al discuss zinc-dependent post-transcriptional regulation and its role in hepatocyte fate and liver regeneration in alcohol-associated liver disease. This work highlights the importance of understanding how cellular regulatory mechanisms influence the liver’s response to injury.
📄 "Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease"
Read the paper here: gut.bmj.com/content/75/11/2085
DOI: 10.1136/gutjnl-2025-337941
📖 Gut, November 2026 | Hepatology — #gutcommentary
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#alcohol #liverdisease -
Gut Journal
@Gut_BMJ
How much can pegylated interferon add to nucleos(t)ide analogue therapy when the goal is hepatitis B surface antigen clearance?
Dongelmans et al. present “HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)” via gut.bmj.com/content/75/10/2000
The PROSPER individual participant data meta-analysis brings together eight prospective clinical trials involving 581 patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy with added peg-IFN.
At the end of follow-up, 8.6% of patients achieved HBsAg loss overall. The likelihood of HBsAg clearance was strongly related to the HBsAg level at the start of peg-IFN therapy: HBsAg loss occurred in 37.7% of patients with baseline HBsAg below 100 IU/mL, compared with 9.8% in those with levels of 100–1000 IU/mL and 2.3% in those with levels ≥1000 IU/mL.
Among patients starting with higher HBsAg levels, peg-IFN therapy also produced substantial declines over treatment, potentially bringing some patients below thresholds relevant to emerging therapeutic strategies.
The findings provide important individual-level evidence for understanding which patients may derive the greatest benefit from peg-IFN add-on therapy and how treatment response may contribute to evolving strategies aimed at functional cure of chronic hepatitis B.
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal
@Gut_BMJ
Could pancreatic tumour cells effectively ‘reprogramme’ the immune cells that are supposed to attack them?
Zhou et al. present “Trogocytosis-orchestrated CLDN18.2-‘dressed’ CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade” via gut.bmj.com/content/75/10/1983
This study identifies an unexpected mechanism in which CD8+ T cells acquire the tumour-associated antigen CLDN18.2 directly from pancreatic cancer cells through a process known as trogocytosis.
CLDN18.2-positive CD8+ T cells were associated with poorer prognosis and immunotherapy resistance. Once acquired by T cells, CLDN18.2 suppressed glucose uptake and glycolysis, impairing T-cell activation, proliferation and cytotoxic function. Mechanistically, CLDN18.2 promoted β-catenin degradation through a GSK3β/CK1α-dependent pathway.
The researchers also found that these altered T cells preferentially homed to the bone marrow, where they promoted myeloid differentiation and contributed to a wider immune-senescence programme.
Importantly, experimental targeting of the CLDN18.2–β-catenin interaction with the peptide PC18.1 restored T-cell function and enhanced the response to immunotherapy in preclinical models.
The findings reveal an unusual form of tumour–immune-cell interaction in which a tumour-associated protein is transferred onto T cells and acts as a metabolic immune checkpoint, potentially opening new therapeutic avenues in pancreatic cancer.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
This month’s @Gut_BMJ features research spanning colorectal cancer and the gut microbiome, liver disease, pancreatic cancer, autoimmune gastritis, endoscopy and the gut–reproductive tract axis. Explore the studies and clinical insights shaping our understanding of gastrointestinal disease.
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
The November issue of @Gut_BMJ has the #gutfrontcover showing the beautiful Gateshead Millennium Bridge, Newcastle-upon-Tyne, UK. This is to celebrate the #guteditorschoice by Louca et al.
What can the gut microbiome reveal about colorectal neoplasia at different stages and across different subtypes?
In this month’s #guteditorschoice, Louca et al explore gut microbiome signatures across colorectal neoplasia stages and subtypes, investigating how microbial patterns differ as colorectal lesions develop. The findings offer insights into the relationship between the gut microbiome and colorectal neoplasia.
📄 Read the paper "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" via: gut.bmj.com/content/75/11/2118 DOI: 10.1136/gutjnl-2025-337478
🎧 The November #gutpodcast discussing this #guteditorschoice paper will be available on:
• Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
• Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
• Podbean: gutbmj.podbean.com
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
@FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🫁 #pancreas #acutepancreatitis #pancreatitis #lunginjury
How might a fatty acid contribute to lung injury during hypertriglyceridaemia-associated acute pancreatitis?
Bai et al investigate how oleic acid may contribute to lung injury in hypertriglyceridaemia-associated acute pancreatitis. Their study examines the PIEZO1/NR4A1/CPT1A axis and its role in endothelial fatty acid oxidation, offering insight into a potential mechanism linking metabolic disturbance with organ injury.
📄 “Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation”
Read the paper here: gut.bmj.com/content/75/11/2199
DOI: 10.1136/gutjnl-2025-336441
📖 Gut, November 2026 | Pancreas
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal reposted
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal reposted
ESGE
@ESGE_news
⏰You have until midnight CET to apply for the ESGE Research Camp!
Spend 2.5 days developing your research idea through unique blend of scientific rigour, networking & direct interaction with expert faculty, including editors of @Gut_BMJ & @endoscopyjrnl
🔗www.esge.com/events/esge-research-camp -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
Many congratulations to Dr Chris Black @DrCJBlack and Dr Nuru Noor @Y_ECCO_IBD on their #uegrisingstars2026 @my_ueg awards. Chris and Nuru are exceptional clinical academics and we are very proud that both are excellent @FrontGastro_BMJ Lead Associate Editors!
@BritSocGastro @Gut_BMJ @BMJOpen_Gastro @PhilSmithIsBack
@dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @alex_ford12399 #uegweek #uegweek2026 #ueg2026 -
Gut Journal
@Gut_BMJ
Could bacteria within gastric tumours actively influence cancer metabolism and metastatic behaviour?
Zeng et al. present “Acinetobacter baumannii promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation” via gut.bmj.com/content/75/10/1963
This study identifies Acinetobacter baumannii as a tumour-associated bacterium that is enriched in gastric cancer tissue and associated with advanced tumour stage and intratumoural nicotinic acid levels.
Using integrated intratumoural microbiome and metabolome analyses together with genetic, molecular and in vivo approaches, the researchers show that A. baumannii and its metabolite nicotinic acid can promote gastric cancer progression and metastasis.
The findings point to a previously underappreciated interaction between the intratumoural microbiome and cancer metabolism, in which microbial-derived metabolic signals can reshape NAD metabolism and glycolytic activity within tumour cells.
The work adds to growing evidence that the microbiome may contribute directly to tumour biology — not simply reflecting the environment created by cancer, but potentially helping to drive disease progression.
#microbiome #gastriccancer -
Gut Journal
@Gut_BMJ
🩺 #stomach #gastriccancer #autoimmunegastritis
What does an international study reveal about autoimmune gastritis and the risk of gastric neoplasia?
Lenti et al investigate the clinical characteristics of autoimmune gastritis and its associated gastric neoplastic risk across an international multicentre cohort. The findings contribute to the understanding of this condition and the clinical factors relevant to patient assessment and follow-up.
📄 “Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study”
Read the paper here: gut.bmj.com/content/75/11/2171
DOI: 10.1136/gutjnl-2025-337458
📖 Gut, November 2026 | Stomach
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
📝 #gutblog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #gutblog: blogs.bmj.com/gut/2026/10/24/gutblog-preclinical-stages-o…
🔗 Read the paper in Gut: gut.bmj.com/content/75/11/2225
#crohnsdisease #ibd #faecalcalprotectin #preventionresearch -
Gut Journal
@Gut_BMJ
🧪 #gicancer #pancreaticcancer
Can targeting guanine nucleotide depletion expose a new vulnerability in pancreatic cancer?
Wu et al use integrated screening approaches to investigate guanine nucleotide depletion as a potential strategy against pancreatic cancer. Their work examines the role of IMPDH2 and explores whether this approach could enhance the effects of KRAS inhibition.
📄 “Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition”
Read the paper here: gut.bmj.com/content/75/11/2156
DOI: 10.1136/gutjnl-2025-336235
📖 Gut, November 2026 | GI cancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
Can a common population of cancer-associated fibroblasts help explain how tumours metastasise across different cancer types?
Gao et al. present “SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers” via gut.bmj.com/content/75/10/1950
Using a pan-cancer single-cell transcriptomic analysis of 554 specimens across 14 cancer types, this study identifies a conserved SDC1+ cancer-associated fibroblast population associated with advanced tumour stage and poorer outcomes.
The researchers demonstrate that these fibroblasts promote tumour-cell migration, invasion and lymphatic metastasis through secretion of connective tissue growth factor (CTGF), which activates FGFR3 signalling in tumour cells and promotes epithelial–mesenchymal transition.
The study further identifies KLF6 as an upstream regulator of CTGF, establishing a KLF6–CTGF–FGFR3 signalling axis linking stromal cells to tumour dissemination. Blocking CTGF or FGFR3 signalling reduced these pro-metastatic effects in experimental models.
The findings provide mechanistic insight into how the tumour microenvironment can actively drive metastasis and highlight a potentially targetable stromal pathway shared across multiple cancers.
#tumour #metastasis -
Gut Journal
@Gut_BMJ
🎯 #gicancer
Could stromal biomarkers help identify colorectal cancers that respond poorly to immunotherapy?
Coma et al present a stromal biomarker-based framework for identifying colorectal cancers with mismatch repair proficiency/microsatellite stability (pMMR/MSS) and mismatch repair deficiency/microsatellite instability (dMMR/MSI). The study focuses on identifying patients with poor outcomes and limited benefit from immunotherapy, potentially helping refine risk assessment and treatment selection.
📄 "Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy"
Read the paper here: gut.bmj.com/content/75/11/2143
DOI: 10.1136/gutjnl-2025-336804
📖 Gut, November 2026 | GI cancer #colorectalcancer
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
Could one liver enzyme have far more biological roles than its traditional place in the urea cycle suggests?
#gutrecentadvancesinbasicscience paper by Chen et al. presents “CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine” via gut.bmj.com/content/75/10/2055
This review examines the expanding biology of carbamoyl phosphate synthetase 1 (CPS1), a highly abundant mitochondrial enzyme best known for catalysing the first step of the hepatic urea cycle.
CPS1 is also physiologically secreted into bile and can enter the circulation following hepatocyte injury. Its abundance, selective release and short serum half-life make it a potentially valuable biomarker of acute liver injury, particularly acute liver failure associated with acetaminophen toxicity.
The review also highlights an unexpected non-enzymatic role for CPS1 as an immune modulator. Following its release into the circulation, CPS1 can be taken up by monocytes and promote differentiation towards anti-inflammatory cells that home to and protect the injured liver.
Beyond liver injury, CPS1 is increasingly implicated in cancer, where altered expression can influence metabolic reprogramming and the tumour microenvironment.
The work illustrates how a protein traditionally viewed through the lens of hepatic nitrogen metabolism is emerging as a multifunctional molecule linking metabolism, bile biology, liver injury, immunity and cancer.
#acuteliverinjury #cps1 -
Gut Journal
@Gut_BMJ
What happens in the rectal mucosa before — and potentially as part of — perianal fistulising Crohn’s disease?
Gudiño et al. present “TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease” via gut.bmj.com/content/75/10/1922
Using single-cell RNA sequencing of rectal biopsies from patients with Crohn’s disease with and without perianal fistulising disease, together with functional studies in T cells, tissue explants, fibroblasts and epithelial cultures, this study identifies a distinct molecular signature associated with fistulising disease.
The rectal mucosa of patients with perianal fistulising disease showed cellular and transcriptional alterations that were independent of luminal inflammation. The researchers implicate TL1A activation in CD4+ T cells and identify lymphotoxin β and IL-22 as downstream mediators affecting fibroblast and epithelial compartments.
Importantly, the TL1A–LTα1β2/IL-22 pathway operates independently of TNF signalling, suggesting that these molecular changes may persist even in the context of anti-TNF therapy.
The findings provide new insight into the mechanisms that may predispose to perianal fistulising disease and support further investigation of TL1A-directed approaches in this challenging complication of Crohn’s disease.
#crohnsdisease #perianaldisease #tl1a -
Gut Journal reposted
Hesam Hakim
@hesamhakim
Crohn's surgery gives something rare in a chronic disease: a known restart date, with recurrence in up to 90% within a year.
If the signatures seen before diagnosis also come back before recurrence, that window is where prevention could be tested in people.
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal reposted
Hesam Hakim
@hesamhakim
A gut metabolite that protects the brain after stroke, with the route mapped: kynurenic acid acts on nerve cells in the gut wall, the vagus nerve carries the signal up, and the brain's immune cells calm down.
It worked given by mouth in animal models, which makes it easy to test in patients.
Gut Journal
@Gut_BMJ
Could a metabolite produced in the gut help protect the brain after stroke?
Zhang et al. present “Kynurenic acid mitigates post stroke brain damage through the gut-brain neural circuit” via gut.bmj.com/content/75/10/1910
This study identifies a previously unrecognised gut–brain neural circuit involving kynurenic acid (KYNA). Intestinal KYNA levels were reduced in patients with acute ischaemic stroke, and KYNA levels were associated with neurological recovery at three months in both training and validation cohorts.
In experimental stroke models, oral KYNA supplementation improved poststroke cerebral injury by activating GPR35 on enteric neurons and triggering vagal signalling. This pathway ultimately influenced brain regions including the nucleus tractus solitarius, hippocampus and hypothalamus, promoting anti-inflammatory microglial polarisation and enhancing neuronal α7 nicotinic acetylcholine receptor activity.
The findings provide striking evidence that intestinal metabolites can influence neurological recovery through a defined gut–brain neural pathway and identify KYNA–GPR35–vagus signalling as a potential therapeutic avenue for stroke recovery.
#gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal
@Gut_BMJ
Could a metabolite produced in the gut help protect the brain after stroke?
Zhang et al. present “Kynurenic acid mitigates post stroke brain damage through the gut-brain neural circuit” via gut.bmj.com/content/75/10/1910
This study identifies a previously unrecognised gut–brain neural circuit involving kynurenic acid (KYNA). Intestinal KYNA levels were reduced in patients with acute ischaemic stroke, and KYNA levels were associated with neurological recovery at three months in both training and validation cohorts.
In experimental stroke models, oral KYNA supplementation improved poststroke cerebral injury by activating GPR35 on enteric neurons and triggering vagal signalling. This pathway ultimately influenced brain regions including the nucleus tractus solitarius, hippocampus and hypothalamus, promoting anti-inflammatory microglial polarisation and enhancing neuronal α7 nicotinic acetylcholine receptor activity.
The findings provide striking evidence that intestinal metabolites can influence neurological recovery through a defined gut–brain neural pathway and identify KYNA–GPR35–vagus signalling as a potential therapeutic avenue for stroke recovery.
#gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
🌉 #gutfrontcover | #guteditorschoice | #gutpodcast
🦠 Can the gut microbiome help identify precancerous colorectal lesions?
In this #guteditorschoice study, Louca et al analyse stool microbiome data from 1,762 people undergoing colonoscopy to investigate microbial signatures across colorectal neoplasia stages and subtypes.
🔬 The findings reveal that associations between the gut microbiome and precancerous lesions were generally weak and inconsistent, with no robust microbial signature identified. Adding microbiome data to clinical and demographic factors offered only a modest improvement in identifying high-risk neoplasia. These results highlight the need for further longitudinal research to establish how microbial changes relate to colorectal cancer development.
📄 "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" - 🔗 Read the paper: gut.bmj.com/content/75/11/2118
🎧 Listen out for the #gutpodcast discussing this #guteditorschoice paper, coming soon to:
🍎 Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
🟢 Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
🎙️ Podbean: gutbmj.podbean.com
📖 Gut, November 2026 | Gut microbiota
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#gutmicrobiome #colorectalcancer #colorectalneoplasia #microbiomeresearch -
Gut Journal reposted
Jonas Ludvigsson
@ludvigsson
Happy to se our paper about concepts in early #celiac disease (the B4CeD project) published in @Gut_BMJ. Thanks to all co-authors especially Jialu Yao for contributions🙏.
pubmed.ncbi.nlm.nih.gov/42919659/
@karolinskainst
#coeliac #gluten -
Gut Journal
@Gut_BMJ
🧫 #gutrecentadvancesinbasicscience
How might microbes along the gut–reproductive tract axis influence gynaecological cancer?
In this #gutrecentadvancesinbasicscience paper, Chen et al explore how microbial communities may influence the development and treatment of gynaecological cancers through the gut–reproductive tract axis. The article reviews emerging links between microbial activity, cancer pathogenesis and potential therapeutic approaches.
📄 “Modulating the gut-reproductive tract axis: microbial influence on gynaecological cancer pathogenesis and treatment”
Read the paper here: gut.bmj.com/content/75/11/2278
DOI: 10.1136/gutjnl-2025-337778
📖 Gut, November 2026 | #gutrecentadvancesinbasicscience
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🔬 #gutendoscopynews
Can EUS-guided measurement of portal vein pressure accurately reflect pressure measured during surgery?
Singh et al examine the accuracy of endoscopic ultrasound (EUS)-guided direct portal vein pressure measurement by comparing it with intraoperative measurements. The comparison addresses an important question for the assessment of portal hypertension and the potential clinical role of this technique.
📄 "How accurate is EUS-guided direct portal vein pressure measurement? A comparison with intraoperative measurements" - read the paper here: gut.bmj.com/content/75/11/2088
DOI: 10.1136/gutjnl-2025-335661
📖 Gut, November 2026 | Endoscopy — #gutendoscopynews
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
🧬 #gutrecentadvancesinclinicalpractice
Could genetic testing help explain adult cholestatic liver disease when standard investigations leave questions unanswered?
In this #gutrecentadvancesinclinicalpractice paper, Liebe et al discuss the use of genetic analysis in adult cholestatic liver disease, drawing lessons from progressive paediatric syndromes and cohort studies. The article considers how genetic insights can improve understanding of disease and support clinical assessment.
📄 “Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies”
Read the paper here: gut.bmj.com/content/75/11/2267
DOI: 10.1136/gutjnl-2025-337027
📖 Gut, November 2026 | #gutrecentadvancesinclinicalpractice — Hepatology
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y -
Gut Journal
@Gut_BMJ
How common are disorders of gut–brain interaction around the world — and how has their epidemiology changed since Rome IV?
Sperber et al. present “Rome V global epidemiology and validation survey: prevalence of disorders of gut–brain interaction and comparison with the Rome IV global epidemiology study” via gut.bmj.com/content/75/10/1887
This major global epidemiology and validation study provides updated estimates of disorders of gut–brain interaction using the Rome V diagnostic criteria and compares the findings with the previous Rome IV global epidemiology study.
The work provides important contemporary evidence on the worldwide burden of disorders of gut–brain interaction and helps assess the impact of updated diagnostic criteria on the identification of these conditions. The findings reinforce the substantial global burden of disorders such as irritable bowel syndrome and functional dyspepsia, while providing an important foundation for future epidemiological research and clinical care.
#dgbi #romev #epidemiology @alex_ford12399 -
Gut Journal
@Gut_BMJ
#guteditorschoice
MASLD is increasingly recognised as a multisystem metabolic disorder — but what does this mean for colorectal cancer risk?
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
This international consensus statement addresses the relationship between MASLD and colorectal cancer across epidemiology, pathogenesis and management. A multidisciplinary panel of 35 international experts reached consensus on all 17 statements considered.
The panel concludes that MASLD is associated with increased colorectal cancer risk and that a greater metabolic burden is associated with further risk. More severe MASLD is also associated with worse outcomes among patients with both MASLD and colorectal cancer.
The consensus highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic factors such as leptin and adiponectin. It also discusses potential risk-reduction strategies including lifestyle-associated weight loss, earlier risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists.
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
🎙️ It is also the subject of the October #gutpodcast, coming soon. -
Gut Journal
@Gut_BMJ
How much can pegylated interferon add to nucleos(t)ide analogue therapy when the goal is hepatitis B surface antigen clearance?
Dongelmans et al. present “HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)” via gut.bmj.com/content/75/10/2000
The PROSPER individual participant data meta-analysis brings together eight prospective clinical trials involving 581 patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy with added peg-IFN.
At the end of follow-up, 8.6% of patients achieved HBsAg loss overall. The likelihood of HBsAg clearance was strongly related to the HBsAg level at the start of peg-IFN therapy: HBsAg loss occurred in 37.7% of patients with baseline HBsAg below 100 IU/mL, compared with 9.8% in those with levels of 100–1000 IU/mL and 2.3% in those with levels ≥1000 IU/mL.
Among patients starting with higher HBsAg levels, peg-IFN therapy also produced substantial declines over treatment, potentially bringing some patients below thresholds relevant to emerging therapeutic strategies.
The findings provide important individual-level evidence for understanding which patients may derive the greatest benefit from peg-IFN add-on therapy and how treatment response may contribute to evolving strategies aimed at functional cure of chronic hepatitis B.
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
🧬 #gutcommentary | Hepatology
How does zinc help determine the fate of liver cells during alcohol-associated liver disease?
Fernandez-Barrena et al discuss zinc-dependent post-transcriptional regulation and its role in hepatocyte fate and liver regeneration in alcohol-associated liver disease. This work highlights the importance of understanding how cellular regulatory mechanisms influence the liver’s response to injury.
📄 "Zinc-dependent post-transcriptional control of hepatocyte fate in and regeneration of alcohol-associated liver disease"
Read the paper here: gut.bmj.com/content/75/11/2085
DOI: 10.1136/gutjnl-2025-337941
📖 Gut, November 2026 | Hepatology — #gutcommentary
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
#alcohol #liverdisease -
Gut Journal
@Gut_BMJ
We hope you enjoy this October 2026 issue of @Gut_BMJ, featuring important advances across neurogastroenterology, disorders of gut–brain interaction, inflammatory bowel disease, gastrointestinal and pancreatic cancer, hepatology and the gut–liver axis. Read the issue via gut.bmj.com/content/75/10
🦠 The #gutfrontcover features a spectacular skyline across the bridge in Wenzhou, Zhejiang Province, China, celebrating the #guteditorschoice study by Wu et al. on colorectal cancer in metabolic dysfunction-associated steatotic liver disease.
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
The paper questions how should we think about colorectal cancer risk in people living with metabolic dysfunction-associated steatotic liver disease?
This international Delphi consensus brings together 35 experts from across six continents to address the epidemiology, pathogenesis and management of colorectal cancer in MASLD. Consensus was achieved on all 17 statements, with the panel recognising an increased risk of colorectal cancer in people with MASLD, with greater metabolic burden associated with further risk and more severe MASLD linked to worse outcomes.
The consensus also highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic management, weight loss and risk-adapted colorectal cancer screening. The authors propose greater clinical vigilance and a more integrated approach to metabolic and colorectal cancer risk in MASLD.
🎙️ This important study is also this month’s #gutpodcast — coming soon! -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal reposted
Cancer Library VCC
@VCCLibrary
EUropean consensus on the Resolution Of SympToms After oesophago-gastric Resection (EUROSTAR): Peri-Operative Quality Initiative (POQI) consensus statement. gut.bmj.com/content/early/2026/10/14/gutjnl-2025-337109
-
Gut Journal reposted
Cancer Library VCC
@VCCLibrary
Multisite metastatic atlas of gastric #cancer identifies C/EBPβ as a regulator promoting liver metastasis. gut.bmj.com/content/early/2026/10/20/gutjnl-2026-339195
-
Gut Journal
@Gut_BMJ
This month’s @Gut_BMJ features research spanning colorectal cancer and the gut microbiome, liver disease, pancreatic cancer, autoimmune gastritis, endoscopy and the gut–reproductive tract axis. Explore the studies and clinical insights shaping our understanding of gastrointestinal disease.
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
The November issue of @Gut_BMJ has the #gutfrontcover showing the beautiful Gateshead Millennium Bridge, Newcastle-upon-Tyne, UK. This is to celebrate the #guteditorschoice by Louca et al.
What can the gut microbiome reveal about colorectal neoplasia at different stages and across different subtypes?
In this month’s #guteditorschoice, Louca et al explore gut microbiome signatures across colorectal neoplasia stages and subtypes, investigating how microbial patterns differ as colorectal lesions develop. The findings offer insights into the relationship between the gut microbiome and colorectal neoplasia.
📄 Read the paper "Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes" via: gut.bmj.com/content/75/11/2118 DOI: 10.1136/gutjnl-2025-337478
🎧 The November #gutpodcast discussing this #guteditorschoice paper will be available on:
• Apple Podcasts: podcasts.apple.com/gb/podcast/gut-podcast/id330976727
• Spotify: open.spotify.com/show/33PdKlxZivzvXD3DM1FUK4
• Podbean: gutbmj.podbean.com
🔗 Read the full November issue here: gut.bmj.com/content/75/11?current-issue=y
@FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
Could pancreatic tumour cells effectively ‘reprogramme’ the immune cells that are supposed to attack them?
Zhou et al. present “Trogocytosis-orchestrated CLDN18.2-‘dressed’ CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade” via gut.bmj.com/content/75/10/1983
This study identifies an unexpected mechanism in which CD8+ T cells acquire the tumour-associated antigen CLDN18.2 directly from pancreatic cancer cells through a process known as trogocytosis.
CLDN18.2-positive CD8+ T cells were associated with poorer prognosis and immunotherapy resistance. Once acquired by T cells, CLDN18.2 suppressed glucose uptake and glycolysis, impairing T-cell activation, proliferation and cytotoxic function. Mechanistically, CLDN18.2 promoted β-catenin degradation through a GSK3β/CK1α-dependent pathway.
The researchers also found that these altered T cells preferentially homed to the bone marrow, where they promoted myeloid differentiation and contributed to a wider immune-senescence programme.
Importantly, experimental targeting of the CLDN18.2–β-catenin interaction with the peptide PC18.1 restored T-cell function and enhanced the response to immunotherapy in preclinical models.
The findings reveal an unusual form of tumour–immune-cell interaction in which a tumour-associated protein is transferred onto T cells and acts as a metabolic immune checkpoint, potentially opening new therapeutic avenues in pancreatic cancer.
#pancreaticcancer -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
Many congratulations to Dr Chris Black @DrCJBlack and Dr Nuru Noor @Y_ECCO_IBD on their #uegrisingstars2026 @my_ueg awards. Chris and Nuru are exceptional clinical academics and we are very proud that both are excellent @FrontGastro_BMJ Lead Associate Editors!
@BritSocGastro @Gut_BMJ @BMJOpen_Gastro @PhilSmithIsBack
@dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @alex_ford12399 #uegweek #uegweek2026 #ueg2026 -
Gut Journal
@Gut_BMJ
Could bacteria within gastric tumours actively influence cancer metabolism and metastatic behaviour?
Zeng et al. present “Acinetobacter baumannii promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation” via gut.bmj.com/content/75/10/1963
This study identifies Acinetobacter baumannii as a tumour-associated bacterium that is enriched in gastric cancer tissue and associated with advanced tumour stage and intratumoural nicotinic acid levels.
Using integrated intratumoural microbiome and metabolome analyses together with genetic, molecular and in vivo approaches, the researchers show that A. baumannii and its metabolite nicotinic acid can promote gastric cancer progression and metastasis.
The findings point to a previously underappreciated interaction between the intratumoural microbiome and cancer metabolism, in which microbial-derived metabolic signals can reshape NAD metabolism and glycolytic activity within tumour cells.
The work adds to growing evidence that the microbiome may contribute directly to tumour biology — not simply reflecting the environment created by cancer, but potentially helping to drive disease progression.
#microbiome #gastriccancer -
Gut Journal
@Gut_BMJ
Can a common population of cancer-associated fibroblasts help explain how tumours metastasise across different cancer types?
Gao et al. present “SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers” via gut.bmj.com/content/75/10/1950
Using a pan-cancer single-cell transcriptomic analysis of 554 specimens across 14 cancer types, this study identifies a conserved SDC1+ cancer-associated fibroblast population associated with advanced tumour stage and poorer outcomes.
The researchers demonstrate that these fibroblasts promote tumour-cell migration, invasion and lymphatic metastasis through secretion of connective tissue growth factor (CTGF), which activates FGFR3 signalling in tumour cells and promotes epithelial–mesenchymal transition.
The study further identifies KLF6 as an upstream regulator of CTGF, establishing a KLF6–CTGF–FGFR3 signalling axis linking stromal cells to tumour dissemination. Blocking CTGF or FGFR3 signalling reduced these pro-metastatic effects in experimental models.
The findings provide mechanistic insight into how the tumour microenvironment can actively drive metastasis and highlight a potentially targetable stromal pathway shared across multiple cancers.
#tumour #metastasis -
Gut Journal reposted
Immune Regulation News
@Immune_News
#tregs in autoimmune liver diseases (AILDs). 💭
This @Gut_BMJ review provides a disease-dependent and context-dependent framework for understanding Treg dysregulation in AILDs and identifies key priorities for future mechanistic and translational research.
📚 gut.bmj.com/content/early/2026/10/01/gutjnl-2026-338812
#openaccess #autoimmuity -
Gut Journal reposted
Hesam Hakim
@hesamhakim
The honest difficulty here:
Chemotherapy reshapes the gut community itself, so a difference measured after treatment can be the drug's work rather than the reason it worked. The bacterial drug-handling genes are the lead; only pre-treatment sampling says which way the arrow runs.
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal reposted
Ken Oba |放射線科医 × 読影DX
@OikodomeoRad
膵炎から4週間。壁のある液体貯留を、全部「仮性嚢胞」と呼んでよい?
改訂Atlanta分類では、仮性嚢胞は実質的に液体のみ。被包化壊死(WON)は壊死物質を含む。
日数と大きさに加えて、中身をレポートに残す。治療法を相談するときにも大事な違い。
doi.org/10.1136/gutjnl-2012-302779 -
Gut Journal
@Gut_BMJ
What happens in the rectal mucosa before — and potentially as part of — perianal fistulising Crohn’s disease?
Gudiño et al. present “TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease” via gut.bmj.com/content/75/10/1922
Using single-cell RNA sequencing of rectal biopsies from patients with Crohn’s disease with and without perianal fistulising disease, together with functional studies in T cells, tissue explants, fibroblasts and epithelial cultures, this study identifies a distinct molecular signature associated with fistulising disease.
The rectal mucosa of patients with perianal fistulising disease showed cellular and transcriptional alterations that were independent of luminal inflammation. The researchers implicate TL1A activation in CD4+ T cells and identify lymphotoxin β and IL-22 as downstream mediators affecting fibroblast and epithelial compartments.
Importantly, the TL1A–LTα1β2/IL-22 pathway operates independently of TNF signalling, suggesting that these molecular changes may persist even in the context of anti-TNF therapy.
The findings provide new insight into the mechanisms that may predispose to perianal fistulising disease and support further investigation of TL1A-directed approaches in this challenging complication of Crohn’s disease.
#crohnsdisease #perianaldisease #tl1a -
Gut Journal
@Gut_BMJ
Could one liver enzyme have far more biological roles than its traditional place in the urea cycle suggests?
#gutrecentadvancesinbasicscience paper by Chen et al. presents “CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine” via gut.bmj.com/content/75/10/2055
This review examines the expanding biology of carbamoyl phosphate synthetase 1 (CPS1), a highly abundant mitochondrial enzyme best known for catalysing the first step of the hepatic urea cycle.
CPS1 is also physiologically secreted into bile and can enter the circulation following hepatocyte injury. Its abundance, selective release and short serum half-life make it a potentially valuable biomarker of acute liver injury, particularly acute liver failure associated with acetaminophen toxicity.
The review also highlights an unexpected non-enzymatic role for CPS1 as an immune modulator. Following its release into the circulation, CPS1 can be taken up by monocytes and promote differentiation towards anti-inflammatory cells that home to and protect the injured liver.
Beyond liver injury, CPS1 is increasingly implicated in cancer, where altered expression can influence metabolic reprogramming and the tumour microenvironment.
The work illustrates how a protein traditionally viewed through the lens of hepatic nitrogen metabolism is emerging as a multifunctional molecule linking metabolism, bile biology, liver injury, immunity and cancer.
#acuteliverinjury #cps1 -
Gut Journal
@Gut_BMJ
Could a metabolite produced in the gut help protect the brain after stroke?
Zhang et al. present “Kynurenic acid mitigates post stroke brain damage through the gut-brain neural circuit” via gut.bmj.com/content/75/10/1910
This study identifies a previously unrecognised gut–brain neural circuit involving kynurenic acid (KYNA). Intestinal KYNA levels were reduced in patients with acute ischaemic stroke, and KYNA levels were associated with neurological recovery at three months in both training and validation cohorts.
In experimental stroke models, oral KYNA supplementation improved poststroke cerebral injury by activating GPR35 on enteric neurons and triggering vagal signalling. This pathway ultimately influenced brain regions including the nucleus tractus solitarius, hippocampus and hypothalamus, promoting anti-inflammatory microglial polarisation and enhancing neuronal α7 nicotinic acetylcholine receptor activity.
The findings provide striking evidence that intestinal metabolites can influence neurological recovery through a defined gut–brain neural pathway and identify KYNA–GPR35–vagus signalling as a potential therapeutic avenue for stroke recovery.
#gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal
@Gut_BMJ
New #gutvideo...
🧬 Can tumour metabolism help switch off the immune system in MASH-HCC?
A new study in Gut by Wu et al. uncovers a fascinating link between tumour metabolism and immune dysfunction in MASH-associated hepatocellular carcinoma (MASH-HCC).
📄 “PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction”
The study shows that loss of PCK1 in tumour cells increases the lipid mediator 12-HETE, which impairs CD8⁺ T-cell function and may allow tumours to progress.
Importantly, targeting this pathway enhanced anti-tumour responses to anti-PD-1 immunotherapy in preclinical models. 🔬
A striking example of how metabolism, inflammation and cancer immunity intersect — and a potential new avenue for understanding and treating MASH-HCC.
📖 Read the paper:
gut.bmj.com/content/75/9/1816
🎥 Watch the #gutvideo:
www.youtube.com/watch?v=IMc-xQi3mc4&list=PL80fezoRY4BDr-o…
#mash #masld #hcc #hepatology #gastroenterology #livercancer #immunotherapy #cd8tcells #tumourmicroenvironment #gutjournal #gutvideo -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
#guteditorschoice
MASLD is increasingly recognised as a multisystem metabolic disorder — but what does this mean for colorectal cancer risk?
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
This international consensus statement addresses the relationship between MASLD and colorectal cancer across epidemiology, pathogenesis and management. A multidisciplinary panel of 35 international experts reached consensus on all 17 statements considered.
The panel concludes that MASLD is associated with increased colorectal cancer risk and that a greater metabolic burden is associated with further risk. More severe MASLD is also associated with worse outcomes among patients with both MASLD and colorectal cancer.
The consensus highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic factors such as leptin and adiponectin. It also discusses potential risk-reduction strategies including lifestyle-associated weight loss, earlier risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists.
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
🎙️ It is also the subject of the October #gutpodcast, coming soon. -
Gut Journal
@Gut_BMJ
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
Listen to the latest #gutpodcast on the #guteditorschoice paper in September 2026. The study by Awoniyi et al. looks at the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ Listen to the #gutpodcast via:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ The Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
Access the paper “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via
gut.bmj.com/content/75/9/1711 -
Gut Journal
@Gut_BMJ
How common are disorders of gut–brain interaction around the world — and how has their epidemiology changed since Rome IV?
Sperber et al. present “Rome V global epidemiology and validation survey: prevalence of disorders of gut–brain interaction and comparison with the Rome IV global epidemiology study” via gut.bmj.com/content/75/10/1887
This major global epidemiology and validation study provides updated estimates of disorders of gut–brain interaction using the Rome V diagnostic criteria and compares the findings with the previous Rome IV global epidemiology study.
The work provides important contemporary evidence on the worldwide burden of disorders of gut–brain interaction and helps assess the impact of updated diagnostic criteria on the identification of these conditions. The findings reinforce the substantial global burden of disorders such as irritable bowel syndrome and functional dyspepsia, while providing an important foundation for future epidemiological research and clinical care.
#dgbi #romev #epidemiology @alex_ford12399 -
Gut Journal
@Gut_BMJ
We hope you enjoy this October 2026 issue of @Gut_BMJ, featuring important advances across neurogastroenterology, disorders of gut–brain interaction, inflammatory bowel disease, gastrointestinal and pancreatic cancer, hepatology and the gut–liver axis. Read the issue via gut.bmj.com/content/75/10
🦠 The #gutfrontcover features a spectacular skyline across the bridge in Wenzhou, Zhejiang Province, China, celebrating the #guteditorschoice study by Wu et al. on colorectal cancer in metabolic dysfunction-associated steatotic liver disease.
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
The paper questions how should we think about colorectal cancer risk in people living with metabolic dysfunction-associated steatotic liver disease?
This international Delphi consensus brings together 35 experts from across six continents to address the epidemiology, pathogenesis and management of colorectal cancer in MASLD. Consensus was achieved on all 17 statements, with the panel recognising an increased risk of colorectal cancer in people with MASLD, with greater metabolic burden associated with further risk and more severe MASLD linked to worse outcomes.
The consensus also highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic management, weight loss and risk-adapted colorectal cancer screening. The authors propose greater clinical vigilance and a more integrated approach to metabolic and colorectal cancer risk in MASLD.
🎙️ This important study is also this month’s #gutpodcast — coming soon! -
Gut Journal
@Gut_BMJ
How much can pegylated interferon add to nucleos(t)ide analogue therapy when the goal is hepatitis B surface antigen clearance?
Dongelmans et al. present “HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)” via gut.bmj.com/content/75/10/2000
The PROSPER individual participant data meta-analysis brings together eight prospective clinical trials involving 581 patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy with added peg-IFN.
At the end of follow-up, 8.6% of patients achieved HBsAg loss overall. The likelihood of HBsAg clearance was strongly related to the HBsAg level at the start of peg-IFN therapy: HBsAg loss occurred in 37.7% of patients with baseline HBsAg below 100 IU/mL, compared with 9.8% in those with levels of 100–1000 IU/mL and 2.3% in those with levels ≥1000 IU/mL.
Among patients starting with higher HBsAg levels, peg-IFN therapy also produced substantial declines over treatment, potentially bringing some patients below thresholds relevant to emerging therapeutic strategies.
The findings provide important individual-level evidence for understanding which patients may derive the greatest benefit from peg-IFN add-on therapy and how treatment response may contribute to evolving strategies aimed at functional cure of chronic hepatitis B.
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
Why do some PNPLA3-I148M carriers develop advanced #masld? A new Gut study links disrupted intestinal barriers, microbiota-associated ceramides and liver injury. Microbiota-targeted approaches helped in mice, not yet patients. 🧬
doi.org/10.1136/gutjnl-2026-338178
#microbiome -
Gut Journal
@Gut_BMJ
Could pancreatic tumour cells effectively ‘reprogramme’ the immune cells that are supposed to attack them?
Zhou et al. present “Trogocytosis-orchestrated CLDN18.2-‘dressed’ CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade” via gut.bmj.com/content/75/10/1983
This study identifies an unexpected mechanism in which CD8+ T cells acquire the tumour-associated antigen CLDN18.2 directly from pancreatic cancer cells through a process known as trogocytosis.
CLDN18.2-positive CD8+ T cells were associated with poorer prognosis and immunotherapy resistance. Once acquired by T cells, CLDN18.2 suppressed glucose uptake and glycolysis, impairing T-cell activation, proliferation and cytotoxic function. Mechanistically, CLDN18.2 promoted β-catenin degradation through a GSK3β/CK1α-dependent pathway.
The researchers also found that these altered T cells preferentially homed to the bone marrow, where they promoted myeloid differentiation and contributed to a wider immune-senescence programme.
Importantly, experimental targeting of the CLDN18.2–β-catenin interaction with the peptide PC18.1 restored T-cell function and enhanced the response to immunotherapy in preclinical models.
The findings reveal an unusual form of tumour–immune-cell interaction in which a tumour-associated protein is transferred onto T cells and acts as a metabolic immune checkpoint, potentially opening new therapeutic avenues in pancreatic cancer.
#pancreaticcancer -
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
PUFAs are not always beneficial. In people with fatty liver (MASH), Omega-3 PUFAs are beneficial while Omega-6 PUFAs may worsen the disease. @Gut_BMJ
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal reposted
BSG
@BritSocGastro
📢 The October 2026 BSG Gut Highlights are now live!
Read abstract summaries of the best and most interesting articles recently published in Gut in #oesophageal, #neurogastroenterology, #ibd, #hepatology, and gut microbiota 💡
📄 www.bsg.org.uk/web-education/bsg-gut-highlights-october-2026
@Gut_BMJ -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
Could bacteria within gastric tumours actively influence cancer metabolism and metastatic behaviour?
Zeng et al. present “Acinetobacter baumannii promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation” via gut.bmj.com/content/75/10/1963
This study identifies Acinetobacter baumannii as a tumour-associated bacterium that is enriched in gastric cancer tissue and associated with advanced tumour stage and intratumoural nicotinic acid levels.
Using integrated intratumoural microbiome and metabolome analyses together with genetic, molecular and in vivo approaches, the researchers show that A. baumannii and its metabolite nicotinic acid can promote gastric cancer progression and metastasis.
The findings point to a previously underappreciated interaction between the intratumoural microbiome and cancer metabolism, in which microbial-derived metabolic signals can reshape NAD metabolism and glycolytic activity within tumour cells.
The work adds to growing evidence that the microbiome may contribute directly to tumour biology — not simply reflecting the environment created by cancer, but potentially helping to drive disease progression.
#microbiome #gastriccancer -
Gut Journal reposted
Digestivo Área Hospitalaria Costa del Sol
@digestivoascs
🔬 Nueva publicación en Gut.
El Dr. Robin Rivera Irigoin, de nuestro Servicio de Aparato Digestivo, participa en el ensayo multicéntrico SIMBA.
💊 La simvastatina no demostró reducir las recurrencias de pancreatitis frente a placebo.
@ASCostadelSol @Gut_BMJ -
Gut Journal reposted
Digestivo Área Hospitalaria Costa del Sol
@digestivoascs
📖 Puedes consultar el artículo completo, publicado en Gut, aquí:
gut.bmj.com/content/75/6/1160.long -
Gut Journal reposted
Blumberg Institute
@BlumbergInstit1
📰 New publication in Gut featuring #bsbi faculty member Dr. Ying-Hsiu Su explores HBV DNA integration patterns in HBeAg-negative chronic hepatitis B, including DNA repair, biological selection and clonal expansion.
Learn more🔗: gut.bmj.com/content/early/2026/09/28/gutjnl-2026-340701
#hbv #hepatitisb #research -
Gut Journal
@Gut_BMJ
Can a common population of cancer-associated fibroblasts help explain how tumours metastasise across different cancer types?
Gao et al. present “SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers” via gut.bmj.com/content/75/10/1950
Using a pan-cancer single-cell transcriptomic analysis of 554 specimens across 14 cancer types, this study identifies a conserved SDC1+ cancer-associated fibroblast population associated with advanced tumour stage and poorer outcomes.
The researchers demonstrate that these fibroblasts promote tumour-cell migration, invasion and lymphatic metastasis through secretion of connective tissue growth factor (CTGF), which activates FGFR3 signalling in tumour cells and promotes epithelial–mesenchymal transition.
The study further identifies KLF6 as an upstream regulator of CTGF, establishing a KLF6–CTGF–FGFR3 signalling axis linking stromal cells to tumour dissemination. Blocking CTGF or FGFR3 signalling reduced these pro-metastatic effects in experimental models.
The findings provide mechanistic insight into how the tumour microenvironment can actively drive metastasis and highlight a potentially targetable stromal pathway shared across multiple cancers.
#tumour #metastasis -
Gut Journal
@Gut_BMJ
What happens in the rectal mucosa before — and potentially as part of — perianal fistulising Crohn’s disease?
Gudiño et al. present “TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease” via gut.bmj.com/content/75/10/1922
Using single-cell RNA sequencing of rectal biopsies from patients with Crohn’s disease with and without perianal fistulising disease, together with functional studies in T cells, tissue explants, fibroblasts and epithelial cultures, this study identifies a distinct molecular signature associated with fistulising disease.
The rectal mucosa of patients with perianal fistulising disease showed cellular and transcriptional alterations that were independent of luminal inflammation. The researchers implicate TL1A activation in CD4+ T cells and identify lymphotoxin β and IL-22 as downstream mediators affecting fibroblast and epithelial compartments.
Importantly, the TL1A–LTα1β2/IL-22 pathway operates independently of TNF signalling, suggesting that these molecular changes may persist even in the context of anti-TNF therapy.
The findings provide new insight into the mechanisms that may predispose to perianal fistulising disease and support further investigation of TL1A-directed approaches in this challenging complication of Crohn’s disease.
#crohnsdisease #perianaldisease #tl1a -
Gut Journal
@Gut_BMJ
Could one liver enzyme have far more biological roles than its traditional place in the urea cycle suggests?
#gutrecentadvancesinbasicscience paper by Chen et al. presents “CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine” via gut.bmj.com/content/75/10/2055
This review examines the expanding biology of carbamoyl phosphate synthetase 1 (CPS1), a highly abundant mitochondrial enzyme best known for catalysing the first step of the hepatic urea cycle.
CPS1 is also physiologically secreted into bile and can enter the circulation following hepatocyte injury. Its abundance, selective release and short serum half-life make it a potentially valuable biomarker of acute liver injury, particularly acute liver failure associated with acetaminophen toxicity.
The review also highlights an unexpected non-enzymatic role for CPS1 as an immune modulator. Following its release into the circulation, CPS1 can be taken up by monocytes and promote differentiation towards anti-inflammatory cells that home to and protect the injured liver.
Beyond liver injury, CPS1 is increasingly implicated in cancer, where altered expression can influence metabolic reprogramming and the tumour microenvironment.
The work illustrates how a protein traditionally viewed through the lens of hepatic nitrogen metabolism is emerging as a multifunctional molecule linking metabolism, bile biology, liver injury, immunity and cancer.
#acuteliverinjury #cps1 -
Gut Journal
@Gut_BMJ
New #gutvideo...
🧬 Can tumour metabolism help switch off the immune system in MASH-HCC?
A new study in Gut by Wu et al. uncovers a fascinating link between tumour metabolism and immune dysfunction in MASH-associated hepatocellular carcinoma (MASH-HCC).
📄 “PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction”
The study shows that loss of PCK1 in tumour cells increases the lipid mediator 12-HETE, which impairs CD8⁺ T-cell function and may allow tumours to progress.
Importantly, targeting this pathway enhanced anti-tumour responses to anti-PD-1 immunotherapy in preclinical models. 🔬
A striking example of how metabolism, inflammation and cancer immunity intersect — and a potential new avenue for understanding and treating MASH-HCC.
📖 Read the paper:
gut.bmj.com/content/75/9/1816
🎥 Watch the #gutvideo:
www.youtube.com/watch?v=IMc-xQi3mc4&list=PL80fezoRY4BDr-o…
#mash #masld #hcc #hepatology #gastroenterology #livercancer #immunotherapy #cd8tcells #tumourmicroenvironment #gutjournal #gutvideo -
Gut Journal
@Gut_BMJ
Could a metabolite produced in the gut help protect the brain after stroke?
Zhang et al. present “Kynurenic acid mitigates post stroke brain damage through the gut-brain neural circuit” via gut.bmj.com/content/75/10/1910
This study identifies a previously unrecognised gut–brain neural circuit involving kynurenic acid (KYNA). Intestinal KYNA levels were reduced in patients with acute ischaemic stroke, and KYNA levels were associated with neurological recovery at three months in both training and validation cohorts.
In experimental stroke models, oral KYNA supplementation improved poststroke cerebral injury by activating GPR35 on enteric neurons and triggering vagal signalling. This pathway ultimately influenced brain regions including the nucleus tractus solitarius, hippocampus and hypothalamus, promoting anti-inflammatory microglial polarisation and enhancing neuronal α7 nicotinic acetylcholine receptor activity.
The findings provide striking evidence that intestinal metabolites can influence neurological recovery through a defined gut–brain neural pathway and identify KYNA–GPR35–vagus signalling as a potential therapeutic avenue for stroke recovery.
#gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal reposted
Hong Jae Chon
@hongjaechon
💡 Consensus on #hcc clinical trial design for systemic Tx plus surgery or #lrt @Gut_BMJ
👉 Limited burden: LRT + systemic Tx vs LRT alone (PFS + OS)
👉 Larger burden or Vp1-2: systemic Tx + LRT vs systemic Tx alone (PFS + OS)
DOI: doi.org/10.1136/gutjnl-2026-339505
#liverx #neoadjuvant #clinicaltrial @ILCAnews @EASLnews @myESMO
Cancer Library VCC
@VCCLibrary
Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. gut.bmj.com/content/early/2026/09/24/gutjnl-2026-339505
-
Gut Journal
@Gut_BMJ
#guteditorschoice
MASLD is increasingly recognised as a multisystem metabolic disorder — but what does this mean for colorectal cancer risk?
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
This international consensus statement addresses the relationship between MASLD and colorectal cancer across epidemiology, pathogenesis and management. A multidisciplinary panel of 35 international experts reached consensus on all 17 statements considered.
The panel concludes that MASLD is associated with increased colorectal cancer risk and that a greater metabolic burden is associated with further risk. More severe MASLD is also associated with worse outcomes among patients with both MASLD and colorectal cancer.
The consensus highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic factors such as leptin and adiponectin. It also discusses potential risk-reduction strategies including lifestyle-associated weight loss, earlier risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists.
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
🎙️ It is also the subject of the October #gutpodcast, coming soon. -
Gut Journal
@Gut_BMJ
How common are disorders of gut–brain interaction around the world — and how has their epidemiology changed since Rome IV?
Sperber et al. present “Rome V global epidemiology and validation survey: prevalence of disorders of gut–brain interaction and comparison with the Rome IV global epidemiology study” via gut.bmj.com/content/75/10/1887
This major global epidemiology and validation study provides updated estimates of disorders of gut–brain interaction using the Rome V diagnostic criteria and compares the findings with the previous Rome IV global epidemiology study.
The work provides important contemporary evidence on the worldwide burden of disorders of gut–brain interaction and helps assess the impact of updated diagnostic criteria on the identification of these conditions. The findings reinforce the substantial global burden of disorders such as irritable bowel syndrome and functional dyspepsia, while providing an important foundation for future epidemiological research and clinical care.
#dgbi #romev #epidemiology @alex_ford12399 -
Gut Journal
@Gut_BMJ
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
Listen to the latest #gutpodcast on the #guteditorschoice paper in September 2026. The study by Awoniyi et al. looks at the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ Listen to the #gutpodcast via:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ The Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
Access the paper “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via
gut.bmj.com/content/75/9/1711 -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal
@Gut_BMJ
What can the immune response teach us about achieving a functional cure for chronic hepatitis B? This #recentadvancesinbasicscience #gutrecentadvancesinbasicscience paper reviews this in detail.
Thimme et al. present “Decoding HBV-specific adaptive immunity: from natural clearance to cure” via gut.bmj.com/content/75/9/1857
This comprehensive review examines how HBV-specific CD8+ and CD4+ T cells and B cells contribute to viral clearance during acute infection — and why these immune responses become profoundly impaired during chronic infection.
The authors highlight growing evidence that immune dysfunction in chronic HBV is more complex and heterogeneous than the traditional concept of T-cell exhaustion suggests. Understanding these distinct immune defects may be crucial for developing more effective therapeutic vaccines, immune checkpoint strategies and T-cell-based approaches.
The review also highlights a key challenge: although immune-based therapies are promising, restoring effective HBV-specific immunity and achieving sustained HBsAg loss remains difficult.
A deeper understanding of HBV-specific adaptive immunity could therefore be central to the next generation of functional-cure strategies.
#hbv #hepatitisbvirus -
Gut Journal
@Gut_BMJ
We hope you enjoy this October 2026 issue of @Gut_BMJ, featuring important advances across neurogastroenterology, disorders of gut–brain interaction, inflammatory bowel disease, gastrointestinal and pancreatic cancer, hepatology and the gut–liver axis. Read the issue via gut.bmj.com/content/75/10
🦠 The #gutfrontcover features a spectacular skyline across the bridge in Wenzhou, Zhejiang Province, China, celebrating the #guteditorschoice study by Wu et al. on colorectal cancer in metabolic dysfunction-associated steatotic liver disease.
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
The paper questions how should we think about colorectal cancer risk in people living with metabolic dysfunction-associated steatotic liver disease?
This international Delphi consensus brings together 35 experts from across six continents to address the epidemiology, pathogenesis and management of colorectal cancer in MASLD. Consensus was achieved on all 17 statements, with the panel recognising an increased risk of colorectal cancer in people with MASLD, with greater metabolic burden associated with further risk and more severe MASLD linked to worse outcomes.
The consensus also highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic management, weight loss and risk-adapted colorectal cancer screening. The authors propose greater clinical vigilance and a more integrated approach to metabolic and colorectal cancer risk in MASLD.
🎙️ This important study is also this month’s #gutpodcast — coming soon! -
Gut Journal
@Gut_BMJ
How much can pegylated interferon add to nucleos(t)ide analogue therapy when the goal is hepatitis B surface antigen clearance?
Dongelmans et al. present “HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)” via gut.bmj.com/content/75/10/2000
The PROSPER individual participant data meta-analysis brings together eight prospective clinical trials involving 581 patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy with added peg-IFN.
At the end of follow-up, 8.6% of patients achieved HBsAg loss overall. The likelihood of HBsAg clearance was strongly related to the HBsAg level at the start of peg-IFN therapy: HBsAg loss occurred in 37.7% of patients with baseline HBsAg below 100 IU/mL, compared with 9.8% in those with levels of 100–1000 IU/mL and 2.3% in those with levels ≥1000 IU/mL.
Among patients starting with higher HBsAg levels, peg-IFN therapy also produced substantial declines over treatment, potentially bringing some patients below thresholds relevant to emerging therapeutic strategies.
The findings provide important individual-level evidence for understanding which patients may derive the greatest benefit from peg-IFN add-on therapy and how treatment response may contribute to evolving strategies aimed at functional cure of chronic hepatitis B.
#hepatitisb #hbv -
Gut Journal reposted
Mike Thompson, MD, PhD, FASCO
@mtmdphd
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience [Oct 1, 2026]
Maddalen et al. @skopetz @Gut_BMJ
gut.bmj.com/content/early/2026/10/01/gutjnl-2026-339167 #crcsm #ctdna #mrd #liquidbiopsy HT @dr_dirican -
Gut Journal reposted
Bruno Ramos-Molina, PhD
@Brunorm84
Microbiota-host genetic interactions modulate #masld risk in PNPLA3I148M carriers via ceramides and are reversible by targeted microbial interventions @Gut_BMJ gut.bmj.com/content/early/2026/10/05/gutjnl-2026-338178
-
Gut Journal
@Gut_BMJ
Could pancreatic tumour cells effectively ‘reprogramme’ the immune cells that are supposed to attack them?
Zhou et al. present “Trogocytosis-orchestrated CLDN18.2-‘dressed’ CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade” via gut.bmj.com/content/75/10/1983
This study identifies an unexpected mechanism in which CD8+ T cells acquire the tumour-associated antigen CLDN18.2 directly from pancreatic cancer cells through a process known as trogocytosis.
CLDN18.2-positive CD8+ T cells were associated with poorer prognosis and immunotherapy resistance. Once acquired by T cells, CLDN18.2 suppressed glucose uptake and glycolysis, impairing T-cell activation, proliferation and cytotoxic function. Mechanistically, CLDN18.2 promoted β-catenin degradation through a GSK3β/CK1α-dependent pathway.
The researchers also found that these altered T cells preferentially homed to the bone marrow, where they promoted myeloid differentiation and contributed to a wider immune-senescence programme.
Importantly, experimental targeting of the CLDN18.2–β-catenin interaction with the peptide PC18.1 restored T-cell function and enhanced the response to immunotherapy in preclinical models.
The findings reveal an unusual form of tumour–immune-cell interaction in which a tumour-associated protein is transferred onto T cells and acts as a metabolic immune checkpoint, potentially opening new therapeutic avenues in pancreatic cancer.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Autoimmune gastritis has traditionally been viewed mainly as a risk factor for gastric neuroendocrine tumours and non-cardia gastric adenocarcinoma. But could its cancer risk extend further?
Read the #recentadvancesinclinicalpractice #gutrecentadvancesinclinicalpractice by Lenti et al. entitled “Autoimmune gastritis: a hidden gateway to cardia and oesophageal cancers beyond non-cardia gastric adenocarcinoma” via gut.bmj.com/content/75/9/1845
This review brings together emerging epidemiological and clinical evidence suggesting that autoimmune gastritis and pernicious anaemia may also be associated with malignancies involving the gastric cardia, gastro-oesophageal junction and oesophagus.
The authors explore possible mechanisms including corpus-predominant atrophy, intestinal metaplasia and vitamin B12 deficiency, while highlighting important gaps in our current understanding.
The review challenges us to think beyond the traditional boundaries of autoimmune gastritis and raises important questions about future risk stratification and surveillance.
#autoimmunegastritis -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
Could bacteria within gastric tumours actively influence cancer metabolism and metastatic behaviour?
Zeng et al. present “Acinetobacter baumannii promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation” via gut.bmj.com/content/75/10/1963
This study identifies Acinetobacter baumannii as a tumour-associated bacterium that is enriched in gastric cancer tissue and associated with advanced tumour stage and intratumoural nicotinic acid levels.
Using integrated intratumoural microbiome and metabolome analyses together with genetic, molecular and in vivo approaches, the researchers show that A. baumannii and its metabolite nicotinic acid can promote gastric cancer progression and metastasis.
The findings point to a previously underappreciated interaction between the intratumoural microbiome and cancer metabolism, in which microbial-derived metabolic signals can reshape NAD metabolism and glycolytic activity within tumour cells.
The work adds to growing evidence that the microbiome may contribute directly to tumour biology — not simply reflecting the environment created by cancer, but potentially helping to drive disease progression.
#microbiome #gastriccancer -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience
@Gut_BMJ
gut.bmj.com/content/early/2026/10/01/gutjnl-2026-339167 -
Gut Journal reposted
Dr. Rupa Banerjee
@DrRupaBanerjee1
Diet matters .. including that of the mother during pregnancy .. MOMMY IBD study & more . Is it all via the microbiome ?
Elizabeth A Spencer MD MS
@pedsIBDdoc
Does diet at age 1 matter? In 81,280 Scandinavian children, higher diet quality at 12 months was linked to about 25% lower IBD risk, and sugary drinks to higher risk. Few cases and wide CIs, but it points to an early window. #ibd #ibdprevention
doi.org/10.1136/gutjnl-2023-330971 -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
Can a common population of cancer-associated fibroblasts help explain how tumours metastasise across different cancer types?
Gao et al. present “SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers” via gut.bmj.com/content/75/10/1950
Using a pan-cancer single-cell transcriptomic analysis of 554 specimens across 14 cancer types, this study identifies a conserved SDC1+ cancer-associated fibroblast population associated with advanced tumour stage and poorer outcomes.
The researchers demonstrate that these fibroblasts promote tumour-cell migration, invasion and lymphatic metastasis through secretion of connective tissue growth factor (CTGF), which activates FGFR3 signalling in tumour cells and promotes epithelial–mesenchymal transition.
The study further identifies KLF6 as an upstream regulator of CTGF, establishing a KLF6–CTGF–FGFR3 signalling axis linking stromal cells to tumour dissemination. Blocking CTGF or FGFR3 signalling reduced these pro-metastatic effects in experimental models.
The findings provide mechanistic insight into how the tumour microenvironment can actively drive metastasis and highlight a potentially targetable stromal pathway shared across multiple cancers.
#tumour #metastasis -
Gut Journal
@Gut_BMJ
Why does pancreatic cancer remain so resistant to immunotherapy?
Zeng et al. present “NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis” via gut.bmj.com/content/75/9/1753
This study identifies a previously unrecognised pathway linking NSUN6 deficiency to an immunosuppressive tumour microenvironment. Loss of NSUN6 reduces KDM5A expression and increases CCL2, promoting the accumulation and polarisation of tumour-promoting macrophages and suppressing CD8+ T-cell-mediated antitumour immunity.
Importantly, blocking CCL2 reversed macrophage accumulation and restored sensitivity to immune checkpoint blockade in experimental models.
The findings identify the NSUN6–KDM5A–CCL2 axis as a potential therapeutic target and suggest a strategy for making pancreatic cancer more responsive to immunotherapy.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Could one liver enzyme have far more biological roles than its traditional place in the urea cycle suggests?
#gutrecentadvancesinbasicscience paper by Chen et al. presents “CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine” via gut.bmj.com/content/75/10/2055
This review examines the expanding biology of carbamoyl phosphate synthetase 1 (CPS1), a highly abundant mitochondrial enzyme best known for catalysing the first step of the hepatic urea cycle.
CPS1 is also physiologically secreted into bile and can enter the circulation following hepatocyte injury. Its abundance, selective release and short serum half-life make it a potentially valuable biomarker of acute liver injury, particularly acute liver failure associated with acetaminophen toxicity.
The review also highlights an unexpected non-enzymatic role for CPS1 as an immune modulator. Following its release into the circulation, CPS1 can be taken up by monocytes and promote differentiation towards anti-inflammatory cells that home to and protect the injured liver.
Beyond liver injury, CPS1 is increasingly implicated in cancer, where altered expression can influence metabolic reprogramming and the tumour microenvironment.
The work illustrates how a protein traditionally viewed through the lens of hepatic nitrogen metabolism is emerging as a multifunctional molecule linking metabolism, bile biology, liver injury, immunity and cancer.
#acuteliverinjury #cps1 -
Gut Journal
@Gut_BMJ
Adenoma detection is one of the most important quality measures in colonoscopy — but does achieving a high adenoma detection rate mean that the risk of subsequent colorectal cancer has been eliminated?
Frazzoni et al. present “Adenoma detection and subsequent colorectal cancer risk: is the race really over?” via gut.bmj.com/content/75/9/1651
This thought-provoking Endoscopy News article considers the continuing relationship between adenoma detection and colorectal cancer risk, highlighting why high-quality colonoscopy remains a dynamic process rather than a finish line.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
What happens in the rectal mucosa before — and potentially as part of — perianal fistulising Crohn’s disease?
Gudiño et al. present “TL1A-activated T cells remodel the rectal mucosa in patients with Crohn’s disease with perianal fistulising disease” via gut.bmj.com/content/75/10/1922
Using single-cell RNA sequencing of rectal biopsies from patients with Crohn’s disease with and without perianal fistulising disease, together with functional studies in T cells, tissue explants, fibroblasts and epithelial cultures, this study identifies a distinct molecular signature associated with fistulising disease.
The rectal mucosa of patients with perianal fistulising disease showed cellular and transcriptional alterations that were independent of luminal inflammation. The researchers implicate TL1A activation in CD4+ T cells and identify lymphotoxin β and IL-22 as downstream mediators affecting fibroblast and epithelial compartments.
Importantly, the TL1A–LTα1β2/IL-22 pathway operates independently of TNF signalling, suggesting that these molecular changes may persist even in the context of anti-TNF therapy.
The findings provide new insight into the mechanisms that may predispose to perianal fistulising disease and support further investigation of TL1A-directed approaches in this challenging complication of Crohn’s disease.
#crohnsdisease #perianaldisease #tl1a -
Gut Journal
@Gut_BMJ
Could the biology that precedes Crohn’s disease also help explain why the disease returns after surgery?
The #gutrecentadvancesinclinicalpractice paper by Chen et al. presents “From preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions” via gut.bmj.com/content/75/10/2044
This review brings together emerging evidence from preclinical and postoperative Crohn’s disease cohorts, proposing that these apparently different stages of disease may share important biological mechanisms.
The authors highlight common predictive signatures involving genetic susceptibility, immune mediators such as CXCL9 and interleukin 6, microbial changes involving organisms including Faecalibacterium and Ruminococcus, gut-barrier dysfunction and systemic inflammation.
The review also explores emerging approaches including glycomics, urine metabolomics and high-dimensional immunophenotyping, which may help refine risk stratification and reveal the interactions between host, microbiome and immune system.
The postoperative setting may therefore provide a particularly useful human model for studying disease recurrence and testing biomarker-guided preventive strategies that could ultimately be relevant across the Crohn’s disease spectrum.
#crohnsdisease #ibd #genetics -
Gut Journal reposted
Sergey Minaev
@sminaev2015
Prior endoscopic surveillance and diagnosis of #barrett-related #dysplasia and #cancer: evidence from a nationwide Dutch cohort #some4surgery gut.bmj.com/content/early/2026/09/21/gutjnl-2025-337477
-
Gut Journal
@Gut_BMJ
Could a metabolite produced in the gut help protect the brain after stroke?
Zhang et al. present “Kynurenic acid mitigates post stroke brain damage through the gut-brain neural circuit” via gut.bmj.com/content/75/10/1910
This study identifies a previously unrecognised gut–brain neural circuit involving kynurenic acid (KYNA). Intestinal KYNA levels were reduced in patients with acute ischaemic stroke, and KYNA levels were associated with neurological recovery at three months in both training and validation cohorts.
In experimental stroke models, oral KYNA supplementation improved poststroke cerebral injury by activating GPR35 on enteric neurons and triggering vagal signalling. This pathway ultimately influenced brain regions including the nucleus tractus solitarius, hippocampus and hypothalamus, promoting anti-inflammatory microglial polarisation and enhancing neuronal α7 nicotinic acetylcholine receptor activity.
The findings provide striking evidence that intestinal metabolites can influence neurological recovery through a defined gut–brain neural pathway and identify KYNA–GPR35–vagus signalling as a potential therapeutic avenue for stroke recovery.
#gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
New #gutvideo...
🧬 Can tumour metabolism help switch off the immune system in MASH-HCC?
A new study in Gut by Wu et al. uncovers a fascinating link between tumour metabolism and immune dysfunction in MASH-associated hepatocellular carcinoma (MASH-HCC).
📄 “PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction”
The study shows that loss of PCK1 in tumour cells increases the lipid mediator 12-HETE, which impairs CD8⁺ T-cell function and may allow tumours to progress.
Importantly, targeting this pathway enhanced anti-tumour responses to anti-PD-1 immunotherapy in preclinical models. 🔬
A striking example of how metabolism, inflammation and cancer immunity intersect — and a potential new avenue for understanding and treating MASH-HCC.
📖 Read the paper:
gut.bmj.com/content/75/9/1816
🎥 Watch the #gutvideo:
www.youtube.com/watch?v=IMc-xQi3mc4&list=PL80fezoRY4BDr-o…
#mash #masld #hcc #hepatology #gastroenterology #livercancer #immunotherapy #cd8tcells #tumourmicroenvironment #gutjournal #gutvideo -
Gut Journal
@Gut_BMJ
How long should colonoscopists spend withdrawing the colonoscope — and how does this interact with computer-aided detection?
Djinbachian et al. present “Withdrawal time, CADe and adenoma detection: a prospective study” via gut.bmj.com/content/75/9/1647
This prospective study examines the relationship between withdrawal time, the use of computer-aided detection (CADe) and adenoma detection. The findings add to the growing evidence that both human performance and artificial intelligence can influence the quality of colonoscopy, with important implications for optimising colorectal cancer prevention through better adenoma detection.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
#guteditorschoice
MASLD is increasingly recognised as a multisystem metabolic disorder — but what does this mean for colorectal cancer risk?
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
This international consensus statement addresses the relationship between MASLD and colorectal cancer across epidemiology, pathogenesis and management. A multidisciplinary panel of 35 international experts reached consensus on all 17 statements considered.
The panel concludes that MASLD is associated with increased colorectal cancer risk and that a greater metabolic burden is associated with further risk. More severe MASLD is also associated with worse outcomes among patients with both MASLD and colorectal cancer.
The consensus highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic factors such as leptin and adiponectin. It also discusses potential risk-reduction strategies including lifestyle-associated weight loss, earlier risk-adapted colorectal cancer screening, bariatric surgery and GLP-1 receptor agonists.
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
🎙️ It is also the subject of the October #gutpodcast, coming soon. -
Gut Journal
@Gut_BMJ
How common are disorders of gut–brain interaction around the world — and how has their epidemiology changed since Rome IV?
Sperber et al. present “Rome V global epidemiology and validation survey: prevalence of disorders of gut–brain interaction and comparison with the Rome IV global epidemiology study” via gut.bmj.com/content/75/10/1887
This major global epidemiology and validation study provides updated estimates of disorders of gut–brain interaction using the Rome V diagnostic criteria and compares the findings with the previous Rome IV global epidemiology study.
The work provides important contemporary evidence on the worldwide burden of disorders of gut–brain interaction and helps assess the impact of updated diagnostic criteria on the identification of these conditions. The findings reinforce the substantial global burden of disorders such as irritable bowel syndrome and functional dyspepsia, while providing an important foundation for future epidemiological research and clinical care.
#dgbi #romev #epidemiology @alex_ford12399 -
Gut Journal
@Gut_BMJ
Could the brain become a therapeutic target for abdominal pain in IBS?
Weng et al. present “Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex” via gut.bmj.com/content/75/9/1682
This study explores low-frequency repetitive transcranial magnetic stimulation (rTMS) as a non-invasive approach to reducing visceral pain in patients with IBS with diarrhoea. By implicating inhibition of the medial prefrontal cortex in the reduction of visceral pain, the findings provide further evidence that altered brain–gut signalling is central to IBS and suggest a potential new avenue for neuromodulatory treatment.
The work adds to the growing recognition that treating disorders of gut–brain interaction may require approaches that target both the gastrointestinal tract and the nervous system.
#ibs -
Gut Journal
@Gut_BMJ
We hope you enjoy this October 2026 issue of @Gut_BMJ, featuring important advances across neurogastroenterology, disorders of gut–brain interaction, inflammatory bowel disease, gastrointestinal and pancreatic cancer, hepatology and the gut–liver axis. Read the issue via gut.bmj.com/content/75/10
🦠 The #gutfrontcover features a spectacular skyline across the bridge in Wenzhou, Zhejiang Province, China, celebrating the #guteditorschoice study by Wu et al. on colorectal cancer in metabolic dysfunction-associated steatotic liver disease.
Wu et al. present “Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement” via gut.bmj.com/content/75/10/2009
The paper questions how should we think about colorectal cancer risk in people living with metabolic dysfunction-associated steatotic liver disease?
This international Delphi consensus brings together 35 experts from across six continents to address the epidemiology, pathogenesis and management of colorectal cancer in MASLD. Consensus was achieved on all 17 statements, with the panel recognising an increased risk of colorectal cancer in people with MASLD, with greater metabolic burden associated with further risk and more severe MASLD linked to worse outcomes.
The consensus also highlights the potential importance of the gut–liver axis and gut dysbiosis, alongside metabolic management, weight loss and risk-adapted colorectal cancer screening. The authors propose greater clinical vigilance and a more integrated approach to metabolic and colorectal cancer risk in MASLD.
🎙️ This important study is also this month’s #gutpodcast — coming soon! -
Gut Journal
@Gut_BMJ
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
Listen to the latest #gutpodcast on the #guteditorschoice paper in September 2026. The study by Awoniyi et al. looks at the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ Listen to the #gutpodcast via:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ The Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
Access the paper “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via
gut.bmj.com/content/75/9/1711 -
Gut Journal
@Gut_BMJ
Could the food additives we consume provide measurable clues about Crohn’s disease activity?
Zhang et al. present “Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach” via gut.bmj.com/content/75/9/1695
The ENIGMA study takes an innovative approach by directly measuring artificial sweeteners and the emulsifier polysorbate-80 (P-80) and its metabolites in patients with Crohn’s disease and controls. Patients with Crohn’s disease had higher levels of several artificial sweeteners, while P-80 was extensively metabolised and its metabolites were associated with increased intestinal permeability and disease activity.
Importantly, a model combining sweeteners and P-80 metabolites was able to distinguish active from inactive Crohn’s disease, with strong performance in independent validation cohorts.
The findings raise exciting possibilities for non-invasive biomarkers of disease activity while providing new insight into how dietary exposures and intestinal barrier function may interact in Crohn’s disease.
#crohnsdisease #artificalsweeteners -
Gut Journal
@Gut_BMJ
Listen to the new 🎙️ #gutpodcast for October 2026
What is the link between MASLD and colorectal cancer?
In this month’s #gutpodcast, Professor Ming-Hua Zheng discusses the new international Delphi consensus statement exploring the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and colorectal cancer (CRC). Professor Zheng is interviewed by Dr Philip Smith, Digital and Education Editor of Gut.
🔎 Key takeaways:
• MASLD is associated with an increased risk of colorectal cancer, with metabolic burden appearing to further increase that risk.
• The severity of MASLD matters — more advanced disease is associated with poorer outcomes among people who develop both MASLD and CRC.
• The relationship may extend beyond shared risk factors. The gut–liver axis and gut dysbiosis are highlighted as potentially important mechanisms linking MASLD and CRC, alongside metabolic and hormonal pathways involving leptin and adiponectin.
• The consensus highlights the importance of clinical vigilance for CRC in people with MASLD, including consideration of risk-adapted approaches to screening.
• Lifestyle-based weight loss and metabolic risk reduction are highlighted, alongside emerging approaches such as bariatric surgery and GLP-1 receptor agonists, as potential strategies to reduce risk.
The international consensus brings together expert opinion across epidemiology, pathogenesis and management of CRC in people with MASLD.
🎧 Listen to the #gutpodcast:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/the-risk-of-colorectal-canc…
▶️ Spotify:
open.spotify.com/episode/6EVN0uvNCT6IIGVjxLZ3Yv
▶️ Web / Podbean:
gutbmj.podbean.com/e/the-risk-of-colorectal-cancer-with-m…
📄 Read the paper:
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement, Gut, October 2026; 75:2009–2018.
gut.bmj.com/content/75/10/2009
#gutpodcast #gastroenterology #hepatology #masld #mash #colorectalcancer #crc #gutliveraxis #liverdisease #cancerprevention -
Gut Journal
@Gut_BMJ
What can the immune response teach us about achieving a functional cure for chronic hepatitis B? This #recentadvancesinbasicscience #gutrecentadvancesinbasicscience paper reviews this in detail.
Thimme et al. present “Decoding HBV-specific adaptive immunity: from natural clearance to cure” via gut.bmj.com/content/75/9/1857
This comprehensive review examines how HBV-specific CD8+ and CD4+ T cells and B cells contribute to viral clearance during acute infection — and why these immune responses become profoundly impaired during chronic infection.
The authors highlight growing evidence that immune dysfunction in chronic HBV is more complex and heterogeneous than the traditional concept of T-cell exhaustion suggests. Understanding these distinct immune defects may be crucial for developing more effective therapeutic vaccines, immune checkpoint strategies and T-cell-based approaches.
The review also highlights a key challenge: although immune-based therapies are promising, restoring effective HBV-specific immunity and achieving sustained HBsAg loss remains difficult.
A deeper understanding of HBV-specific adaptive immunity could therefore be central to the next generation of functional-cure strategies.
#hbv #hepatitisbvirus -
Gut Journal
@Gut_BMJ
How much can pegylated interferon add to nucleos(t)ide analogue therapy when the goal is hepatitis B surface antigen clearance?
Dongelmans et al. present “HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)” via gut.bmj.com/content/75/10/2000
The PROSPER individual participant data meta-analysis brings together eight prospective clinical trials involving 581 patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy with added peg-IFN.
At the end of follow-up, 8.6% of patients achieved HBsAg loss overall. The likelihood of HBsAg clearance was strongly related to the HBsAg level at the start of peg-IFN therapy: HBsAg loss occurred in 37.7% of patients with baseline HBsAg below 100 IU/mL, compared with 9.8% in those with levels of 100–1000 IU/mL and 2.3% in those with levels ≥1000 IU/mL.
Among patients starting with higher HBsAg levels, peg-IFN therapy also produced substantial declines over treatment, potentially bringing some patients below thresholds relevant to emerging therapeutic strategies.
The findings provide important individual-level evidence for understanding which patients may derive the greatest benefit from peg-IFN add-on therapy and how treatment response may contribute to evolving strategies aimed at functional cure of chronic hepatitis B.
#hepatitisb #hbv -
Gut Journal reposted
Cancer Library VCC
@VCCLibrary
Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. gut.bmj.com/content/early/2026/09/24/gutjnl-2026-339505
-
Gut Journal
@Gut_BMJ
Autoimmune gastritis has traditionally been viewed mainly as a risk factor for gastric neuroendocrine tumours and non-cardia gastric adenocarcinoma. But could its cancer risk extend further?
Read the #recentadvancesinclinicalpractice #gutrecentadvancesinclinicalpractice by Lenti et al. entitled “Autoimmune gastritis: a hidden gateway to cardia and oesophageal cancers beyond non-cardia gastric adenocarcinoma” via gut.bmj.com/content/75/9/1845
This review brings together emerging epidemiological and clinical evidence suggesting that autoimmune gastritis and pernicious anaemia may also be associated with malignancies involving the gastric cardia, gastro-oesophageal junction and oesophagus.
The authors explore possible mechanisms including corpus-predominant atrophy, intestinal metaplasia and vitamin B12 deficiency, while highlighting important gaps in our current understanding.
The review challenges us to think beyond the traditional boundaries of autoimmune gastritis and raises important questions about future risk stratification and surveillance.
#autoimmunegastritis -
Gut Journal
@Gut_BMJ
What is the optimal surgical approach for adenocarcinoma of the oesophagogastric junction?
Zheng et al. present “Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study” via gut.bmj.com/content/75/9/1726
Drawing on the large prospective CLAEG registry across 44 high-volume centres and more than 2,000 radical resections, this study provides valuable real-world data on lymph-node metastasis patterns and surgical outcomes. The analysis helps clarify where metastatic lymph nodes are most commonly found and examines important questions around the extent and type of surgery.
The findings provide practical evidence to inform surgical decision-making for this increasingly important and challenging cancer.
#ogcancer #gastriccancer -
Gut Journal
@Gut_BMJ
Why does pancreatic cancer remain so resistant to immunotherapy?
Zeng et al. present “NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis” via gut.bmj.com/content/75/9/1753
This study identifies a previously unrecognised pathway linking NSUN6 deficiency to an immunosuppressive tumour microenvironment. Loss of NSUN6 reduces KDM5A expression and increases CCL2, promoting the accumulation and polarisation of tumour-promoting macrophages and suppressing CD8+ T-cell-mediated antitumour immunity.
Importantly, blocking CCL2 reversed macrophage accumulation and restored sensitivity to immune checkpoint blockade in experimental models.
The findings identify the NSUN6–KDM5A–CCL2 axis as a potential therapeutic target and suggest a strategy for making pancreatic cancer more responsive to immunotherapy.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
How does the liver regenerate so rapidly after ALPPS surgery?
Yan et al. present “CD177+ neutrophils drive extracellular matrix remodelling and HGF-alpha release in ALPPS-induced liver regeneration” via gut.bmj.com/content/75/9/1771
Using single-cell RNA sequencing, spatial transcriptomics, clinical cohorts and experimental models, this study identifies CD177+ neutrophils as important drivers of liver regeneration following associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
The researchers show that these neutrophils promote endothelial transmigration, extracellular matrix degradation and release of hepatocyte growth factor alpha (HGF-α), creating a regenerative environment for the liver.
The findings reveal a previously underappreciated role for neutrophils in surgical liver regeneration and could ultimately inform strategies to enhance liver regeneration in patients with limited hepatic reserve. -
Gut Journal
@Gut_BMJ
We hope you enjoy this September 2026 issue of @Gut_BMJ
From dysbiotic microbiota driving colorectal cancer in PSC-IBD to AI-assisted colonoscopy, neuromodulation for IBS, dietary biomarkers in Crohn’s disease and new mechanisms of pancreatic and liver biology, this September issue demonstrates how rapidly gastroenterology is evolving.
Several themes stand out:
🦠 The microbiome and its metabolites are emerging as active drivers of intestinal inflammation and cancer.
🤖 Artificial intelligence and advanced endoscopic techniques are continuing to reshape colorectal cancer prevention.
🧠 The brain–gut axis offers new therapeutic opportunities for disorders such as IBS.
🥤 Dietary exposures and food additives may provide measurable biological signatures of Crohn’s disease activity.
🧬 Tumour biology and epigenetic regulation are revealing new mechanisms of immune suppression and treatment resistance.
🫀 Liver regeneration is increasingly understood as a complex interaction between immune cells, stromal biology and tissue remodelling.
🧪 Immune profiling may ultimately be essential for developing a functional cure for chronic hepatitis B.
👉 Read the full September 2026 issue of Gut:
gut.bmj.com/content/75/9
🦠 #gutfrontcover | Editor’s Choice
This month’s #gutfrontcover features the Legendary Old Well in Chapel Hill, North Carolina, celebrating the Editor’s Choice study by Awoniyi et al. on the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ The study is also the focus of this month’s #gutpodcast, discussing the relationship between dysbiosis, PSC-UC and colorectal neoplasia.
▶️ Listen on Apple Podcasts: podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify: open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website: gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal reposted
Shomron Ben-Horin
@ShomronH
Interesting study in @Gut_BMJ from @Siew_C_Ng : Polysurbate 80 (the commonly used E433 emulsifier that smoothes processed foods like ice cream, dairy, sauces,mayo &more) is degraded to 5 metabolites in the body and impairs gut barrier
share.google/vM7BTnHKdWwU5t4sg -
Gut Journal reposted
Anirban Maitra
@Aiims1742
Our review is online at @Gut_BMJ concurrent with #aacrpan26
Metastatic #pancreaticcancer: from human disease to preclinical modelling
gut.bmj.com/content/early/2026/09/24/gutjnl-2025-336334
Co-authored with @jiminmin_v @PeterYuMD @Perlmutter_CC @nyulangone & colleagues from @CNIOStopCancer -
Gut Journal
@Gut_BMJ
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
PSC-associated IBD carries a particularly high risk of colorectal neoplasia. This study provides important mechanistic insight into how the gut microbiome may contribute to that risk.
The authors demonstrate that dysbiotic microbiota can promote colitis-associated colorectal cancer while producing a distinctive bile-acid signature. These findings strengthen the emerging view that microbial communities and their metabolites can actively shape the intestinal environment in ways that influence carcinogenesis.
🎙️ It is also the subject of the September #gutpodcast.
▶️ Listen on Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
Adenoma detection is one of the most important quality measures in colonoscopy — but does achieving a high adenoma detection rate mean that the risk of subsequent colorectal cancer has been eliminated?
Frazzoni et al. present “Adenoma detection and subsequent colorectal cancer risk: is the race really over?” via gut.bmj.com/content/75/9/1651
This thought-provoking Endoscopy News article considers the continuing relationship between adenoma detection and colorectal cancer risk, highlighting why high-quality colonoscopy remains a dynamic process rather than a finish line.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
🧬🦠 What connects a Western diet, the gut microbiome and colorectal cancer?
New #gutpodcast with Dr Soeren Ocvirk discusses new research by Osswald et al. in Gut: “Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.”
The study provides experimental evidence that secondary bile acids—particularly deoxycholic acid (DCA)—produced by 7α-dehydroxylating gut bacteria can promote colorectal tumour development in the context of a Western diet.
Using a combination of a porcine CRC model, multi-omics, gnotobiotic mouse models and human colon organoids, the researchers show that specific bile-acid-producing bacteria can increase DCA production, epithelial proliferation and tumour burden.
Importantly, manipulating this pathway reduced tumour-promoting effects, pointing towards the gut microbiome–bile acid axis as a potential target for prevention.
For clinicians and scientists, this is an important step from correlation towards causality.
For everyone else: it adds another piece to the puzzle of how what we eat, our gut microbes and the chemistry they produce may interact in colorectal cancer risk.
🎧 Listen to Dr Ocvirk discuss the study:
▶️ Apple: podcasts.apple.com/us/podcast/western-diet-associated-col…
▶️ Spotify: open.spotify.com/episode/0pcOjOucAMzBi7guY6uS9E
▶️ Web: gutbmj.podbean.com/e/western-diet-associated-colorectal-c…
📄 Paper: gut.bmj.com/content/75/8/1505
#gutpodcast #colorectalcancer #crc #gutmicrobiome #bileacids #microbiome #cancerresearch #gastroenterology #guthealth -
Gut Journal reposted
Matthew Armstrong 💙
@Drfattyliver
@Gut_BMJ automated skeletal muscle metrics in routine CT reports to flag sarcopenia in cirrhosis. Should this be incorporated into routine practice? Read our article @liverphysio @EASLedu @BASLedu @BritSocGastro gut.bmj.com/cgi/rapidpdf/gutjnl-2026-340144?ijkey=ictbWPM…
-
Gut Journal reposted
Maria Mironova, MD, MHSc, FACP
@Mironova_MD
🚨Important paper alert
Clinical practice update on treating MASH with F2–F3
✅2 drugs: resmetirom & sema
✅NIT-based diagnosis & monitoring
✅Approach to pts already on GLP-1 RAs
✅Defining response, switching & combining drugs
@DrLoomba @NoureddinMD
gut.bmj.com/content/early/2026/09/11/gutjnl-2026-340031 -
Gut Journal reposted
Shifang Li
@LeeFruce
Happy to share some of my research, which highlights that the CTCF-rs705704-SUOX axis plays an important role in the association between hypothyroidism and MASLD. @Gut_BMJ #masld #hypothyroidism
gut.bmj.com/content/early/2026/09/24/gutjnl-2026-339457 -
Gut Journal reposted
Immunology Podcast
@ImmunoPodcast
Dr. Pil Soo Sung and team, including Min Gu Kim, discovered that IgA binding to liver #myeloid cells is associated with IL-1-linked inflammation and liver injury in alcohol-associated liver disease. 🌡️
Read more: gut.bmj.com/content/early/2026/09/06/gutjnl-2026-338715
🎙️ Listen to the discussion: -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
What defines a healthy gut microbiome?
Here is what we know and current research gaps
@Gut_BMJ
gut.bmj.com/content/73/11/1893 -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies
gut.bmj.com/content/early/2026/09/24/gutjnl-2026-339505 -
Gut Journal
@Gut_BMJ
New #gutvideo...
🧬 Can tumour metabolism help switch off the immune system in MASH-HCC?
A new study in Gut by Wu et al. uncovers a fascinating link between tumour metabolism and immune dysfunction in MASH-associated hepatocellular carcinoma (MASH-HCC).
📄 “PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction”
The study shows that loss of PCK1 in tumour cells increases the lipid mediator 12-HETE, which impairs CD8⁺ T-cell function and may allow tumours to progress.
Importantly, targeting this pathway enhanced anti-tumour responses to anti-PD-1 immunotherapy in preclinical models. 🔬
A striking example of how metabolism, inflammation and cancer immunity intersect — and a potential new avenue for understanding and treating MASH-HCC.
📖 Read the paper:
gut.bmj.com/content/75/9/1816
🎥 Watch the #gutvideo:
www.youtube.com/watch?v=IMc-xQi3mc4&list=PL80fezoRY4BDr-o…
#mash #masld #hcc #hepatology #gastroenterology #livercancer #immunotherapy #cd8tcells #tumourmicroenvironment #gutjournal #gutvideo -
Gut Journal
@Gut_BMJ
Could the brain become a therapeutic target for abdominal pain in IBS?
Weng et al. present “Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex” via gut.bmj.com/content/75/9/1682
This study explores low-frequency repetitive transcranial magnetic stimulation (rTMS) as a non-invasive approach to reducing visceral pain in patients with IBS with diarrhoea. By implicating inhibition of the medial prefrontal cortex in the reduction of visceral pain, the findings provide further evidence that altered brain–gut signalling is central to IBS and suggest a potential new avenue for neuromodulatory treatment.
The work adds to the growing recognition that treating disorders of gut–brain interaction may require approaches that target both the gastrointestinal tract and the nervous system.
#ibs -
Gut Journal
@Gut_BMJ
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
Listen to the latest #gutpodcast on the #guteditorschoice paper in September 2026. The study by Awoniyi et al. looks at the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ Listen to the #gutpodcast via:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ The Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
Access the paper “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via
gut.bmj.com/content/75/9/1711 -
Gut Journal
@Gut_BMJ
Could the food additives we consume provide measurable clues about Crohn’s disease activity?
Zhang et al. present “Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach” via gut.bmj.com/content/75/9/1695
The ENIGMA study takes an innovative approach by directly measuring artificial sweeteners and the emulsifier polysorbate-80 (P-80) and its metabolites in patients with Crohn’s disease and controls. Patients with Crohn’s disease had higher levels of several artificial sweeteners, while P-80 was extensively metabolised and its metabolites were associated with increased intestinal permeability and disease activity.
Importantly, a model combining sweeteners and P-80 metabolites was able to distinguish active from inactive Crohn’s disease, with strong performance in independent validation cohorts.
The findings raise exciting possibilities for non-invasive biomarkers of disease activity while providing new insight into how dietary exposures and intestinal barrier function may interact in Crohn’s disease.
#crohnsdisease #artificalsweeteners -
Gut Journal
@Gut_BMJ
What can the immune response teach us about achieving a functional cure for chronic hepatitis B? This #recentadvancesinbasicscience #gutrecentadvancesinbasicscience paper reviews this in detail.
Thimme et al. present “Decoding HBV-specific adaptive immunity: from natural clearance to cure” via gut.bmj.com/content/75/9/1857
This comprehensive review examines how HBV-specific CD8+ and CD4+ T cells and B cells contribute to viral clearance during acute infection — and why these immune responses become profoundly impaired during chronic infection.
The authors highlight growing evidence that immune dysfunction in chronic HBV is more complex and heterogeneous than the traditional concept of T-cell exhaustion suggests. Understanding these distinct immune defects may be crucial for developing more effective therapeutic vaccines, immune checkpoint strategies and T-cell-based approaches.
The review also highlights a key challenge: although immune-based therapies are promising, restoring effective HBV-specific immunity and achieving sustained HBsAg loss remains difficult.
A deeper understanding of HBV-specific adaptive immunity could therefore be central to the next generation of functional-cure strategies.
#hbv #hepatitisbvirus -
Gut Journal
@Gut_BMJ
How long should colonoscopists spend withdrawing the colonoscope — and how does this interact with computer-aided detection?
Djinbachian et al. present “Withdrawal time, CADe and adenoma detection: a prospective study” via gut.bmj.com/content/75/9/1647
This prospective study examines the relationship between withdrawal time, the use of computer-aided detection (CADe) and adenoma detection. The findings add to the growing evidence that both human performance and artificial intelligence can influence the quality of colonoscopy, with important implications for optimising colorectal cancer prevention through better adenoma detection.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
Autoimmune gastritis has traditionally been viewed mainly as a risk factor for gastric neuroendocrine tumours and non-cardia gastric adenocarcinoma. But could its cancer risk extend further?
Read the #recentadvancesinclinicalpractice #gutrecentadvancesinclinicalpractice by Lenti et al. entitled “Autoimmune gastritis: a hidden gateway to cardia and oesophageal cancers beyond non-cardia gastric adenocarcinoma” via gut.bmj.com/content/75/9/1845
This review brings together emerging epidemiological and clinical evidence suggesting that autoimmune gastritis and pernicious anaemia may also be associated with malignancies involving the gastric cardia, gastro-oesophageal junction and oesophagus.
The authors explore possible mechanisms including corpus-predominant atrophy, intestinal metaplasia and vitamin B12 deficiency, while highlighting important gaps in our current understanding.
The review challenges us to think beyond the traditional boundaries of autoimmune gastritis and raises important questions about future risk stratification and surveillance.
#autoimmunegastritis -
Gut Journal
@Gut_BMJ
What is the optimal surgical approach for adenocarcinoma of the oesophagogastric junction?
Zheng et al. present “Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study” via gut.bmj.com/content/75/9/1726
Drawing on the large prospective CLAEG registry across 44 high-volume centres and more than 2,000 radical resections, this study provides valuable real-world data on lymph-node metastasis patterns and surgical outcomes. The analysis helps clarify where metastatic lymph nodes are most commonly found and examines important questions around the extent and type of surgery.
The findings provide practical evidence to inform surgical decision-making for this increasingly important and challenging cancer.
#ogcancer #gastriccancer -
Gut Journal
@Gut_BMJ
Why does pancreatic cancer remain so resistant to immunotherapy?
Zeng et al. present “NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis” via gut.bmj.com/content/75/9/1753
This study identifies a previously unrecognised pathway linking NSUN6 deficiency to an immunosuppressive tumour microenvironment. Loss of NSUN6 reduces KDM5A expression and increases CCL2, promoting the accumulation and polarisation of tumour-promoting macrophages and suppressing CD8+ T-cell-mediated antitumour immunity.
Importantly, blocking CCL2 reversed macrophage accumulation and restored sensitivity to immune checkpoint blockade in experimental models.
The findings identify the NSUN6–KDM5A–CCL2 axis as a potential therapeutic target and suggest a strategy for making pancreatic cancer more responsive to immunotherapy.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
How does the liver regenerate so rapidly after ALPPS surgery?
Yan et al. present “CD177+ neutrophils drive extracellular matrix remodelling and HGF-alpha release in ALPPS-induced liver regeneration” via gut.bmj.com/content/75/9/1771
Using single-cell RNA sequencing, spatial transcriptomics, clinical cohorts and experimental models, this study identifies CD177+ neutrophils as important drivers of liver regeneration following associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
The researchers show that these neutrophils promote endothelial transmigration, extracellular matrix degradation and release of hepatocyte growth factor alpha (HGF-α), creating a regenerative environment for the liver.
The findings reveal a previously underappreciated role for neutrophils in surgical liver regeneration and could ultimately inform strategies to enhance liver regeneration in patients with limited hepatic reserve. -
Gut Journal
@Gut_BMJ
🦠 Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients
New #gutscience journal research by Halle-Smith et al. asks an important question: could the bacteria living in our gut be linked to how well pancreatic cancer responds to chemotherapy?
The researchers found differences in the gut microbiome of patients who responded differently to neoadjuvant chemotherapy. Some of the differences involved bacterial genes linked to how medicines are processed.
Why could this matter for clinicians and patients? 🩺
Pancreatic cancer can be difficult to treat, and patients can respond very differently to the same treatment. Understanding whether the gut microbiome is linked to treatment response could eventually help researchers develop better ways to predict — and potentially improve — how patients respond to therapy.
It is still too early to use the microbiome to guide individual treatment, but these findings add to growing evidence that the microbes living in our gut could be relevant to cancer care.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000023
#gutscience #pancreaticcancer #cancerresearch #gutmicrobiome #microbiome #chemotherapy #precisionmedicine #translationalresearch @druppygill @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal reposted
robert verdonk
@rcverdonk
Treat exocrine dysfunction! BUT don’t expect it to 🔽 pain 👉🏻Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis: a double-blind, parallel-group, placebo-controlled, randomised trial gut.bmj.com/content/early/2026/09/15/gutjnl-2026-338802
-
Gut Journal reposted
Mohamed Shiha
@Mo_Shiha
Global epidemiology of disorders of gut–brain interaction: new insights with Rome V gut.bmj.com/content/early/2026/09/15/gutjnl-2026-340229
-
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
From ferroptic hepatocytes to fibrosis to malignant transformation.
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal
@Gut_BMJ
We hope you enjoy this September 2026 issue of @Gut_BMJ
From dysbiotic microbiota driving colorectal cancer in PSC-IBD to AI-assisted colonoscopy, neuromodulation for IBS, dietary biomarkers in Crohn’s disease and new mechanisms of pancreatic and liver biology, this September issue demonstrates how rapidly gastroenterology is evolving.
Several themes stand out:
🦠 The microbiome and its metabolites are emerging as active drivers of intestinal inflammation and cancer.
🤖 Artificial intelligence and advanced endoscopic techniques are continuing to reshape colorectal cancer prevention.
🧠 The brain–gut axis offers new therapeutic opportunities for disorders such as IBS.
🥤 Dietary exposures and food additives may provide measurable biological signatures of Crohn’s disease activity.
🧬 Tumour biology and epigenetic regulation are revealing new mechanisms of immune suppression and treatment resistance.
🫀 Liver regeneration is increasingly understood as a complex interaction between immune cells, stromal biology and tissue remodelling.
🧪 Immune profiling may ultimately be essential for developing a functional cure for chronic hepatitis B.
👉 Read the full September 2026 issue of Gut:
gut.bmj.com/content/75/9
🦠 #gutfrontcover | Editor’s Choice
This month’s #gutfrontcover features the Legendary Old Well in Chapel Hill, North Carolina, celebrating the Editor’s Choice study by Awoniyi et al. on the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ The study is also the focus of this month’s #gutpodcast, discussing the relationship between dysbiosis, PSC-UC and colorectal neoplasia.
▶️ Listen on Apple Podcasts: podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify: open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website: gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal
@Gut_BMJ
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
PSC-associated IBD carries a particularly high risk of colorectal neoplasia. This study provides important mechanistic insight into how the gut microbiome may contribute to that risk.
The authors demonstrate that dysbiotic microbiota can promote colitis-associated colorectal cancer while producing a distinctive bile-acid signature. These findings strengthen the emerging view that microbial communities and their metabolites can actively shape the intestinal environment in ways that influence carcinogenesis.
🎙️ It is also the subject of the September #gutpodcast.
▶️ Listen on Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal
@Gut_BMJ
Adenoma detection is one of the most important quality measures in colonoscopy — but does achieving a high adenoma detection rate mean that the risk of subsequent colorectal cancer has been eliminated?
Frazzoni et al. present “Adenoma detection and subsequent colorectal cancer risk: is the race really over?” via gut.bmj.com/content/75/9/1651
This thought-provoking Endoscopy News article considers the continuing relationship between adenoma detection and colorectal cancer risk, highlighting why high-quality colonoscopy remains a dynamic process rather than a finish line.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
🧬🦠 What connects a Western diet, the gut microbiome and colorectal cancer?
New #gutpodcast with Dr Soeren Ocvirk discusses new research by Osswald et al. in Gut: “Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.”
The study provides experimental evidence that secondary bile acids—particularly deoxycholic acid (DCA)—produced by 7α-dehydroxylating gut bacteria can promote colorectal tumour development in the context of a Western diet.
Using a combination of a porcine CRC model, multi-omics, gnotobiotic mouse models and human colon organoids, the researchers show that specific bile-acid-producing bacteria can increase DCA production, epithelial proliferation and tumour burden.
Importantly, manipulating this pathway reduced tumour-promoting effects, pointing towards the gut microbiome–bile acid axis as a potential target for prevention.
For clinicians and scientists, this is an important step from correlation towards causality.
For everyone else: it adds another piece to the puzzle of how what we eat, our gut microbes and the chemistry they produce may interact in colorectal cancer risk.
🎧 Listen to Dr Ocvirk discuss the study:
▶️ Apple: podcasts.apple.com/us/podcast/western-diet-associated-col…
▶️ Spotify: open.spotify.com/episode/0pcOjOucAMzBi7guY6uS9E
▶️ Web: gutbmj.podbean.com/e/western-diet-associated-colorectal-c…
📄 Paper: gut.bmj.com/content/75/8/1505
#gutpodcast #colorectalcancer #crc #gutmicrobiome #bileacids #microbiome #cancerresearch #gastroenterology #guthealth -
Gut Journal
@Gut_BMJ
🧬 Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice
New #gutscience journal research by Abot et al. explores an intriguing link between the movement of the gut and blood sugar control.
In diabetic mice, the researchers found that catestatin reduced excessive movement of the duodenum (the first part of the small intestine) and improved glucose tolerance. Longer-term treatment was also associated with less weight gain and lower levels of fat in the liver.
Why does this matter for clinicians and patients? 🩺
The gut does much more than digest food. How quickly food moves through the intestine can influence metabolism and blood glucose levels. Understanding these connections could eventually reveal new ways to treat metabolic diseases such as diabetes.
This is early, preclinical research in mice, so further studies are needed to find out whether these effects could translate into new treatments for people.
📖 Read the paper: gutscience.bmj.com/content/1/1/e000021
#gutscience #diabetes #guthealth #metabolism #gastroenterology #translationalresearch #medicalresearch @BMJOpen_Gastro @FrontGastro_BMJ @Gut_BMJ -
Gut Journal
@Gut_BMJ
Could the brain become a therapeutic target for abdominal pain in IBS?
Weng et al. present “Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex” via gut.bmj.com/content/75/9/1682
This study explores low-frequency repetitive transcranial magnetic stimulation (rTMS) as a non-invasive approach to reducing visceral pain in patients with IBS with diarrhoea. By implicating inhibition of the medial prefrontal cortex in the reduction of visceral pain, the findings provide further evidence that altered brain–gut signalling is central to IBS and suggest a potential new avenue for neuromodulatory treatment.
The work adds to the growing recognition that treating disorders of gut–brain interaction may require approaches that target both the gastrointestinal tract and the nervous system.
#ibs -
Gut Journal reposted
Abdul Rasheed
@a_rasheed_12
1/4 🧬 New publication in @Gut_BMJ!
Very happy to share our study: “Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis” — a double-blind, placebo-controlled, randomised trial. -
Gut Journal reposted
Abdul Rasheed
@a_rasheed_12
4/4 Moving beyond an “all-comers” approach towards phenotype- and mechanism-based treatment may be an important direction for future research in pancreatic pain. #pancreaticpain #gastroenterology #clinicalresearch gut.bmj.com/content/early/2026/09/15/gutjnl-2026-338802
-
Gut Journal reposted
Abdul Rasheed
@a_rasheed_12
Our publication in @Gut_BMJ Grateful to @Dr_RupjyotiTalukdar @AIGHospitals and entire pancreatology team for giving me opportunity to contribute to this meaningful work
-
Gut Journal reposted
Anjan Dhar
@anjan_dhar6
With recent publications busting the hype around CADe and ADR, this important paper defines the relationship between CWT and CADe. If you are not using AI, ensure a CWT > 6min, preferably closer to 10min to achieve a high ADR and PPDR. @BSGTrainees
Gut Journal
@Gut_BMJ
How long should colonoscopists spend withdrawing the colonoscope — and how does this interact with computer-aided detection?
Djinbachian et al. present “Withdrawal time, CADe and adenoma detection: a prospective study” via gut.bmj.com/content/75/9/1647
This prospective study examines the relationship between withdrawal time, the use of computer-aided detection (CADe) and adenoma detection. The findings add to the growing evidence that both human performance and artificial intelligence can influence the quality of colonoscopy, with important implications for optimising colorectal cancer prevention through better adenoma detection.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
How long should colonoscopists spend withdrawing the colonoscope — and how does this interact with computer-aided detection?
Djinbachian et al. present “Withdrawal time, CADe and adenoma detection: a prospective study” via gut.bmj.com/content/75/9/1647
This prospective study examines the relationship between withdrawal time, the use of computer-aided detection (CADe) and adenoma detection. The findings add to the growing evidence that both human performance and artificial intelligence can influence the quality of colonoscopy, with important implications for optimising colorectal cancer prevention through better adenoma detection.
#endoscopynews #gutendoscopynews -
Gut Journal
@Gut_BMJ
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
Listen to the latest #gutpodcast on the #guteditorschoice paper in September 2026. The study by Awoniyi et al. looks at the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ Listen to the #gutpodcast via:
▶️ Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ The Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
Access the paper “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via
gut.bmj.com/content/75/9/1711 -
Gut Journal
@Gut_BMJ
Could the food additives we consume provide measurable clues about Crohn’s disease activity?
Zhang et al. present “Quantifying artificial sweeteners and emulsifiers in Crohn’s disease and its relationship with disease activity: the ENIGMA study – a novel and targeted approach” via gut.bmj.com/content/75/9/1695
The ENIGMA study takes an innovative approach by directly measuring artificial sweeteners and the emulsifier polysorbate-80 (P-80) and its metabolites in patients with Crohn’s disease and controls. Patients with Crohn’s disease had higher levels of several artificial sweeteners, while P-80 was extensively metabolised and its metabolites were associated with increased intestinal permeability and disease activity.
Importantly, a model combining sweeteners and P-80 metabolites was able to distinguish active from inactive Crohn’s disease, with strong performance in independent validation cohorts.
The findings raise exciting possibilities for non-invasive biomarkers of disease activity while providing new insight into how dietary exposures and intestinal barrier function may interact in Crohn’s disease.
#crohnsdisease #artificalsweeteners -
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
The gut–liver axis may have an IgA arm. In Gut, IgA binding to hepatic myeloid cells tracked with IL-1-linked inflammation in ALD; blocking immune-cell trafficking reduced IgA-bound macrophages and liver injury in mice. 🧬 doi.org/10.1136/gutjnl-2026-338715 #hepatology #immunology
-
Gut Journal reposted
VCU Stravitz-Sanyal Institute for Liver Disease
@VCU_Liver
NEW from @Gut_BMJ: International expert panel (including @ArunJSanyalVCU) review for the use of resmetirom and semaglutide in the management of #mash-related fibrosis: clinical practice update. #livertwitter gut.bmj.com/content/early/2026/09/11/gutjnl-2026-340031
-
Gut Journal
@Gut_BMJ
What can the immune response teach us about achieving a functional cure for chronic hepatitis B? This #recentadvancesinbasicscience #gutrecentadvancesinbasicscience paper reviews this in detail.
Thimme et al. present “Decoding HBV-specific adaptive immunity: from natural clearance to cure” via gut.bmj.com/content/75/9/1857
This comprehensive review examines how HBV-specific CD8+ and CD4+ T cells and B cells contribute to viral clearance during acute infection — and why these immune responses become profoundly impaired during chronic infection.
The authors highlight growing evidence that immune dysfunction in chronic HBV is more complex and heterogeneous than the traditional concept of T-cell exhaustion suggests. Understanding these distinct immune defects may be crucial for developing more effective therapeutic vaccines, immune checkpoint strategies and T-cell-based approaches.
The review also highlights a key challenge: although immune-based therapies are promising, restoring effective HBV-specific immunity and achieving sustained HBsAg loss remains difficult.
A deeper understanding of HBV-specific adaptive immunity could therefore be central to the next generation of functional-cure strategies.
#hbv #hepatitisbvirus -
Gut Journal
@Gut_BMJ
New #gutvideo...
🧬 Can tumour metabolism help switch off the immune system in MASH-HCC?
A new study in Gut by Wu et al. uncovers a fascinating link between tumour metabolism and immune dysfunction in MASH-associated hepatocellular carcinoma (MASH-HCC).
📄 “PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction”
The study shows that loss of PCK1 in tumour cells increases the lipid mediator 12-HETE, which impairs CD8⁺ T-cell function and may allow tumours to progress.
Importantly, targeting this pathway enhanced anti-tumour responses to anti-PD-1 immunotherapy in preclinical models. 🔬
A striking example of how metabolism, inflammation and cancer immunity intersect — and a potential new avenue for understanding and treating MASH-HCC.
📖 Read the paper:
gut.bmj.com/content/75/9/1816
🎥 Watch the #gutvideo:
www.youtube.com/watch?v=IMc-xQi3mc4&list=PL80fezoRY4BDr-o…
#mash #masld #hcc #hepatology #gastroenterology #livercancer #immunotherapy #cd8tcells #tumourmicroenvironment #gutjournal #gutvideo -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal reposted
Roberto Vargas Pino
@robvargas01
Debemos prestar más atención al cardias y zona de esófago inferior ya que el riesgo aumenta con una gastritis autoinmune
Gut Journal
@Gut_BMJ
Autoimmune gastritis has traditionally been viewed mainly as a risk factor for gastric neuroendocrine tumours and non-cardia gastric adenocarcinoma. But could its cancer risk extend further?
Read the #recentadvancesinclinicalpractice #gutrecentadvancesinclinicalpractice by Lenti et al. entitled “Autoimmune gastritis: a hidden gateway to cardia and oesophageal cancers beyond non-cardia gastric adenocarcinoma” via gut.bmj.com/content/75/9/1845
This review brings together emerging epidemiological and clinical evidence suggesting that autoimmune gastritis and pernicious anaemia may also be associated with malignancies involving the gastric cardia, gastro-oesophageal junction and oesophagus.
The authors explore possible mechanisms including corpus-predominant atrophy, intestinal metaplasia and vitamin B12 deficiency, while highlighting important gaps in our current understanding.
The review challenges us to think beyond the traditional boundaries of autoimmune gastritis and raises important questions about future risk stratification and surveillance.
#autoimmunegastritis -
Gut Journal
@Gut_BMJ
The study is this month’s #guteditorschoice and features on the #gutfrontcover.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
PSC-associated IBD carries a particularly high risk of colorectal neoplasia. This study provides important mechanistic insight into how the gut microbiome may contribute to that risk.
The authors demonstrate that dysbiotic microbiota can promote colitis-associated colorectal cancer while producing a distinctive bile-acid signature. These findings strengthen the emerging view that microbial communities and their metabolites can actively shape the intestinal environment in ways that influence carcinogenesis.
🎙️ It is also the subject of the September #gutpodcast.
▶️ Listen on Apple Podcasts:
podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify:
open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website:
gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal
@Gut_BMJ
Autoimmune gastritis has traditionally been viewed mainly as a risk factor for gastric neuroendocrine tumours and non-cardia gastric adenocarcinoma. But could its cancer risk extend further?
Read the #recentadvancesinclinicalpractice #gutrecentadvancesinclinicalpractice by Lenti et al. entitled “Autoimmune gastritis: a hidden gateway to cardia and oesophageal cancers beyond non-cardia gastric adenocarcinoma” via gut.bmj.com/content/75/9/1845
This review brings together emerging epidemiological and clinical evidence suggesting that autoimmune gastritis and pernicious anaemia may also be associated with malignancies involving the gastric cardia, gastro-oesophageal junction and oesophagus.
The authors explore possible mechanisms including corpus-predominant atrophy, intestinal metaplasia and vitamin B12 deficiency, while highlighting important gaps in our current understanding.
The review challenges us to think beyond the traditional boundaries of autoimmune gastritis and raises important questions about future risk stratification and surveillance.
#autoimmunegastritis -
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
Ferroptosis-Immune Crosstalk in MASLD @Gut_BMJ
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal
@Gut_BMJ
What is the optimal surgical approach for adenocarcinoma of the oesophagogastric junction?
Zheng et al. present “Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study” via gut.bmj.com/content/75/9/1726
Drawing on the large prospective CLAEG registry across 44 high-volume centres and more than 2,000 radical resections, this study provides valuable real-world data on lymph-node metastasis patterns and surgical outcomes. The analysis helps clarify where metastatic lymph nodes are most commonly found and examines important questions around the extent and type of surgery.
The findings provide practical evidence to inform surgical decision-making for this increasingly important and challenging cancer.
#ogcancer #gastriccancer -
Gut Journal
@Gut_BMJ
How does the liver regenerate so rapidly after ALPPS surgery?
Yan et al. present “CD177+ neutrophils drive extracellular matrix remodelling and HGF-alpha release in ALPPS-induced liver regeneration” via gut.bmj.com/content/75/9/1771
Using single-cell RNA sequencing, spatial transcriptomics, clinical cohorts and experimental models, this study identifies CD177+ neutrophils as important drivers of liver regeneration following associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
The researchers show that these neutrophils promote endothelial transmigration, extracellular matrix degradation and release of hepatocyte growth factor alpha (HGF-α), creating a regenerative environment for the liver.
The findings reveal a previously underappreciated role for neutrophils in surgical liver regeneration and could ultimately inform strategies to enhance liver regeneration in patients with limited hepatic reserve. -
Gut Journal
@Gut_BMJ
We hope you enjoy this September 2026 issue of @Gut_BMJ
From dysbiotic microbiota driving colorectal cancer in PSC-IBD to AI-assisted colonoscopy, neuromodulation for IBS, dietary biomarkers in Crohn’s disease and new mechanisms of pancreatic and liver biology, this September issue demonstrates how rapidly gastroenterology is evolving.
Several themes stand out:
🦠 The microbiome and its metabolites are emerging as active drivers of intestinal inflammation and cancer.
🤖 Artificial intelligence and advanced endoscopic techniques are continuing to reshape colorectal cancer prevention.
🧠 The brain–gut axis offers new therapeutic opportunities for disorders such as IBS.
🥤 Dietary exposures and food additives may provide measurable biological signatures of Crohn’s disease activity.
🧬 Tumour biology and epigenetic regulation are revealing new mechanisms of immune suppression and treatment resistance.
🫀 Liver regeneration is increasingly understood as a complex interaction between immune cells, stromal biology and tissue remodelling.
🧪 Immune profiling may ultimately be essential for developing a functional cure for chronic hepatitis B.
👉 Read the full September 2026 issue of Gut:
gut.bmj.com/content/75/9
🦠 #gutfrontcover | Editor’s Choice
This month’s #gutfrontcover features the Legendary Old Well in Chapel Hill, North Carolina, celebrating the Editor’s Choice study by Awoniyi et al. on the relationship between dysbiotic microbiota, bile acids and colorectal cancer in PSC-associated IBD.
Awoniyi et al. present “Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model” via gut.bmj.com/content/75/9/1711
Can changes in the gut microbiome help explain why patients with primary sclerosing cholangitis and inflammatory bowel disease are at increased risk of colorectal cancer?
This important study provides compelling evidence that dysbiotic gut microbiota can actively drive colitis-associated colorectal cancer, while also producing a distinctive bile-acid profile in a PSC-IBD model. The work strengthens the concept that the microbiome is not simply a marker of intestinal disease but can play a mechanistic role in cancer development.
By linking microbial dysbiosis, altered bile-acid metabolism and tumour development, the study highlights potentially important opportunities for understanding — and eventually modifying — colorectal cancer risk in PSC-associated IBD.
🎙️ The study is also the focus of this month’s #gutpodcast, discussing the relationship between dysbiosis, PSC-UC and colorectal neoplasia.
▶️ Listen on Apple Podcasts: podcasts.apple.com/us/podcast/dysbiosis-drives-psc-uc-ass…
▶️ Listen on Spotify: open.spotify.com/episode/08AhGAfrGtd6QFGkHSYPvr
▶️ Listen on the Gut Podcast website: gutbmj.podbean.com/e/primary-sclerosing-cholangitis-assoc…
#gutfrontcover #gutcover #gutpodcast -
Gut Journal
@Gut_BMJ
🧬🦠 What connects a Western diet, the gut microbiome and colorectal cancer?
New #gutpodcast with Dr Soeren Ocvirk discusses new research by Osswald et al. in Gut: “Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.”
The study provides experimental evidence that secondary bile acids—particularly deoxycholic acid (DCA)—produced by 7α-dehydroxylating gut bacteria can promote colorectal tumour development in the context of a Western diet.
Using a combination of a porcine CRC model, multi-omics, gnotobiotic mouse models and human colon organoids, the researchers show that specific bile-acid-producing bacteria can increase DCA production, epithelial proliferation and tumour burden.
Importantly, manipulating this pathway reduced tumour-promoting effects, pointing towards the gut microbiome–bile acid axis as a potential target for prevention.
For clinicians and scientists, this is an important step from correlation towards causality.
For everyone else: it adds another piece to the puzzle of how what we eat, our gut microbes and the chemistry they produce may interact in colorectal cancer risk.
🎧 Listen to Dr Ocvirk discuss the study:
▶️ Apple: podcasts.apple.com/us/podcast/western-diet-associated-col…
▶️ Spotify: open.spotify.com/episode/0pcOjOucAMzBi7guY6uS9E
▶️ Web: gutbmj.podbean.com/e/western-diet-associated-colorectal-c…
📄 Paper: gut.bmj.com/content/75/8/1505
#gutpodcast #colorectalcancer #crc #gutmicrobiome #bileacids #microbiome #cancerresearch #gastroenterology #guthealth -
Gut Journal reposted
Ignacio Soriano
@ISoriano_Moruno
Many thanks to all our co-authors and collaborators!@clpalles @KittySherwood @drthorn @jfertaj @OxfordOncology @OxfordMedSci
Read the paper in @Gut_BMJ:
gut.bmj.com/content/early/2026/09/11/gutjnl-2026-338390
#colorectalcancer #cancergenetics #lynchsyndrome
5/5 -
Gut Journal reposted
Ignacio Soriano
@ISoriano_Moruno
Could MSH3 and MLH3 be considered Lynch syndrome genes?
Our new study in @Gut_BMJ shows that heterozygous germline loss-of-function variants in MSH3 and MLH3 increase colorectal cancer risk ~2-fold.
A short thread on what we found 🧵👇
1/5 -
Gut Journal reposted
Jia-Feng Wu
@wjifng716447
Circulating HBV RNA and HBsAg seroconversion in patients with chronic HBV infection: a long-term follow-up study starting from childhood in Taiwan gut.bmj.com/content/75/8/1565
-
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
In the paper, we discuss about how genetic factors interact with downstream processes to transition fatty liver to MASH and liver cancer. @Gut_BMJ
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal reposted
Bruno Ramos-Molina, PhD
@Brunorm84
Happy to share our new publication, out now in @Gut_BMJ (IF=24.6)!! “#ferroptosis, immune activation and #mash-related #hcc”. Proud to have worked with @drshafikuchay and @CUBEROlab on this review. @IMIB_RMurcia @FFIS_CARM gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728
-
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
Excited to share our latest paper in @Gut_BMJ Fruits of 6-month hard work. With amazing guys @Brunorm84 @CUBEROlab
A paper in recent advances in MASH basic sciences 🙏🏼
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal reposted
Camilo J. Llamoza-Torres
@CamiloJT
Ferroptosis, immune activation and MASH-related HCC gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 Great contribution, Bruno, Mohammad, and Francisco! Congratulations!
-
Gut Journal reposted
M Shafi Kuchay
@drshafikuchay
In this paper, we hv also discussed how cardioprotective polyunsaturated fatty acids (PUFAs) in healthy individuals become hepatotoxic in the setting of MASLD.
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal reposted
Lynsey C
@lynseycorless
Delighted to share the Gastroenterology & Hepatology Research Delivery Taskforce, co-produced by membership of @NIHRrdn GI/Hep Specialty Group, @BritSocGastro Research Committee and @BASLedu Research Development Group published in @FrontGastro_BMJ fg.bmj.com/content/flgastro/early/2026/09/08/flgastro-202…
-
Gut Journal reposted
Lynsey C
@lynseycorless
We must do all we can to support, sustain and grow research participation in UK GI/Hep. The Taskforce brings our collective efforts together for maximum impact. Linked Gut Commentary on why this is so important gut.bmj.com/content/gutjnl/early/2026/09/08/gutjnl-2026-3…
-
Gut Journal reposted
Félix Pastor
Lipid peroxidation and PUFA loading in the susceptible cell are key vulnerabilities. This research gives us concrete targets for anti-aging interventions.
M Shafi Kuchay
@drshafikuchay
Excited to share our latest paper in @Gut_BMJ Fruits of 6-month hard work. With amazing guys @Brunorm84 @CUBEROlab
A paper in recent advances in MASH basic sciences 🙏🏼
gut.bmj.com/content/early/2026/09/10/gutjnl-2026-339728 -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal reposted
BibliotecaHUVH
@BibliotecaHUVH
Excessive supragastric belching can be identified in up to one-fifth of patients with conclusive gastro-oesophageal reflux disease. gut.bmj.com/content/early/2026/09/06/gutjnl-2026-339248 #hvhebron #ad
-
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal reposted
BSG
@BritSocGastro
🤩 We are delighted to share the September 2026 BSG Gut Highlights!
Read abstract summaries of the best and most interesting articles recently published in Gut in #hepatology, #pancreas, #ibd, #stomach, and gut microbiota 💡
👉 www.bsg.org.uk/web-education/bsg-gut-highlights-september…
@Gut_BMJ -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🚨 ⚠️ Last chance to sign up for this excellent webinar tomorrow ⚠️ 🚨
Our amazing panel of @EndoTx @gastro3570 @poodocnisha @manuknayar
⭐ 🤩.
This is not one to miss for any aspiring interventional endoscopists, but will also be hugely relevant for all acute med/ gastro/ hep trainees!
Sign up below ⬇️ ⬇️ ⬇️
www.bsg.org.uk/events/bsg-webinar-fgglobal-advanced-endos…
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media
#gitwitter #livertwitter #gastroenterology #endoscopy #eus #ercp #emr #meded -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal reposted
Healio Gastroenterology
@HealioGastro
📡 Serologic profiling identified differences in antibody response up to 10 years before diagnosis of #crohnsdisease, research in @Gut_BMJ showed.
👀 Notably, researchers found elevated reactivity to #herpesvirus, especially Epstein-Barr virus. vist.ly/5h3h3 -
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Proteomic landscape of pan-tissue neuroendocrine carcinomas defines subtype-specific functional architectures, biomarkers and therapeutic targets | Gut gut.bmj.com/content/early/2026/08/26/gutjnl-2026-339593
-
Gut Journal reposted
BibliotecaHUVH
@BibliotecaHUVH
From pressure to prognosis: establishing a common language for portal hypertension in advanced chronic liver disease gut.bmj.com/content/early/2026/08/25/gutjnl-2026-339845 #hvhebron #hepato
-
Gut Journal reposted
Sáfárné Hatrágyi Henrietta
@HatragyiSafarne
Childhood exposure to a sibling with Crohn's disease alters gut microbiome and Crohn's disease susceptibility
👇
gut.bmj.com/content/early/2026/08/25/gutjnl-2026-339257 -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Survey is published in @Gut_BMJ
gut.bmj.com/content/early/2026/08/16/gutjnl-2026-339666
Rome Foundation
@RomeFoundation
New Rome V data provide an updated global view of disorders of gut-brain interaction (DGBI) in adults.
Across 15 countries, 40.9% of adults met criteria for at least one #dgbi, with differences observed by age, sex, and diagnosis.
Explore the findings: theromefoundation.org/rome-foundation-releases-key-data-o… -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Survey is published in
@Gut_BMJ
gut.bmj.com/content/early/2026/08/16/gutjnl-2026-339667
Rome Foundation
@RomeFoundation
Across four countries, 28% of children ages 0–17 met criteria for at least one DGBI, with impacts extending to disability, psychosocial symptoms, healthcare use, and caregiver burden.
Explore the findings: theromefoundation.org/rome-foundation-releases-key-data-o… -
Gut Journal reposted
Eric Topol
@EricTopol
citation link gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
-
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal reposted
Aleksandar Gavric
@GavricAle
Careful examination of the resection site revealed at least DMI type 3. Target sign can be seen on the specimen.
Defect was closed and patient discharged with antibiotic therapy.
Original "Deep mural injury" article: share.google/PEkwnZJ0XSbBm3u6T
Aleksandar Gavric
@GavricAle
13-mm lesion (transversum) in a patient with Lynch syndrome, removed en bloc by hEMR using a 25-mm monofilament snare.
What do you think about the post-EMR defect? Would you close it?
@frankbalaguer @kevinjmonahan
@BilalMohammadMD @drkeithsiau @AlmomaniMD -
Gut Journal reposted
BibliotecaHUVH
@BibliotecaHUVH
Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study. gut.bmj.com/content/early/2026/08/16/gutjnl-2026-339666 #hvhebron #ad [Text complet]
-
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🌍 Exciting news from Frontline Gastroenterology! 🤝
We are delighted to announce a new affiliation between Frontline Gastroenterology (FG) and the Arab Society of Gastrointestinal Endoscopy (ARSGE).
The agreement was formally signed by Professor Abed AL-Lehaibi, President of ARSGE; Professor Eyad Gadour, Chairperson of Research and Development at ARSGE; and Dr Phil Smith, Editor-in-Chief of Frontline Gastroenterology. ✍️
This important collaboration reflects our shared commitment to advancing high-quality clinical practice, education, research and innovation across gastroenterology, hepatology and gastrointestinal endoscopy — in the Arab region and internationally. 🌐🔬📚
We look forward to closer scientific exchange and to creating new opportunities to share high-quality research, clinical education and evidence-based developments with the global GI community.
🔗 Read the full announcement:
fg.bmj.com/pages/frontline-gastroenterology-announces-aff…
#frontlinegastroenterology #gastroenterology #endoscopy #hepatology #research #medicaleducation #collaboration
@PhilSmithIsBack @Gut @BMJOpen_Gastro @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Just published online in @Gut_BMJ
Prevalence of paediatric DGBI in 4 nations according to Rome V criteria.
Multinational prevalence and burden of paediatric disorders of gut–brain interaction: results of the Rome Foundation paediatric global study gut.bmj.com/content/early/2026/08/16/gutjnl-2026-339667 -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
📢 Join the next Frontline Gastroenterology Global Webinar!
From bowel to bile ducts: All you need to know
Hear from leading experts:
👩⚕️ Dr Nisha Patel
👨⚕️ Dr Manu Nayar
👨⚕️ Prof. Pradeep Bhandari
📅 Wednesday 9 September 2026
🕖 19:00 BST
A practical update covering key advances in luminal GI, hepatobiliary and pancreatic disease, and interventional endoscopy.
#gitwitter #frontlinegastroenterology #gastroenterology #endoscopy #hepatology #meded #foamed #gi
@BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman -
Gut Journal reposted
Ying Cao
@NeuralGrndState
The core property of cancer cells is neural stemness. Resistance is always there if neural stemness is not effectively suppressed. @Gut_BMJ
'Understanding ..neural stemness as the core property of cancer cell and the basic rules ..'
www.frontiersin.org/journals/cell-and-developmental-biolo…
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal reposted
Today’s Insights IBD
@IBDinsights
An excellent topic for an Editor’s Choice paper to be highlighted on the front cover.
“Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer” by Osswald et al.
gut.bmj.com/content/75/8/1505
#bileacids
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal reposted
BSG
@BritSocGastro
We are delighted to share the August 2026 BSG Gut Highlights, highlighting the best and most interesting articles published either online or in print in Gut.
Read them here, along with a new lay version without the medical jargon 👉 www.bsg.org.uk/web-education/bsg-gut-highlights-august-2026
@Gut_BMJ -
Gut Journal reposted
Cancer Library VCC
@VCCLibrary
Impact of surveillance colonoscopy on #colorectalcancer incidence and mortality in Lynch syndrome: a national observational cohort study of patients in the English NHS 2010–2022. gut.bmj.com/content/early/2026/08/06/gutjnl-2025-337379
-
Gut Journal reposted
Pancreatic Cell News
@PancreaticCell
Dr. Volker Ellenrieder's lab identified a highly aggressive GSK3β subtype that predicts early recurrence, poor survival and cisplatin resistance in #pdac.
Read the full paper in @Gut_BMJ: gut.bmj.com/content/75/8/1520
#openaccess -
Gut Journal reposted
Hong Jae Chon
@hongjaechon
🔥 Extracellular vesicles (#evs) — tiny particles cells release into blood may predict #hcc #immunotherapy response.
New multicenter study in @Gut_BMJ (n=202)!
👉 EVs carrying PD-L1/PD-1/CTLA-4 predict who responds to immunotherapy
👉 Patients with low levels of any of these three markers have much better PFS (11-16 vs 2-3 mo)
👉 Not seen in TKI-treated patients → EV signal is ICI-specific, not just prognostic
👉 In relapsing patients, EV levels rise 36-42 weeks before imaging showed progression
🧐 A liquid biopsy that could guide both patient selection and early resistance detection.
@ILCAnews @myESMO @EASLnews
Full text: doi.org/10.1136/gutjnl-2025-337617
#liverx #livercancer #liquidbiopsy #extracellularvesicles -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC | Gut gut.bmj.com/content/early/2026/08/06/gutjnl-2025-337617
-
Gut Journal reposted
Alexander Ford
@alex_ford12399
Just published online in @Gut_BMJ, prevalence of all DGBI globally using Rome V criteria.
Rome V global epidemiology and validation survey: prevalence of disorders of gut–brain interaction and comparison with the Rome IV global epidemiology study gut.bmj.com/content/early/2026/08/16/gutjnl-2026-339666 -
Gut Journal reposted
Alexander Ford
@alex_ford12399
First ever assessment of prevalence of DGBI in children in multiple countries simultaneously. Almost 30% meet criteria for DGBI in this landmark study.
-
Gut Journal reposted
Extracellular Matrix News
@ExtracellMatrix
New findings from @FudanUniversity reveal a neutrophil-mediated mechanism driving surgical liver regeneration and support the potential of CD177+ neutrophil infusion to establish a proregenerative environment for #liverfailure therapeutic strategies.
⚗️ gut.bmj.com/content/75/9/1771.long -
Gut Journal reposted
Dr. Santiago Blanco Rey, MD, MSc
@SantiBlancoRey
📊 Roma V confirma que los trastornos de interacción intestino-cerebro son una carga global: 40,9% de 28.771 adultos en 15 países cumplió criterios para ≥1 (vs. 40,5% con Roma IV). ¿Estamos diagnosticando lo suficiente o sobrediagnosticando? doi.org/10.1136/gutjnl-2026-339666
-
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
📢 #gutcommentary
How does normal stomach lining become cancerous? In this insightful #gutcommentary, Togasaki and Sato explore the evolving understanding of intestinal metaplasia—a precancerous change in which the stomach lining begins to resemble the intestine.
"Decoding intestinal metaplasia: a step towards understanding gastric tumourigenesis" via gut.bmj.com/content/75/8/1457
The authors discuss how recent advances in lineage tracing, stem cell biology and molecular profiling are shedding new light on the cellular origins of intestinal metaplasia and its progression towards gastric cancer. Rather than viewing intestinal metaplasia as a single entity, emerging evidence suggests it represents a dynamic and heterogeneous process with distinct biological pathways and varying cancer risk.
As our understanding of these early changes improves, there is growing potential to develop more accurate risk stratification, earlier detection and targeted strategies to prevent gastric cancer before it develops.
👉 Read the commentary here: gut.bmj.com/content/75/8/1457
#gastriccancer #intestinalmetaplasia #cancerprevention #precisionmedicine #pathology -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal
@Gut_BMJ
Diffuse gastric cancer remains one of the most aggressive forms of stomach cancer.
Decourtye-Espiard et al. present "E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model" via
gut.bmj.com/content/75/8/1466
Using an elegant experimental model, the authors demonstrate that loss of E-cadherin specifically within Cd44-positive gastric stem-like cells is sufficient to initiate diffuse gastric cancer. The study provides valuable insight into the earliest cellular events underlying tumour development and strengthens our understanding of how inherited or acquired alterations in E-cadherin drive gastric carcinogenesis. These findings may ultimately inform earlier detection and prevention strategies for individuals at increased genetic risk.
#gastriccancer -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
📝 New #gutblog now available!
Our latest #gutblog explores the paper "Low-frequency repetitive transcranial magnetic stimulation attenuates visceral pain in IBS with diarrhoea via inhibition of the medial prefrontal cortex" by Weng et al.
Visceral hypersensitivity is a hallmark of IBS with diarrhoea (IBS-D), yet effective non-pharmacological treatments remain limited. In this study, Weng et al. demonstrate that low-frequency repetitive transcranial magnetic stimulation (rTMS) reduced visceral pain by suppressing activity within the medial prefrontal cortex, a key brain region involved in pain processing. Their findings reveal an important brain-gut mechanism underlying IBS-D and suggest that low-frequency rTMS could represent a promising non-invasive therapeutic strategy for managing chronic visceral pain.
📖 Read the #gutblog:
blogs.bmj.com/gut/2026/08/05/gutblog-low-frequency-repeti…
📄 Read the paper:
gut.bmj.com/content/early/2026/02/02/gutjnl-2025-337612
#gutblog #ibs #ibsd #visceralpain #braingutaxis #neuromodulation -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
📢 #gutcommentary
How does normal stomach lining become cancerous? In this insightful #gutcommentary, Togasaki and Sato explore the evolving understanding of intestinal metaplasia—a precancerous change in which the stomach lining begins to resemble the intestine.
"Decoding intestinal metaplasia: a step towards understanding gastric tumourigenesis" via gut.bmj.com/content/75/8/1457
The authors discuss how recent advances in lineage tracing, stem cell biology and molecular profiling are shedding new light on the cellular origins of intestinal metaplasia and its progression towards gastric cancer. Rather than viewing intestinal metaplasia as a single entity, emerging evidence suggests it represents a dynamic and heterogeneous process with distinct biological pathways and varying cancer risk.
As our understanding of these early changes improves, there is growing potential to develop more accurate risk stratification, earlier detection and targeted strategies to prevent gastric cancer before it develops.
👉 Read the commentary here: gut.bmj.com/content/75/8/1457
#gastriccancer #intestinalmetaplasia #cancerprevention #precisionmedicine #pathology -
Gut Journal
@Gut_BMJ
Diffuse gastric cancer remains one of the most aggressive forms of stomach cancer.
Decourtye-Espiard et al. present "E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model" via
gut.bmj.com/content/75/8/1466
Using an elegant experimental model, the authors demonstrate that loss of E-cadherin specifically within Cd44-positive gastric stem-like cells is sufficient to initiate diffuse gastric cancer. The study provides valuable insight into the earliest cellular events underlying tumour development and strengthens our understanding of how inherited or acquired alterations in E-cadherin drive gastric carcinogenesis. These findings may ultimately inform earlier detection and prevention strategies for individuals at increased genetic risk.
#gastriccancer -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal reposted
Icahn School of Medicine at Mount Sinai
@IcahnMountSinai
Researchers at Mount Sinai have identified immune system changes that can be detected up to 10 years before inflammatory bowel disease (IBD) develops, offering new insight into how the disease begins.
Published in @Gut_BMJ, the study is one of the most comprehensive investigations to date of the preclinical phase of IBD. Using antibody profiling technology, researchers analyzed nearly 2,000 blood samples collected over about a decade from people who later developed Crohn's disease or ulcerative colitis.
They identified unique antibody signatures against viruses and bacteria — particularly Epstein-Barr virus and bacterial flagellins — that were present years before diagnosis, suggesting that abnormal immune activity begins long before the disease becomes clinically apparent.
The findings could eventually help identify people at increased risk for IBD, particularly relatives of patients with the disease, and guide future prevention strategies.
Read more: mshs.co/4hPVfrk
@DOMSinaiNYC @MountSinaiGI @JeanFredericCo1
#ibd #crohnsdisease #ulcerativecolitis #research -
Gut Journal reposted
Kevin Monahan
@kevinjmonahan
In our new paper @Gut_BMJ we show (perhaps counter-intuitively...) that more frequent colonoscopy in #lynchsyndrome does not reduce CRC incidence... however does reduce overall mortality - congrats Cassie Huntley and co-authors gut.bmj.com/content/early/2026/08/06/gutjnl-2025-337379
-
Gut Journal reposted
João Gorgulho
@gorgulho_joao
🚨 New in @Gut_BMJ
Our multicentre prospective study shows that circulating EV-derived PD-1, PD-L1 & CTLA-4 predict response to ICI therapy and identify both primary and acquired resistance in advanced #hcc.
@JohannvonFelden
gut.bmj.com/content/early/2026/08/06/gutjnl-2025-337617
#liquidbiopsy #immunotherapy -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Just published in @Gut_BMJ
Faecal proteases and immune signatures drive subtype-specific enteric neuronal activation in IBS gut.bmj.com/content/early/2026/08/03/gutjnl-2025-337949 by Ridzal et al revealing fundamentally different pathological mechanisms between IBS-D and IBS-C. -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Recently published in @Gut_BMJ
By Snijkers et al.
In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial gut.bmj.com/content/early/2026/07/23/gutjnl-2026-338385 -
Gut Journal reposted
Alexander Ford
@alex_ford12399
In-person therapist-delivered hypnotherapy best, but good response rates for smartphone-based self-guided hypnotherapy highlighting its potential as a broadly applicable and cost-effective treatment in #ibs
-
Gut Journal reposted
Alexander Ford
@alex_ford12399
Just published in @Gut_BMJ by Huntley et al.
Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome: a national observational cohort study of patients in the English NHS 2010–2022 gut.bmj.com/content/early/2026/08/06/gutjnl-2025-337379 -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Elegant study showing reduced all-cause mortality among regularly surveilled Lynch syndrome pts, which may indicate an impact of surveillance on CRC-specific mortality.
-
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal reposted
Yuri Gorelik
@GorelikYuri
Very cool concept not just for trials but for medical practice in general
Imagine a huge database of all medical events in all people
Each medical encounter will dynamically be matched to previously seen events in similar patients to optimize management
gut.bmj.com/content/75/8/1607.full -
Gut Journal
@Gut_BMJ
Our latest #guteditorschoice paper, "DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson's disease" by Jeong et al., is now available as a #gutpodcast.
Using a gut-brain axis model of Parkinson's disease, Jeong et al. found that the DPP-4 inhibitor sitagliptin reduced gut inflammation, suppressed TLR2-mediated inflammatory signalling, limited the spread of pathological α-synuclein from the gut to the brain via the vagus nerve, protected neurons and improved motor function. Sitagliptin also altered the gut microbiome towards a profile that may help counter Parkinson's disease pathology, supporting DPP-4 inhibitors as a potential therapeutic strategy.
📖 Read the paper:
gut.bmj.com/content/75/7/1307
🎧 Listen:
Apple: podcasts.apple.com/us/podcast/dpp-4-inhibitors-and-parkin…
Spotify: open.spotify.com/episode/3i4p5QQDmtzvw7ISIFc1xB
Web: gutbmj.podbean.com/e/dpp-4-inhibitors-and-parkinson-s-dis…
#guteditorschoice #gutpodcast #parkinsonsdisease #gutbrainaxis #microbiome -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Clonal evolution driving timing and sites of postsurgical recurrences in hepatocellular carcinoma | Gut gut.bmj.com/content/early/2026/07/30/gutjnl-2026-339683
-
Gut Journal reposted
National Cancer Centre Singapore
@NCCS_SG
🎉 Congratulations to Prof Pierce Chow, Prof Tam Wai Leong and Mr Karthik Sekar on their latest study published in @Gut_BMJ , which uncovers new molecular pathways driving disease recurrence and introduces a new tool to predict it ✨
Read the full press release: www.nccs.com.sg/news/patient-care/singapore-team-develops…
#nccsresearch #cancerresearch #precisiononcology #livercancer #hepatocellularcarcinoma -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
Congratulations to Dr Penelope Edwards (St Mark's Hospital, London) on winning the BMJ Gut Best Laboratory Science Abstract award.
📸 Pictured at the recent British Society of Gastroenterology Annual Meeting in Liverpool with Gut Editors-in-Chief (left to right): Professor William Grady, Professor Thomas Rösch and Professor Matias A. Avila.
🏆 Award-winning abstract: Evidence of Systemic Immune Activation in Peripheral Blood in Patients with Lynch Syndrome.
This research provides new insights into the immune response associated with Lynch syndrome, the most common inherited cause of colorectal cancer. By identifying evidence of systemic immune activation in patients' peripheral blood, the study advances our understanding of how the immune system responds in individuals with Lynch syndrome. These findings could contribute to the development of improved biomarkers for cancer risk assessment, surveillance and, ultimately, strategies for earlier detection and prevention.
Read the abstract here: gut.bmj.com/content/75/Suppl_1/A13.2
Congratulations to Dr Edwards and the research team on this well-deserved recognition for outstanding laboratory science with the potential to improve the understanding and management of Lynch syndrome.
#bsglive2026 #gutjournal #lynchsyndrome #colorectalcancer #cancerresearch #laboratoryscience #gastroenterology @BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
Hashem el- Serag
@SeragHashem
Several outcome scoring systems are promising for specific LRTs and populations. However, most models have high risk of bias, underscoring the need for further development and validation. gut.bmj.com/content/early/2026/07/08/gutjnl-2025-337557
-
Gut Journal
@Gut_BMJ
📢 #gutcommentary
How does normal stomach lining become cancerous? In this insightful #gutcommentary, Togasaki and Sato explore the evolving understanding of intestinal metaplasia—a precancerous change in which the stomach lining begins to resemble the intestine.
"Decoding intestinal metaplasia: a step towards understanding gastric tumourigenesis" via gut.bmj.com/content/75/8/1457
The authors discuss how recent advances in lineage tracing, stem cell biology and molecular profiling are shedding new light on the cellular origins of intestinal metaplasia and its progression towards gastric cancer. Rather than viewing intestinal metaplasia as a single entity, emerging evidence suggests it represents a dynamic and heterogeneous process with distinct biological pathways and varying cancer risk.
As our understanding of these early changes improves, there is growing potential to develop more accurate risk stratification, earlier detection and targeted strategies to prevent gastric cancer before it develops.
👉 Read the commentary here: gut.bmj.com/content/75/8/1457
#gastriccancer #intestinalmetaplasia #cancerprevention #precisionmedicine #pathology -
Gut Journal
@Gut_BMJ
Diffuse gastric cancer remains one of the most aggressive forms of stomach cancer.
Decourtye-Espiard et al. present "E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model" via
gut.bmj.com/content/75/8/1466
Using an elegant experimental model, the authors demonstrate that loss of E-cadherin specifically within Cd44-positive gastric stem-like cells is sufficient to initiate diffuse gastric cancer. The study provides valuable insight into the earliest cellular events underlying tumour development and strengthens our understanding of how inherited or acquired alterations in E-cadherin drive gastric carcinogenesis. These findings may ultimately inform earlier detection and prevention strategies for individuals at increased genetic risk.
#gastriccancer -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal reposted
Syed A. Ahmad
@SyedAAhmad5
Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer @gut_bmj gut.bmj.com/content/75/8/1505
-
Gut Journal reposted
Syed A. Ahmad
@SyedAAhmad5
GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair @gut_bmj gut.bmj.com/content/75/8/1520
-
Gut Journal reposted
Syed A. Ahmad
@SyedAAhmad5
Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients @gut_bmj gutscience.bmj.com/content/1/1/e000023
-
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal reposted
BSG
@BritSocGastro
Congratulations to the 2026 BMJ Gut Best Laboratory Science Abstract winner Dr Penelope Edwards, St Mark's Hospital! 👏
Read Penelope's winning abstract submission in @Gut_BMJ on 'Evidence of Systemic Immune Activation in Peripheral Blood in Patients with Lynch Syndrome' -
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal reposted
Dr Nitin Jagtap
@miNitinjagtap
Gut RCT: therapist-guided GDH achieved a 48% response rate compared with 33% for an app in IBS pain. Non-inferiority was not demonstrated, but this does not mean clear inferiority: 230/285 planned participants were randomised, with a confidence interval of −29.3% to +0.9%.
Overall, results suggest therapists may still have an advantage where available, while highlighting the need to improve engagement and uptake of app-based care. gut.bmj.com/content/early/2026/07/23/gutjnl-2026-338385 #ibs #pain #gitwitter @Gut_BMJ @AniruddhaGI @krithivk @doc_zubin @NGMJournal #digitaltherapy @AnandVKulkarni2 @AIGHospitals -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal reposted
GI Nutrition Foundation
@GI_NutritionFdn
The new @BritSocGastro guidelines on #celiacdisease diagnosis and management in adults are now out
✅ Who to test for celiac
✅ Adult diagnostic pathway (patients should consume a gluten-containing diet prior to testing for celiac disease!)
✅ Long-term follow-up
✅ Celiac disease mimickers:
🔸Infections (e.g., Helicobacter pylori, giardiasis)
🔸Drugs (non-steroidal anti-inflammatory drugs, proton pump inhibitors)
🔸Others (e.g., Crohn's disease, autoimmune disease)
✅ The ins and outs of a gluten-free diet
💡Disease advocacy groups and registered dietitians are key for reliable information about celiac disease and the gluten-free diet
✅ Management of refractory symptoms
✅ Food portions that contain 3 g of gluten that can be used for a gluten challenge
📚Read the guidelines here in @Gut_BMJ:
gut.bmj.com/content/early/2026/07/09/gutjnl-2025-337747 -
Gut Journal reposted
-
Gut Journal reposted
Muddasir Ayaz, MD
@TheGastrologer
Excited to see where this goes
Constipation/diarrhea very difficult to treat in this patient population and if the DPP4 class can alleviate would be a wonderful option for a historically undertreated group
Gut Journal
@Gut_BMJ
#guteditorschoice - Jeong et al. present “DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease” via gut.bmj.com/content/75/7/1307
This important translational study provides compelling evidence that DPP-4 inhibition can modify gut–brain axis pathology in Parkinson’s disease. Using experimental models, the authors demonstrate reductions in intestinal inflammation, α-synuclein accumulation and neurodegeneration, accompanied by favourable alterations in the gut microbiome. The findings support growing interest in the gastrointestinal origins of Parkinson’s disease and suggest that drug repurposing strategies may offer novel disease-modifying approaches.
#parkinsonsdisease #gutbrainaxis -
Gut Journal reposted
Pancreatic Cell News
@PancreaticCell
Researchers revealed that LY6D marks a persistent gastric-like cell state that drives #pancreaticcancer initiation and metastasis. @Gut_BMJ
gut.bmj.com/content/75/8/1534 -
Gut Journal reposted
Weiwei Zhai
@weiwei_beijing
Super excited to publish this piece on HCC metastasis in GUT @Gut_BMJ with Ying ZHANG, Wai Leong TAM and Pierce CHOW gut.bmj.com/content/early/2026/07/21/gutjnl-2026-338227
-
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study | Gut gut.bmj.com/content/early/2026/07/24/gutjnl-2025-335863
-
Gut Journal reposted
Alexander Ford
@alex_ford12399
Important and much anticipated RCT of therapist-delivered vs. smartphone-delivered gut-directed hypnotherapy in #ibs from @IBS_Maastricht now published online in @Gut_BMJ
gut.bmj.com/content/early/2026/07/23/gutjnl-2026-338385 -
Gut Journal reposted
Oliver Tavabie
@OTavabie
Pleased to share our @LindAlliance psp in cirrhosis published in @Gut_BMJ today! Led by @drgautammehta, document highlights what patients, carers, HCPs and researchers would like prioritized over the next 10yrs!
@BASLedu @BritSocGastro @LiverUK_charity
gut.bmj.com/content/gutjnl/early/2026/06/25/gutjnl-2026-3… -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
"Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice" via gutscience.bmj.com/content/1/1/e000021
Read the NEW #gutscience paper by Abot et al online and open access now!
@druppygill #type2diabetes -
Gut Journal
@Gut_BMJ
Congratulations to Dr Penelope Edwards (St Mark's Hospital, London) on winning the BMJ Gut Best Laboratory Science Abstract award.
📸 Pictured at the recent British Society of Gastroenterology Annual Meeting in Liverpool with Gut Editors-in-Chief (left to right): Professor William Grady, Professor Thomas Rösch and Professor Matias A. Avila.
🏆 Award-winning abstract: Evidence of Systemic Immune Activation in Peripheral Blood in Patients with Lynch Syndrome.
This research provides new insights into the immune response associated with Lynch syndrome, the most common inherited cause of colorectal cancer. By identifying evidence of systemic immune activation in patients' peripheral blood, the study advances our understanding of how the immune system responds in individuals with Lynch syndrome. These findings could contribute to the development of improved biomarkers for cancer risk assessment, surveillance and, ultimately, strategies for earlier detection and prevention.
Read the abstract here: gut.bmj.com/content/75/Suppl_1/A13.2
Congratulations to Dr Edwards and the research team on this well-deserved recognition for outstanding laboratory science with the potential to improve the understanding and management of Lynch syndrome.
#bsglive2026 #gutjournal #lynchsyndrome #colorectalcancer #cancerresearch #laboratoryscience #gastroenterology @BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
📢 #gutcommentary
How does normal stomach lining become cancerous? In this insightful #gutcommentary, Togasaki and Sato explore the evolving understanding of intestinal metaplasia—a precancerous change in which the stomach lining begins to resemble the intestine.
"Decoding intestinal metaplasia: a step towards understanding gastric tumourigenesis" via gut.bmj.com/content/75/8/1457
The authors discuss how recent advances in lineage tracing, stem cell biology and molecular profiling are shedding new light on the cellular origins of intestinal metaplasia and its progression towards gastric cancer. Rather than viewing intestinal metaplasia as a single entity, emerging evidence suggests it represents a dynamic and heterogeneous process with distinct biological pathways and varying cancer risk.
As our understanding of these early changes improves, there is growing potential to develop more accurate risk stratification, earlier detection and targeted strategies to prevent gastric cancer before it develops.
👉 Read the commentary here: gut.bmj.com/content/75/8/1457
#gastriccancer #intestinalmetaplasia #cancerprevention #precisionmedicine #pathology -
Gut Journal
@Gut_BMJ
New #gutscience paper by Halle-Smith et al entitled
"Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients" via
gutscience.bmj.com/content/1/1/e000023
#oa #pancreaticcancer @druppygill -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal
@Gut_BMJ
Diffuse gastric cancer remains one of the most aggressive forms of stomach cancer.
Decourtye-Espiard et al. present "E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model" via
gut.bmj.com/content/75/8/1466
Using an elegant experimental model, the authors demonstrate that loss of E-cadherin specifically within Cd44-positive gastric stem-like cells is sufficient to initiate diffuse gastric cancer. The study provides valuable insight into the earliest cellular events underlying tumour development and strengthens our understanding of how inherited or acquired alterations in E-cadherin drive gastric carcinogenesis. These findings may ultimately inform earlier detection and prevention strategies for individuals at increased genetic risk.
#gastriccancer -
Gut Journal
@Gut_BMJ
Excellent #gutrecentadvancesinbasicscience paper by Zhou et al. entitled present “AI-empowered human microbiome research” accessed via
gut.bmj.com/content/75/7/1432
Artificial intelligence is increasingly transforming microbiome science. This review explores how machine learning and AI approaches are accelerating microbial discovery, improving predictive modelling and uncovering complex host–microbe interactions. The article highlights how computational approaches may help translate microbiome research into clinical practice.
#ai #microbiome -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
#gutrecentadvancesinclinicalpractice paper by Deshpande et al. presents “Basal crypt dysplasia in Barrett’s oesophagus: ready for prime time?” via
gut.bmj.com/content/75/7/1425
Diagnostic pathology continues to evolve in Barrett’s oesophagus. This clinical review evaluates the evidence supporting basal crypt dysplasia as an important precursor lesion and discusses its potential role in risk stratification and surveillance strategies.
#barrettsoesophagus #dysplasia -
Gut Journal
@Gut_BMJ
Chen et al. present “Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics” via
gut.bmj.com/content/75/7/1367
Cancer-associated fibroblasts are often viewed as promoters of tumour progression, yet this elegant single-cell multiomics study reveals a fibroblast subset associated with improved outcomes in pancreatic cancer. The identification of complement-secreting CAFs highlights the complexity of the tumour microenvironment and may refine future stromal-targeted therapeutic approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
Wang et al. present “Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer” via
gut.bmj.com/content/75/7
Can liquid biomarkers predict immunotherapy response? This highly innovative study combines urinary proteomics with single-cell and spatial transcriptomics to characterise the tumour microenvironment in biliary tract cancer. The approach offers exciting possibilities for non-invasive biomarker development and precision oncology.
#biomarkers #proteomics -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
#guteditorschoice - Jeong et al. present “DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease” via gut.bmj.com/content/75/7/1307
This important translational study provides compelling evidence that DPP-4 inhibition can modify gut–brain axis pathology in Parkinson’s disease. Using experimental models, the authors demonstrate reductions in intestinal inflammation, α-synuclein accumulation and neurodegeneration, accompanied by favourable alterations in the gut microbiome. The findings support growing interest in the gastrointestinal origins of Parkinson’s disease and suggest that drug repurposing strategies may offer novel disease-modifying approaches.
#parkinsonsdisease #gutbrainaxis -
Gut Journal
@Gut_BMJ
Read the paper by Zhou et al. present “Streptococcus anginosus-derived methionine promotes gastric cancer progression” via
gut.bmj.com/content/75/7/1279
The microbiome continues to emerge as an important driver of cancer biology. This study identifies a mechanistic link between Streptococcus anginosus and gastric cancer progression through microbial methionine metabolism. The findings further strengthen evidence that tumour-associated microbes can influence metabolic pathways within the tumour microenvironment and may provide future therapeutic targets.
#microbiome #gastriccancer -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Read the paper by Lee et al. on “Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health”
gut.bmj.com/content/75/7/1338
Microbial metabolism continues to reveal unexpected therapeutic opportunities. The authors identify a previously unrecognised fermentation pathway in Dysosmobacter welbionis, a bacterium associated with favourable metabolic and liver health. By linking myo-inositol metabolism to butyrate production, the study advances our understanding of beneficial microbial functions and potential microbiome-based interventions.
#microbiome -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
Read the #gutendoscopynews by Wu et al. on “Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures” via
gut.bmj.com/content/75/7/1276
Can advanced endoscopy reduce the burden of repeated dilatations for long benign oesophageal strictures?
Wu et al. describe an innovative endoscopic approach using mucosal and submucosal cutting techniques to treat difficult long-segment strictures. By directly targeting fibrotic tissue, this strategy may provide more durable symptom relief and reduce the need for repeated interventions.
This paper highlights how increasingly sophisticated endoscopic techniques are expanding treatment options for complex benign oesophageal disease and may offer selected patients an alternative to more invasive surgical approaches.
#strictures #oesophageal #endoscopy -
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal
@Gut_BMJ
Read the paper by Hou et al. on “Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites” via
gut.bmj.com/content/75/7/1322
Chemotherapy toxicity remains a major challenge in oncology. This study demonstrates how Bacteroides intestinalis influences irinotecan toxicity through microbial tryptophan metabolites, highlighting the growing importance of host–microbiome interactions in determining treatment response. These findings may eventually support personalised strategies to reduce treatment-related toxicity.
#microbiome -
Gut Journal
@Gut_BMJ
Why do some patients develop chronic symptoms following gastrointestinal infection?
Marasco et al. present “Post-infection disorders of gut-brain interaction: results of the Rome Foundation Global Epidemiology Study” via
gut.bmj.com/content/75/7/1297
This major international epidemiological study examines the global burden of post-infectious disorders of gut–brain interaction, providing important insights into geographical variation, risk factors and disease prevalence. The findings improve our understanding of functional gastrointestinal disorders and may help identify populations at increased risk.
#gutbrainaxis #postinfection -
Gut Journal reposted
Sáfárné Hatrágyi Henrietta
@HatragyiSafarne
Akkermansia muciniphila enhances washed microbiota transplantation in the treatment of epilepsy
👇
gut.bmj.com/content/75/Suppl_2/A483 -
Gut Journal
@Gut_BMJ
📢 #gutcommentary
How does normal stomach lining become cancerous? In this insightful #gutcommentary, Togasaki and Sato explore the evolving understanding of intestinal metaplasia—a precancerous change in which the stomach lining begins to resemble the intestine.
"Decoding intestinal metaplasia: a step towards understanding gastric tumourigenesis" via gut.bmj.com/content/75/8/1457
The authors discuss how recent advances in lineage tracing, stem cell biology and molecular profiling are shedding new light on the cellular origins of intestinal metaplasia and its progression towards gastric cancer. Rather than viewing intestinal metaplasia as a single entity, emerging evidence suggests it represents a dynamic and heterogeneous process with distinct biological pathways and varying cancer risk.
As our understanding of these early changes improves, there is growing potential to develop more accurate risk stratification, earlier detection and targeted strategies to prevent gastric cancer before it develops.
👉 Read the commentary here: gut.bmj.com/content/75/8/1457
#gastriccancer #intestinalmetaplasia #cancerprevention #precisionmedicine #pathology -
Gut Journal reposted
BMJ Open Gastro
@BMJOpen_Gastro
Congratulations to Dr Amar Srinivasa, winner of the BMJ Open Gastroenterology Best Clinical Science Abstract award at #bsglive2026. 🏆 Pictured with Editor-in-Chief Dr Christian Selinger. Read the abstract: gut.bmj.com/content/75/Suppl_1/A1 @Gut_BMJ @FrontGastro_BMJ @ChristianSelin3 #bmjog
-
Gut Journal
@Gut_BMJ
We hope you enjoy this July 2026 issue of Gut, which showcases important advances spanning the gut–brain axis, microbiome science, gastrointestinal oncology, hepatology, immunometabolism and artificial intelligence. Across multiple disciplines, this month’s issue highlights how systems biology, single-cell technologies, microbial metabolism and AI-driven approaches are increasingly transforming our understanding of disease mechanisms and therapeutic opportunities.
The #gutfrontcover shows the magnificent Gyeongbukgung Palace, Seoul, Republic of Korea. Read in this issue the exciting work by Jeong et al reporting how Sitagliptin, a DPP-4 inhibitor, alleviates gut-brain axis pathology in a pre-clinical model of Parkinson's disease via gut.bmj.com/content/75/7?current-issue=y. The study highlights the growing importance of intestinal inflammation, microbial interactions and neuroimmune signalling in neurodegenerative disease and raises the exciting possibility of repurposing established metabolic therapies for neurological disorders. Read the #guteditorschoice here: gut.bmj.com/content/75/7/1307
#parkinsonsdisease #sitagliptin #microbiome #hepatology #ai -
Gut Journal
@Gut_BMJ
"Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice" via gutscience.bmj.com/content/1/1/e000021
Read the NEW #gutscience paper by Abot et al online and open access now!
@druppygill #type2diabetes -
Gut Journal
@Gut_BMJ
Diffuse gastric cancer remains one of the most aggressive forms of stomach cancer.
Decourtye-Espiard et al. present "E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model" via
gut.bmj.com/content/75/8/1466
Using an elegant experimental model, the authors demonstrate that loss of E-cadherin specifically within Cd44-positive gastric stem-like cells is sufficient to initiate diffuse gastric cancer. The study provides valuable insight into the earliest cellular events underlying tumour development and strengthens our understanding of how inherited or acquired alterations in E-cadherin drive gastric carcinogenesis. These findings may ultimately inform earlier detection and prevention strategies for individuals at increased genetic risk.
#gastriccancer -
Gut Journal
@Gut_BMJ
How liver cells regulate inflammatory injury remains an area of intense investigation.
Chen et al. present "A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis" via
gut.bmj.com/content/75/8/1573
This elegant mechanistic study identifies A20 as a key regulator of ferroptosis through modification of KEAP1, limiting liver injury in autoimmune hepatitis. The findings complement this issue's accompanying commentary and highlight ferroptosis as an increasingly important therapeutic target in immune-mediated liver disease.
#autoimmunehepatitis -
Gut Journal
@Gut_BMJ
Excellent #gutrecentadvancesinbasicscience paper by Zhou et al. entitled present “AI-empowered human microbiome research” accessed via
gut.bmj.com/content/75/7/1432
Artificial intelligence is increasingly transforming microbiome science. This review explores how machine learning and AI approaches are accelerating microbial discovery, improving predictive modelling and uncovering complex host–microbe interactions. The article highlights how computational approaches may help translate microbiome research into clinical practice.
#ai #microbiome -
Gut Journal reposted
Keith Siau
@drkeithsiau
Here are the original figures from the coeliac guideline - let me know if you prefer these!
5️⃣ Diagnostic algorithm
6️⃣ Coeliac mimics
7️⃣ Portions needed before coeliac testing
8️⃣ Management of refractory symptoms
gut.bmj.com/content/early/2026/07/09/gutjnl-2025-337747 -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Bueloni et al. entitled "Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications" via
gut.bmj.com/content/75/8/1620
Epigenetic therapies are rapidly moving from laboratory research towards clinical practice. This comprehensive review discusses how targeting reversible epigenetic changes may improve treatment for hepatocellular carcinoma. By summarising recent advances and emerging clinical applications, the authors highlight a promising new generation of therapies that could complement existing systemic treatments.
#hcc #epigenetics -
Gut Journal
@Gut_BMJ
Cancer stem cells are thought to fuel tumour growth and recurrence.
Shi et al. present "LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis" via
gut.bmj.com/content/75/8/1534
The authors identify LY6D as a marker of persistent stem-like cells that sustain pancreatic tumour development. By improving understanding of the cellular populations responsible for tumour maintenance, this study highlights a promising therapeutic target that could help overcome one of the major challenges in pancreatic cancer treatment.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
#gutrecentadvancesinclinicalpractice paper by Deshpande et al. presents “Basal crypt dysplasia in Barrett’s oesophagus: ready for prime time?” via
gut.bmj.com/content/75/7/1425
Diagnostic pathology continues to evolve in Barrett’s oesophagus. This clinical review evaluates the evidence supporting basal crypt dysplasia as an important precursor lesion and discusses its potential role in risk stratification and surveillance strategies.
#barrettsoesophagus #dysplasia -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
Congratulations to Professor Peter Irving (Guy's and St Thomas' NHS Foundation Trust) on winning the "BMJ Frontline Gastroenterology Best Patient Benefit in Gastroenterology Abstract award"
📸 Pictured at the recent British Society of Gastroenterology @BritSocGastro Annual Meeting in Liverpool, Professor Peter Irving receives the award from Dr Philip Smith, Editor-in-Chief of Frontline Gastroenterology.
🏆 Award-winning abstract: Randomised controlled trial of withdrawal of thiopurines when switching from intravenous to subcutaneous infliximab: Results of the MINIMISE study.
The MINIMISE study addressed an important question in inflammatory bowel disease (IBD) care: can patients safely stop thiopurines when switching from intravenous to subcutaneous infliximab?
In this multicentre randomised controlled trial, patients in stable remission who discontinued thiopurines after switching to subcutaneous infliximab had outcomes that were non-inferior to those who continued combination therapy. There was no increase in clinically significant anti-drug antibodies or disease activity over 24 weeks, supporting the possibility of simplifying treatment while avoiding the long-term risks associated with thiopurines. These findings have the potential to reduce medication burden and improve the long-term safety of care for many people living with IBD. Abstract available via gut.bmj.com/content/75/Suppl_1/A39.2
Congratulations to Professor Irving and the entire MINIMISE study team on this well-deserved recognition for research with the potential to improve patient care.
#bsglive2026 #gastroenterology #ibd #research #patientbenefit #inflammatoryboweldisease #clinicalresearch @Gut_BMJ @BMJOpen_Gastro @PhilSmithIsBack -
Gut Journal
@Gut_BMJ
Congratulations to Dr Penelope Edwards (St Mark's Hospital, London) on winning the BMJ Gut Best Laboratory Science Abstract award.
📸 Pictured at the recent British Society of Gastroenterology Annual Meeting in Liverpool with Gut Editors-in-Chief (left to right): Professor William Grady, Professor Thomas Rösch and Professor Matias A. Avila.
🏆 Award-winning abstract: Evidence of Systemic Immune Activation in Peripheral Blood in Patients with Lynch Syndrome.
This research provides new insights into the immune response associated with Lynch syndrome, the most common inherited cause of colorectal cancer. By identifying evidence of systemic immune activation in patients' peripheral blood, the study advances our understanding of how the immune system responds in individuals with Lynch syndrome. These findings could contribute to the development of improved biomarkers for cancer risk assessment, surveillance and, ultimately, strategies for earlier detection and prevention.
Read the abstract here: gut.bmj.com/content/75/Suppl_1/A13.2
Congratulations to Dr Edwards and the research team on this well-deserved recognition for outstanding laboratory science with the potential to improve the understanding and management of Lynch syndrome.
#bsglive2026 #gutjournal #lynchsyndrome #colorectalcancer #cancerresearch #laboratoryscience #gastroenterology @BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
InSiGHT
@insightmeeting
🧬 CTNNA1 & hereditary diffuse gastric cancer
A new study of 351 carrier families and >37,000 controls expands our understanding of CTNNA1-associated disease and helps inform variant interpretation, counselling, and surveillance.
📖 Read: gut.bmj.com/content/75/5/872
#hdgc #genetics -
Gut Journal
@Gut_BMJ
Can the bacteria living in our gut influence how diet drives cancer?
Read the #guteditorschoice by Osswald et al. on "Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer" via
gut.bmj.com/content/75/8/1505
This outstanding study demonstrates that gut microbes convert dietary components into secondary bile acids that actively promote colorectal cancer in the setting of a Western diet. By identifying a direct mechanistic link between microbial metabolism and tumour development, the authors provide important evidence that the microbiome is not simply associated with cancer but can actively contribute to disease progression. The findings open exciting opportunities to develop dietary, microbial and metabolic interventions aimed at reducing colorectal cancer risk.
#microbiome #westerndiet #colorectalcancer -
Gut Journal
@Gut_BMJ
Chen et al. present “Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics” via
gut.bmj.com/content/75/7/1367
Cancer-associated fibroblasts are often viewed as promoters of tumour progression, yet this elegant single-cell multiomics study reveals a fibroblast subset associated with improved outcomes in pancreatic cancer. The identification of complement-secreting CAFs highlights the complexity of the tumour microenvironment and may refine future stromal-targeted therapeutic approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
New #gutscience paper by Halle-Smith et al entitled
"Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients" via
gutscience.bmj.com/content/1/1/e000023
#oa #pancreaticcancer @druppygill -
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal
@Gut_BMJ
Wang et al. present “Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer” via
gut.bmj.com/content/75/7
Can liquid biomarkers predict immunotherapy response? This highly innovative study combines urinary proteomics with single-cell and spatial transcriptomics to characterise the tumour microenvironment in biliary tract cancer. The approach offers exciting possibilities for non-invasive biomarker development and precision oncology.
#biomarkers #proteomics -
Gut Journal
@Gut_BMJ
Older patients are particularly vulnerable to liver injury following surgery and transplantation
Liu et al. present "Crosstalk between liver sinusoidal endothelial cells and hepatocytes via IL-1α–IL1R1 axis exacerbates ischaemia/reperfusion injury in aged livers" via
gut.bmj.com/content/75/8/1548
This mechanistic study demonstrates how communication between liver endothelial cells and hepatocytes through the IL-1α–IL1R1 signalling pathway drives increased tissue injury in ageing livers. By identifying this inflammatory pathway, the work provides potential targets for therapies aimed at improving outcomes following liver surgery and transplantation.
#livertransplantation -
Gut Journal reposted
Sylvie Deborde
@sylvie_deborde
I am very excited to share our work recently published in Gut. Thanks to the team and our collaborators! gut.bmj.com/content/early/2026/07/01/gutjnl-2025-337316
-
Gut Journal
@Gut_BMJ
#guteditorschoice - Jeong et al. present “DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease” via gut.bmj.com/content/75/7/1307
This important translational study provides compelling evidence that DPP-4 inhibition can modify gut–brain axis pathology in Parkinson’s disease. Using experimental models, the authors demonstrate reductions in intestinal inflammation, α-synuclein accumulation and neurodegeneration, accompanied by favourable alterations in the gut microbiome. The findings support growing interest in the gastrointestinal origins of Parkinson’s disease and suggest that drug repurposing strategies may offer novel disease-modifying approaches.
#parkinsonsdisease #gutbrainaxis -
Gut Journal
@Gut_BMJ
Read the paper by Zhou et al. present “Streptococcus anginosus-derived methionine promotes gastric cancer progression” via
gut.bmj.com/content/75/7/1279
The microbiome continues to emerge as an important driver of cancer biology. This study identifies a mechanistic link between Streptococcus anginosus and gastric cancer progression through microbial methionine metabolism. The findings further strengthen evidence that tumour-associated microbes can influence metabolic pathways within the tumour microenvironment and may provide future therapeutic targets.
#microbiome #gastriccancer -
Gut Journal
@Gut_BMJ
Predicting inflammatory bowel disease (IBD) flares remains a major clinical challenge.
Constantine-Cooke et al. present "Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PREdiCCt prospective cohort study" via
gut.bmj.com/content/75/8/1491
Drawing on the large prospective PREdiCCt cohort, this study examines how demographic characteristics, clinical features and dietary habits influence the likelihood of disease relapse. The findings improve understanding of potentially modifiable environmental risk factors and may help clinicians better identify patients at increased risk of future flares.
#ibd -
Gut Journal
@Gut_BMJ
We hope you enjoy this August 2026 issue of @Gut_BMJ, which brings together exciting advances across the microbiome, colorectal cancer, hepatology, inflammatory bowel disease, pancreatic cancer and gastrointestinal genetics. This month’s issue highlights how microbial metabolism, precision immunology, genetics and systems biology continue to deepen our understanding of gastrointestinal disease while paving the way for more personalised diagnostics and targeted therapies.
This issue also features an Editor’s Choice paper by Osswald et al., highlighted on the #gutfrontcover. The cover features the Golden Angel of Peace (Friedensengel) in Munich, Germany, celebrating this important work demonstrating how secondary bile acids produced by gut bacteria promote Western diet-associated colorectal cancer. The study provides compelling evidence that diet, the microbiome and microbial metabolism work together to influence cancer development, further strengthening the growing interest in targeting the microbiome as a strategy for cancer prevention and treatment. Read this paper here: gut.bmj.com/content/75/8/1505
There are also important advances in cancer biology:
• Gastric cancer may begin with E-cadherin loss in gastric stem-like cells.
• Two complementary pancreatic cancer studies identify new drivers of tumour growth and therapy resistance.
• Epigenetic therapies continue to emerge as promising treatments for liver cancer.
The issue also highlights exciting developments in hepatology:
• New mechanisms underlying liver injury in ageing.
• Long-term biomarkers predicting hepatitis B outcomes.
• Immune responses following antiviral treatment withdrawal.
• Anti-PD-1 immunotherapy shows encouraging early results in chronic hepatitis B.
• New insight into ferroptosis and autoimmune hepatitis.
In IBD and gut physiology:
• The PREdiCCt study identifies factors associated with IBD flares.
• Large-scale genetics links vitamin B1 metabolism to gut motility.
• Digital twins are highlighted as a future tool for personalised IBD care and smarter clinical trials.
Bottom line?
This issue showcases how microbiome science, genetics, immunology and computational medicine are increasingly converging to transform gastroenterology. From understanding how diet influences colorectal cancer to developing personalised treatments for liver disease and inflammatory bowel disease, the future of digestive health continues to move towards more precise, mechanism-based care.
👉 Read the full August issue here:
gut.bmj.com/content/75/8
@FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
✨ Your next discovery deserves the right home. Submit to #gutscience
#gutscience is the newest journal in the prestigious "Gut portfolio", published by @bmj_company in partnership with the @BritSocGastro its renowned sister journals: @Gut_BMJ, @FrontGastro_BMJ, and @BMJOpen_Gastro. Together, the portfolio offers a home for world-class research across the full spectrum of gastroenterology and hepatology.
Led by Editor-in-Chief Dr Upkar S. Gill @druppygill, #gutscience is dedicated exclusively to fundamental and discovery science, providing a specialist platform for high-impact basic and translational research that advances our understanding of gastrointestinal and liver biology.
Why submit to #gutscience?
🔬 A dedicated journal for cutting-edge basic, translational and discovery science
🌍 Fully open access, ensuring your research reaches a global audience
⭐ Backed by the editorial excellence and scientific reputation of the @Gut_BMJ family of journals
🤝 Published in partnership with the @BritSocGastro
🔄 Seamless manuscript transfer within the Gut portfolio to help your work find the most appropriate journal
🚀 Continuous online publication, digital features and broad visibility for your research
Whether you're exploring molecular mechanisms, the microbiome, physiology, immunology or pioneering new approaches in digestive health, #gutscience is the destination for research that lays the foundations for tomorrow's clinical advances.
📩 Submit your manuscript and become part of the next generation of discovery in gastroenterology and hepatology via gutscience.bmj.com
#gutscience #bsg #gastroenterology #hepatology #discoveryscience #translationalresearch #microbiome #openaccess #academicpublishing #digestivehealth #bmj -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Both the epithelial barrier and the gut vascular barrier matter in celiac disease
@maria_rescigno et al. update their relevance from bench to bedside
@Gut_BMJ
gut.bmj.com/content/early/2026/07/08/gutjnl-2026-339151 -
Gut Journal reposted
BSG
@BritSocGastro
We are delighted to present the July 2026 BSG Gut Highlights! 🎉
This month's edition features summaries of papers on GI cancer, #hepatology, gut microbiota, and #pancreas from the Gut journal. Check them out here 👉 www.bsg.org.uk/web-education/bsg-gut-highlights-july-2026
@Gut_BMJ -
Gut Journal
@Gut_BMJ
Digital twins are emerging as one of the most exciting developments in precision medicine.
Colwill et al. present the #gutrecentadvancesinclinicalpractice paper "Digital twins in IBD—bridging data, biology and trial innovation" via
gut.bmj.com/content/75/8/1607
This state-of-the-art review explores how virtual patient models could integrate clinical information, imaging, molecular biology and real-world data to predict disease progression and treatment response in inflammatory bowel disease. The article highlights the potential for digital twins to transform clinical trials and deliver more personalised patient care.
#ibd #digitaltwins -
Gut Journal
@Gut_BMJ
Treatment resistance remains one of the greatest barriers to improving survival in pancreatic cancer.
Latif et al. present "GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair" via
gut.bmj.com/content/75/8/1520
This study identifies a distinct molecular subtype characterised by high GSK3β and NFATc1 activity that drives resistance to therapy. Importantly, targeting this pathway restores treatment sensitivity by influencing DNA repair mechanisms. The findings provide new insight into pancreatic cancer biology and may support the future development of precision treatment strategies for patients with resistant disease.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Read the paper by Lee et al. on “Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health”
gut.bmj.com/content/75/7/1338
Microbial metabolism continues to reveal unexpected therapeutic opportunities. The authors identify a previously unrecognised fermentation pathway in Dysosmobacter welbionis, a bacterium associated with favourable metabolic and liver health. By linking myo-inositol metabolism to butyrate production, the study advances our understanding of beneficial microbial functions and potential microbiome-based interventions.
#microbiome -
Gut Journal reposted
Mauro D’Amato
@damato_mauro
thanks for inviting me and for highlighting our work!
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal
@Gut_BMJ
Read the #gutendoscopynews by Wu et al. on “Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures” via
gut.bmj.com/content/75/7/1276
Can advanced endoscopy reduce the burden of repeated dilatations for long benign oesophageal strictures?
Wu et al. describe an innovative endoscopic approach using mucosal and submucosal cutting techniques to treat difficult long-segment strictures. By directly targeting fibrotic tissue, this strategy may provide more durable symptom relief and reduce the need for repeated interventions.
This paper highlights how increasingly sophisticated endoscopic techniques are expanding treatment options for complex benign oesophageal disease and may offer selected patients an alternative to more invasive surgical approaches.
#strictures #oesophageal #endoscopy -
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal
@Gut_BMJ
Can our genes reveal new ways to improve gut motility? 🧬💩
Our latest #gutblog by Professor D'Amato explores how one of the largest genetic studies of stool frequency identifies vitamin B1 (thiamine) metabolism and other actionable biological pathways involved in regulating gut motility. The findings open new avenues for understanding disorders such as IBS and could help inform future precision therapies.
📝 Read the #gutblog: blogs.bmj.com/gut/2026/07/14/gutblog-genetic-dissection-o…
📄 Read the paper: gut.bmj.com/content/75/8/1480
@damato_mauro @CICbioGUNE @Ikerbasque #cicbiogune @brta_eus @uniLUM
#gutjournal #guthealth #genetics #gwas #vitaminb1 #thiamine #ibs #precisionmedicine #neurogastroenterology -
Gut Journal reposted
Mohamed Shiha
@Mo_Shiha
🚨 The new @BritSocGastro guidelines on coeliac disease are out in @Gut_BMJ ! 🇬🇧🇮🇹🇸🇪🇦🇺
📄shorturl.at/7NkBp
✅ No-biopsy diagnosis in selected adults
✅ Clearer pathways for potential & seronegative disease
✅ Updated biopsy standards
✅ Follow-up and refractory cases -
Gut Journal
@Gut_BMJ
Why do some patients develop chronic symptoms following gastrointestinal infection?
Marasco et al. present “Post-infection disorders of gut-brain interaction: results of the Rome Foundation Global Epidemiology Study” via
gut.bmj.com/content/75/7/1297
This major international epidemiological study examines the global burden of post-infectious disorders of gut–brain interaction, providing important insights into geographical variation, risk factors and disease prevalence. The findings improve our understanding of functional gastrointestinal disorders and may help identify populations at increased risk.
#gutbrainaxis #postinfection -
Gut Journal
@Gut_BMJ
Read the paper by Hou et al. on “Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites” via
gut.bmj.com/content/75/7/1322
Chemotherapy toxicity remains a major challenge in oncology. This study demonstrates how Bacteroides intestinalis influences irinotecan toxicity through microbial tryptophan metabolites, highlighting the growing importance of host–microbiome interactions in determining treatment response. These findings may eventually support personalised strategies to reduce treatment-related toxicity.
#microbiome -
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
AIH is not only an immune-cell disease. ⚖️
A study identifies a hepatocyte A20–KEAP1–NRF2 axis that restrains ferroptosis, supported by experimental AIH and human biopsies. Still preclinical—but a useful reminder to look beyond inflammation.
doi.org/10.1136/gutjnl-2025-336363
#aih -
Gut Journal
@Gut_BMJ
We hope you enjoy this July 2026 issue of Gut, which showcases important advances spanning the gut–brain axis, microbiome science, gastrointestinal oncology, hepatology, immunometabolism and artificial intelligence. Across multiple disciplines, this month’s issue highlights how systems biology, single-cell technologies, microbial metabolism and AI-driven approaches are increasingly transforming our understanding of disease mechanisms and therapeutic opportunities.
The #gutfrontcover shows the magnificent Gyeongbukgung Palace, Seoul, Republic of Korea. Read in this issue the exciting work by Jeong et al reporting how Sitagliptin, a DPP-4 inhibitor, alleviates gut-brain axis pathology in a pre-clinical model of Parkinson's disease via gut.bmj.com/content/75/7?current-issue=y. The study highlights the growing importance of intestinal inflammation, microbial interactions and neuroimmune signalling in neurodegenerative disease and raises the exciting possibility of repurposing established metabolic therapies for neurological disorders. Read the #guteditorschoice here: gut.bmj.com/content/75/7/1307
#parkinsonsdisease #sitagliptin #microbiome #hepatology #ai -
Gut Journal
@Gut_BMJ
Excellent #gutrecentadvancesinbasicscience paper by Zhou et al. entitled present “AI-empowered human microbiome research” accessed via
gut.bmj.com/content/75/7/1432
Artificial intelligence is increasingly transforming microbiome science. This review explores how machine learning and AI approaches are accelerating microbial discovery, improving predictive modelling and uncovering complex host–microbe interactions. The article highlights how computational approaches may help translate microbiome research into clinical practice.
#ai #microbiome -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards | Gut gut.bmj.com/content/early/2026/07/10/gutjnl-2025-337567
-
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Outcome scoring systems for locoregional therapy in hepatocellular carcinoma: a systematic review | Gut gut.bmj.com/content/early/2026/07/08/gutjnl-2025-337557
-
Gut Journal
@Gut_BMJ
#gutrecentadvancesinclinicalpractice paper by Deshpande et al. presents “Basal crypt dysplasia in Barrett’s oesophagus: ready for prime time?” via
gut.bmj.com/content/75/7/1425
Diagnostic pathology continues to evolve in Barrett’s oesophagus. This clinical review evaluates the evidence supporting basal crypt dysplasia as an important precursor lesion and discusses its potential role in risk stratification and surveillance strategies.
#barrettsoesophagus #dysplasia -
Gut Journal reposted
Huiluo Cao 曹慧荦
@hlcao
Streptococcus anginosus-derived methionine promotes gastric cancer progression | Gut gut.bmj.com/content/75/7/1279
-
Gut Journal reposted
Mauro D’Amato
@damato_mauro
🔥🔥this is now out in full!🔥🔥
Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility gut.bmj.com/content/75/8/1480 -
Gut Journal reposted
CIC bioGUNE
@CICbioGUNE
#biogune_research | 🧬 An international study @Gut_BMJ led by @damato_mauro @Ikerbasque #cicbiogune @brta_eus & @uniLUM, identifies a genetic link between irritable bowel syndrome and triglyceride metabolism
🔗 www.cicbiogune.es/news/genetic-study-ibs-lipid-metabolism -
Gut Journal reposted
Cancer Stem Cell News
@cancerscnews
A new @Gut_BMJ paper out of @sjtu1896 defines the LY6D+ #gastric-like cell state as a key driver linking early pre-malignant heterogeneity to #pdac initiation and progression. gut.bmj.com/content/75/8/1534.long🚗
LY6D represents a pan-stage therapeutic target 🎯 and a candidate biomarker for early detection and therapeutic targeting. -
Gut Journal reposted
Intestinal Cell News
@Intestinal_Cell
Researchers from the University of Otago show that loss of E-cadherin in CD44-positive gastric cells is sufficient to initiate diffuse #gastriccancer, with TP53 loss accelerating disease progression.
Learn more at @Gut_BMJ:
🔖 gut.bmj.com/content/75/8/1466 -
Gut Journal reposted
Mauro D’Amato
@damato_mauro
🔥hot off the press🔥
our latest #gwas of IBS in 2.8 million people highlights novel links to #triglycerides and cardiometabolic pathways, and actionable targets for drug testing and repurposing
gut.bmj.com/content/early/2026/07/01/gutjnl-2026-338800.s… -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Important step toward precision nutrition in IBD: diet–inflammation links appear to be mediated by distinct microbial pathways in Crohn’s disease and ulcerative colitis. Promising mechanistic insight, but prospective dietary intervention studies are needed before translating specific foods or taxa into routine care.
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal reposted
GI Nutrition Foundation
@GI_NutritionFdn
Both epithelial and vascular gut barriers are compromised in #celiacdisease
@maria_rescigno, @wm_marlicz et al. summarize in @Gut_BMJ changes observed in the intestinal permeability in celiac disease
The consequence of the passage of bacteria and macromolecules from the intestinal mucosa into the bloodstream may have potential health consequences
💡The good news is that the simplest way to restore intestinal permeability and the microbiota could be ideal nutrition
👉 Follow us to keep updated on science-based, actionable resources to help integrate nutrition in the management of GI conditions
gut.bmj.com/content/early/2026/07/08/gutjnl-2026-339151 -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🚨🚨🚨 YOUR CHANCE TO MAKE EDITORS CHOICE 🏆 🏆 🏆
FG is delighted to announce that we now have a dedicated page on ResearchGate 👇 👇 👇
www.researchgate.net/journal/Frontline-Gastroenterology-2…
What do I need to do?
1. FOLLOW
2. SHARE YOUR WORK
Publish. Disseminate. Educate.
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman -
Gut Journal
@Gut_BMJ
Chen et al. present “Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics” via
gut.bmj.com/content/75/7/1367
Cancer-associated fibroblasts are often viewed as promoters of tumour progression, yet this elegant single-cell multiomics study reveals a fibroblast subset associated with improved outcomes in pancreatic cancer. The identification of complement-secreting CAFs highlights the complexity of the tumour microenvironment and may refine future stromal-targeted therapeutic approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal
@Gut_BMJ
"Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice" via gutscience.bmj.com/content/1/1/e000021
Read the NEW #gutscience paper by Abot et al online and open access now!
@druppygill #type2diabetes -
Gut Journal
@Gut_BMJ
Wang et al. present “Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer” via
gut.bmj.com/content/75/7
Can liquid biomarkers predict immunotherapy response? This highly innovative study combines urinary proteomics with single-cell and spatial transcriptomics to characterise the tumour microenvironment in biliary tract cancer. The approach offers exciting possibilities for non-invasive biomarker development and precision oncology.
#biomarkers #proteomics -
Gut Journal
@Gut_BMJ
New #gutscience paper by Halle-Smith et al entitled
"Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients" via
gutscience.bmj.com/content/1/1/e000023
#oa #pancreaticcancer @druppygill -
Gut Journal
@Gut_BMJ
#guteditorschoice - Jeong et al. present “DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease” via gut.bmj.com/content/75/7/1307
This important translational study provides compelling evidence that DPP-4 inhibition can modify gut–brain axis pathology in Parkinson’s disease. Using experimental models, the authors demonstrate reductions in intestinal inflammation, α-synuclein accumulation and neurodegeneration, accompanied by favourable alterations in the gut microbiome. The findings support growing interest in the gastrointestinal origins of Parkinson’s disease and suggest that drug repurposing strategies may offer novel disease-modifying approaches.
#parkinsonsdisease #gutbrainaxis -
Gut Journal
@Gut_BMJ
Read the paper by Zhou et al. present “Streptococcus anginosus-derived methionine promotes gastric cancer progression” via
gut.bmj.com/content/75/7/1279
The microbiome continues to emerge as an important driver of cancer biology. This study identifies a mechanistic link between Streptococcus anginosus and gastric cancer progression through microbial methionine metabolism. The findings further strengthen evidence that tumour-associated microbes can influence metabolic pathways within the tumour microenvironment and may provide future therapeutic targets.
#microbiome #gastriccancer -
Gut Journal reposted
InSiGHT
@insightmeeting
RNF43 loss-of-function mutations matter—but germline and somatic events may not mean the same thing.
New findings highlight differences in genotype–phenotype associations and improve our understanding of inherited vs sporadic CRC.
📖 Read more: gut.bmj.com/content/75/7/1353
#crc -
Gut Journal
@Gut_BMJ
Read the paper by Lee et al. on “Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health”
gut.bmj.com/content/75/7/1338
Microbial metabolism continues to reveal unexpected therapeutic opportunities. The authors identify a previously unrecognised fermentation pathway in Dysosmobacter welbionis, a bacterium associated with favourable metabolic and liver health. By linking myo-inositol metabolism to butyrate production, the study advances our understanding of beneficial microbial functions and potential microbiome-based interventions.
#microbiome -
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal
@Gut_BMJ
Read the #gutendoscopynews by Wu et al. on “Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures” via
gut.bmj.com/content/75/7/1276
Can advanced endoscopy reduce the burden of repeated dilatations for long benign oesophageal strictures?
Wu et al. describe an innovative endoscopic approach using mucosal and submucosal cutting techniques to treat difficult long-segment strictures. By directly targeting fibrotic tissue, this strategy may provide more durable symptom relief and reduce the need for repeated interventions.
This paper highlights how increasingly sophisticated endoscopic techniques are expanding treatment options for complex benign oesophageal disease and may offer selected patients an alternative to more invasive surgical approaches.
#strictures #oesophageal #endoscopy -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast by Professor Wei Wang on the paper by Wu et al entitled
"Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis" via
▶️ Apple: podcasts.apple.com/us/podcast/defining-a-gut-peritoneum-a…
▶️ Spotify: open.spotify.com/episode/7l2RiPQD8y20jZgjHF7rlb
▶️ Web: gutbmj.podbean.com/e/defining-a-gut-peritoneum-axis-in-en…
Paper accessed via gut.bmj.com/content/75/6/1110
#endometriosis #netosis -
Gut Journal
@Gut_BMJ
Why do some patients develop chronic symptoms following gastrointestinal infection?
Marasco et al. present “Post-infection disorders of gut-brain interaction: results of the Rome Foundation Global Epidemiology Study” via
gut.bmj.com/content/75/7/1297
This major international epidemiological study examines the global burden of post-infectious disorders of gut–brain interaction, providing important insights into geographical variation, risk factors and disease prevalence. The findings improve our understanding of functional gastrointestinal disorders and may help identify populations at increased risk.
#gutbrainaxis #postinfection -
Gut Journal reposted
Parham Habibzadeh
@HabibzadehMD
New @Gut_BMJ study uses single-cell multiomics in #pdac to identify complement-secreting CAFs (csCAFs) linked to better prognosis in pancreatic cancer!
⭐️csCAFs & iCAFs share transcriptional/epigenetic profiles & chromatin accessibility. csCAF composition declines during carcinogenesis; trajectory analysis shows they can differentiate into iCAFs.
⭐️Higher csCAFs associate with longer OS & RFS, lower TGF-β ligands, fewer M2 TAMs, more lipid mediators & spatially defined CXCL12-CXCR4 interactions with T cells.
❓What does this mean for reprogramming CAFs as therapy? -
Gut Journal
@Gut_BMJ
New #gutvideo from Liu et al on the paper entitled
"Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers" via
www.youtube.com/watch?v=Jk0E5TTCLUw
Paper accessed via
gut.bmj.com/content/75/5/937
#asd #bacterialgenomes @CUHKMedicine -
Gut Journal
@Gut_BMJ
Read the paper by Hou et al. on “Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites” via
gut.bmj.com/content/75/7/1322
Chemotherapy toxicity remains a major challenge in oncology. This study demonstrates how Bacteroides intestinalis influences irinotecan toxicity through microbial tryptophan metabolites, highlighting the growing importance of host–microbiome interactions in determining treatment response. These findings may eventually support personalised strategies to reduce treatment-related toxicity.
#microbiome -
Gut Journal
@Gut_BMJ
We hope you enjoy this July 2026 issue of Gut, which showcases important advances spanning the gut–brain axis, microbiome science, gastrointestinal oncology, hepatology, immunometabolism and artificial intelligence. Across multiple disciplines, this month’s issue highlights how systems biology, single-cell technologies, microbial metabolism and AI-driven approaches are increasingly transforming our understanding of disease mechanisms and therapeutic opportunities.
The #gutfrontcover shows the magnificent Gyeongbukgung Palace, Seoul, Republic of Korea. Read in this issue the exciting work by Jeong et al reporting how Sitagliptin, a DPP-4 inhibitor, alleviates gut-brain axis pathology in a pre-clinical model of Parkinson's disease via gut.bmj.com/content/75/7?current-issue=y. The study highlights the growing importance of intestinal inflammation, microbial interactions and neuroimmune signalling in neurodegenerative disease and raises the exciting possibility of repurposing established metabolic therapies for neurological disorders. Read the #guteditorschoice here: gut.bmj.com/content/75/7/1307
#parkinsonsdisease #sitagliptin #microbiome #hepatology #ai -
Gut Journal
@Gut_BMJ
Excellent #gutrecentadvancesinbasicscience paper by Zhou et al. entitled present “AI-empowered human microbiome research” accessed via
gut.bmj.com/content/75/7/1432
Artificial intelligence is increasingly transforming microbiome science. This review explores how machine learning and AI approaches are accelerating microbial discovery, improving predictive modelling and uncovering complex host–microbe interactions. The article highlights how computational approaches may help translate microbiome research into clinical practice.
#ai #microbiome -
Gut Journal
@Gut_BMJ
#gutrecentadvancesinclinicalpractice paper by Deshpande et al. presents “Basal crypt dysplasia in Barrett’s oesophagus: ready for prime time?” via
gut.bmj.com/content/75/7/1425
Diagnostic pathology continues to evolve in Barrett’s oesophagus. This clinical review evaluates the evidence supporting basal crypt dysplasia as an important precursor lesion and discusses its potential role in risk stratification and surveillance strategies.
#barrettsoesophagus #dysplasia -
Gut Journal reposted
SAMI ALMOMEN
@SALMOMEN
Urgent versus early ERCP in mild-to-moderate acute cholangitis: a randomised controlled trial | Gut gut.bmj.com/content/early/2026/05/20/gutjnl-2025-337279
-
Gut Journal
@Gut_BMJ
Chen et al. present “Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics” via
gut.bmj.com/content/75/7/1367
Cancer-associated fibroblasts are often viewed as promoters of tumour progression, yet this elegant single-cell multiomics study reveals a fibroblast subset associated with improved outcomes in pancreatic cancer. The identification of complement-secreting CAFs highlights the complexity of the tumour microenvironment and may refine future stromal-targeted therapeutic approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Wang et al. present “Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer” via
gut.bmj.com/content/75/7
Can liquid biomarkers predict immunotherapy response? This highly innovative study combines urinary proteomics with single-cell and spatial transcriptomics to characterise the tumour microenvironment in biliary tract cancer. The approach offers exciting possibilities for non-invasive biomarker development and precision oncology.
#biomarkers #proteomics -
Gut Journal reposted
BSG
@BritSocGastro
Presenting BSG EndoBridge 2026 Special Issue of @FrontGastro_BMJ by leading endoscopists in the UK and India
🔗 fg.bmj.com/content/17/e1 (Open Access)
GI neoplasia: oesophageal, Barrett's, gastric, duodenal, colonic & IBD-associated; Underwater endoscopy:
Optimising ERCP -
Gut Journal reposted
Alessandro Mannucci, MD
@AlexMannucci
Can treating H.Pylori prevent CRC?
A new long-term study reveals that H. pylori eradication significantly reduces CRC risk, but the benefit is heavily concentrated in patients with high genetic susceptibility.
@Gut_BMJ
gut.bmj.com/content/early/2026/06/30/gutjnl-2026-338156 -
Gut Journal reposted
BSG
@BritSocGastro
Presenting BSG EndoBridge 2026 Special Issue of @FrontGastro_BMJ by leading endoscopists in the UK and India
🔗 fg.bmj.com/content/17/e1
Diathermy fundamentals ⚖️ Bariatric & metabolic endoscopy 📷 Anti-reflux endotherapy 📷 Advanced EUS-guided interventions 📷 Live endoscopy -
Gut Journal reposted
Kenneth Rainin Foundation
@KR_Foundation
Synergy Awards grantees Dr. Markus Neurath and Dr. Arif Ekici found that GPR15L is a host-defense peptide that plays a beneficial role in the pathogenesis of intestinal inflammation and may have potential as a future therapeutic approach in IBD. gut.bmj.com/content/early/2026/05/28/gutjnl-2025-337619
-
Gut Journal
@Gut_BMJ
"Catestatin decreases duodenal hypermotility to improve glucose homeostasis in diabetic male mice" via gutscience.bmj.com/content/1/1/e000021
Read the NEW #gutscience paper by Abot et al online and open access now!
@druppygill #type2diabetes -
Gut Journal
@Gut_BMJ
Read the paper by Zhou et al. present “Streptococcus anginosus-derived methionine promotes gastric cancer progression” via
gut.bmj.com/content/75/7/1279
The microbiome continues to emerge as an important driver of cancer biology. This study identifies a mechanistic link between Streptococcus anginosus and gastric cancer progression through microbial methionine metabolism. The findings further strengthen evidence that tumour-associated microbes can influence metabolic pathways within the tumour microenvironment and may provide future therapeutic targets.
#microbiome #gastriccancer -
Gut Journal
@Gut_BMJ
#guteditorschoice - Jeong et al. present “DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease” via gut.bmj.com/content/75/7/1307
This important translational study provides compelling evidence that DPP-4 inhibition can modify gut–brain axis pathology in Parkinson’s disease. Using experimental models, the authors demonstrate reductions in intestinal inflammation, α-synuclein accumulation and neurodegeneration, accompanied by favourable alterations in the gut microbiome. The findings support growing interest in the gastrointestinal origins of Parkinson’s disease and suggest that drug repurposing strategies may offer novel disease-modifying approaches.
#parkinsonsdisease #gutbrainaxis -
Gut Journal reposted
Enrique de-Madaria
@DeMadaria
Watch this video abstract of our SIMBA trial, published in @Gut_BMJ
Simvastatin vs placebo in the prevention of recurrent pancreatitis, a double blind randomized trial
@Lguilabert1 @isabial_iis @GVAsanitat
👇👇👇
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o… -
Gut Journal reposted
Lucía Guilabert
@Lguilabert1
Take a look👀 at our video 📹summary from the SIMBA trial, our last trial published in @Gut_BMJ
Simvastatin🤜🏼🤛🏼placebo for RAP
@DeMadaria @isabial_iis
Complete paper here: gut.bmj.com/content/75/6/1160
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
Functional cure in HBV may depend partly on antibody quality, not just quantity.
Wang et al. link functional anti-preS1 responses with viral control in chronic hepatitis B.
doi.org/10.1136/gutjnl-2025-337810
#hbv #hepatology -
Gut Journal reposted
Keith Siau
@drkeithsiau
"Management of neoplasia in IBD" - a state of the art review in @FrontGastro_BMJ, as part of the special BSG Endobridge edition 🔦🆕
1️⃣ Surveillance intervals in IBD (UPDATED)
2️⃣ Surveillance techniques in IBD
3️⃣ How to describe lesions (using SCENIC)
4️⃣ Management of dysplasia in IBD
📸: fg.bmj.com/content/17/e1/e72 -
Gut Journal reposted
BSG
@BritSocGastro
BSG EndoBridge Series (10/15): Underwater Endoscopy
What happens when we remove the air and add water? 💧 Water-aided colonoscopy 📷 Underwater EMR 📷
Open access on the special edition: fg.bmj.com/content/17/e1/e112 -
Gut Journal
@Gut_BMJ
Read the paper by Lee et al. on “Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health”
gut.bmj.com/content/75/7/1338
Microbial metabolism continues to reveal unexpected therapeutic opportunities. The authors identify a previously unrecognised fermentation pathway in Dysosmobacter welbionis, a bacterium associated with favourable metabolic and liver health. By linking myo-inositol metabolism to butyrate production, the study advances our understanding of beneficial microbial functions and potential microbiome-based interventions.
#microbiome -
Gut Journal
@Gut_BMJ
Read the #gutendoscopynews by Wu et al. on “Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures” via
gut.bmj.com/content/75/7/1276
Can advanced endoscopy reduce the burden of repeated dilatations for long benign oesophageal strictures?
Wu et al. describe an innovative endoscopic approach using mucosal and submucosal cutting techniques to treat difficult long-segment strictures. By directly targeting fibrotic tissue, this strategy may provide more durable symptom relief and reduce the need for repeated interventions.
This paper highlights how increasingly sophisticated endoscopic techniques are expanding treatment options for complex benign oesophageal disease and may offer selected patients an alternative to more invasive surgical approaches.
#strictures #oesophageal #endoscopy -
Gut Journal
@Gut_BMJ
NEW #gutvideo by Dr Chaysavanh Manichanh on the paper by Mayorga et al entitled
"Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis" via
www.youtube.com/watch?v=JZsVQ6dEzhk
Access the paper via:
gut.bmj.com/content/75/6/1136
#microbiome #ibd #uc #crohnsdisease -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast by Professor Wei Wang on the paper by Wu et al entitled
"Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis" via
▶️ Apple: podcasts.apple.com/us/podcast/defining-a-gut-peritoneum-a…
▶️ Spotify: open.spotify.com/episode/7l2RiPQD8y20jZgjHF7rlb
▶️ Web: gutbmj.podbean.com/e/defining-a-gut-peritoneum-axis-in-en…
Paper accessed via gut.bmj.com/content/75/6/1110
#endometriosis #netosis -
Gut Journal
@Gut_BMJ
Why do some patients develop chronic symptoms following gastrointestinal infection?
Marasco et al. present “Post-infection disorders of gut-brain interaction: results of the Rome Foundation Global Epidemiology Study” via
gut.bmj.com/content/75/7/1297
This major international epidemiological study examines the global burden of post-infectious disorders of gut–brain interaction, providing important insights into geographical variation, risk factors and disease prevalence. The findings improve our understanding of functional gastrointestinal disorders and may help identify populations at increased risk.
#gutbrainaxis #postinfection -
Gut Journal
@Gut_BMJ
Brilliant #gutvideo by @Lguilabert1 summarising the SIMBA trial led by @DeMadaria and others
Watch the #gutvideo on the paper
"Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial)" via
www.youtube.com/watch?v=ODcqWHD9qfg&list=PL80fezoRY4BDr-o…
Access the paper via: gut.bmj.com/content/75/6/1160
#pancreatitis #simvastatin #simbatrial -
Gut Journal
@Gut_BMJ
New #gutscience paper by Halle-Smith et al entitled
"Gut microbiome composition is associated with response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients" via
gutscience.bmj.com/content/1/1/e000023
#oa #pancreaticcancer @druppygill -
Gut Journal reposted
Keith Siau
@drkeithsiau
"Dispelling myths and misconceptions of constipation" - a summary of the 12 most common myths from this @FrontGastro_BMJ review 🆕💡
fg.bmj.com/content/early/2026/06/25/flgastro-2025-103547 -
Gut Journal reposted
BSG
@BritSocGastro
The special edition of @FrontGastro_BMJ featuring articles from EndoBridge 2026 is now out!
@BSGTrainees @BSGNurses -
Gut Journal
@Gut_BMJ
New #gutvideo from Liu et al on the paper entitled
"Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers" via
www.youtube.com/watch?v=Jk0E5TTCLUw
Paper accessed via
gut.bmj.com/content/75/5/937
#asd #bacterialgenomes @CUHKMedicine -
Gut Journal
@Gut_BMJ
Read the paper by Hou et al. on “Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites” via
gut.bmj.com/content/75/7/1322
Chemotherapy toxicity remains a major challenge in oncology. This study demonstrates how Bacteroides intestinalis influences irinotecan toxicity through microbial tryptophan metabolites, highlighting the growing importance of host–microbiome interactions in determining treatment response. These findings may eventually support personalised strategies to reduce treatment-related toxicity.
#microbiome -
Gut Journal
@Gut_BMJ
Excellent #gutrecentadvancesinbasicscience paper by Zhou et al. entitled present “AI-empowered human microbiome research” accessed via
gut.bmj.com/content/75/7/1432
Artificial intelligence is increasingly transforming microbiome science. This review explores how machine learning and AI approaches are accelerating microbial discovery, improving predictive modelling and uncovering complex host–microbe interactions. The article highlights how computational approaches may help translate microbiome research into clinical practice.
#ai #microbiome -
Gut Journal
@Gut_BMJ
We hope you enjoy this July 2026 issue of Gut, which showcases important advances spanning the gut–brain axis, microbiome science, gastrointestinal oncology, hepatology, immunometabolism and artificial intelligence. Across multiple disciplines, this month’s issue highlights how systems biology, single-cell technologies, microbial metabolism and AI-driven approaches are increasingly transforming our understanding of disease mechanisms and therapeutic opportunities.
The #gutfrontcover shows the magnificent Gyeongbukgung Palace, Seoul, Republic of Korea. Read in this issue the exciting work by Jeong et al reporting how Sitagliptin, a DPP-4 inhibitor, alleviates gut-brain axis pathology in a pre-clinical model of Parkinson's disease via gut.bmj.com/content/75/7?current-issue=y. The study highlights the growing importance of intestinal inflammation, microbial interactions and neuroimmune signalling in neurodegenerative disease and raises the exciting possibility of repurposing established metabolic therapies for neurological disorders. Read the #guteditorschoice here: gut.bmj.com/content/75/7/1307
#parkinsonsdisease #sitagliptin #microbiome #hepatology #ai -
Gut Journal reposted
Alexander Ford
@alex_ford12399
Our latest paper is published in @Gut_BMJ looking at relative efficacy of behavioural therapies and gut-brain neuromodulators in #ibs.
gut.bmj.com/content/early/2026/06/25/gutjnl-2026-339311.full
@Maiskh_ @VivekGoodoory @DrCJBlack @DrElyseThakur @PaulMoayyedi -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🎙️ New FG podcast | Endoscopy training is at a crossroads
The linked FG articles show why this matters:
🔴 84% not ready for consultant gastro posts
🔴 94% report barriers to endoscopy training
🔴 67% attend on days off to gain experience
🔴 57% of colorectal trainees have no regular colonoscopy list
This is not just a training issue.
It is a future workforce and patient-care issue.
Listen + read 👇
▶️ Apple: podcasts.apple.com/us/podcast/endoscopy-and-colonoscopy-t…
▶️ Spotify: open.spotify.com/episode/3vYwEmRmI4ZzuZnToejZKV?nd=1&dlsi…
▶️ Web: fgbmj.podbean.com/e/endoscopy-and-colonoscopy-training-in…
British Society of Gastroenterology survey of UK gastroenterology trainees 2024: how is training shaping up? fg.bmj.com/content/17/4/297
Survey of the current experience of colonoscopy training for colorectal surgical trainees in the UK fg.bmj.com/content/17/4/306
@JAG_Endoscopy commentary on the UK colorectal surgical colonoscopy training survey fg.bmj.com/content/17/4/293
Is Shape of Training working for gastroenterology? @JAG_Endoscopy Commentary on 2024 BSG trainee survey fg.bmj.com/content/flgastro/17/4/295.full.pdf
#gastroenterology #endoscopy #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @BAPENUK -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
It's time to optimize and standardize donor screening for fecal microbiota transplantation
This perspective in @Gut_BMJ update where are we and future directions in donor screening:
gut.bmj.com/content/75/3/635 -
Gut Journal reposted
Jose Carlos Machado
@joseclm
Our latest study, published in Gut, reveals how mismatch repair-deficient colorectal tumors escape immune destruction while retaining immunogenic neoantigens that can be therapeutically targeted. @i3S_UPorto @FMUPorto @UPorto @NFdeMiranda @jlcosta_pt gut.bmj.com/content/early/2026/06/16/gutjnl-2025-336834
-
Gut Journal reposted
Roman Liebe
@LiebeRoman
What can a genome analyst do to help paediatricians and hepatologists in their treatment decisions?
Our recent summary outlining the role of gastrogenomics in finding causes of disturbed bile flow across age groups: "First, stop the itch"
gut.bmj.com/content/early/2026/06/16/gutjnl-2025-337027.long -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
What does the future of microbiome research look like?
Nice reading from @bhmullish & colleagues @BritSocGastro Gut Microbiota for Health panel taking stock of where we have come in the last decade in translating gut microbiome research:
@Gut_BMJ
gut.bmj.com/content/early/2026/06/02/gutjnl-2026-338252 -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast by Professor Wei Wang on the paper by Wu et al entitled
"Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis" via
▶️ Apple: podcasts.apple.com/us/podcast/defining-a-gut-peritoneum-a…
▶️ Spotify: open.spotify.com/episode/7l2RiPQD8y20jZgjHF7rlb
▶️ Web: gutbmj.podbean.com/e/defining-a-gut-peritoneum-axis-in-en…
Paper accessed via gut.bmj.com/content/75/6/1110
#endometriosis #netosis -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
📢📢 We are delighted to present the BSG EndoBridge 2026 Special Issue of Frontline Gastroenterology — a collection of expert reviews from leading endoscopists in the UK and India, inspired by one of the most innovative and collaborative meetings in the international endoscopy calendar.
🔗 fg.bmj.com/content/17/e1 (Open Access)
🔬 GI neoplasia: oesophageal, Barrett's, gastric, duodenal, colonic & IBD-associated
🚪 Third-space endoscopy
💧 Underwater endoscopy
⚡ Diathermy fundamentals
⚖️ Bariatric & metabolic endoscopy
🔥 Anti-reflux endotherapy
🟢 Optimising ERCP
🟡 Advanced EUS-guided interventions
🎥 Live endoscopy in 2026 and beyond
As highlighted by Editor-in-Chief @PhilSmithIsBack, this special issue captures the current state-of-the-art while exploring the innovations that will shape endoscopy practice for years to come.
#bsg2026 #frontlinegastroenterology #endoscopy #bsgendobridge #ercp #eus #esd #emr #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy @EndoCollabcom @JAG_Endoscopy @SimonMEverett @gastro3570 @drkeithsiau @DrOmerAhmad @Dunnepdj @shraddha_gulati @CardiffGastro @DrBuHayee @poodocnisha @Sharm_Sub -
Gut Journal reposted
BSG
@BritSocGastro
With 4 #journals there are plenty of opportunities to submit articles to the @bmj_company - why not pop
Over to the stand for a chat? #bsglive26 @FrontGastro_BMJ @gutscience_ @Gut_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
New #gutvideo from Liu et al on the paper entitled
"Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers" via
www.youtube.com/watch?v=Jk0E5TTCLUw
Paper accessed via
gut.bmj.com/content/75/5/937
#asd #bacterialgenomes @CUHKMedicine -
Gut Journal
@Gut_BMJ
Fang et al. present “Immune-related adverse events are a potent predictor of post-transplant rejection in HCC” via
gut.bmj.com/content/75/6/1201
As immunotherapy expands in hepatocellular carcinoma, balancing efficacy and safety becomes increasingly important. This multicentre study shows that immune-related adverse events strongly predict post-transplant rejection, providing clinically important information for patient selection and monitoring.
#hcc -
Gut Journal
@Gut_BMJ
The #guteditorschoice paper by Wu et al. is entitled
“Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis” via
gut.bmj.com/content/75/6/1110
It shows a major mechanistic advance in endometriosis research. Wu et al. demonstrate that gut microbial translocation into the peritoneal cavity can trigger NETosis, promoting inflammatory pathways that drive endometriosis progression. This study provides compelling evidence linking the gut microbiome directly to disease pathogenesis and opens exciting opportunities for microbiome-targeted therapies and immune modulation strategies.
#endometriosis #netosis #microbiome -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinclinicalpractice paper by Iacucci et al. on “Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics” via
gut.bmj.com/content/75/6/1237
Can recurrence prediction become truly personalised? This review explores how artificial intelligence and multi-omics technologies may transform postoperative management in Crohn’s disease, moving the field towards precision surveillance and tailored therapy.
#crohnsdisease #ibd #multiomics #ai -
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal
@Gut_BMJ
Yuan et al. present “ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation” via
gut.bmj.com/content/75/6/1186
Fibrosis remains central to chronic liver disease progression. This study uncovers a novel regulatory pathway involving ISG15 and CREB1 in hepatic stellate cells, deepening our mechanistic understanding of fibrogenesis and identifying potential antifibrotic targets.
#fibrosis #liverfibrosis -
Gut Journal
@Gut_BMJ
Read the paper by Chen et al. on “Engineered virus-hunter vaccine overcomes HBV immune tolerance” via
gut.bmj.com/content/75/6/1211
Achieving immune control in chronic HBV remains a major goal. This innovative vaccine strategy successfully overcomes immune tolerance in preclinical models, representing an exciting step towards curative immunotherapeutic approaches for hepatitis B.
#hbv #hepatitisb -
Gut Journal reposted
Immunology Podcast
@ImmunoPodcast
A single-cell atlas of severe acute #pancreatitis has helped identify a TNF-α–driven immune-endothelial circuit that causes microvascular failure and disease progression.
📖 Check out the study: gut.bmj.com/content/early/2026/06/03/gutjnl-2025-337183
🎧 Listen to the discussion: www.immunologypodcast.com/ep-134-outsmarting-tuberculosis… -
Gut Journal
@Gut_BMJ
Important paper in Gut! 📢 New study maps the evolution of pancreatic cysts to cancer
Cui et al. used spatial transcriptomics to map progression from IPMNs to pancreatic ductal adenocarcinoma—revealing it’s not linear, but follows distinct molecular paths.
Early-stage lesions showed active immune surveillance (T cells and NK cells), while progression was marked by a shift to an immunosuppressive environment with expansion of regulatory T cells and fibroblasts.
Intriguingly, histologically similar high-grade lesions with different malignant potential were found to be molecularly distinct.
Malignant trajectories were characterised by upregulation of invasion-associated genes (e.g. CLDN1) + TGF-β / IL-17 signalling.
⚖️ Are we over-treating some IPMNs while missing aggressive disease in others?
This study highlights the limitations of current risk stratification and the promise of spatially resolved biomarkers.
Check the paper: doi: gut.bmj.com/content/75/4/801
Social Media summary by Dr John P Thomas, Chain-Florey Clinical Research Fellow, Imperial College London, London, UK -
Gut Journal
@Gut_BMJ
Liu et al. present “KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy” via
gut.bmj.com/content/75/6/1169
Why do targeted therapies fail in pancreatic cancer? This study identifies a KRAS-driven molecular mechanism that alters CLDN18.2 biology and reduces therapeutic efficacy. The work provides valuable insight into resistance pathways and may guide future precision treatment approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Gut Feeling or Brain Fog?
Obesity is often associated with poor attention, but the cause is unclear. In a study of 1,000+ people, researchers found links between obesity, altered gut microbes, and worse attention. Higher levels of 3-hydroxyanthranilic acid (3-HAA), a gut-related metabolite, were linked with better attention. In animal models, restoring 3-HAA improved attention deficits. These findings suggest an important gut–brain pathway in obesity.
⚖️Could targeting gut microbes or 3-HAA help reduce brain fog in obesity?
🔎Check the paper "Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity" via gut.bmj.com/content/75/4/705
Social Media summary by Dr Daniela Toumazi, CT2 Internal Medicine Trainee, Broomfield Hospital, Mid and South Essex NHS Trust, UK -
Gut Journal
@Gut_BMJ
In this paper Xiong et al. present “Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity” via
gut.bmj.com/content/75/6/1147
Immune checkpoint inhibitor colitis remains a major clinical challenge. This important translational study demonstrates that targeting MLCK1 can reduce gastrointestinal toxicity while preserving antitumour immune responses—an exciting step towards safer cancer immunotherapy.
#ici #colitis -
Gut Journal reposted
Immune Regulation News
@Immune_News
SPP1+ #macrophages established an immunosuppressive niche in colorectal cancer tumor-draining lymph nodes by promoting CD137+ #treg maturation via the SPP1-CD44-NF-κB1 axis. | @Gut_BMJ
📚 Learn more: gut.bmj.com/content/early/2026/06/12/gutjnl-2025-337038.long -
Gut Journal reposted
BSG
@BritSocGastro
We are delighted to present the June 2026 BSG Gut Highlights! 🎉
This month's edition features summaries of papers on IBD, pancreas, colon, and stomach, from the Gut journal. Check them out here 👉 www.bsg.org.uk/web-education/bsg-gut-highlights-june-2026
@Gut_BMJ -
Gut Journal reposted
NYU Pain Research Center
@NYUPainResearch
NEW PRC PAPER 🚨 from Nestor Jimenez-Vargas and the Bunnett Lab reveals how elevated proteases and histamine drive IBS visceral pain, showing that a prolonged intracellular PAR2 receptor signaling loop keeps the H1 receptor active to maintain pain. gut.bmj.com/content/early/2026/05/19/gutjnl-2025-337991.long
-
Gut Journal
@Gut_BMJ
We hope you enjoy this June 2026 issue of @Gut_BMJ, showcasing exciting advances across immunology, microbiome science, hepatology, pancreatic cancer and inflammatory disease. This month’s issue highlights how translational research and systems biology are reshaping our understanding of inflammation, cancer progression and therapeutic resistance.
This issue also features an Editor’s Choice paper by Wu et al., highlighted on the #gutfrontcover which shows the beautiful Canton Tower, Guangzhou, China. The paper is also discussed in the upcoming #gutpodcast with Professor Wei Wang. The study explores how intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis, providing fascinating new insight into the microbiome–immune axis in the disease and could reshape how we think about endometriosis pathogenesis and treatment.
There’s also major progress in cancer immunology this month:
• Tumour-infiltrating B cells are shown to influence chemoimmunotherapy response in cholangiocarcinoma
• MLCK1 targeting may reduce checkpoint inhibitor colitis without compromising antitumour immunity
• New mechanisms of resistance to CLDN18.2-targeted therapy are identified in pancreatic cancer
The microbiome remains front and centre too:
• Plant-derived nanovesicles modulate microbial metabolism in rheumatoid arthritis
• Gut microbial pathways continue to emerge as therapeutic targets across systemic disease
In hepatology, the issue explores:
• Novel fibrosis pathways involving ISG15
• Predictors of post-transplant rejection after immunotherapy in HCC
• A promising engineered vaccine strategy to overcome HBV immune tolerance
And looking ahead, reviews on AI-enabled Crohn’s disease management and spatial single-cell omics highlight how precision medicine is rapidly becoming reality.
Bottom line?
This issue captures the future direction of the field: combining immunology, microbiome science, AI and molecular medicine to deliver increasingly personalised care.
👉 Read the full June issue here:
gut.bmj.com/content/75/6?current-issue=y
#immunology #microbiome #hepatology #pancreaticcancer #ibd @FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Lean MASLD: for better or worse?
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research.
⚖️ Has lean MASLD been wrongly risk stratified in clinical practice?
🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via gut.bmj.com/content/75/4/772
Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast by Professor Wei Wang on the paper by Wu et al entitled
"Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis" via
▶️ Apple: podcasts.apple.com/us/podcast/defining-a-gut-peritoneum-a…
▶️ Spotify: open.spotify.com/episode/7l2RiPQD8y20jZgjHF7rlb
▶️ Web: gutbmj.podbean.com/e/defining-a-gut-peritoneum-axis-in-en…
Paper accessed via gut.bmj.com/content/75/6/1110
#endometriosis #netosis -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major complication of type 2 diabetes.
Watch the #gutvideo here: www.youtube.com/watch?v=q3yWznwVmj8&list=PL80fezoRY4BDr-o…
Read the paper here: gut.bmj.com/content/75/5/949
Researchers focused on tryptophan metabolism and the microbial metabolite indole-3-propionic acid (IPA), which has anti-inflammatory and barrier-protective effects. Using diabetic mouse models, they showed that restoring tryptophan absorption through engineered probiotics, tryptophan-containing dipeptides, or direct IPA supplementation improved gut barrier integrity, reduced inflammation, enhanced glucose regulation, and prevented retinal damage. Human participants with DR had significantly lower IPA levels and higher markers of gut permeability and toxic metabolites compared with diabetics without DR and healthy controls. The study suggests that impaired gut–retina communication plays a key role in DR progression. Overall, IPA emerged as both a potential biomarker for detecting diabetic retinopathy and a promising therapeutic target for preventing or slowing retinal damage in diabetes.
#diabeticretinopathy -
Gut Journal
@Gut_BMJ
Read the paper by Han et al. entitled “Pueraria lobata-derived exosome-like nanovesicles alleviate rheumatoid arthritis via targeting Ruminococcus gnavus phenylethylamine production” via
gut.bmj.com/content/75/6/1123
Microbiome therapeutics continue to evolve rapidly. This study shows how plant-derived nanovesicles can modulate microbial metabolism and reduce inflammatory arthritis, highlighting an innovative cross-talk between dietary compounds, gut microbes and systemic immunity. -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Suo et al. entitled “Spatial single-cell omics: new insights into liver diseases” via
gut.bmj.com/content/75/6/1248
Spatial and single-cell technologies are revolutionising hepatology research. This review highlights how these approaches are uncovering cellular interactions and disease mechanisms with unprecedented resolution, accelerating discovery across liver disease.
#singlecellomics -
Gut Journal
@Gut_BMJ
Milardi et al. present “Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome” via gut.bmj.com/content/75/6/1097
How does the tumour microenvironment shape treatment response? This study identifies an immunosuppressive role for tumour-infiltrating B cells in intrahepatic cholangiocarcinoma, demonstrating how they influence chemoimmunotherapy outcomes. The findings add important complexity to our understanding of tumour immunity and may help refine future immunotherapeutic strategies.
#cholangiocarcinoma -
Gut Journal reposted
Sonia Melo
@Sonia_A_Melo
The work by the group of @joseclm helps explain how highly mutated, immune-visible cancers evade elimination.
@i3S_UPorto
gut.bmj.com/content/early/2026/06/10/gutjnl-2025-336834.full -
Gut Journal reposted
ESGE
@ESGE_news
Paper 1. Urgent versus early ERCP in mild-to-moderate acute cholangitis: a randomised controlled trial 🔗 gut.bmj.com/content/early/2026/05/20/gutjnl-2025-337279
Presenter: @miNitinjagtap
Discussant: @GWebster_endo -
Gut Journal
@Gut_BMJ
New #gutvideo from Liu et al on the paper entitled
"Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers" via
www.youtube.com/watch?v=Jk0E5TTCLUw
Paper accessed via
gut.bmj.com/content/75/5/937
#asd #bacterialgenomes @CUHKMedicine -
Gut Journal
@Gut_BMJ
The #guteditorschoice paper by Wu et al. is entitled
“Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis” via
gut.bmj.com/content/75/6/1110
It shows a major mechanistic advance in endometriosis research. Wu et al. demonstrate that gut microbial translocation into the peritoneal cavity can trigger NETosis, promoting inflammatory pathways that drive endometriosis progression. This study provides compelling evidence linking the gut microbiome directly to disease pathogenesis and opens exciting opportunities for microbiome-targeted therapies and immune modulation strategies.
#endometriosis #netosis #microbiome -
Gut Journal
@Gut_BMJ
Fang et al. present “Immune-related adverse events are a potent predictor of post-transplant rejection in HCC” via
gut.bmj.com/content/75/6/1201
As immunotherapy expands in hepatocellular carcinoma, balancing efficacy and safety becomes increasingly important. This multicentre study shows that immune-related adverse events strongly predict post-transplant rejection, providing clinically important information for patient selection and monitoring.
#hcc -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinclinicalpractice paper by Iacucci et al. on “Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics” via
gut.bmj.com/content/75/6/1237
Can recurrence prediction become truly personalised? This review explores how artificial intelligence and multi-omics technologies may transform postoperative management in Crohn’s disease, moving the field towards precision surveillance and tailored therapy.
#crohnsdisease #ibd #multiomics #ai -
Gut Journal
@Gut_BMJ
Read the paper by Chen et al. on “Engineered virus-hunter vaccine overcomes HBV immune tolerance” via
gut.bmj.com/content/75/6/1211
Achieving immune control in chronic HBV remains a major goal. This innovative vaccine strategy successfully overcomes immune tolerance in preclinical models, representing an exciting step towards curative immunotherapeutic approaches for hepatitis B.
#hbv #hepatitisb -
Gut Journal
@Gut_BMJ
Yuan et al. present “ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation” via
gut.bmj.com/content/75/6/1186
Fibrosis remains central to chronic liver disease progression. This study uncovers a novel regulatory pathway involving ISG15 and CREB1 in hepatic stellate cells, deepening our mechanistic understanding of fibrogenesis and identifying potential antifibrotic targets.
#fibrosis #liverfibrosis -
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🟠 Portal hypertension: beyond varices
New in Frontline Gastroenterology (Open Access): The BSG position statement supports interim use of AASLD guidance — with important UK caveats.
📍 Focus on clinically significant portal hypertension
📊 Use VCTE + platelets to risk stratify
✅ Carvedilol preferred where appropriate
🩺 Endoscopy still matters in the “grey zone”
⚠️ Individualise decisions around NSBB tolerance and contraindications
A timely update while UK trial data are awaited.
🔗 fg.bmj.com/content/early/2026/06/04/flgastro-2026-103698
#frontlinegastroenterology #hepatology #cirrhosis #portalhypertension #livertwitter
Fantastic co-author group: @DunnePdj @DTrip2015 @DrVishalCPatel @jamesbmaurice @drmarkmcphail @lynseycorless @IanARowe @EwanForrest1 @AdrianStanleyGI
@basl_events @heppharm @livernursing @LiverAHPs @Liver4Lifeuk @f4liverresearch @IQILS_Liver @LiverTrust @EASLedu @EASLnews @BritSocGastro @BavenoCoop @BCLC_group @ILCAnews @APASLnews @liverfellow @my_ueg @UKCPAGastro
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @drkeithsiau @ebtapper @DrLChina @acv69cardenas @GeriKeane @ClinicLiver -
Gut Journal
@Gut_BMJ
Liu et al. present “KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy” via
gut.bmj.com/content/75/6/1169
Why do targeted therapies fail in pancreatic cancer? This study identifies a KRAS-driven molecular mechanism that alters CLDN18.2 biology and reduces therapeutic efficacy. The work provides valuable insight into resistance pathways and may guide future precision treatment approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Important paper in Gut! 📢 New study maps the evolution of pancreatic cysts to cancer
Cui et al. used spatial transcriptomics to map progression from IPMNs to pancreatic ductal adenocarcinoma—revealing it’s not linear, but follows distinct molecular paths.
Early-stage lesions showed active immune surveillance (T cells and NK cells), while progression was marked by a shift to an immunosuppressive environment with expansion of regulatory T cells and fibroblasts.
Intriguingly, histologically similar high-grade lesions with different malignant potential were found to be molecularly distinct.
Malignant trajectories were characterised by upregulation of invasion-associated genes (e.g. CLDN1) + TGF-β / IL-17 signalling.
⚖️ Are we over-treating some IPMNs while missing aggressive disease in others?
This study highlights the limitations of current risk stratification and the promise of spatially resolved biomarkers.
Check the paper: doi: gut.bmj.com/content/75/4/801
Social Media summary by Dr John P Thomas, Chain-Florey Clinical Research Fellow, Imperial College London, London, UK -
Gut Journal
@Gut_BMJ
In this paper Xiong et al. present “Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity” via
gut.bmj.com/content/75/6/1147
Immune checkpoint inhibitor colitis remains a major clinical challenge. This important translational study demonstrates that targeting MLCK1 can reduce gastrointestinal toxicity while preserving antitumour immune responses—an exciting step towards safer cancer immunotherapy.
#ici #colitis -
Gut Journal
@Gut_BMJ
Gut Feeling or Brain Fog?
Obesity is often associated with poor attention, but the cause is unclear. In a study of 1,000+ people, researchers found links between obesity, altered gut microbes, and worse attention. Higher levels of 3-hydroxyanthranilic acid (3-HAA), a gut-related metabolite, were linked with better attention. In animal models, restoring 3-HAA improved attention deficits. These findings suggest an important gut–brain pathway in obesity.
⚖️Could targeting gut microbes or 3-HAA help reduce brain fog in obesity?
🔎Check the paper "Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity" via gut.bmj.com/content/75/4/705
Social Media summary by Dr Daniela Toumazi, CT2 Internal Medicine Trainee, Broomfield Hospital, Mid and South Essex NHS Trust, UK -
Gut Journal
@Gut_BMJ
We hope you enjoy this June 2026 issue of @Gut_BMJ, showcasing exciting advances across immunology, microbiome science, hepatology, pancreatic cancer and inflammatory disease. This month’s issue highlights how translational research and systems biology are reshaping our understanding of inflammation, cancer progression and therapeutic resistance.
This issue also features an Editor’s Choice paper by Wu et al., highlighted on the #gutfrontcover which shows the beautiful Canton Tower, Guangzhou, China. The paper is also discussed in the upcoming #gutpodcast with Professor Wei Wang. The study explores how intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis, providing fascinating new insight into the microbiome–immune axis in the disease and could reshape how we think about endometriosis pathogenesis and treatment.
There’s also major progress in cancer immunology this month:
• Tumour-infiltrating B cells are shown to influence chemoimmunotherapy response in cholangiocarcinoma
• MLCK1 targeting may reduce checkpoint inhibitor colitis without compromising antitumour immunity
• New mechanisms of resistance to CLDN18.2-targeted therapy are identified in pancreatic cancer
The microbiome remains front and centre too:
• Plant-derived nanovesicles modulate microbial metabolism in rheumatoid arthritis
• Gut microbial pathways continue to emerge as therapeutic targets across systemic disease
In hepatology, the issue explores:
• Novel fibrosis pathways involving ISG15
• Predictors of post-transplant rejection after immunotherapy in HCC
• A promising engineered vaccine strategy to overcome HBV immune tolerance
And looking ahead, reviews on AI-enabled Crohn’s disease management and spatial single-cell omics highlight how precision medicine is rapidly becoming reality.
Bottom line?
This issue captures the future direction of the field: combining immunology, microbiome science, AI and molecular medicine to deliver increasingly personalised care.
👉 Read the full June issue here:
gut.bmj.com/content/75/6?current-issue=y
#immunology #microbiome #hepatology #pancreaticcancer #ibd @FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Lean MASLD: for better or worse?
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research.
⚖️ Has lean MASLD been wrongly risk stratified in clinical practice?
🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via gut.bmj.com/content/75/4/772
Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez -
Gut Journal reposted
Endothelial Cell News
@endothelialnews
📢 New in @Gut_BMJ!
Researchers have identified a TNF-α-driven immune-endothelial feedback loop involving CD8⁺ T cells and NKG2D signaling as a key cause of #microvasculardamage in severe #acutepancreatitis.
Read the study: gut.bmj.com/content/early/2026/06/03/gutjnl-2025-337183 -
Gut Journal reposted
Jasmohan Bajaj
@JasmohanBajaj
Chronic kidney disease, #cirrhosis & global health=bad outcomes! @CLEARED_liver report led by #florencewong @Gut_BMJ
CKD in 1/5th =⬆️mortality, #aki & readmissions
CKD ⬆️ in high income countries
Read⤵️
pubmed.ncbi.nlm.nih.gov/42248676/ -
Gut Journal
@Gut_BMJ
Read the paper by Han et al. entitled “Pueraria lobata-derived exosome-like nanovesicles alleviate rheumatoid arthritis via targeting Ruminococcus gnavus phenylethylamine production” via
gut.bmj.com/content/75/6/1123
Microbiome therapeutics continue to evolve rapidly. This study shows how plant-derived nanovesicles can modulate microbial metabolism and reduce inflammatory arthritis, highlighting an innovative cross-talk between dietary compounds, gut microbes and systemic immunity. -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major complication of type 2 diabetes.
Watch the #gutvideo here: www.youtube.com/watch?v=q3yWznwVmj8&list=PL80fezoRY4BDr-o…
Read the paper here: gut.bmj.com/content/75/5/949
Researchers focused on tryptophan metabolism and the microbial metabolite indole-3-propionic acid (IPA), which has anti-inflammatory and barrier-protective effects. Using diabetic mouse models, they showed that restoring tryptophan absorption through engineered probiotics, tryptophan-containing dipeptides, or direct IPA supplementation improved gut barrier integrity, reduced inflammation, enhanced glucose regulation, and prevented retinal damage. Human participants with DR had significantly lower IPA levels and higher markers of gut permeability and toxic metabolites compared with diabetics without DR and healthy controls. The study suggests that impaired gut–retina communication plays a key role in DR progression. Overall, IPA emerged as both a potential biomarker for detecting diabetic retinopathy and a promising therapeutic target for preventing or slowing retinal damage in diabetes.
#diabeticretinopathy -
Gut Journal
@Gut_BMJ
Can colonoscopy after a positive FIT safely wait?
This large French cohort study (374k+ patients) found that delaying colonoscopy—even up to 24 months—did not meaningfully increase colorectal cancer (CRC), advanced CRC, or advanced adenoma risk. With high compliance (86.6%) and most procedures done within ~3 months, outcomes were instead driven more by patient factors (age, sex, FIT haemoglobin level) than timing. These findings challenge prior assumptions that delays beyond 3–12 months are harmful and suggest the slow adenoma–carcinoma sequence may allow more flexibility.
⚖️ Are strict 1–3 month targets less important than ensuring patients actually complete colonoscopy?
🔎 Focus may need to shift from speed to maximising uptake after positive FIT—where the real risk lies.
Read the paper "Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study" via
gut.bmj.com/content/75/4/748
Social media summary by Dr Anahita Sharma, ST6 Gastroenterology Registrar, Merseyside, UK @AnahitaS -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast by Professor Wei Wang on the paper by Wu et al entitled
"Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis" via
▶️ Apple: podcasts.apple.com/us/podcast/defining-a-gut-peritoneum-a…
▶️ Spotify: open.spotify.com/episode/7l2RiPQD8y20jZgjHF7rlb
▶️ Web: gutbmj.podbean.com/e/defining-a-gut-peritoneum-axis-in-en…
Paper accessed via gut.bmj.com/content/75/6/1110
#endometriosis #netosis -
Gut Journal
@Gut_BMJ
Milardi et al. present “Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome” via gut.bmj.com/content/75/6/1097
How does the tumour microenvironment shape treatment response? This study identifies an immunosuppressive role for tumour-infiltrating B cells in intrahepatic cholangiocarcinoma, demonstrating how they influence chemoimmunotherapy outcomes. The findings add important complexity to our understanding of tumour immunity and may help refine future immunotherapeutic strategies.
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Suo et al. entitled “Spatial single-cell omics: new insights into liver diseases” via
gut.bmj.com/content/75/6/1248
Spatial and single-cell technologies are revolutionising hepatology research. This review highlights how these approaches are uncovering cellular interactions and disease mechanisms with unprecedented resolution, accelerating discovery across liver disease.
#singlecellomics -
Gut Journal
@Gut_BMJ
New #gutvideo from Liu et al on the paper entitled
"Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers" via
www.youtube.com/watch?v=Jk0E5TTCLUw
Paper accessed via
gut.bmj.com/content/75/5/937
#asd #bacterialgenomes @CUHKMedicine -
Gut Journal reposted
Lumír Kunovský
@LumirKunovsky
📢🔥AI meets #gastroenterology practice:
➡️ mapping large language model use across #europe – EuroGI-AI project
✒️ @KralJan ✒️ 👏
📘 @FrontGastro_BMJ 🔵
👉fg.bmj.com/content/early/2026/06/04/flgastro-2025-103584.…
🟢 @my_ueg 🟢
#gitwitter #meded -
Gut Journal
@Gut_BMJ
The #guteditorschoice paper by Wu et al. is entitled
“Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis” via
gut.bmj.com/content/75/6/1110
It shows a major mechanistic advance in endometriosis research. Wu et al. demonstrate that gut microbial translocation into the peritoneal cavity can trigger NETosis, promoting inflammatory pathways that drive endometriosis progression. This study provides compelling evidence linking the gut microbiome directly to disease pathogenesis and opens exciting opportunities for microbiome-targeted therapies and immune modulation strategies.
#endometriosis #netosis #microbiome -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinclinicalpractice paper by Iacucci et al. on “Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics” via
gut.bmj.com/content/75/6/1237
Can recurrence prediction become truly personalised? This review explores how artificial intelligence and multi-omics technologies may transform postoperative management in Crohn’s disease, moving the field towards precision surveillance and tailored therapy.
#crohnsdisease #ibd #multiomics #ai -
Gut Journal
@Gut_BMJ
Fang et al. present “Immune-related adverse events are a potent predictor of post-transplant rejection in HCC” via
gut.bmj.com/content/75/6/1201
As immunotherapy expands in hepatocellular carcinoma, balancing efficacy and safety becomes increasingly important. This multicentre study shows that immune-related adverse events strongly predict post-transplant rejection, providing clinically important information for patient selection and monitoring.
#hcc -
Gut Journal reposted
SOT Hub
@SOT_Hub
New publication 📝 Data from a multicenter, retrospective, Chinese cohort study, published in @Gut_BMJ, show that immune-related AEs after pretransplant ICIs were associated with a higher risk of rejection in adults with HCC undergoing #livertransplantation (OR, 9.17; p < 0.001).
Learn more about liver transplantation: solidorgantransplantationhub.com/types/abdominal-transpla…
#transplant #organtransplant #transplantmedicine #mednews #meded -
Gut Journal reposted
Junbin Qian
@JunbinQian
📢 Excited to share our new paper in @Gut_BMJ! We uncover the TNF‑α/ULBP/NKG2D axis that amplifies microvascular damage in Severe Acute Pancreatitis, a disease with high mortality. Promising therapeutic target!
🔗[gut.bmj.com/content/early/2026/06/03/gutjnl-2025-337183.long]
#gastroenterology #pancreatology #sap -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Is the gut microbiome a potential therapeutic target in endometriosis?
New findings in @Gut_BMJ showed that intraperitoneal translocation of gut microbiota induces neutrophil extracellular traps formation and promotes endometriosis:
gut.bmj.com/content/75/6/1110 -
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal
@Gut_BMJ
Yuan et al. present “ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation” via
gut.bmj.com/content/75/6/1186
Fibrosis remains central to chronic liver disease progression. This study uncovers a novel regulatory pathway involving ISG15 and CREB1 in hepatic stellate cells, deepening our mechanistic understanding of fibrogenesis and identifying potential antifibrotic targets.
#fibrosis #liverfibrosis -
Gut Journal
@Gut_BMJ
Read the paper by Chen et al. on “Engineered virus-hunter vaccine overcomes HBV immune tolerance” via
gut.bmj.com/content/75/6/1211
Achieving immune control in chronic HBV remains a major goal. This innovative vaccine strategy successfully overcomes immune tolerance in preclinical models, representing an exciting step towards curative immunotherapeutic approaches for hepatitis B.
#hbv #hepatitisb -
Gut Journal
@Gut_BMJ
Liu et al. present “KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy” via
gut.bmj.com/content/75/6/1169
Why do targeted therapies fail in pancreatic cancer? This study identifies a KRAS-driven molecular mechanism that alters CLDN18.2 biology and reduces therapeutic efficacy. The work provides valuable insight into resistance pathways and may guide future precision treatment approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Important paper in Gut! 📢 New study maps the evolution of pancreatic cysts to cancer
Cui et al. used spatial transcriptomics to map progression from IPMNs to pancreatic ductal adenocarcinoma—revealing it’s not linear, but follows distinct molecular paths.
Early-stage lesions showed active immune surveillance (T cells and NK cells), while progression was marked by a shift to an immunosuppressive environment with expansion of regulatory T cells and fibroblasts.
Intriguingly, histologically similar high-grade lesions with different malignant potential were found to be molecularly distinct.
Malignant trajectories were characterised by upregulation of invasion-associated genes (e.g. CLDN1) + TGF-β / IL-17 signalling.
⚖️ Are we over-treating some IPMNs while missing aggressive disease in others?
This study highlights the limitations of current risk stratification and the promise of spatially resolved biomarkers.
Check the paper: doi: gut.bmj.com/content/75/4/801
Social Media summary by Dr John P Thomas, Chain-Florey Clinical Research Fellow, Imperial College London, London, UK -
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
Gut Feeling or Brain Fog?
Obesity is often associated with poor attention, but the cause is unclear. In a study of 1,000+ people, researchers found links between obesity, altered gut microbes, and worse attention. Higher levels of 3-hydroxyanthranilic acid (3-HAA), a gut-related metabolite, were linked with better attention. In animal models, restoring 3-HAA improved attention deficits. These findings suggest an important gut–brain pathway in obesity.
⚖️Could targeting gut microbes or 3-HAA help reduce brain fog in obesity?
🔎Check the paper "Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity" via gut.bmj.com/content/75/4/705
Social Media summary by Dr Daniela Toumazi, CT2 Internal Medicine Trainee, Broomfield Hospital, Mid and South Essex NHS Trust, UK -
Gut Journal
@Gut_BMJ
In this paper Xiong et al. present “Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity” via
gut.bmj.com/content/75/6/1147
Immune checkpoint inhibitor colitis remains a major clinical challenge. This important translational study demonstrates that targeting MLCK1 can reduce gastrointestinal toxicity while preserving antitumour immune responses—an exciting step towards safer cancer immunotherapy.
#ici #colitis -
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
Interesting Gut paper in Lynch syndrome: MAIT cell enrichment in the colon was linked to immune surveillance and CRC risk. A useful reminder that genotype matters, but tissue immunity may shape penetrance. 🧬
#immunology #gastroenterology
doi.org/10.1136/gutjnl-2025-337343 -
Gut Journal reposted
Bruno Ramos-Molina, PhD
@Brunorm84
Blocking MOXD1-derived ACOX1 peroxisome trafficking suppresses #mash @Gut_BMJ gut.bmj.com/content/early/2026/05/21/gutjnl-2025-337802.a…
-
Gut Journal reposted
Nestor Jiménez
@niva64
I'm very happy to share our latest study on how proteases and histamine signaling contribute in IBS abdominal pain related. Our research shows that PAR2 signaling sensitises and maintains histamine receptor 1 activity to amplify and maintain pain. gut.bmj.com/content/early/2026/05/19/gutjnl-2025-337991
-
Gut Journal reposted
DrCJFrandrup
@DRCJFrandrup
Key finding in Gut this week: PAR2 endosomal signaling amplifies histamine-driven pain in IBS. This receptor-receptor crosstalk is a potential new target for visceral pain management beyond standard approaches.
gut.bmj.com/content/early/2026/05/19/gutjnl-2025-337991
#medtwitter -
Gut Journal reposted
Rajan kanth
@kanthMD
In patients with mild-to-moderate acute cholangitis, urgent ERCP within 24 hours was not superior to early ERCP within 24–48 hours and is associated with a higher rate of procedure-related adverse events #ercp #gitwitter #medtwitter gut.bmj.com/content/early/2026/05/20/gutjnl-2025-337279
-
Gut Journal reposted
Oncology News
@Oncologynewspro
New in @Gut_BMJ : Prof. Deng Yanhong’s team from China found PTEN loss drives immune evasion in MSS colorectal cancer via NRF2-autophagy, impairing MHC-I and CD8+ T-cell recognition. ML385 restored anti-PD-1 sensitivity in preclinical models. #colorectalcancer #immunotherapy
-
Gut Journal reposted
Ruben Hernaez
@ruben_hernaez
Ikponmwosa Enofe @Stanford_GI giving @bcm_gihep GR highlights a provocative RCT @Gut_BMJ paper gut.bmj.com/content/75/1/24 Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial
-
Gut Journal reposted
AoT
@AoT_WE
Mayo Clinic's REDMOD model can now detect pancreatic cancer up to three years before clinical diagnosis — validating a capability @EricTopol described on Agents of Tech long before the headlines caught up.
In this clip, Topol explains how China had already deployed opportunistic AI on routine abdominal and chest CT scans to surface pancreatic cancer findings that were never the reason the scan was ordered — and that physicians routinely miss. The @MayoClinic study, published in the journal @Gut_BMJ, confirms this is no longer a theoretical frontier. REDMOD identified the most common form of pancreatic cancer roughly 16 months early in nearly three out of four cases, nearly doubling specialist detection rates on the same imaging data.
For health system leaders and investors evaluating AI integration, the clinical and operational question is no longer whether opportunistic detection works — it is how quickly existing imaging infrastructure can be instrumented to act on it before more preventable deaths accumulate on the timeline.
We've put a link to the full episode with Eric Topol and our hosts Autria Godfrey, @stephenjhorn, and @Laila_Rizvi in the first comment.
#pancreaticcancer #redmod #medicalai #aidiseaseprediction #pancreaticcancerdetection -
Gut Journal reposted
Healio Gastroenterology
@HealioGastro
❗ New data in @Gut_BMJ found antidiarrheals, analgesics and corticosteroids also boost risk for #cdiff
✍️ “This excellent work is a starting point for further assessment,” Dr. Paul Feuerstadt @yalemed told Healio, but not a reason to stop needed meds. vist.ly/55wvb -
Gut Journal reposted
Rirong Chen, M.D.
@RirongChen
🎉 Thrilled to share our latest review published in @Gut_BMJ!
"From the preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions."
gut.bmj.com/content/early/2026/05/28/gutjnl-2025-337981 -
Gut Journal reposted
Sun-Ho Lee, MD, PhD
@SunHoLee15
Excited to share our review highlighting shared mechanisms across the preclinical phase of CD and postoperative recurrence, now published in @Gut_BMJ.
The concept of postoperative CD recurrence as a model for studying early triggers of CD and prevention strategies.
@RirongChen @TurpinWilliams @The_GEMProject @MatthieuAllez @CroitoruKen @guthealthmd
Rirong Chen, M.D.
@RirongChen
🎉 Thrilled to share our latest review published in @Gut_BMJ!
"From the preclinical phase of Crohn’s disease to postoperative recurrence: shared mechanisms and potential interventions."
gut.bmj.com/content/early/2026/05/28/gutjnl-2025-337981 -
Gut Journal reposted
Dr Nitin Jagtap
@miNitinjagtap
Curent guidel: STOP PPIs aftr EVL
New RCT @Gut_BMJ : rebleding 28% → 11.5% with PPIs.
All deaths in no-PPI group-rebleeding-related.
tim2rewrit #bavenovii doi.org/10.1136/gutjnl-2026-338098 #gitwitter #hepatology #portalhypertension #livertwitter @EASLedu @AASLDtweets @BavenoConsensus -
Gut Journal reposted
robert verdonk
@rcverdonk
Very cool and very important new findings. How to intervene in chronic pancreatitis progression? 👉🏻 🏃 🚴 🏊 Physical activity reshapes intrapancreatic immune and inflammatory programmes to restrain chronic pancreatitis gut.bmj.com/content/early/2026/05/28/gutjnl-2025-337862
-
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
Physical activity is not just “general health advice.”
A new #gut study links activity in chronic pancreatitis to reshaped intrapancreatic immune programs.
Mechanism ≠ prescription, but it moves lifestyle advice closer to biology.
#gastroenterology
doi.org/10.1136/gutjnl-2025-337862 -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Could gut microbial signatures predict postoperative recurrence in Crohn’s disease?
@RirongChen, @SunHoLee15 et al. suggest a pragmatic human model to test biomarker-guided preventive approaches applicable across the CD spectrum
@Gut_BMJ
gut.bmj.com/content/early/2026/05/28/gutjnl-2025-337981 -
Gut Journal reposted
Ben Mullish
@bhmullish
Pleased to see out this paper in @Gut_BMJ on behalf of the @BritSocGastro Gut Microbiota for Health panel - taking stock of where we have come in the last decade in translating gut #microbiome research: gut.bmj.com/content/early/2026/06/02/gutjnl-2026-338252 @IHepatology @ImperialMDR @eurfmt
-
Gut Journal reposted
Ben Mullish
@bhmullish
Spoiler: we think quite a bit but there is still a lot more work to do (kudos to @lauren_r925 for the figures):
-
Gut Journal reposted
Aitor Viribay
@MVAitor
Scientists (@borjammt et al) identified a single gut bacterium associated with stronger grip, leg press and bench press in humans - and supplementing it boosted strength in mice. It increased muscle fibre size and shifted fibres toward fast-twitch. Read👇
gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980.info -
Gut Journal reposted
Metabolism, Digestion & Reproduction
@ImperialMDR
Important new paper from our MDR researchers and collaborators, assessing the progress made over the last decade in translating gut #microbiome research ⬇️
Ben Mullish
@bhmullish
Pleased to see out this paper in @Gut_BMJ on behalf of the @BritSocGastro Gut Microbiota for Health panel - taking stock of where we have come in the last decade in translating gut #microbiome research: gut.bmj.com/content/early/2026/06/02/gutjnl-2026-338252 @IHepatology @ImperialMDR @eurfmt
-
Gut Journal
@Gut_BMJ
Lean MASLD: for better or worse?
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research.
⚖️ Has lean MASLD been wrongly risk stratified in clinical practice?
🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via gut.bmj.com/content/75/4/772
Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez -
Gut Journal
@Gut_BMJ
We hope you enjoy this June 2026 issue of @Gut_BMJ, showcasing exciting advances across immunology, microbiome science, hepatology, pancreatic cancer and inflammatory disease. This month’s issue highlights how translational research and systems biology are reshaping our understanding of inflammation, cancer progression and therapeutic resistance.
This issue also features an Editor’s Choice paper by Wu et al., highlighted on the #gutfrontcover which shows the beautiful Canton Tower, Guangzhou, China. The paper is also discussed in the upcoming #gutpodcast with Professor Wei Wang. The study explores how intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis, providing fascinating new insight into the microbiome–immune axis in the disease and could reshape how we think about endometriosis pathogenesis and treatment.
There’s also major progress in cancer immunology this month:
• Tumour-infiltrating B cells are shown to influence chemoimmunotherapy response in cholangiocarcinoma
• MLCK1 targeting may reduce checkpoint inhibitor colitis without compromising antitumour immunity
• New mechanisms of resistance to CLDN18.2-targeted therapy are identified in pancreatic cancer
The microbiome remains front and centre too:
• Plant-derived nanovesicles modulate microbial metabolism in rheumatoid arthritis
• Gut microbial pathways continue to emerge as therapeutic targets across systemic disease
In hepatology, the issue explores:
• Novel fibrosis pathways involving ISG15
• Predictors of post-transplant rejection after immunotherapy in HCC
• A promising engineered vaccine strategy to overcome HBV immune tolerance
And looking ahead, reviews on AI-enabled Crohn’s disease management and spatial single-cell omics highlight how precision medicine is rapidly becoming reality.
Bottom line?
This issue captures the future direction of the field: combining immunology, microbiome science, AI and molecular medicine to deliver increasingly personalised care.
👉 Read the full June issue here:
gut.bmj.com/content/75/6?current-issue=y
#immunology #microbiome #hepatology #pancreaticcancer #ibd @FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major complication of type 2 diabetes.
Watch the #gutvideo here: www.youtube.com/watch?v=q3yWznwVmj8&list=PL80fezoRY4BDr-o…
Read the paper here: gut.bmj.com/content/75/5/949
Researchers focused on tryptophan metabolism and the microbial metabolite indole-3-propionic acid (IPA), which has anti-inflammatory and barrier-protective effects. Using diabetic mouse models, they showed that restoring tryptophan absorption through engineered probiotics, tryptophan-containing dipeptides, or direct IPA supplementation improved gut barrier integrity, reduced inflammation, enhanced glucose regulation, and prevented retinal damage. Human participants with DR had significantly lower IPA levels and higher markers of gut permeability and toxic metabolites compared with diabetics without DR and healthy controls. The study suggests that impaired gut–retina communication plays a key role in DR progression. Overall, IPA emerged as both a potential biomarker for detecting diabetic retinopathy and a promising therapeutic target for preventing or slowing retinal damage in diabetes.
#diabeticretinopathy -
Gut Journal
@Gut_BMJ
Can colonoscopy after a positive FIT safely wait?
This large French cohort study (374k+ patients) found that delaying colonoscopy—even up to 24 months—did not meaningfully increase colorectal cancer (CRC), advanced CRC, or advanced adenoma risk. With high compliance (86.6%) and most procedures done within ~3 months, outcomes were instead driven more by patient factors (age, sex, FIT haemoglobin level) than timing. These findings challenge prior assumptions that delays beyond 3–12 months are harmful and suggest the slow adenoma–carcinoma sequence may allow more flexibility.
⚖️ Are strict 1–3 month targets less important than ensuring patients actually complete colonoscopy?
🔎 Focus may need to shift from speed to maximising uptake after positive FIT—where the real risk lies.
Read the paper "Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study" via
gut.bmj.com/content/75/4/748
Social media summary by Dr Anahita Sharma, ST6 Gastroenterology Registrar, Merseyside, UK @AnahitaS -
Gut Journal
@Gut_BMJ
Read the paper by Han et al. entitled “Pueraria lobata-derived exosome-like nanovesicles alleviate rheumatoid arthritis via targeting Ruminococcus gnavus phenylethylamine production” via
gut.bmj.com/content/75/6/1123
Microbiome therapeutics continue to evolve rapidly. This study shows how plant-derived nanovesicles can modulate microbial metabolism and reduce inflammatory arthritis, highlighting an innovative cross-talk between dietary compounds, gut microbes and systemic immunity. -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Suo et al. entitled “Spatial single-cell omics: new insights into liver diseases” via
gut.bmj.com/content/75/6/1248
Spatial and single-cell technologies are revolutionising hepatology research. This review highlights how these approaches are uncovering cellular interactions and disease mechanisms with unprecedented resolution, accelerating discovery across liver disease.
#singlecellomics -
Gut Journal
@Gut_BMJ
Milardi et al. present “Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome” via gut.bmj.com/content/75/6/1097
How does the tumour microenvironment shape treatment response? This study identifies an immunosuppressive role for tumour-infiltrating B cells in intrahepatic cholangiocarcinoma, demonstrating how they influence chemoimmunotherapy outcomes. The findings add important complexity to our understanding of tumour immunity and may help refine future immunotherapeutic strategies.
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
Fang et al. present “Immune-related adverse events are a potent predictor of post-transplant rejection in HCC” via
gut.bmj.com/content/75/6/1201
As immunotherapy expands in hepatocellular carcinoma, balancing efficacy and safety becomes increasingly important. This multicentre study shows that immune-related adverse events strongly predict post-transplant rejection, providing clinically important information for patient selection and monitoring.
#hcc -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinclinicalpractice paper by Iacucci et al. on “Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics” via
gut.bmj.com/content/75/6/1237
Can recurrence prediction become truly personalised? This review explores how artificial intelligence and multi-omics technologies may transform postoperative management in Crohn’s disease, moving the field towards precision surveillance and tailored therapy.
#crohnsdisease #ibd #multiomics #ai -
Gut Journal
@Gut_BMJ
The #guteditorschoice paper by Wu et al. is entitled
“Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis” via
gut.bmj.com/content/75/6/1110
It shows a major mechanistic advance in endometriosis research. Wu et al. demonstrate that gut microbial translocation into the peritoneal cavity can trigger NETosis, promoting inflammatory pathways that drive endometriosis progression. This study provides compelling evidence linking the gut microbiome directly to disease pathogenesis and opens exciting opportunities for microbiome-targeted therapies and immune modulation strategies.
#endometriosis #netosis #microbiome -
Gut Journal
@Gut_BMJ
Yuan et al. present “ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation” via
gut.bmj.com/content/75/6/1186
Fibrosis remains central to chronic liver disease progression. This study uncovers a novel regulatory pathway involving ISG15 and CREB1 in hepatic stellate cells, deepening our mechanistic understanding of fibrogenesis and identifying potential antifibrotic targets.
#fibrosis #liverfibrosis -
Gut Journal
@Gut_BMJ
Read the paper by Chen et al. on “Engineered virus-hunter vaccine overcomes HBV immune tolerance” via
gut.bmj.com/content/75/6/1211
Achieving immune control in chronic HBV remains a major goal. This innovative vaccine strategy successfully overcomes immune tolerance in preclinical models, representing an exciting step towards curative immunotherapeutic approaches for hepatitis B.
#hbv #hepatitisb -
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal
@Gut_BMJ
#gutscience is an international, open-access journal focused on the fundamental biology of the gut and liver. It publishes cutting-edge research on how digestive diseases work at molecular and cellular levels, linking basic science with clinical impact. Closely aligned with @BritSocGastro and the leading journal @Gut_BMJ, it aims to drive innovation in diagnostics, treatments and personalised medicine. By bridging lab research and real-world care, Gut Science supports global collaboration and advances understanding of gastrointestinal health and disease.
Visit the website here: gutscience.bmj.com @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Liu et al. present “KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy” via
gut.bmj.com/content/75/6/1169
Why do targeted therapies fail in pancreatic cancer? This study identifies a KRAS-driven molecular mechanism that alters CLDN18.2 biology and reduces therapeutic efficacy. The work provides valuable insight into resistance pathways and may guide future precision treatment approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Important paper in Gut! 📢 New study maps the evolution of pancreatic cysts to cancer
Cui et al. used spatial transcriptomics to map progression from IPMNs to pancreatic ductal adenocarcinoma—revealing it’s not linear, but follows distinct molecular paths.
Early-stage lesions showed active immune surveillance (T cells and NK cells), while progression was marked by a shift to an immunosuppressive environment with expansion of regulatory T cells and fibroblasts.
Intriguingly, histologically similar high-grade lesions with different malignant potential were found to be molecularly distinct.
Malignant trajectories were characterised by upregulation of invasion-associated genes (e.g. CLDN1) + TGF-β / IL-17 signalling.
⚖️ Are we over-treating some IPMNs while missing aggressive disease in others?
This study highlights the limitations of current risk stratification and the promise of spatially resolved biomarkers.
Check the paper: doi: gut.bmj.com/content/75/4/801
Social Media summary by Dr John P Thomas, Chain-Florey Clinical Research Fellow, Imperial College London, London, UK -
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
Gut Feeling or Brain Fog?
Obesity is often associated with poor attention, but the cause is unclear. In a study of 1,000+ people, researchers found links between obesity, altered gut microbes, and worse attention. Higher levels of 3-hydroxyanthranilic acid (3-HAA), a gut-related metabolite, were linked with better attention. In animal models, restoring 3-HAA improved attention deficits. These findings suggest an important gut–brain pathway in obesity.
⚖️Could targeting gut microbes or 3-HAA help reduce brain fog in obesity?
🔎Check the paper "Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity" via gut.bmj.com/content/75/4/705
Social Media summary by Dr Daniela Toumazi, CT2 Internal Medicine Trainee, Broomfield Hospital, Mid and South Essex NHS Trust, UK -
Gut Journal
@Gut_BMJ
In this paper Xiong et al. present “Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity” via
gut.bmj.com/content/75/6/1147
Immune checkpoint inhibitor colitis remains a major clinical challenge. This important translational study demonstrates that targeting MLCK1 can reduce gastrointestinal toxicity while preserving antitumour immune responses—an exciting step towards safer cancer immunotherapy.
#ici #colitis -
Gut Journal
@Gut_BMJ
Lean MASLD: for better or worse?
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research.
⚖️ Has lean MASLD been wrongly risk stratified in clinical practice?
🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via gut.bmj.com/content/75/4/772
Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez -
Gut Journal
@Gut_BMJ
We hope you enjoy this June 2026 issue of @Gut_BMJ, showcasing exciting advances across immunology, microbiome science, hepatology, pancreatic cancer and inflammatory disease. This month’s issue highlights how translational research and systems biology are reshaping our understanding of inflammation, cancer progression and therapeutic resistance.
This issue also features an Editor’s Choice paper by Wu et al., highlighted on the #gutfrontcover which shows the beautiful Canton Tower, Guangzhou, China. The paper is also discussed in the upcoming #gutpodcast with Professor Wei Wang. The study explores how intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis, providing fascinating new insight into the microbiome–immune axis in the disease and could reshape how we think about endometriosis pathogenesis and treatment.
There’s also major progress in cancer immunology this month:
• Tumour-infiltrating B cells are shown to influence chemoimmunotherapy response in cholangiocarcinoma
• MLCK1 targeting may reduce checkpoint inhibitor colitis without compromising antitumour immunity
• New mechanisms of resistance to CLDN18.2-targeted therapy are identified in pancreatic cancer
The microbiome remains front and centre too:
• Plant-derived nanovesicles modulate microbial metabolism in rheumatoid arthritis
• Gut microbial pathways continue to emerge as therapeutic targets across systemic disease
In hepatology, the issue explores:
• Novel fibrosis pathways involving ISG15
• Predictors of post-transplant rejection after immunotherapy in HCC
• A promising engineered vaccine strategy to overcome HBV immune tolerance
And looking ahead, reviews on AI-enabled Crohn’s disease management and spatial single-cell omics highlight how precision medicine is rapidly becoming reality.
Bottom line?
This issue captures the future direction of the field: combining immunology, microbiome science, AI and molecular medicine to deliver increasingly personalised care.
👉 Read the full June issue here:
gut.bmj.com/content/75/6?current-issue=y
#immunology #microbiome #hepatology #pancreaticcancer #ibd @FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
Read the paper by Han et al. entitled “Pueraria lobata-derived exosome-like nanovesicles alleviate rheumatoid arthritis via targeting Ruminococcus gnavus phenylethylamine production” via
gut.bmj.com/content/75/6/1123
Microbiome therapeutics continue to evolve rapidly. This study shows how plant-derived nanovesicles can modulate microbial metabolism and reduce inflammatory arthritis, highlighting an innovative cross-talk between dietary compounds, gut microbes and systemic immunity. -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major complication of type 2 diabetes.
Watch the #gutvideo here: www.youtube.com/watch?v=q3yWznwVmj8&list=PL80fezoRY4BDr-o…
Read the paper here: gut.bmj.com/content/75/5/949
Researchers focused on tryptophan metabolism and the microbial metabolite indole-3-propionic acid (IPA), which has anti-inflammatory and barrier-protective effects. Using diabetic mouse models, they showed that restoring tryptophan absorption through engineered probiotics, tryptophan-containing dipeptides, or direct IPA supplementation improved gut barrier integrity, reduced inflammation, enhanced glucose regulation, and prevented retinal damage. Human participants with DR had significantly lower IPA levels and higher markers of gut permeability and toxic metabolites compared with diabetics without DR and healthy controls. The study suggests that impaired gut–retina communication plays a key role in DR progression. Overall, IPA emerged as both a potential biomarker for detecting diabetic retinopathy and a promising therapeutic target for preventing or slowing retinal damage in diabetes.
#diabeticretinopathy -
Gut Journal
@Gut_BMJ
Can colonoscopy after a positive FIT safely wait?
This large French cohort study (374k+ patients) found that delaying colonoscopy—even up to 24 months—did not meaningfully increase colorectal cancer (CRC), advanced CRC, or advanced adenoma risk. With high compliance (86.6%) and most procedures done within ~3 months, outcomes were instead driven more by patient factors (age, sex, FIT haemoglobin level) than timing. These findings challenge prior assumptions that delays beyond 3–12 months are harmful and suggest the slow adenoma–carcinoma sequence may allow more flexibility.
⚖️ Are strict 1–3 month targets less important than ensuring patients actually complete colonoscopy?
🔎 Focus may need to shift from speed to maximising uptake after positive FIT—where the real risk lies.
Read the paper "Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study" via
gut.bmj.com/content/75/4/748
Social media summary by Dr Anahita Sharma, ST6 Gastroenterology Registrar, Merseyside, UK @AnahitaS -
Gut Journal
@Gut_BMJ
Milardi et al. present “Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome” via gut.bmj.com/content/75/6/1097
How does the tumour microenvironment shape treatment response? This study identifies an immunosuppressive role for tumour-infiltrating B cells in intrahepatic cholangiocarcinoma, demonstrating how they influence chemoimmunotherapy outcomes. The findings add important complexity to our understanding of tumour immunity and may help refine future immunotherapeutic strategies.
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Suo et al. entitled “Spatial single-cell omics: new insights into liver diseases” via
gut.bmj.com/content/75/6/1248
Spatial and single-cell technologies are revolutionising hepatology research. This review highlights how these approaches are uncovering cellular interactions and disease mechanisms with unprecedented resolution, accelerating discovery across liver disease.
#singlecellomics -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
Seb
@ibdseb
Interception Vs Primary Prevention in #ibd
Consider: scalability , practicality , bang for the buck , cost , global impact
Please debate this : we thought long and hard before this 👇 paper
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal reposted
Uma Mahadevan
@UmaMahadevanIBD
If you haven’t reviewed the Global Consensus on Management of pregnancy and IBD, here is a quick video and link to article in @Gut_BMJ @JulsgaardMette @MLongMD @Siew_C_Ng @PIANOIBD
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal
@Gut_BMJ
The #guteditorschoice paper by Wu et al. is entitled
“Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis” via
gut.bmj.com/content/75/6/1110
It shows a major mechanistic advance in endometriosis research. Wu et al. demonstrate that gut microbial translocation into the peritoneal cavity can trigger NETosis, promoting inflammatory pathways that drive endometriosis progression. This study provides compelling evidence linking the gut microbiome directly to disease pathogenesis and opens exciting opportunities for microbiome-targeted therapies and immune modulation strategies.
#endometriosis #netosis #microbiome -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinclinicalpractice paper by Iacucci et al. on “Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics” via
gut.bmj.com/content/75/6/1237
Can recurrence prediction become truly personalised? This review explores how artificial intelligence and multi-omics technologies may transform postoperative management in Crohn’s disease, moving the field towards precision surveillance and tailored therapy.
#crohnsdisease #ibd #multiomics #ai -
Gut Journal
@Gut_BMJ
Fang et al. present “Immune-related adverse events are a potent predictor of post-transplant rejection in HCC” via
gut.bmj.com/content/75/6/1201
As immunotherapy expands in hepatocellular carcinoma, balancing efficacy and safety becomes increasingly important. This multicentre study shows that immune-related adverse events strongly predict post-transplant rejection, providing clinically important information for patient selection and monitoring.
#hcc -
Gut Journal
@Gut_BMJ
Read the paper by Chen et al. on “Engineered virus-hunter vaccine overcomes HBV immune tolerance” via
gut.bmj.com/content/75/6/1211
Achieving immune control in chronic HBV remains a major goal. This innovative vaccine strategy successfully overcomes immune tolerance in preclinical models, representing an exciting step towards curative immunotherapeutic approaches for hepatitis B.
#hbv #hepatitisb -
Gut Journal
@Gut_BMJ
Yuan et al. present “ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation” via
gut.bmj.com/content/75/6/1186
Fibrosis remains central to chronic liver disease progression. This study uncovers a novel regulatory pathway involving ISG15 and CREB1 in hepatic stellate cells, deepening our mechanistic understanding of fibrogenesis and identifying potential antifibrotic targets.
#fibrosis #liverfibrosis -
Gut Journal
@Gut_BMJ
New #gutvideo by @UmaMahadevanIBD @PIANOIBD
Pregnancy in women with inflammatory bowel disease (IBD) remains complex, with limited high-quality evidence and significant variation in care worldwide. Differences in provider knowledge, access to resources, and conflicting guidelines can affect medication adherence, pregnancy decisions, and outcomes for mothers and babies. The Global Consensus Consortium—bringing together 39 IBD experts and 7 patient advocates from 6 continents—reviewed the evidence using GRADE and RAND methodologies to develop practical, data-driven recommendations. Their work includes 34 formal recommendations and 35 consensus statements aimed at improving global care for women with IBD during pregnancy, always prioritising maternal health to support infant health.
Watch the #gutvideo by Uma Mahadevan now on the paper
"Global consensus statement on the management of pregnancy in inflammatory bowel disease" via
www.youtube.com/watch?v=MnX5qWkjGLc&list=PL80fezoRY4BDr-o…
Paper via gut.bmj.com/content/75/2/1
#pregnancy #ibd -
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal
@Gut_BMJ
A key mechanistic advance in eosinophilic oesophagitis. Sasaki et al. identify FOXM1 as a central regulator of IL-13-driven epithelial dysfunction, showing that its inhibition attenuates inflammation and tissue remodelling. This work opens the door to targeted therapies aimed at upstream drivers of disease rather than downstream inflammation alone.
Sasaki et al. present “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis” via
gut.bmj.com/content/75/5/857
#il13 #eoe #eosinophilicoesophagitis -
Gut Journal reposted
Nadeem Tehami
@helpatologist
Timely publication for Bank Holdiay Weekend @NHSEngland @drmwjames
Cholangitis
Urgent ERCP <24 hours ❌
Early ERCP within 24–48 hours ✅
Should not be delayed further, as previous data suggest worse outcomes when intervention is delayed >72 hours
Congrats @miNitinjagtap et al
Dr Nitin Jagtap
@miNitinjagtap
-
Gut Journal reposted
Matthias Hardtke-Wolenski
@HardtkeWolenski
ICI colitis remains a major limit of cancer immunotherapy. In Gut, targeting epithelial MLCK1 decoupled colitis from antitumour immunity in models and patient-derived analyses — a cautious but compelling toxicity-sparing concept. doi.org/10.1136/gutjnl-2025-337780 #immunotherapy #gut
-
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
A fascinating mechanistic step forward in EoE biology. Beyond eosinophilic inflammation, this study highlights FOXM1 as a potential driver of epithelial remodeling, basal hyperplasia, and barrier dysfunction.
Restoring epithelial homeostasis may ultimately become just as important as suppressing inflammation in achieving durable remission in EoE. Outstanding translational work by the authors. 👏
#gastroenterology #medtwitter #meded
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
#gutscience is an international, open-access journal focused on the fundamental biology of the gut and liver. It publishes cutting-edge research on how digestive diseases work at molecular and cellular levels, linking basic science with clinical impact. Closely aligned with @BritSocGastro and the leading journal @Gut_BMJ, it aims to drive innovation in diagnostics, treatments and personalised medicine. By bridging lab research and real-world care, Gut Science supports global collaboration and advances understanding of gastrointestinal health and disease.
Visit the website here: gutscience.bmj.com @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Fibrosis remains a major unmet need in Crohn’s disease. This study by Zhou et al. links metabolic reprogramming in fibroblasts to fibrotic progression, highlighting the pentose phosphate pathway as a potential therapeutic target.
Read “Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease” via gut.bmj.com/content/75/5/905
#fibrosis #ibd #crohnsdisease -
Gut Journal
@Gut_BMJ
This large international dataset expands the phenotypic and molecular spectrum of CTNNA1-associated hereditary gastric cancer. The findings have important implications for genetic counselling, surveillance and risk stratification in affected families.
Lobo et al. present the paper “Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls” via
gut.bmj.com/content/75/5/872
#hereditarycancer #gastriccancer -
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
Liu et al. present “KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy” via
gut.bmj.com/content/75/6/1169
Why do targeted therapies fail in pancreatic cancer? This study identifies a KRAS-driven molecular mechanism that alters CLDN18.2 biology and reduces therapeutic efficacy. The work provides valuable insight into resistance pathways and may guide future precision treatment approaches.
#pancreaticcancer -
Gut Journal
@Gut_BMJ
Important paper in Gut! 📢 New study maps the evolution of pancreatic cysts to cancer
Cui et al. used spatial transcriptomics to map progression from IPMNs to pancreatic ductal adenocarcinoma—revealing it’s not linear, but follows distinct molecular paths.
Early-stage lesions showed active immune surveillance (T cells and NK cells), while progression was marked by a shift to an immunosuppressive environment with expansion of regulatory T cells and fibroblasts.
Intriguingly, histologically similar high-grade lesions with different malignant potential were found to be molecularly distinct.
Malignant trajectories were characterised by upregulation of invasion-associated genes (e.g. CLDN1) + TGF-β / IL-17 signalling.
⚖️ Are we over-treating some IPMNs while missing aggressive disease in others?
This study highlights the limitations of current risk stratification and the promise of spatially resolved biomarkers.
Check the paper: doi: gut.bmj.com/content/75/4/801
Social Media summary by Dr John P Thomas, Chain-Florey Clinical Research Fellow, Imperial College London, London, UK -
Gut Journal reposted
Sundeep Lakhtakia
@DrLakhtakia
Congrats Nitin @miNitinjagtap
& Hardik @drhrr for leading this very important clinical study. -
Gut Journal reposted
Dr Nitin Jagtap
@miNitinjagtap
-
Gut Journal reposted
BSG
@BritSocGastro
New month, new insights 🔬
The latest BSG Gut Highlights are here covering key advances, clinical updates, and must-read research across #gastroenterology & #hepatology.
Catch up on the May 2026 edition 👇
www.bsg.org.uk/web-education/bsg-gut-highlights-may-2026
@Gut_BMJ -
Gut Journal
@Gut_BMJ
In this paper Xiong et al. present “Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity” via
gut.bmj.com/content/75/6/1147
Immune checkpoint inhibitor colitis remains a major clinical challenge. This important translational study demonstrates that targeting MLCK1 can reduce gastrointestinal toxicity while preserving antitumour immune responses—an exciting step towards safer cancer immunotherapy.
#ici #colitis -
Gut Journal
@Gut_BMJ
Gut Feeling or Brain Fog?
Obesity is often associated with poor attention, but the cause is unclear. In a study of 1,000+ people, researchers found links between obesity, altered gut microbes, and worse attention. Higher levels of 3-hydroxyanthranilic acid (3-HAA), a gut-related metabolite, were linked with better attention. In animal models, restoring 3-HAA improved attention deficits. These findings suggest an important gut–brain pathway in obesity.
⚖️Could targeting gut microbes or 3-HAA help reduce brain fog in obesity?
🔎Check the paper "Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity" via gut.bmj.com/content/75/4/705
Social Media summary by Dr Daniela Toumazi, CT2 Internal Medicine Trainee, Broomfield Hospital, Mid and South Essex NHS Trust, UK -
Gut Journal
@Gut_BMJ
Prasad et al. present “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” via gut.bmj.com/content/75/5/949
This work identifies a microbial metabolite linking intestinal dysfunction to retinal disease, offering both a biomarker and a potential therapeutic target.
#diabeticretinopathy #microbiota -
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal
@Gut_BMJ
We hope you enjoy this June 2026 issue of @Gut_BMJ, showcasing exciting advances across immunology, microbiome science, hepatology, pancreatic cancer and inflammatory disease. This month’s issue highlights how translational research and systems biology are reshaping our understanding of inflammation, cancer progression and therapeutic resistance.
This issue also features an Editor’s Choice paper by Wu et al., highlighted on the #gutfrontcover which shows the beautiful Canton Tower, Guangzhou, China. The paper is also discussed in the upcoming #gutpodcast with Professor Wei Wang. The study explores how intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis, providing fascinating new insight into the microbiome–immune axis in the disease and could reshape how we think about endometriosis pathogenesis and treatment.
There’s also major progress in cancer immunology this month:
• Tumour-infiltrating B cells are shown to influence chemoimmunotherapy response in cholangiocarcinoma
• MLCK1 targeting may reduce checkpoint inhibitor colitis without compromising antitumour immunity
• New mechanisms of resistance to CLDN18.2-targeted therapy are identified in pancreatic cancer
The microbiome remains front and centre too:
• Plant-derived nanovesicles modulate microbial metabolism in rheumatoid arthritis
• Gut microbial pathways continue to emerge as therapeutic targets across systemic disease
In hepatology, the issue explores:
• Novel fibrosis pathways involving ISG15
• Predictors of post-transplant rejection after immunotherapy in HCC
• A promising engineered vaccine strategy to overcome HBV immune tolerance
And looking ahead, reviews on AI-enabled Crohn’s disease management and spatial single-cell omics highlight how precision medicine is rapidly becoming reality.
Bottom line?
This issue captures the future direction of the field: combining immunology, microbiome science, AI and molecular medicine to deliver increasingly personalised care.
👉 Read the full June issue here:
gut.bmj.com/content/75/6?current-issue=y
#immunology #microbiome #hepatology #pancreaticcancer #ibd @FrontGastro_BMJ @BMJOpen_Gastro @BritSocGastro -
Gut Journal
@Gut_BMJ
NEW #gutblog by Professor Antoni Castells, Professor Andrea Buron and Professor Uri Ladabaum on the paper
"Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening" via
blogs.bmj.com/gut/2026/04/23/gutblog-effect-of-long-term-…
Read the full paper via
gut.bmj.com/content/75/5/984
#fit #crc #screening #colorectalcancer -
Gut Journal
@Gut_BMJ
Lean MASLD: for better or worse?
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global cause of chronic liver disease, affecting both obese and lean individuals. In a large study of 186,221 participants across three cohorts with 14-year follow-up, lean MASLD was linked to worse outcomes than non-lean MASLD. It showed higher risks of liver-related events, liver-related mortality, and all-cause mortality, despite similar cancer risk and lower cardiovascular disease incidence. These findings highlight a distinct risk profile, suggesting BMI alone is insufficient for assessment and emphasizing the need for tailored management and further research.
⚖️ Has lean MASLD been wrongly risk stratified in clinical practice?
🔎 Check out the the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" via gut.bmj.com/content/75/4/772
Social Media summary by Dr David Gomez, ST4 Gastroenterology, Royal Free London NHS Foundation Trust, London, UK @DrDAGomez -
Gut Journal
@Gut_BMJ
Inamdar et al. present the paper “Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis” via
gut.bmj.com/content/75/5/1003
The paper describes a mechanistic bridge between inflammation and cancer. It shows how inherited pancreatic disease primes tissue for oncogenic transformation, shedding light on early events in pancreatic cancer development.
#pancreaticcancer #pancreatitis -
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
Read the #gutcommentary by Campani and Nault ("New player in inflammation-driver liver carcinogenesis: pirin on fire!") who highlight pirin as an emerging mediator linking chronic inflammation to hepatocellular carcinoma (HCC).
Building on new data, they describe how pirin amplifies key inflammatory signalling pathways, notably NF-κB and STAT3, reinforcing a tumour-promoting microenvironment in the liver. This positions pirin as a critical node connecting oxidative stress, immune responses, and malignant transformation. The #gutcommentary underscores its potential as both a biomarker and therapeutic target in inflammation-driven liver cancer. Overall, pirin is framed as a “new player on fire,” advancing understanding of how persistent inflammation fuels hepatocarcinogenesis. Read the commentary here: gut.bmj.com/content/75/5/849
This perspective is grounded in Ma et al., also a paper in this May issue (gut.bmj.com/content/75/5/1016who) who demonstrate that nuclear pirin drives HCC through a redox-dependent positive feedback loop, amplifying inflammatory signalling and cytokine production, thereby providing the mechanistic basis for its clinical relevance.
#pirin #hcc -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo on the paper by Prasad et al. “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” which investigates how disruptions in gut health contribute to diabetic retinopathy (DR), a major complication of type 2 diabetes.
Watch the #gutvideo here: www.youtube.com/watch?v=q3yWznwVmj8&list=PL80fezoRY4BDr-o…
Read the paper here: gut.bmj.com/content/75/5/949
Researchers focused on tryptophan metabolism and the microbial metabolite indole-3-propionic acid (IPA), which has anti-inflammatory and barrier-protective effects. Using diabetic mouse models, they showed that restoring tryptophan absorption through engineered probiotics, tryptophan-containing dipeptides, or direct IPA supplementation improved gut barrier integrity, reduced inflammation, enhanced glucose regulation, and prevented retinal damage. Human participants with DR had significantly lower IPA levels and higher markers of gut permeability and toxic metabolites compared with diabetics without DR and healthy controls. The study suggests that impaired gut–retina communication plays a key role in DR progression. Overall, IPA emerged as both a potential biomarker for detecting diabetic retinopathy and a promising therapeutic target for preventing or slowing retinal damage in diabetes.
#diabeticretinopathy -
Gut Journal
@Gut_BMJ
Can colonoscopy after a positive FIT safely wait?
This large French cohort study (374k+ patients) found that delaying colonoscopy—even up to 24 months—did not meaningfully increase colorectal cancer (CRC), advanced CRC, or advanced adenoma risk. With high compliance (86.6%) and most procedures done within ~3 months, outcomes were instead driven more by patient factors (age, sex, FIT haemoglobin level) than timing. These findings challenge prior assumptions that delays beyond 3–12 months are harmful and suggest the slow adenoma–carcinoma sequence may allow more flexibility.
⚖️ Are strict 1–3 month targets less important than ensuring patients actually complete colonoscopy?
🔎 Focus may need to shift from speed to maximising uptake after positive FIT—where the real risk lies.
Read the paper "Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study" via
gut.bmj.com/content/75/4/748
Social media summary by Dr Anahita Sharma, ST6 Gastroenterology Registrar, Merseyside, UK @AnahitaS -
Gut Journal
@Gut_BMJ
Read the paper by Han et al. entitled “Pueraria lobata-derived exosome-like nanovesicles alleviate rheumatoid arthritis via targeting Ruminococcus gnavus phenylethylamine production” via
gut.bmj.com/content/75/6/1123
Microbiome therapeutics continue to evolve rapidly. This study shows how plant-derived nanovesicles can modulate microbial metabolism and reduce inflammatory arthritis, highlighting an innovative cross-talk between dietary compounds, gut microbes and systemic immunity. -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Milardi et al. present “Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome” via gut.bmj.com/content/75/6/1097
How does the tumour microenvironment shape treatment response? This study identifies an immunosuppressive role for tumour-infiltrating B cells in intrahepatic cholangiocarcinoma, demonstrating how they influence chemoimmunotherapy outcomes. The findings add important complexity to our understanding of tumour immunity and may help refine future immunotherapeutic strategies.
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
Read the #recentadvancesinbasicscience paper by Suo et al. entitled “Spatial single-cell omics: new insights into liver diseases” via
gut.bmj.com/content/75/6/1248
Spatial and single-cell technologies are revolutionising hepatology research. This review highlights how these approaches are uncovering cellular interactions and disease mechanisms with unprecedented resolution, accelerating discovery across liver disease.
#singlecellomics -
Gut Journal
@Gut_BMJ
A compelling demonstration of how specific microbes can drive disease. Tan et al. show that this bacterium promotes colitis and cancer through "NETosis" activation, providing mechanistic insight into microbe-driven inflammation and carcinogenesis.
Tan et al. present “Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation" via
gut.bmj.com/content/75/5/920
#colitis #colorectalcancer -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis | Gut gut.bmj.com/content/early/2026/05/14/gutjnl-2025-337838
-
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal
@Gut_BMJ
A key mechanistic advance in eosinophilic oesophagitis. Sasaki et al. identify FOXM1 as a central regulator of IL-13-driven epithelial dysfunction, showing that its inhibition attenuates inflammation and tissue remodelling. This work opens the door to targeted therapies aimed at upstream drivers of disease rather than downstream inflammation alone.
Sasaki et al. present “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis” via
gut.bmj.com/content/75/5/857
#il13 #eoe #eosinophilicoesophagitis -
Gut Journal reposted
Hepatic Cell News
@hepaticcellnews
Scientists examine and identify the role of ISG15 as a key suppressor of liver fibrosis in hepatic stellate cells. #liverfibrosis
🔓 #openaccess at @Gut_BMJ
Learn more here:
gut.bmj.com/content/75/6/1186 -
Gut Journal
@Gut_BMJ
Fibrosis remains a major unmet need in Crohn’s disease. This study by Zhou et al. links metabolic reprogramming in fibroblasts to fibrotic progression, highlighting the pentose phosphate pathway as a potential therapeutic target.
Read “Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease” via gut.bmj.com/content/75/5/905
#fibrosis #ibd #crohnsdisease -
Gut Journal
@Gut_BMJ
This large international dataset expands the phenotypic and molecular spectrum of CTNNA1-associated hereditary gastric cancer. The findings have important implications for genetic counselling, surveillance and risk stratification in affected families.
Lobo et al. present the paper “Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls” via
gut.bmj.com/content/75/5/872
#hereditarycancer #gastriccancer -
Gut Journal reposted
Immune Regulation News
@Immune_News
Using murine models, researchers identified tumor necrosis factor secreted by CD8+ and CD4+ T cells as an upstream regulator that induces #colitis through this MLCK-dependent mechanism
👉 Give it a read in @Gut_BMJ: gut.bmj.com/content/75/6/1147 -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Can probiotic drinks boost our brain health?
New findings suggest that probiotic yogurt might influence how the brain and gut interact, but more research is needed to understand their importance
@Gut_BMJ
gut.bmj.com/content/75/3/511 -
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal
@Gut_BMJ
Prasad et al. present “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” via gut.bmj.com/content/75/5/949
This work identifies a microbial metabolite linking intestinal dysfunction to retinal disease, offering both a biomarker and a potential therapeutic target.
#diabeticretinopathy #microbiota -
Gut Journal reposted
Valerie Chew
@Valeriechew29
This large prospective multicohort study (~188,000 participants, ~14-year follow-up) published in @Gut_BMJ shows that "lean" MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
NEW #gutblog by Professor Antoni Castells, Professor Andrea Buron and Professor Uri Ladabaum on the paper
"Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening" via
blogs.bmj.com/gut/2026/04/23/gutblog-effect-of-long-term-…
Read the full paper via
gut.bmj.com/content/75/5/984
#fit #crc #screening #colorectalcancer -
Gut Journal
@Gut_BMJ
#gutscience is an international, open-access journal focused on the fundamental biology of the gut and liver. It publishes cutting-edge research on how digestive diseases work at molecular and cellular levels, linking basic science with clinical impact. Closely aligned with @BritSocGastro and the leading journal @Gut_BMJ, it aims to drive innovation in diagnostics, treatments and personalised medicine. By bridging lab research and real-world care, Gut Science supports global collaboration and advances understanding of gastrointestinal health and disease.
Visit the website here: gutscience.bmj.com @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Inamdar et al. present the paper “Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis” via
gut.bmj.com/content/75/5/1003
The paper describes a mechanistic bridge between inflammation and cancer. It shows how inherited pancreatic disease primes tissue for oncogenic transformation, shedding light on early events in pancreatic cancer development.
#pancreaticcancer #pancreatitis -
Gut Journal
@Gut_BMJ
We hope you enjoy this May 2026 issue of @Gut_BMJ, bringing together impactful research across oesophageal disease, gastrointestinal cancer, microbiome science, hepatology and acute care. This issue highlights how mechanistic biology, large-scale datasets and emerging technologies are converging to refine disease understanding and unlock new therapeutic strategies.
This issue also features an Editor’s Choice paper by Sasaki et al., highlighted on the #gutfrontcover and soon to be explored in the #gutpodcast (gutbmj.podbean.com). The #gutcover features Benjamin Franklin Parkway in Philadelphia, USA, celebrating this important work demonstrating how FOXM1 inhibition reduces IL-13-driven epithelial remodelling and inflammation in eosinophilic oesophagitis. It’s a great example of how we’re moving towards targeting the root cause of inflammation, not just treating symptoms.
There’s also a strong tech angle this month. One standout explores how large language models could help detect colorectal polyps during endoscopy—hinting at a future where AI actively supports real-time clinical decisions.
Cancer research is another major focus:
• New data refine genetic risk in hereditary gastric cancer
• Multi-omics approaches are uncovering new treatment targets
• Pancreatic studies reveal how chronic inflammation and genetics combine to drive early cancer development
The microbiome continues to impress, with studies linking gut bacteria to:
• Autism biomarkers
• Diabetic retinopathy
• Even stress-related cancer metastasis
It’s not just theory either—these findings are increasingly pointing towards real diagnostic and therapeutic possibilities.
On the clinical side, there are practical takeaways too:
• Better adherence improves colorectal cancer screening outcomes
• New evidence helps guide nutrition in acute pancreatitis
• Combination therapies are advancing hepatitis B treatment
And globally, there’s an important perspective on how we might prevent IBD, especially in rapidly changing regions.
Bottom line?
This issue really highlights a shift in the field—towards earlier detection, smarter use of technology, and treatments that are more personalised and mechanism-driven.
👉 Read the full issue: gut.bmj.com/content/75/5
@BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro #gutissue #gutcover #gutfrontcover -
Gut Journal reposted
Arndt Vogel
@ArndtVogel
Immune-related adverse events are a potent predictor
of post-transplant rejection in HCC: a multicentre retrospective cohort study
@Gut_BMJ
doi.org/10.1136/gutjnl-2025-336719
👉Identifying irAEs could serve as a potential biomarker may enhance patient selection and risk stratification before LT
@myESMO @EASLedu @ILCAnews -
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
Read the #gutcommentary by Campani and Nault ("New player in inflammation-driver liver carcinogenesis: pirin on fire!") who highlight pirin as an emerging mediator linking chronic inflammation to hepatocellular carcinoma (HCC).
Building on new data, they describe how pirin amplifies key inflammatory signalling pathways, notably NF-κB and STAT3, reinforcing a tumour-promoting microenvironment in the liver. This positions pirin as a critical node connecting oxidative stress, immune responses, and malignant transformation. The #gutcommentary underscores its potential as both a biomarker and therapeutic target in inflammation-driven liver cancer. Overall, pirin is framed as a “new player on fire,” advancing understanding of how persistent inflammation fuels hepatocarcinogenesis. Read the commentary here: gut.bmj.com/content/75/5/849
This perspective is grounded in Ma et al., also a paper in this May issue (gut.bmj.com/content/75/5/1016who) who demonstrate that nuclear pirin drives HCC through a redox-dependent positive feedback loop, amplifying inflammatory signalling and cytokine production, thereby providing the mechanistic basis for its clinical relevance.
#pirin #hcc -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
A compelling demonstration of how specific microbes can drive disease. Tan et al. show that this bacterium promotes colitis and cancer through "NETosis" activation, providing mechanistic insight into microbe-driven inflammation and carcinogenesis.
Tan et al. present “Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation" via
gut.bmj.com/content/75/5/920
#colitis #colorectalcancer -
Gut Journal reposted
Seb
@ibdseb
#ibd prevention is a critical approach needed as it evolves into a global 🌎 disease
Most of the focus has been on interception trials
Is interception affordable to the world particularly global south - I don’t think so
In this paper we suggest another approach - sieve concept - using the model of non-communicable disease prevention . Please comment , discuss, critique
The upcoming @LancetGastroHep commission will incorporate global preventive strategies in #ibd This is a more pragmatic approach
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal reposted
Joseantonio Trujillo
@Joseatrujillo
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
-
Gut Journal reposted
Keith Siau
@drkeithsiau
This BSG guidance document is like a textbook for upper GI endoscopy and is a must read for endoscopists and trainees 💡🆕
This media couldn't be displayed. See it on the original post. -
Gut Journal reposted
Keith Siau
@drkeithsiau
Here are some of the highlights ‼️
1️⃣ Where to take photos
2️⃣ How to describe lesions
3️⃣ Barrett’s assessment
4️⃣ Gastric intestinal metaplasia
📸: @FrontGastro_BMJ
fg.bmj.com/content/early/2026/04/28/flgastro-2025-103455 -
Gut Journal
@Gut_BMJ
#gutscience is an international, open-access journal focused on the fundamental biology of the gut and liver. It publishes cutting-edge research on how digestive diseases work at molecular and cellular levels, linking basic science with clinical impact. Closely aligned with @BritSocGastro and the leading journal @Gut_BMJ, it aims to drive innovation in diagnostics, treatments and personalised medicine. By bridging lab research and real-world care, Gut Science supports global collaboration and advances understanding of gastrointestinal health and disease.
Visit the website here: gutscience.bmj.com @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal reposted
Thor Halfdanarson
@OncoThor
Very interesting data from @MayoClinic on AI-driven detection of visually occult pancreatic adenocarcinoma. Higher sensitivity than radiologists. Outstanding work from Dr. Ajit Goenka and the @MayoRadiology team!
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal
@Gut_BMJ
A key mechanistic advance in eosinophilic oesophagitis. Sasaki et al. identify FOXM1 as a central regulator of IL-13-driven epithelial dysfunction, showing that its inhibition attenuates inflammation and tissue remodelling. This work opens the door to targeted therapies aimed at upstream drivers of disease rather than downstream inflammation alone.
Sasaki et al. present “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis” via
gut.bmj.com/content/75/5/857
#il13 #eoe #eosinophilicoesophagitis -
Gut Journal
@Gut_BMJ
New on the #gutpodcast: a fascinating discussion on the future of treatment for Eosinophilic oesophagitis and the emerging therapeutic potential of FOXM1 inhibition.
In this episode, Dr Philip Smith speaks with Professor Amanda Muir about their latest Gut paper, “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis”, published in @Gut_BMJ in May 2026.
The conversation explores how IL-13-driven inflammation contributes to epithelial remodelling and disease progression in eosinophilic oesophagitis (EoE), and how targeting FOXM1 could represent a promising new therapeutic strategy. The study highlights the important role of epithelial biology in disease pathogenesis and suggests that FOXM1 inhibition may help reduce both inflammatory activity and tissue remodelling associated with EoE.
The episode also discusses the translational significance of these findings, potential clinical implications, and how this research could shape future precision therapies for patients living with this increasingly recognised condition.
Listen now:
▶️ Apple: podcasts.apple.com/us/podcast/eosinophilic-oesophagitis-t…
▶️ Spotify: open.spotify.com/episode/501c1TD1uuN9yuQi5JUt27
▶️ Web: gutbmj.podbean.com/e/eosinophilic-oesophagitis-the-therap…
Read the paper here: gut.bmj.com/content/75/5/857
#eoe -
Gut Journal
@Gut_BMJ
This large international dataset expands the phenotypic and molecular spectrum of CTNNA1-associated hereditary gastric cancer. The findings have important implications for genetic counselling, surveillance and risk stratification in affected families.
Lobo et al. present the paper “Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls” via
gut.bmj.com/content/75/5/872
#hereditarycancer #gastriccancer -
Gut Journal
@Gut_BMJ
Fibrosis remains a major unmet need in Crohn’s disease. This study by Zhou et al. links metabolic reprogramming in fibroblasts to fibrotic progression, highlighting the pentose phosphate pathway as a potential therapeutic target.
Read “Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease” via gut.bmj.com/content/75/5/905
#fibrosis #ibd #crohnsdisease -
Gut Journal reposted
iBio
@iBio_me
Next-generation #ai for visually occult #pancreatic #cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability.
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal reposted
Society for Mucosal Immunology
@socmucimm
Read #smimemberpaper by Croitoru and colleagues in @Gut_BMJ from the PIONIR (Preventing IBD ONset in Individuals at Risk) trial on calprotectin to identify at-risk individuals during the potential pre-CD stage for enrolment in prevention trials.
gut.bmj.com/content/early/2026/01/09/gutjnl-2025-336368 -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Fascinating mechanistic work—reinforces how tightly chronic inflammation and oxidative stress drive HCC progression. Targeting pathways like Pirin may eventually open new preventive or therapeutic strategies in inflammation-driven liver cancer.
#hcc #livertwitter #medx
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal
@Gut_BMJ
Prasad et al. present “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” via gut.bmj.com/content/75/5/949
This work identifies a microbial metabolite linking intestinal dysfunction to retinal disease, offering both a biomarker and a potential therapeutic target.
#diabeticretinopathy #microbiota -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
IBD is no longer just genetics, but a reflection of environment, lifestyle, and early exposures. In practice, small modifiable factors (diet, antibiotics, activity) often shape long-term disease risk more than we realize. #ibd #medtwitter
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal reposted
Samuel Hume
@DrSamuelBHume
Here's the validation data in a broader population, against the performance of two radiologists
Just published in Gut: gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal
@Gut_BMJ
Inamdar et al. present the paper “Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis” via
gut.bmj.com/content/75/5/1003
The paper describes a mechanistic bridge between inflammation and cancer. It shows how inherited pancreatic disease primes tissue for oncogenic transformation, shedding light on early events in pancreatic cancer development.
#pancreaticcancer #pancreatitis -
Gut Journal
@Gut_BMJ
We hope you enjoy this May 2026 issue of @Gut_BMJ, bringing together impactful research across oesophageal disease, gastrointestinal cancer, microbiome science, hepatology and acute care. This issue highlights how mechanistic biology, large-scale datasets and emerging technologies are converging to refine disease understanding and unlock new therapeutic strategies.
This issue also features an Editor’s Choice paper by Sasaki et al., highlighted on the #gutfrontcover and soon to be explored in the #gutpodcast (gutbmj.podbean.com). The #gutcover features Benjamin Franklin Parkway in Philadelphia, USA, celebrating this important work demonstrating how FOXM1 inhibition reduces IL-13-driven epithelial remodelling and inflammation in eosinophilic oesophagitis. It’s a great example of how we’re moving towards targeting the root cause of inflammation, not just treating symptoms.
There’s also a strong tech angle this month. One standout explores how large language models could help detect colorectal polyps during endoscopy—hinting at a future where AI actively supports real-time clinical decisions.
Cancer research is another major focus:
• New data refine genetic risk in hereditary gastric cancer
• Multi-omics approaches are uncovering new treatment targets
• Pancreatic studies reveal how chronic inflammation and genetics combine to drive early cancer development
The microbiome continues to impress, with studies linking gut bacteria to:
• Autism biomarkers
• Diabetic retinopathy
• Even stress-related cancer metastasis
It’s not just theory either—these findings are increasingly pointing towards real diagnostic and therapeutic possibilities.
On the clinical side, there are practical takeaways too:
• Better adherence improves colorectal cancer screening outcomes
• New evidence helps guide nutrition in acute pancreatitis
• Combination therapies are advancing hepatitis B treatment
And globally, there’s an important perspective on how we might prevent IBD, especially in rapidly changing regions.
Bottom line?
This issue really highlights a shift in the field—towards earlier detection, smarter use of technology, and treatments that are more personalised and mechanism-driven.
👉 Read the full issue: gut.bmj.com/content/75/5
@BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro #gutissue #gutcover #gutfrontcover -
Gut Journal
@Gut_BMJ
NEW #gutblog by Professor Antoni Castells, Professor Andrea Buron and Professor Uri Ladabaum on the paper
"Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening" via
blogs.bmj.com/gut/2026/04/23/gutblog-effect-of-long-term-…
Read the full paper via
gut.bmj.com/content/75/5/984
#fit #crc #screening #colorectalcancer -
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
Read the #gutcommentary by Campani and Nault ("New player in inflammation-driver liver carcinogenesis: pirin on fire!") who highlight pirin as an emerging mediator linking chronic inflammation to hepatocellular carcinoma (HCC).
Building on new data, they describe how pirin amplifies key inflammatory signalling pathways, notably NF-κB and STAT3, reinforcing a tumour-promoting microenvironment in the liver. This positions pirin as a critical node connecting oxidative stress, immune responses, and malignant transformation. The #gutcommentary underscores its potential as both a biomarker and therapeutic target in inflammation-driven liver cancer. Overall, pirin is framed as a “new player on fire,” advancing understanding of how persistent inflammation fuels hepatocarcinogenesis. Read the commentary here: gut.bmj.com/content/75/5/849
This perspective is grounded in Ma et al., also a paper in this May issue (gut.bmj.com/content/75/5/1016who) who demonstrate that nuclear pirin drives HCC through a redox-dependent positive feedback loop, amplifying inflammatory signalling and cytokine production, thereby providing the mechanistic basis for its clinical relevance.
#pirin #hcc -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
A compelling demonstration of how specific microbes can drive disease. Tan et al. show that this bacterium promotes colitis and cancer through "NETosis" activation, providing mechanistic insight into microbe-driven inflammation and carcinogenesis.
Tan et al. present “Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation" via
gut.bmj.com/content/75/5/920
#colitis #colorectalcancer -
Gut Journal reposted
Darrell Pardi
@DarrellPardi
Next-generation AI for visually occult pancreatic cancer detection | Gut. Proud that our teams are using AI to improve the detection of pancreatic cancer at an earlier stage, leading to increased opportunities for cure! @MayoClinicGIHep gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
-
Gut Journal reposted
Mike Owens MD FASGE
@MikeOwensMD
Who is doing the study with EUS, MRI and AI such as REMOD for pancreatic cancer screening cohorts?
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Dietary emulsifier sensitivity can be predicted through in vitro gut microbiota system
Read more thanks to @HeloiseRytter, @BenoitChassaing et al. via @Gut_BMJ :
gut.bmj.com/content/74/5/761 -
Gut Journal reposted
Amirhossein Roshanshad, MD
@ARoshanshad
A new radiomics-based model (REDMOD) can detect pancreatic ductal adenocarcinoma on CT scans ~16 months before diagnosis.
This could be a game changer.
🔗 Full paper: gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
#ai #radiology @AjitGoenka @Gut_BMJ
Diagnostic Imaging
@Dx_imaging
Can a Radiomic #ai Model Facilitate Earlier CT Detection of Pancreatic Ductal Adenocarcinoma?
www.diagnosticimaging.com/view/radiomic-ai-model-earlier-…
@RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad
#radiology #radres #ctrad -
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal
@Gut_BMJ
A key mechanistic advance in eosinophilic oesophagitis. Sasaki et al. identify FOXM1 as a central regulator of IL-13-driven epithelial dysfunction, showing that its inhibition attenuates inflammation and tissue remodelling. This work opens the door to targeted therapies aimed at upstream drivers of disease rather than downstream inflammation alone.
Sasaki et al. present “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis” via
gut.bmj.com/content/75/5/857
#il13 #eoe #eosinophilicoesophagitis -
Gut Journal
@Gut_BMJ
This large international dataset expands the phenotypic and molecular spectrum of CTNNA1-associated hereditary gastric cancer. The findings have important implications for genetic counselling, surveillance and risk stratification in affected families.
Lobo et al. present the paper “Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls” via
gut.bmj.com/content/75/5/872
#hereditarycancer #gastriccancer -
Gut Journal
@Gut_BMJ
Fibrosis remains a major unmet need in Crohn’s disease. This study by Zhou et al. links metabolic reprogramming in fibroblasts to fibrotic progression, highlighting the pentose phosphate pathway as a potential therapeutic target.
Read “Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease” via gut.bmj.com/content/75/5/905
#fibrosis #ibd #crohnsdisease -
Gut Journal reposted
Gorka Orive
@gorka_orive
Un sistema de detección temprana basado en Inteligencia Artificial es capaz de detectar el cáncer de páncreas oculto mejor (73 vs 39%) que usando el TAC de los servicios de radiología. gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
-
Gut Journal
@Gut_BMJ
NEW #gutblog by Professor Antoni Castells, Professor Andrea Buron and Professor Uri Ladabaum on the paper
"Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening" via
blogs.bmj.com/gut/2026/04/23/gutblog-effect-of-long-term-…
Read the full paper via
gut.bmj.com/content/75/5/984
#fit #crc #screening #colorectalcancer -
Gut Journal
@Gut_BMJ
Latest #gutscience paper by Sanchez et al related to barrier function entitled
"Non-invasive measurement of intestinal barrier function in environmental enteropathy using transcutaneous fluorescence sensing" via
gutscience.bmj.com/content/1/1/e000011
#barrierfunction @druppygill -
Gut Journal
@Gut_BMJ
Prasad et al. present “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” via gut.bmj.com/content/75/5/949
This work identifies a microbial metabolite linking intestinal dysfunction to retinal disease, offering both a biomarker and a potential therapeutic target.
#diabeticretinopathy #microbiota -
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal reposted
BMJ Group
@bmj_company
AI model (REDMOD) detects very early normally ‘invisible’ tissue changes of pancreatic cancer, finds research in @Gut_BMJ
gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-337266 -
Gut Journal reposted
Armin Zarrintan
@ArminZarrintan
Honored to share our paper on AI detection of visually occult pancreatic cancer, published in @Gut_BMJ
Excited to see vast media coverage.
Grateful to my mentor @AjitGoenka for his leadership.
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
@MayoClinic @MayoRadiology @MayoCancerCare #ai #radiology -
Gut Journal reposted
Khurram Khaliq Bhinder
@kkbhinder
Link:
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
#radiology #ai #artificialintelligence #earlydetection -
Gut Journal reposted
Khurram Khaliq Bhinder
@kkbhinder
Hot off the press 🚨
Our AI-based detection of visually occult pancreatic cancer is now published in @Gut_BMJ
Grateful for the strong global media attention and recognition.
Deep gratitude to my mentor @AjitGoenka for his leadership and guidance.
@MayoRadiology
@MayoCancerCare -
Gut Journal reposted
Yuri Gorelik
@GorelikYuri
Incredible!
Pancreatic cancer screening in low prevalence population is frustrating
CT is a poor modality and pts are diagnosed w advanced disease
Just published @Gut_BMJ - A machine learning model REDMOD showed a 75% sens for early stage disease way earlier than radiologsts (more than 1yr)!
See example below
Amazing -
Gut Journal reposted
Evangelos Felekouras
@felekouras
-
Gut Journal reposted
ilyas sahin, MD
@ilyassahinMD
AI may detect pancreatic cancer before it’s recognizable on CT
~475-day lead time
Higher sensitivity vs radiologists
Early data but promising
Needs prospective validation
@Gut_BMJ * -
Gut Journal reposted
ilyas sahin, MD
@ilyassahinMD
-
Gut Journal reposted
Salvador Pedraza
@salvasapedraza
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
-
Gut Journal reposted
Enrique de-Madaria
@DeMadaria
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability @Gut_BMJ
So interesting!
👇🏻👇🏻👇🏻
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal reposted
Zain Khalpey, MD, PhD, FACS
@ZainKhalpey
AI detecting pancreatic cancer on CT before it’s visible, 73% vs 39% sensitivity with external validation. Earlier signals, earlier decisions.
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266
#medtwitter #aiinmedicine #radiology #oncology -
Gut Journal
@Gut_BMJ
MASLD-related advanced fibrosis in type 2 diabetes
MASLD affects up to 65% of patients with type 2 diabetes — yet it remains widely underdiagnosed outside hepatology clinics. A large multinational study by Chen et al. validated a practical two-step noninvasive pathway to identify advanced liver fibrosis in this high-risk group. The approach is straightforward: all type 2 diabetic patients first undergo a Fibrosis-4 index, and only those with an intermediate score (1.3–2.67) proceed to vibration-controlled transient elastography (VCTE). The pathway was anchored by a biopsy cohort of 352 patients across 7 Chinese centres — providing histological evidence — and further validated in 4,781 patients at 16 sites across the US, Europe, and Asia. It accurately stratified fibrosis risk and predicted long-term liver-related outcomes, outperforming single-test strategies.
⚖️ Could this simple two-step pathway finally make systematic MASLD screening routine in type 2 diabetes clinics worldwide?
🔗 Check the paper: gut.bmj.com/content/75/3/576
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
We hope you enjoy this May 2026 issue of @Gut_BMJ, bringing together impactful research across oesophageal disease, gastrointestinal cancer, microbiome science, hepatology and acute care. This issue highlights how mechanistic biology, large-scale datasets and emerging technologies are converging to refine disease understanding and unlock new therapeutic strategies.
This issue also features an Editor’s Choice paper by Sasaki et al., highlighted on the #gutfrontcover and soon to be explored in the #gutpodcast (gutbmj.podbean.com). The #gutcover features Benjamin Franklin Parkway in Philadelphia, USA, celebrating this important work demonstrating how FOXM1 inhibition reduces IL-13-driven epithelial remodelling and inflammation in eosinophilic oesophagitis. It’s a great example of how we’re moving towards targeting the root cause of inflammation, not just treating symptoms.
There’s also a strong tech angle this month. One standout explores how large language models could help detect colorectal polyps during endoscopy—hinting at a future where AI actively supports real-time clinical decisions.
Cancer research is another major focus:
• New data refine genetic risk in hereditary gastric cancer
• Multi-omics approaches are uncovering new treatment targets
• Pancreatic studies reveal how chronic inflammation and genetics combine to drive early cancer development
The microbiome continues to impress, with studies linking gut bacteria to:
• Autism biomarkers
• Diabetic retinopathy
• Even stress-related cancer metastasis
It’s not just theory either—these findings are increasingly pointing towards real diagnostic and therapeutic possibilities.
On the clinical side, there are practical takeaways too:
• Better adherence improves colorectal cancer screening outcomes
• New evidence helps guide nutrition in acute pancreatitis
• Combination therapies are advancing hepatitis B treatment
And globally, there’s an important perspective on how we might prevent IBD, especially in rapidly changing regions.
Bottom line?
This issue really highlights a shift in the field—towards earlier detection, smarter use of technology, and treatments that are more personalised and mechanism-driven.
👉 Read the full issue: gut.bmj.com/content/75/5
@BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro #gutissue #gutcover #gutfrontcover -
Gut Journal
@Gut_BMJ
Inamdar et al. present the paper “Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis” via
gut.bmj.com/content/75/5/1003
The paper describes a mechanistic bridge between inflammation and cancer. It shows how inherited pancreatic disease primes tissue for oncogenic transformation, shedding light on early events in pancreatic cancer development.
#pancreaticcancer #pancreatitis -
Gut Journal reposted
Eric Topol
@EricTopol
An AI that detects occult pancreatic cancer better than radiologists (73 vs 39%) via CT with external validation
gut.bmj.com/content/early/2026/04/22/gutjnl-2025-337266 -
Gut Journal reposted
Gabe Wilson MD
@Gabe__MD
-
Gut Journal reposted
Θείος Πλούταρχος
@unclePlutarch
Σύστημα Τεχνητής Νοημοσύνης #ai ανιχνεύει αδιάγνωστους καρκίνους του παγκρέατος πολύ καλύτερα από τους ακτινολόγους (73% έναντι 39%), μέσω αξονικής τομογραφίας με εξωτερική επικύρωση.
doi.org/10.1136/gutjnl-2025-337266 -
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
Read the #gutcommentary by Campani and Nault ("New player in inflammation-driver liver carcinogenesis: pirin on fire!") who highlight pirin as an emerging mediator linking chronic inflammation to hepatocellular carcinoma (HCC).
Building on new data, they describe how pirin amplifies key inflammatory signalling pathways, notably NF-κB and STAT3, reinforcing a tumour-promoting microenvironment in the liver. This positions pirin as a critical node connecting oxidative stress, immune responses, and malignant transformation. The #gutcommentary underscores its potential as both a biomarker and therapeutic target in inflammation-driven liver cancer. Overall, pirin is framed as a “new player on fire,” advancing understanding of how persistent inflammation fuels hepatocarcinogenesis. Read the commentary here: gut.bmj.com/content/75/5/849
This perspective is grounded in Ma et al., also a paper in this May issue (gut.bmj.com/content/75/5/1016who) who demonstrate that nuclear pirin drives HCC through a redox-dependent positive feedback loop, amplifying inflammatory signalling and cytokine production, thereby providing the mechanistic basis for its clinical relevance.
#pirin #hcc -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
A compelling demonstration of how specific microbes can drive disease. Tan et al. show that this bacterium promotes colitis and cancer through "NETosis" activation, providing mechanistic insight into microbe-driven inflammation and carcinogenesis.
Tan et al. present “Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation" via
gut.bmj.com/content/75/5/920
#colitis #colorectalcancer -
Gut Journal reposted
Achintya Singh, MD
@AchintyaSinghMD
SYDNEY classification for Deep Mural Injury:
1. Original article: gut.bmj.com/content/66/10/1779
2. Submucosa provides integrity to the organ, beyond it is worrisome, meticulous closure is important
3. Figure
4. For en bloc resection-> lesion size, submucosal invasion increases risk -
Gut Journal reposted
Gianluca Ianiro
@gianluca1aniro
Super @Will_fusco! #microbiomeclinicians
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal
@Gut_BMJ
This #gutrecentadvancesinbasicscience review synthesises emerging evidence linking the microbiome to cardiovascular disease, highlighting shared inflammatory and metabolic pathways.
Fusco et al. present “Gut microbiota and atherosclerosis” - access it via gut.bmj.com/content/75/5/1067
#gutmicrobiota #atherosclerosis @GiovanniCammar9 @gianluca1aniro -
Gut Journal
@Gut_BMJ
#gutscience is an international, open-access journal focused on the fundamental biology of the gut and liver. It publishes cutting-edge research on how digestive diseases work at molecular and cellular levels, linking basic science with clinical impact. Closely aligned with @BritSocGastro and the leading journal @Gut_BMJ, it aims to drive innovation in diagnostics, treatments and personalised medicine. By bridging lab research and real-world care, Gut Science supports global collaboration and advances understanding of gastrointestinal health and disease.
Visit the website here: gutscience.bmj.com @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Birda et al. present the #gutrecentadvancesinclinicalpractice paper entitled
"Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases" via
gut.bmj.com/content/75/5/1055
The paper is a forward-looking framework addressing the rising burden of IBD globally. Birda et al. outline prevention strategies informed by lessons from non-communicable diseases.
@ChhaganBirda @DrAnuraagJ @JoanaTo62523004 @Siew_C_Ng @pakotze @ibdseb @drvishal82 #ibd #globalsouth -
Gut Journal
@Gut_BMJ
A key mechanistic advance in eosinophilic oesophagitis. Sasaki et al. identify FOXM1 as a central regulator of IL-13-driven epithelial dysfunction, showing that its inhibition attenuates inflammation and tissue remodelling. This work opens the door to targeted therapies aimed at upstream drivers of disease rather than downstream inflammation alone.
Sasaki et al. present “FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis” via
gut.bmj.com/content/75/5/857
#il13 #eoe #eosinophilicoesophagitis -
Gut Journal
@Gut_BMJ
MASLD-related advanced fibrosis in type 2 diabetes
MASLD affects up to 65% of patients with type 2 diabetes — yet it remains widely underdiagnosed outside hepatology clinics. A large multinational study by Chen et al. validated a practical two-step noninvasive pathway to identify advanced liver fibrosis in this high-risk group. The approach is straightforward: all type 2 diabetic patients first undergo a Fibrosis-4 index, and only those with an intermediate score (1.3–2.67) proceed to vibration-controlled transient elastography (VCTE). The pathway was anchored by a biopsy cohort of 352 patients across 7 Chinese centres — providing histological evidence — and further validated in 4,781 patients at 16 sites across the US, Europe, and Asia. It accurately stratified fibrosis risk and predicted long-term liver-related outcomes, outperforming single-test strategies.
⚖️ Could this simple two-step pathway finally make systematic MASLD screening routine in type 2 diabetes clinics worldwide?
🔗 Check the paper: gut.bmj.com/content/75/3/576
➡️ Follow us for more highlights from the latest GI research -
Gut Journal reposted
Immune Regulation News
@Immune_News
Researchers summarize the functional alterations of gastric #microbiota from healthy/malignant mucosa, with emphasis on the impact of bacteria on different immune cell populations in gastric tumors, such as CD8 T cells, dendritic cells, and #tregs. 🦠
gut.bmj.com/content/early/2026/04/22/gutjnl-2026-338505.long -
Gut Journal reposted
Alexandre Calon
@Calon_Alex
-
Gut Journal
@Gut_BMJ
Watch the great new #gutvideo with Professor Albrecht Neesse and team on the paper
"Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis" via
www.youtube.com/watch?v=X8zjBfsWPZQ
Access the paper via gut.bmj.com/content/75/2/317
SUMMARY
The study by Ammer-Herrmenau et al. investigates whether the gut microbiota can predict long-term outcomes after acute pancreatitis, particularly the development of post-discharge diabetes mellitus (DM). In a prospective multicentre cohort, stool samples collected at hospital admission revealed that patients who later developed DM had distinct microbial signatures, including reduced diversity and specific compositional shifts.
A predictive model based on 11 microbial species showed high accuracy (AUC ~0.95) for identifying those at risk, outperforming conventional clinical predictors. Microbiota patterns were also linked to recurrent pancreatitis and mortality, suggesting broader prognostic value.
The #gutvideo highlights this as a step toward microbiome-based precision medicine, where early stool analysis could guide care.
Implications
It enables risk-stratified follow-up, earlier diabetes screening, and opens the door to microbiome-targeted interventions to prevent metabolic complications after acute pancreatitis. -
Gut Journal
@Gut_BMJ
Gluten or GUT feeling? 📢
Non-coeliac gluten/wheat sensitivity may be more common than expected. Shiha et al. reviewed 25 studies including 49,476 participants from 16 countries and found around 1 in 10 people across 16 countries self-report symptoms linked to gluten or wheat.
Symptoms commonly included bloating, abdominal discomfort & pain, fatigue, and headache. Women were more likely to report symptoms, and many were already following a gluten-free diet without formal diagnosis.
The condition was also strongly associated with anxiety, depression, and irritable bowel syndrome, suggesting overlap with gut–brain interaction disorders
⚖️ Is non-coeliac gluten sensitivity a separate diagnosis—or rather part of the gut–brain interaction spectrum?
Check the paper: gut.bmj.com/content/75/3/502
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Fibrosis remains a major unmet need in Crohn’s disease. This study by Zhou et al. links metabolic reprogramming in fibroblasts to fibrotic progression, highlighting the pentose phosphate pathway as a potential therapeutic target.
Read “Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease” via gut.bmj.com/content/75/5/905
#fibrosis #ibd #crohnsdisease -
Gut Journal
@Gut_BMJ
This large international dataset expands the phenotypic and molecular spectrum of CTNNA1-associated hereditary gastric cancer. The findings have important implications for genetic counselling, surveillance and risk stratification in affected families.
Lobo et al. present the paper “Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls” via
gut.bmj.com/content/75/5/872
#hereditarycancer #gastriccancer -
Gut Journal
@Gut_BMJ
Latest #gutscience paper by Sanchez et al related to barrier function entitled
"Non-invasive measurement of intestinal barrier function in environmental enteropathy using transcutaneous fluorescence sensing" via
gutscience.bmj.com/content/1/1/e000011
#barrierfunction @druppygill -
Gut Journal
@Gut_BMJ
NEW #gutblog by Professor Antoni Castells, Professor Andrea Buron and Professor Uri Ladabaum on the paper
"Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening" via
blogs.bmj.com/gut/2026/04/23/gutblog-effect-of-long-term-…
Read the full paper via
gut.bmj.com/content/75/5/984
#fit #crc #screening #colorectalcancer -
Gut Journal
@Gut_BMJ
Inflammation-driven cancer pathways remain central in HCC. This study by Ma et al. identifies Pirin as a key mediator, offering a potential new target for therapeutic intervention.
Read the paper entitled "Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor" via
gut.bmj.com/content/75/5/1016
#hcc #inflammation -
Gut Journal
@Gut_BMJ
Prasad et al. present “Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach” via gut.bmj.com/content/75/5/949
This work identifies a microbial metabolite linking intestinal dysfunction to retinal disease, offering both a biomarker and a potential therapeutic target.
#diabeticretinopathy #microbiota -
Gut Journal
@Gut_BMJ
Inamdar et al. present the paper “Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis” via
gut.bmj.com/content/75/5/1003
The paper describes a mechanistic bridge between inflammation and cancer. It shows how inherited pancreatic disease primes tissue for oncogenic transformation, shedding light on early events in pancreatic cancer development.
#pancreaticcancer #pancreatitis -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo by Biyun Zheng et al. via www.youtube.com/watch?v=abCuH-X9occ which explains how they investigated the way gastrin signalling regulates stomach repair and cancer risk through Cck2r⁺ progenitor cells in the gastric corpus. Using mouse lineage-tracing models, the authors show that after gastric injury (e.g. ulcers), circulating gastrin levels rise and stimulate expansion of these progenitor cells, which are key drivers of mucosal regeneration.
In the paper
"Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia"
they demonstrate that higher gastrin levels (hypergastrinaemia)—whether physiological, induced by proton pump inhibitors (PPIs), or via gastrin infusion—lead to faster ulcer healing by expanding these regenerative progenitor cells. In contrast, low gastrin levels (hypogastrinaemia) impair healing and reduce progenitor cell activity.
Importantly, the study also shows that gastrin has a protective role against gastric disease progression. In models of Helicobacter pylori infection and chemically induced cancer, loss of gastrin worsened inflammation, atrophy, and dysplasia, whereas increased gastrin reduced these pre-cancerous changes.
The #gutvideo emphasises this paradigm shift: gastrin is not just an acid-stimulating hormone but a key regulator of repair and cancer prevention in the stomach.
What this means for future patient care:
1. Challenges the traditional concern that PPI-induced hypergastrinaemia is harmful → may actually aid healing
2. Suggests gastrin signalling could be therapeutic in ulcers or mucosal injury
3. Raises caution about over-suppressing gastrin (e.g. long-term profound acid suppression)
4. Opens potential for regenerative or cancer-preventive therapies targeting Cck2r⁺ cells
Bottom line: Gastrin may be protective and reparative, not just a risk factor—shifting how we think about ulcer healing and gastric cancer prevention.
READ the paper via gut.bmj.com/content/75/2/265 -
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
NEW #gutpodcast: "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts"
Dr Philip Smith, Digital and Education Editor of Gut interviews Professor Shanshan Wu and Professor Yuanjie Pang from Beijing, China, on the paper "Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts" published in paper copy in Gut in April 2026.
"Lean MASLD" has traditionally been considered lower risk than obesity-associated disease, with limited and conflicting long-term outcome data. This large prospective multicohort study (~188,000 participants, ~14-year follow-up) shows that lean MASLD is associated with higher liver-related events, liver-related mortality and all-cause mortality, despite lower cardiovascular risk.
This study is important as it challenges BMI-based risk stratification. It demonstrates that “lean” does not equal “low risk,” highlighting a distinct high-risk phenotype. Clinically, it supports more vigilant assessment and follow-up regardless of BMI, and in research, it underscores the need to better understand pathophysiology and develop tailored risk models for lean MASLD.
Listen via
▶️ Apple: podcasts.apple.com/us/podcast/long-term-prognosis-of-lean…
▶️ Spotify: open.spotify.com/episode/0bdGLfPSylo0ZHgTyOlYZW
▶️ Web: gutbmj.podbean.com/e/lean-masld/
Read the paper via gut.bmj.com/content/75/4/772
#masld #leanmasld -
Gut Journal
@Gut_BMJ
We hope you enjoy this May 2026 issue of @Gut_BMJ, bringing together impactful research across oesophageal disease, gastrointestinal cancer, microbiome science, hepatology and acute care. This issue highlights how mechanistic biology, large-scale datasets and emerging technologies are converging to refine disease understanding and unlock new therapeutic strategies.
This issue also features an Editor’s Choice paper by Sasaki et al., highlighted on the #gutfrontcover and soon to be explored in the #gutpodcast (gutbmj.podbean.com). The #gutcover features Benjamin Franklin Parkway in Philadelphia, USA, celebrating this important work demonstrating how FOXM1 inhibition reduces IL-13-driven epithelial remodelling and inflammation in eosinophilic oesophagitis. It’s a great example of how we’re moving towards targeting the root cause of inflammation, not just treating symptoms.
There’s also a strong tech angle this month. One standout explores how large language models could help detect colorectal polyps during endoscopy—hinting at a future where AI actively supports real-time clinical decisions.
Cancer research is another major focus:
• New data refine genetic risk in hereditary gastric cancer
• Multi-omics approaches are uncovering new treatment targets
• Pancreatic studies reveal how chronic inflammation and genetics combine to drive early cancer development
The microbiome continues to impress, with studies linking gut bacteria to:
• Autism biomarkers
• Diabetic retinopathy
• Even stress-related cancer metastasis
It’s not just theory either—these findings are increasingly pointing towards real diagnostic and therapeutic possibilities.
On the clinical side, there are practical takeaways too:
• Better adherence improves colorectal cancer screening outcomes
• New evidence helps guide nutrition in acute pancreatitis
• Combination therapies are advancing hepatitis B treatment
And globally, there’s an important perspective on how we might prevent IBD, especially in rapidly changing regions.
Bottom line?
This issue really highlights a shift in the field—towards earlier detection, smarter use of technology, and treatments that are more personalised and mechanism-driven.
👉 Read the full issue: gut.bmj.com/content/75/5
@BritSocGastro @FrontGastro_BMJ @BMJOpen_Gastro #gutissue #gutcover #gutfrontcover -
Gut Journal reposted
Pancreatic Cell News
@PancreaticCell
Researchers constructed a diagnostic model for chronic #pancreatitis (CP) and depicted molecular landscape of CP based on extracellular vesicle long RNA.
@Gut_BMJ | gut.bmj.com/content/early/2026/04/16/gutjnl-2025-335957 -
Gut Journal reposted
やまだ@へっぽこ研究者|Y.KITA
@tarou_ymd_
プロバイオ飲料はどこまで効果ある?
っていう疑問にわかりやすく答える研究。
腸内細菌と記憶に関する脳領域に変化はあったけど控えめ。健康とかのパラメーターに有意な変化はなし。
小規模なので今後の研究に期待ですが、色んなヨーグルトとかにどこまで期待してええの?っていうのの参考になります
Gut Journal
@Gut_BMJ
🚨 Can probiotic drinks boost our brain health?
Many people are interested in taking probiotics because they’re seen as an easy way to support gut health, improve digestion and potentially boost overall mood by influencing the gut–brain connection. Marx et al., tested whether probiotic yoghurt affects the brain and mental health via the gut–brain connection. Forty healthy women consumed probiotic yoghurt or a placebo for 8 weeks. Small changes were seen in gut bacteria and a brain region linked to memory, but results were modest. No improvements were found in mood, memory, or health markers. Overall, probiotic yoghurt may influence the gut and brain, but its benefits remain unclear.
💡 Take-home: the study suggests that probiotic yoghurt might influence how the brain and gut interact, but more research is needed to confirm these effects and understand their importance.
🔎 Check the paper: gut.bmj.com/content/75/3/511
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
The latest #gutblog has dropped and @drgauravbnigam, the papers' first author summarises the manuscript
"Acute upper gastrointestinal bleeding in the UK: 2022 audit update"
Read the #gutblog via blogs.bmj.com/gut/2026/03/30/gutblog-acute-upper-gastroin…
Read the paper via gut.bmj.com/content/75/4/760
#ugib @BritSocGastro @JAG_Endoscopy @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🚨 Can probiotic drinks boost our brain health?
Many people are interested in taking probiotics because they’re seen as an easy way to support gut health, improve digestion and potentially boost overall mood by influencing the gut–brain connection. Marx et al., tested whether probiotic yoghurt affects the brain and mental health via the gut–brain connection. Forty healthy women consumed probiotic yoghurt or a placebo for 8 weeks. Small changes were seen in gut bacteria and a brain region linked to memory, but results were modest. No improvements were found in mood, memory, or health markers. Overall, probiotic yoghurt may influence the gut and brain, but its benefits remain unclear.
💡 Take-home: the study suggests that probiotic yoghurt might influence how the brain and gut interact, but more research is needed to confirm these effects and understand their importance.
🔎 Check the paper: gut.bmj.com/content/75/3/511
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal reposted
GI Nutrition Foundation
@GI_NutritionFdn
Aspartame, saccharin, sucralose and emulsifier polysorbate-80 are linked to #crohnsdisease activity
@Siew_C_Ng & colleagues found ⬆️ levels of dietary sweeteners (saccharin, sucralose and aspartame) in both stool and urine samples from patients with Crohn's
✅ Fecal P-80 metabolites and artificial sweeteners demonstrate significant associations with active Crohn's
✅ Quantification of food additives and artificial sweeteners in the body could contribute to our understanding of their impact on Crohn's
✅ Food additives can work together in altering the gut: P-80 enhances gut permeability and promotes the penetration of sweeteners across the gut epithelium
💡Artificial sweeteners and emulsifiers aren't inert for the gut and may actively contribute to the development of Crohn's
@Gut_BMJ
📚Read more: gut.bmj.com/content/early/2026/04/08/gutjnl-2024-333999 -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🌟 We are excited to share that a new episode of the @FrontGastro_BMJ podcast has been released on IBD surveillance - beyond the guidelines‼️
We have the pleasure of having Dr. Eathar Shakweh @eathar_s (trainee editor of FG) interview Dr. Shahida Din @ShahidaDin1, Dr. Ross Porter and Dr. Beatriz Gros @Bealoquebea in discussing a recent publication @FrontGastro_BMJ, "a real-world retrospective cohort study of IBD colorectal cancer surveillance", alongside real-world challenges, and what the future of IBD holds. Link to recent publication ➡️ fg.bmj.com/content/17/3/222
🔗 Links below:
▶️ Apple: podcasts.apple.com/us/podcast/ibd-surveillance-beyond-the…
▶️ Spotify: open.spotify.com/episode/3RLDYoLr0rlswvHQfymHVj
▶️ Web: fgbmj.podbean.com/e/ibd-surveillance-beyond-the-guidelines/
Don't miss out ❗ 🤗
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @ulstergastro #gitwitter -
Gut Journal reposted
Alexandre Calon
@Calon_Alex
📢 Our paper is out!
We define CTHRC1-CAFs as #biomarker of response to #immunotherapy in MSS and MSI #crc
Great teamwork @CalonLab @BatlleLab @mariglesiascoma
Thanks @ContraCancerEs for their support
🔗 gut.bmj.com/content/early/2026/04/13/gutjnl-2025-336804 -
Gut Journal
@Gut_BMJ
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
@ParthaP32580643 @DrLakhtakia #ibd #uc #ultrasound -
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal
@Gut_BMJ
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
#gastriccancer -
Gut Journal
@Gut_BMJ
Watch the great new #gutvideo with Professor Albrecht Neesse and team on the paper
"Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis" via
www.youtube.com/watch?v=X8zjBfsWPZQ
Access the paper via gut.bmj.com/content/75/2/317
SUMMARY
The study by Ammer-Herrmenau et al. investigates whether the gut microbiota can predict long-term outcomes after acute pancreatitis, particularly the development of post-discharge diabetes mellitus (DM). In a prospective multicentre cohort, stool samples collected at hospital admission revealed that patients who later developed DM had distinct microbial signatures, including reduced diversity and specific compositional shifts.
A predictive model based on 11 microbial species showed high accuracy (AUC ~0.95) for identifying those at risk, outperforming conventional clinical predictors. Microbiota patterns were also linked to recurrent pancreatitis and mortality, suggesting broader prognostic value.
The #gutvideo highlights this as a step toward microbiome-based precision medicine, where early stool analysis could guide care.
Implications
It enables risk-stratified follow-up, earlier diabetes screening, and opens the door to microbiome-targeted interventions to prevent metabolic complications after acute pancreatitis. -
Gut Journal
@Gut_BMJ
Gluten or GUT feeling? 📢
Non-coeliac gluten/wheat sensitivity may be more common than expected. Shiha et al. reviewed 25 studies including 49,476 participants from 16 countries and found around 1 in 10 people across 16 countries self-report symptoms linked to gluten or wheat.
Symptoms commonly included bloating, abdominal discomfort & pain, fatigue, and headache. Women were more likely to report symptoms, and many were already following a gluten-free diet without formal diagnosis.
The condition was also strongly associated with anxiety, depression, and irritable bowel syndrome, suggesting overlap with gut–brain interaction disorders
⚖️ Is non-coeliac gluten sensitivity a separate diagnosis—or rather part of the gut–brain interaction spectrum?
Check the paper: gut.bmj.com/content/75/3/502
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Leung et al. present the paper “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section)
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
#gutguidelines #hpylori #helicobacterpylori -
Gut Journal
@Gut_BMJ
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
#barretts #esd #cancer -
Gut Journal reposted
Enrique de-Madaria
@DeMadaria
The GOULASH trial has been published in @Gut_BMJ!
Multicentric double-blind RCT in acute pancreatitis
High versus gradually increasing energy in enteral nutrition to all comers with AP
High energy was detrimental
Congrats Katalin and Peter!
gut.bmj.com/content/gutjnl/75/5/995.full.pdf -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
MASH is multifactorial → single-target therapy often insufficient
Combination therapy targets metabolic + hepatic pathways simultaneously
• Potential for better fibrosis regression & metabolic control
• Requires careful patient selection and safety monitoring
• Likely future direction in MASH management
#liverstudy #medtwitter #liverx
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal
@Gut_BMJ
Latest #gutscience paper by Sanchez et al related to barrier function entitled
"Non-invasive measurement of intestinal barrier function in environmental enteropathy using transcutaneous fluorescence sensing" via
gutscience.bmj.com/content/1/1/e000011
#barrierfunction @druppygill -
Gut Journal
@Gut_BMJ
MASLD-related advanced fibrosis in type 2 diabetes
MASLD affects up to 65% of patients with type 2 diabetes — yet it remains widely underdiagnosed outside hepatology clinics. A large multinational study by Chen et al. validated a practical two-step noninvasive pathway to identify advanced liver fibrosis in this high-risk group. The approach is straightforward: all type 2 diabetic patients first undergo a Fibrosis-4 index, and only those with an intermediate score (1.3–2.67) proceed to vibration-controlled transient elastography (VCTE). The pathway was anchored by a biopsy cohort of 352 patients across 7 Chinese centres — providing histological evidence — and further validated in 4,781 patients at 16 sites across the US, Europe, and Asia. It accurately stratified fibrosis risk and predicted long-term liver-related outcomes, outperforming single-test strategies.
⚖️ Could this simple two-step pathway finally make systematic MASLD screening routine in type 2 diabetes clinics worldwide?
🔗 Check the paper: gut.bmj.com/content/75/3/576
➡️ Follow us for more highlights from the latest GI research -
Gut Journal reposted
BSG
@BritSocGastro
🎉 We are delighted to share the March 2026 edition of the BSG Gut Highlights!
This month's edition features abstract summary highlights in endoscopy, neurogastroenterology, hepatology, oesophagus, and gut microbiota.
Read it here 👉 www.bsg.org.uk/web-education/bsg-gut-highlights-april-2026
@Gut_BMJ -
Gut Journal reposted
ぴかこる
@previnsky
大規模研究🇸🇪
CDIリスクとして抗菌薬に加え、既報通りPPIやステロイドも関連
- 抗てんかん薬や精神神経用剤も関連が示唆(※薬効群レベル)
- 脂質異常症治療薬は明確なリスク上昇は示されず
抗菌薬だけでなく、腸内環境に影響する薬剤全体を踏まえたリスク評価が重要
gut.bmj.com/content/early/2026/03/31/gutjnl-2025-337629 -
Gut Journal
@Gut_BMJ
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
#obesity #microbiome -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo by Biyun Zheng et al. via www.youtube.com/watch?v=abCuH-X9occ which explains how they investigated the way gastrin signalling regulates stomach repair and cancer risk through Cck2r⁺ progenitor cells in the gastric corpus. Using mouse lineage-tracing models, the authors show that after gastric injury (e.g. ulcers), circulating gastrin levels rise and stimulate expansion of these progenitor cells, which are key drivers of mucosal regeneration.
In the paper
"Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia"
they demonstrate that higher gastrin levels (hypergastrinaemia)—whether physiological, induced by proton pump inhibitors (PPIs), or via gastrin infusion—lead to faster ulcer healing by expanding these regenerative progenitor cells. In contrast, low gastrin levels (hypogastrinaemia) impair healing and reduce progenitor cell activity.
Importantly, the study also shows that gastrin has a protective role against gastric disease progression. In models of Helicobacter pylori infection and chemically induced cancer, loss of gastrin worsened inflammation, atrophy, and dysplasia, whereas increased gastrin reduced these pre-cancerous changes.
The #gutvideo emphasises this paradigm shift: gastrin is not just an acid-stimulating hormone but a key regulator of repair and cancer prevention in the stomach.
What this means for future patient care:
1. Challenges the traditional concern that PPI-induced hypergastrinaemia is harmful → may actually aid healing
2. Suggests gastrin signalling could be therapeutic in ulcers or mucosal injury
3. Raises caution about over-suppressing gastrin (e.g. long-term profound acid suppression)
4. Opens potential for regenerative or cancer-preventive therapies targeting Cck2r⁺ cells
Bottom line: Gastrin may be protective and reparative, not just a risk factor—shifting how we think about ulcer healing and gastric cancer prevention.
READ the paper via gut.bmj.com/content/75/2/265 -
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal reposted
Pon|食と健康
@PonNutr
原著
Commonly prescribed drugs as risk factors for Clostridioides difficile infections: a Swedish population-based case-control study. Gut, gutjnl-2025-337629.
doi.org/10.1136/gutjnl-2025-337629 -
Gut Journal reposted
Hepatic Cell News
@hepaticcellnews
Scientists investigated the role of the oxidative stress sensor protein Pirin as a critical mediator of inflammation in #hepatocellular carcinoma progression.
🔗 gut.bmj.com/content/75/5/1016 -
Gut Journal reposted
CalonLab
@CalonLab
📢 Published in @Gut_BMJ! We define CTHRC1-CAFs as a #biomarker of clinical outcome and response to #immunotherapy in MSS and MSI #colorectal #cancer.
gut.bmj.com/content/early/2026/04/13/gutjnl-2025-336804
@mariglesiascoma @Calon_Alex @BatlleLab @ClaraMontagut @hospitaldelmar @HMar_research @IRBBarcelona -
Gut Journal reposted
Abhishek Yadav
@aby10GI
Grateful and humbled to share that our study from PGI Chandigarh 🇮🇳has been published in BMJ Gut 🇬🇧
This milestone wouldn’t have been possible without the constant guidance, support, and mentorship of my respected teachers and guides.
@HMandavdhare @drvishal82 @DrJimilShah -
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal
@Gut_BMJ
The latest #gutblog has dropped and @drgauravbnigam, the papers' first author summarises the manuscript
"Acute upper gastrointestinal bleeding in the UK: 2022 audit update"
Read the #gutblog via blogs.bmj.com/gut/2026/03/30/gutblog-acute-upper-gastroin…
Read the paper via gut.bmj.com/content/75/4/760
#ugib @BritSocGastro @JAG_Endoscopy @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🚨 Can probiotic drinks boost our brain health?
Many people are interested in taking probiotics because they’re seen as an easy way to support gut health, improve digestion and potentially boost overall mood by influencing the gut–brain connection. Marx et al., tested whether probiotic yoghurt affects the brain and mental health via the gut–brain connection. Forty healthy women consumed probiotic yoghurt or a placebo for 8 weeks. Small changes were seen in gut bacteria and a brain region linked to memory, but results were modest. No improvements were found in mood, memory, or health markers. Overall, probiotic yoghurt may influence the gut and brain, but its benefits remain unclear.
💡 Take-home: the study suggests that probiotic yoghurt might influence how the brain and gut interact, but more research is needed to confirm these effects and understand their importance.
🔎 Check the paper: gut.bmj.com/content/75/3/511
➡️ Follow us for more highlights from the latest GI research -
Gut Journal reposted
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal
@Gut_BMJ
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation" via gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
#hev #organoids #hepatitisevirus -
Gut Journal reposted
Kohilan Gananandan
@KGananandan
Great fun writing this article on landmark papers in decomp cirrhosis and CSPH.
Thanks @ReibergerThomas and Prof Tsochatzis for being co-authors and @FrontGastro_BMJ for publishing! Check out 👇
doi.org/10.1136/flgastro-2026-103627
@EASLedu @BASLedu @BSGTrainees @AASLDtweets #livertwitter -
Gut Journal
@Gut_BMJ
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
@ParthaP32580643 @DrLakhtakia #ibd #uc #ultrasound -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal reposted
Sáfárné Hatrágyi Henrietta
@HatragyiSafarne
Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells
👇
gut.bmj.com/content/early/2026/04/09/gutjnl-2025-336025 -
Gut Journal
@Gut_BMJ
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
#gastriccancer -
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
MASH is multi-pathway disease—metabolic drivers and intrahepatic injury coexist. Combining incretin-based weight loss with liver-targeted agents (FXR/THR-β/ACC) may deliver broader fibrosis and metabolic benefit than monotherapy in high-risk patients.#medx #gut
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal
@Gut_BMJ
Watch the great new #gutvideo with Professor Albrecht Neesse and team on the paper
"Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis" via
www.youtube.com/watch?v=X8zjBfsWPZQ
Access the paper via gut.bmj.com/content/75/2/317
SUMMARY
The study by Ammer-Herrmenau et al. investigates whether the gut microbiota can predict long-term outcomes after acute pancreatitis, particularly the development of post-discharge diabetes mellitus (DM). In a prospective multicentre cohort, stool samples collected at hospital admission revealed that patients who later developed DM had distinct microbial signatures, including reduced diversity and specific compositional shifts.
A predictive model based on 11 microbial species showed high accuracy (AUC ~0.95) for identifying those at risk, outperforming conventional clinical predictors. Microbiota patterns were also linked to recurrent pancreatitis and mortality, suggesting broader prognostic value.
The #gutvideo highlights this as a step toward microbiome-based precision medicine, where early stool analysis could guide care.
Implications
It enables risk-stratified follow-up, earlier diabetes screening, and opens the door to microbiome-targeted interventions to prevent metabolic complications after acute pancreatitis. -
Gut Journal
@Gut_BMJ
Gluten or GUT feeling? 📢
Non-coeliac gluten/wheat sensitivity may be more common than expected. Shiha et al. reviewed 25 studies including 49,476 participants from 16 countries and found around 1 in 10 people across 16 countries self-report symptoms linked to gluten or wheat.
Symptoms commonly included bloating, abdominal discomfort & pain, fatigue, and headache. Women were more likely to report symptoms, and many were already following a gluten-free diet without formal diagnosis.
The condition was also strongly associated with anxiety, depression, and irritable bowel syndrome, suggesting overlap with gut–brain interaction disorders
⚖️ Is non-coeliac gluten sensitivity a separate diagnosis—or rather part of the gut–brain interaction spectrum?
Check the paper: gut.bmj.com/content/75/3/502
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Leung et al. present the paper “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section)
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
#gutguidelines #hpylori #helicobacterpylori -
Gut Journal
@Gut_BMJ
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
#barretts #esd #cancer -
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal
@Gut_BMJ
Latest #gutscience paper by Sanchez et al related to barrier function entitled
"Non-invasive measurement of intestinal barrier function in environmental enteropathy using transcutaneous fluorescence sensing" via
gutscience.bmj.com/content/1/1/e000011
#barrierfunction @druppygill -
Gut Journal
@Gut_BMJ
MASLD-related advanced fibrosis in type 2 diabetes
MASLD affects up to 65% of patients with type 2 diabetes — yet it remains widely underdiagnosed outside hepatology clinics. A large multinational study by Chen et al. validated a practical two-step noninvasive pathway to identify advanced liver fibrosis in this high-risk group. The approach is straightforward: all type 2 diabetic patients first undergo a Fibrosis-4 index, and only those with an intermediate score (1.3–2.67) proceed to vibration-controlled transient elastography (VCTE). The pathway was anchored by a biopsy cohort of 352 patients across 7 Chinese centres — providing histological evidence — and further validated in 4,781 patients at 16 sites across the US, Europe, and Asia. It accurately stratified fibrosis risk and predicted long-term liver-related outcomes, outperforming single-test strategies.
⚖️ Could this simple two-step pathway finally make systematic MASLD screening routine in type 2 diabetes clinics worldwide?
🔗 Check the paper: gut.bmj.com/content/75/3/576
➡️ Follow us for more highlights from the latest GI research -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
📌 The May issue for Frontline Gastroenterology is now available❗ ➡️ fg.bmj.com/content/17/3?current-issue=y
🟢 This issue is very ✨ special as it is the 1️⃣st time authors have been given the opportunity to design the 📰 front cover, and they sure did a 👌 fine job❗ The front cover accompanies the excellent review paper "🥗 Nutrition in MASLD: a patient focused, evidence-based 👨⚕️ 👩⚕️ clinician’s guide" ➡️ fg.bmj.com/content/17/3/262
👏 Thank you to @KatrinaPekarska Paul N Brennan Dana Ivancovsky Wajcman Jennifer Towey Leah Cox Katie Weatherby Stuart McPherson Jonathan Stine Jose Willemse Wenhao Li @WillAlazawi Jeffrey V Lazarus Richard Parker
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees #gitwitter -
Gut Journal reposted
Phil Smith
@PhilSmithIsBack
Massive thank you to @JVLazarus @KatrinaPekarska @brennap9 and team for this excellent paper and also the amazing #fgfrontcover by @anto_armen @ISGlobalorg too - it is a first for @FrontGastro_BMJ and looks superb! @BritSocGastro @BASLedu @basl_events @BAPENUK #masld #nutrition
Frontline Gastro
@FrontGastro_BMJ
📌 The May issue for Frontline Gastroenterology is now available❗ ➡️ fg.bmj.com/content/17/3?current-issue=y
🟢 This issue is very ✨ special as it is the 1️⃣st time authors have been given the opportunity to design the 📰 front cover, and they sure did a 👌 fine job❗ The front cover accompanies the excellent review paper "🥗 Nutrition in MASLD: a patient focused, evidence-based 👨⚕️ 👩⚕️ clinician’s guide" ➡️ fg.bmj.com/content/17/3/262
👏 Thank you to @KatrinaPekarska Paul N Brennan Dana Ivancovsky Wajcman Jennifer Towey Leah Cox Katie Weatherby Stuart McPherson Jonathan Stine Jose Willemse Wenhao Li @WillAlazawi Jeffrey V Lazarus Richard Parker
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees #gitwitter -
Gut Journal reposted
Pon|食と健康
@PonNutr
原著
Extrinsic lipids are absorbed and accumulate in colorectal cancer. Gut, gutjnl-2025-336377.
doi.org/10.1136/gutjnl-2025-336377 -
Gut Journal
@Gut_BMJ
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
#obesity #microbiome -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo by Biyun Zheng et al. via www.youtube.com/watch?v=abCuH-X9occ which explains how they investigated the way gastrin signalling regulates stomach repair and cancer risk through Cck2r⁺ progenitor cells in the gastric corpus. Using mouse lineage-tracing models, the authors show that after gastric injury (e.g. ulcers), circulating gastrin levels rise and stimulate expansion of these progenitor cells, which are key drivers of mucosal regeneration.
In the paper
"Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia"
they demonstrate that higher gastrin levels (hypergastrinaemia)—whether physiological, induced by proton pump inhibitors (PPIs), or via gastrin infusion—lead to faster ulcer healing by expanding these regenerative progenitor cells. In contrast, low gastrin levels (hypogastrinaemia) impair healing and reduce progenitor cell activity.
Importantly, the study also shows that gastrin has a protective role against gastric disease progression. In models of Helicobacter pylori infection and chemically induced cancer, loss of gastrin worsened inflammation, atrophy, and dysplasia, whereas increased gastrin reduced these pre-cancerous changes.
The #gutvideo emphasises this paradigm shift: gastrin is not just an acid-stimulating hormone but a key regulator of repair and cancer prevention in the stomach.
What this means for future patient care:
1. Challenges the traditional concern that PPI-induced hypergastrinaemia is harmful → may actually aid healing
2. Suggests gastrin signalling could be therapeutic in ulcers or mucosal injury
3. Raises caution about over-suppressing gastrin (e.g. long-term profound acid suppression)
4. Opens potential for regenerative or cancer-preventive therapies targeting Cck2r⁺ cells
Bottom line: Gastrin may be protective and reparative, not just a risk factor—shifting how we think about ulcer healing and gastric cancer prevention.
READ the paper via gut.bmj.com/content/75/2/265 -
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Celiac disease is increasingly viewed as a barrier disorder. Beyond gluten withdrawal, targeting permeability (zonulin pathways, microbiome modulation) may help persistent symptoms—especially in patients with ongoing symptoms despite strict GFD.
#meded #medx
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal reposted
Fernando Gomollón
@fgomollon
Science and medicine are amazing. Changing the concepts
👇👇👇👇👇👇👇👇
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Very interesting—this challenges the classic view of gastrin as purely trophic. In practice, physiological gastrin seems reparative, supporting mucosal healing and possibly reducing dysplasia risk.
#gut #medx #medtwitter #meded
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo by Biyun Zheng et al. via www.youtube.com/watch?v=abCuH-X9occ which explains how they investigated the way gastrin signalling regulates stomach repair and cancer risk through Cck2r⁺ progenitor cells in the gastric corpus. Using mouse lineage-tracing models, the authors show that after gastric injury (e.g. ulcers), circulating gastrin levels rise and stimulate expansion of these progenitor cells, which are key drivers of mucosal regeneration.
In the paper
"Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia"
they demonstrate that higher gastrin levels (hypergastrinaemia)—whether physiological, induced by proton pump inhibitors (PPIs), or via gastrin infusion—lead to faster ulcer healing by expanding these regenerative progenitor cells. In contrast, low gastrin levels (hypogastrinaemia) impair healing and reduce progenitor cell activity.
Importantly, the study also shows that gastrin has a protective role against gastric disease progression. In models of Helicobacter pylori infection and chemically induced cancer, loss of gastrin worsened inflammation, atrophy, and dysplasia, whereas increased gastrin reduced these pre-cancerous changes.
The #gutvideo emphasises this paradigm shift: gastrin is not just an acid-stimulating hormone but a key regulator of repair and cancer prevention in the stomach.
What this means for future patient care:
1. Challenges the traditional concern that PPI-induced hypergastrinaemia is harmful → may actually aid healing
2. Suggests gastrin signalling could be therapeutic in ulcers or mucosal injury
3. Raises caution about over-suppressing gastrin (e.g. long-term profound acid suppression)
4. Opens potential for regenerative or cancer-preventive therapies targeting Cck2r⁺ cells
Bottom line: Gastrin may be protective and reparative, not just a risk factor—shifting how we think about ulcer healing and gastric cancer prevention.
READ the paper via gut.bmj.com/content/75/2/265 -
Gut Journal reposted
GutMicrobiota Health
@GMFHx
Could probiotics improve brain function?
A new study by researchers at Deakin University’s Food and Mood Centre has found that women who ate probiotic yoghurt daily for eight weeks showed changes in brain function linked to mood and memory
@Gut_BMJ
gut.bmj.com/content/75/3/511 -
Gut Journal reposted
Prof Ollie Minton
@drol007
gut.bmj.com/content/74/7/1040 is a beautiful paper 📝 guide and team work
-
Gut Journal reposted
Benjamin Gold
@BenjamminGold
A landmark and important study!
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal reposted
Gaurav Nigam
@drgauravbnigam
Delighted to see this Gut blog published, reflecting on the 2022 UK AUGIB audit and the wider national audit programme.
@kate_oakland
@HearnshawSA
@lil_ratcliffe
@vipuljairath
@AdrianStanleyGI
@DoudsAcdouds
Gut Journal
@Gut_BMJ
The latest #gutblog has dropped and @drgauravbnigam, the papers' first author summarises the manuscript
"Acute upper gastrointestinal bleeding in the UK: 2022 audit update"
Read the #gutblog via blogs.bmj.com/gut/2026/03/30/gutblog-acute-upper-gastroin…
Read the paper via gut.bmj.com/content/75/4/760
#ugib @BritSocGastro @JAG_Endoscopy @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
Hepatic Cell News
@hepaticcellnews
Scientists show that Selenoprotein P deficiency drives liver cancer progression by inducing senescent, immunosuppressive neutrophils, while selenium supplementation restores anti-tumor immunity and enhances immunotherapy.
🔗 gut.bmj.com/content/early/2026/04/01/gutjnl-2025-336422 -
Gut Journal reposted
Keith Siau
@drkeithsiau
Thank you for sharing our paper and for making it freely accessible 🙏
Frontline Gastro
@FrontGastro_BMJ
🌟 Need a refresher on acute upper 🩸 GI bleed management❓ ⬇️
🏃➡️ 🏃♀️➡️ Head over to this exceptional review that summarizes new developments fg.bmj.com/content/early/2025/10/22/flgastro-2025-103282 👏 Thank you to authors: Zia Ur Rahman @MonicaAndrawes Wessam Andrawes @xerobal @iangralnek @drkeithsiau
Don't miss out on learning about new scoring systems to risk stratify patients that incorporate machine-learning and newer technology, resuscitative and post-procedural management, and comparison of national guidelines on this topic❗
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees #gitwitter -
Gut Journal reposted
Francisco Câmara Ferreira
@FranciscoCmar10
Roseburia inulinivorans increases muscle strength gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980
-
Gut Journal reposted
ALI ALKHALIFAH |:| عـلـي الخـليـفـة
@AliAl_khalifah
رابط الدراسة
gut.bmj.com/content/early/2026/03/05/gutjnl-2025-336714 -
Gut Journal
@Gut_BMJ
The latest #gutblog has dropped and @drgauravbnigam, the papers' first author summarises the manuscript
"Acute upper gastrointestinal bleeding in the UK: 2022 audit update"
Read the #gutblog via blogs.bmj.com/gut/2026/03/30/gutblog-acute-upper-gastroin…
Read the paper via gut.bmj.com/content/75/4/760
#ugib @BritSocGastro @JAG_Endoscopy @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🚨 Can probiotic drinks boost our brain health?
Many people are interested in taking probiotics because they’re seen as an easy way to support gut health, improve digestion and potentially boost overall mood by influencing the gut–brain connection. Marx et al., tested whether probiotic yoghurt affects the brain and mental health via the gut–brain connection. Forty healthy women consumed probiotic yoghurt or a placebo for 8 weeks. Small changes were seen in gut bacteria and a brain region linked to memory, but results were modest. No improvements were found in mood, memory, or health markers. Overall, probiotic yoghurt may influence the gut and brain, but its benefits remain unclear.
💡 Take-home: the study suggests that probiotic yoghurt might influence how the brain and gut interact, but more research is needed to confirm these effects and understand their importance.
🔎 Check the paper: gut.bmj.com/content/75/3/511
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal
@Gut_BMJ
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation" via gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
#hev #organoids #hepatitisevirus -
Gut Journal
@Gut_BMJ
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
@ParthaP32580643 @DrLakhtakia #ibd #uc #ultrasound -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal
@Gut_BMJ
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
#gastriccancer -
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal
@Gut_BMJ
Watch the great new #gutvideo with Professor Albrecht Neesse and team on the paper
"Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis" via
www.youtube.com/watch?v=X8zjBfsWPZQ
Access the paper via gut.bmj.com/content/75/2/317
SUMMARY
The study by Ammer-Herrmenau et al. investigates whether the gut microbiota can predict long-term outcomes after acute pancreatitis, particularly the development of post-discharge diabetes mellitus (DM). In a prospective multicentre cohort, stool samples collected at hospital admission revealed that patients who later developed DM had distinct microbial signatures, including reduced diversity and specific compositional shifts.
A predictive model based on 11 microbial species showed high accuracy (AUC ~0.95) for identifying those at risk, outperforming conventional clinical predictors. Microbiota patterns were also linked to recurrent pancreatitis and mortality, suggesting broader prognostic value.
The #gutvideo highlights this as a step toward microbiome-based precision medicine, where early stool analysis could guide care.
Implications
It enables risk-stratified follow-up, earlier diabetes screening, and opens the door to microbiome-targeted interventions to prevent metabolic complications after acute pancreatitis. -
Gut Journal
@Gut_BMJ
Gluten or GUT feeling? 📢
Non-coeliac gluten/wheat sensitivity may be more common than expected. Shiha et al. reviewed 25 studies including 49,476 participants from 16 countries and found around 1 in 10 people across 16 countries self-report symptoms linked to gluten or wheat.
Symptoms commonly included bloating, abdominal discomfort & pain, fatigue, and headache. Women were more likely to report symptoms, and many were already following a gluten-free diet without formal diagnosis.
The condition was also strongly associated with anxiety, depression, and irritable bowel syndrome, suggesting overlap with gut–brain interaction disorders
⚖️ Is non-coeliac gluten sensitivity a separate diagnosis—or rather part of the gut–brain interaction spectrum?
Check the paper: gut.bmj.com/content/75/3/502
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Leung et al. present the paper “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section)
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
#gutguidelines #hpylori #helicobacterpylori -
Gut Journal
@Gut_BMJ
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
#barretts #esd #cancer -
Gut Journal
@Gut_BMJ
Latest #gutscience paper by Sanchez et al related to barrier function entitled
"Non-invasive measurement of intestinal barrier function in environmental enteropathy using transcutaneous fluorescence sensing" via
gutscience.bmj.com/content/1/1/e000011
#barrierfunction @druppygill -
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal
@Gut_BMJ
Watch the latest #gutvideo by Biyun Zheng et al. via www.youtube.com/watch?v=abCuH-X9occ which explains how they investigated the way gastrin signalling regulates stomach repair and cancer risk through Cck2r⁺ progenitor cells in the gastric corpus. Using mouse lineage-tracing models, the authors show that after gastric injury (e.g. ulcers), circulating gastrin levels rise and stimulate expansion of these progenitor cells, which are key drivers of mucosal regeneration.
In the paper
"Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia"
they demonstrate that higher gastrin levels (hypergastrinaemia)—whether physiological, induced by proton pump inhibitors (PPIs), or via gastrin infusion—lead to faster ulcer healing by expanding these regenerative progenitor cells. In contrast, low gastrin levels (hypogastrinaemia) impair healing and reduce progenitor cell activity.
Importantly, the study also shows that gastrin has a protective role against gastric disease progression. In models of Helicobacter pylori infection and chemically induced cancer, loss of gastrin worsened inflammation, atrophy, and dysplasia, whereas increased gastrin reduced these pre-cancerous changes.
The #gutvideo emphasises this paradigm shift: gastrin is not just an acid-stimulating hormone but a key regulator of repair and cancer prevention in the stomach.
What this means for future patient care:
1. Challenges the traditional concern that PPI-induced hypergastrinaemia is harmful → may actually aid healing
2. Suggests gastrin signalling could be therapeutic in ulcers or mucosal injury
3. Raises caution about over-suppressing gastrin (e.g. long-term profound acid suppression)
4. Opens potential for regenerative or cancer-preventive therapies targeting Cck2r⁺ cells
Bottom line: Gastrin may be protective and reparative, not just a risk factor—shifting how we think about ulcer healing and gastric cancer prevention.
READ the paper via gut.bmj.com/content/75/2/265 -
Gut Journal
@Gut_BMJ
Genomic Insights Reveal Achalasia as Immune Disease! 📄🔥
Idiopathic achalasia may not just be a swallowing disorder; it could actually be an immune-driven condition. In a large study of 4,600+ patients vs 10,700+ controls, researchers found strong genetic signals in the immune system, particularly in the HLA region (OR 2.54). They also analysed 30,000+ individual immune cells and discovered that specific killer T cells are highly active in this disease, suggesting that the body’s immune system mistakenly attacks the oesophagus. This study shows how combining genetics and advanced cell analysis can change how we understand and treat complex diseases, moving closer to targeted therapies rather than just symptom control.
⚖️Could targeting specific T-cell pathways transform treatment outcomes in achalasia?
🔎Check the paper: gut.bmj.com/content/75/3/476
➡️Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
#obesity #microbiome -
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal reposted
IM Médico
@IMMedicoHosp
Un equipo internacional identifica bemnifosbuvir, fármaco en ensayos clínicos contra hepatitis C, como tratamiento prometedor contra hepatitis E. Publicado en @Gut_BMJ. #hepatitise #investigación
www.immedicohospitalario.es/noticia/55831/identifican-bem… -
Gut Journal reposted
Ming Cui
@MingCui66
A visual abstract illustrating our findings
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal
@Gut_BMJ
The latest #gutblog has dropped and @drgauravbnigam, the papers' first author summarises the manuscript
"Acute upper gastrointestinal bleeding in the UK: 2022 audit update"
Read the #gutblog via blogs.bmj.com/gut/2026/03/30/gutblog-acute-upper-gastroin…
Read the paper via gut.bmj.com/content/75/4/760
#ugib @BritSocGastro @JAG_Endoscopy @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal
@Gut_BMJ
🚨 Can probiotic drinks boost our brain health?
Many people are interested in taking probiotics because they’re seen as an easy way to support gut health, improve digestion and potentially boost overall mood by influencing the gut–brain connection. Marx et al., tested whether probiotic yoghurt affects the brain and mental health via the gut–brain connection. Forty healthy women consumed probiotic yoghurt or a placebo for 8 weeks. Small changes were seen in gut bacteria and a brain region linked to memory, but results were modest. No improvements were found in mood, memory, or health markers. Overall, probiotic yoghurt may influence the gut and brain, but its benefits remain unclear.
💡 Take-home: the study suggests that probiotic yoghurt might influence how the brain and gut interact, but more research is needed to confirm these effects and understand their importance.
🔎 Check the paper: gut.bmj.com/content/75/3/511
➡️ Follow us for more highlights from the latest GI research -
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal
@Gut_BMJ
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation" via gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
#hev #organoids #hepatitisevirus -
Gut Journal
@Gut_BMJ
Submit your papers to #gutscience journal - part of the @bmj_company @BritSocGastro #gutportfolio
Visit the website here: gutscience.bmj.com
Meet the EIC @druppygill and the Editorial Board team here: gutscience.bmj.com/pages/editorial-board
#gutscience @Gut_BMJ @FrontGastro_BMJ @BMJOpen_Gastro -
Gut Journal reposted
Keith Siau
@drkeithsiau
Data from the latest UK acute upper GI bleeding audit is now out in @Gut_BMJ 🆕🩸
🔗: gut.bmj.com/content/75/4/760 -
Gut Journal
@Gut_BMJ
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
@ParthaP32580643 @DrLakhtakia #ibd #uc #ultrasound -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal
@Gut_BMJ
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
#gastriccancer -
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal reposted
Oncology News
@Oncologynewspro
A groundbreaking consensus guideline on immunotherapy for locally advanced rectal cancer, led by Professors Zhang Zhongtao & Yao Hongwei (Beijing Friendship Hospital), Zhang Zhen (Fudan Cancer Center) & Xu Ruihua (SYSUCC), was published in @Gut_BMJ (IF 26.2)!#crc
-
Gut Journal reposted
Pon|食と健康
@PonNutr
原著
Roseburia inulinivorans increases muscle strength. Gut, gutjnl-2025-336980.
doi.org/10.1136/gutjnl-2025-336980 -
Gut Journal
@Gut_BMJ
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
#barretts #esd #cancer -
Gut Journal
@Gut_BMJ
Leung et al. present the paper “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section)
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
#gutguidelines #hpylori #helicobacterpylori -
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal
@Gut_BMJ
Zhou et al. present the #gutrecentadvancesinclinicalpractice paper “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
#mash -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Fascinating insight—IPMN progression isn’t linear but biologically diverse. In practice, this may explain why similar lesions behave differently. Spatial profiling could refine risk stratification beyond morphology.
#gut #medx #medtwitter #gastroenterology
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal reposted
GI Nutrition Foundation
@GI_NutritionFdn
The intestinal barrier matters in #celiacdisease
@john_damianosMD, @AdamBledsoeMD & colleagues update which nutrients & foods that impact intestinal barrier in celiac disease:
🟢 Nutrients & foods that fortify the intestinal barrier 👉 ⬇️ permeability:
✅ Dietary fibers (particularly fermentable fibers such as resistant starch)
✅ Prebiotics
✅ Polyphenols
✅ Glutamine
✅ Vitamin A
✅ Vitamin D
✅ Zinc
✅ Probiotics (Bifidobacterium longum CECT 7347)
🔴 Nutrients & foods that damage the intestinal barrier 👉 ⬆️ permeability:
✅ Emulsifiers (carboxymethylcellulose and polysorbate 80)
✅ Ethanol
✅ Gluten
✅ High-fat diet
✅ Also metallic nanoparticles, glyphosate, and microplastics
💡Since barrier disruption and increased permeability
are precursors to celiac disease, diet therapies to normalise barrier function could serve to prevent the development of CD in those who are genetically susceptible
@Gut_BMJ
📚Read more: gut.bmj.com/content/75/4/826 -
Gut Journal
@Gut_BMJ
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
#obesity #microbiome -
Gut Journal reposted
Hannah Fang PhD
@HanFang_Hannah
Roseburia inulinivorans increases muscle strength gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980
-
Gut Journal reposted
Lucia Oliveira,MD,PhD
@luciacolorectal
Congratulations @john_damianosMD 👏🏻👏🏻👏🏻
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal reposted
Enrique de-Madaria
@DeMadaria
Celebrating the release of #simbatrial on @Gut_BMJ —we’ve been looking forward to this
@Lguilabert1 @AprendeConDanio -
Gut Journal reposted
BSG Trainees
@BSGTrainees
Another excellent #webinar coming up with @FrontGastro_BMJ this Thursday - and you get 1 CPD point for watching.
#neurogastroenterology
Register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🚨🧠 REMINDER for TOMORROW! Neurogastro made practical — 60 minutes that’ll change how you run clinic.
🗓️ Thursday 26 March 2026
⏰ 19:00–20:00 (GMT)
The #fgglobal Webinar is back and it’s all about how to diagnose, consult and treat gut–brain axis disorders you see every week.
🎤 Expert panel:
👨⚕️ Dr Calum Moulton • 👨⚕️ Prof Alex Ford • 👨⚕️ Dr Chris Black • 👨⚕️ Prof Daniel Keszthelyi
@alex_ford12399 @IBS_Maastricht @DrCJBlack
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #dgbi #ibs #functionaldyspepsia #gastroparesis #gastrotwitter #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @ASPEN_nutrition @BAPENUK @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation
Frontline Gastro
@FrontGastro_BMJ
🚨🧠 REMINDER! Neurogastro made practical — 60 minutes that’ll change how you run clinic.
🗓️ Thursday 26 March 2026
⏰ 19:00–20:00 (GMT)
The #fgglobal Webinar is back and it’s all about how to diagnose, consult and treat gut–brain axis disorders you see every week.
🎤 Expert panel:
👨⚕️ Dr Calum Moulton • 👨⚕️ Prof Alex Ford • 👨⚕️ Dr Chris Black • 👨⚕️ Prof Daniel Keszthelyi
@alex_ford12399 @IBS_Maastricht @DrCJBlack
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #dgbi #ibs #functionaldyspepsia #gastroparesis #gastrotwitter #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @ASPEN_nutrition @BAPENUK @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation
Frontline Gastro
@FrontGastro_BMJ
🚨🧠 Neurogastro made practical — 60 minutes that’ll change how you run clinic.
The #fgglobal Webinar is back (instalment #4) and it’s all about how to diagnose, consult and treat gut–brain axis disorders you see every week.
🗓️ Thursday 26 March 2026
⏰ 19:00–20:00 (GMT)
🎤 Expert panel:
👨⚕️ Dr Calum Moulton • 👨⚕️ Prof Alex Ford • 👨⚕️ Dr Chris Black • 👨⚕️ Prof Daniel Keszthelyi
@alex_ford12399 @IBS_Maastricht @DrCJBlack
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #dgbi #ibs #functionaldyspepsia #gastroparesis #gastrotwitter #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @ASPEN_nutrition @BAPENUK @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation -
Gut Journal
@Gut_BMJ
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
#ipmn #pancreaticcancer -
Gut Journal
@Gut_BMJ
Damianos et al. presents the #gutrecentadvancesinbasicscience paper entitled “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
#coeliacdisease @john_damianosMD @AdamBledsoeMD -
Gut Journal
@Gut_BMJ
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain pangenotype hepatitis E virus propagation" via gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
#hev #organoids #hepatitisevirus -
Gut Journal reposted
Ruben Hernaez
@ruben_hernaez
Engaging talk by @emadelomar looking what's a healthy microbiome @Gut_BMJ
-
Gut Journal reposted
Jiyang Chen
@chenjy415
Our new paper is finally out in @Gut_BMJ ! 🚀
Proud to have contributed as a co-first author to this study. It was a privilege to work alongside such a brilliant team. Congratulations to all my fellow co-authors on this achievement! 👏
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al entitled
"Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure" via
gut.bmj.com/content/75/3/605
#hepatitisb #hbv -
Gut Journal reposted
United European Gastroenterology
@my_ueg
Discover Karl's publication 'Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts' via the link 🔗 gut.bmj.com/content/73/4/590
-
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🚨🧠 REMINDER! Neurogastro made practical — 60 minutes that’ll change how you run clinic.
🗓️ Thursday 26 March 2026
⏰ 19:00–20:00 (GMT)
The #fgglobal Webinar is back and it’s all about how to diagnose, consult and treat gut–brain axis disorders you see every week.
🎤 Expert panel:
👨⚕️ Dr Calum Moulton • 👨⚕️ Prof Alex Ford • 👨⚕️ Dr Chris Black • 👨⚕️ Prof Daniel Keszthelyi
@alex_ford12399 @IBS_Maastricht @DrCJBlack
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #dgbi #ibs #functionaldyspepsia #gastroparesis #gastrotwitter #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @ASPEN_nutrition @BAPENUK @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation
Frontline Gastro
@FrontGastro_BMJ
🚨🧠 Neurogastro made practical — 60 minutes that’ll change how you run clinic.
The #fgglobal Webinar is back (instalment #4) and it’s all about how to diagnose, consult and treat gut–brain axis disorders you see every week.
🗓️ Thursday 26 March 2026
⏰ 19:00–20:00 (GMT)
🎤 Expert panel:
👨⚕️ Dr Calum Moulton • 👨⚕️ Prof Alex Ford • 👨⚕️ Dr Chris Black • 👨⚕️ Prof Daniel Keszthelyi
@alex_ford12399 @IBS_Maastricht @DrCJBlack
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #dgbi #ibs #functionaldyspepsia #gastroparesis #gastrotwitter #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy
@ESPENorg @SENPE_ @ASPEN_nutrition @BAPENUK @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation -
Gut Journal reposted
GastroAGI | Gastroenterology AI
@GastroAGI
Important real-world audit. Despite improved outcomes, patients are older and more comorbid, with gaps in risk stratification and transfusion practices—highlighting ongoing need to optimize early assessment and guideline adherence in AUGIB care.
#meded #medx #medtwitter #gastroenterology
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal
@Gut_BMJ
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
@ParthaP32580643 @DrLakhtakia #ibd #uc #ultrasound -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal
@Gut_BMJ
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
#ugib @BritSocGastro @JAG_Endoscopy @drgauravbnigam -
Gut Journal
@Gut_BMJ
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
#gastriccancer -
Gut Journal
@Gut_BMJ
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
#barretts #esd #cancer -
Gut Journal
@Gut_BMJ
Leung et al. present the paper “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section)
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
#gutguidelines #hpylori #helicobacterpylori -
Gut Journal reposted
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal
@Gut_BMJ
Read the first ever published #gutscience paper online now!
Letai et al have published the paper
"Epithelial and stromal remodelling in murine Crohn’s disease-like ileitis" via
gutscience.bmj.com/content/1/1/e000008
#crohnsdisease #ibd @druppygill @BritSocGastro @bmj_company @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
We hope you enjoy this April 2026 issue of Gut (gut.bmj.com/content/75/4), bringing together cutting-edge research spanning hepatology, gastrointestinal cancer, microbiome science and endoscopic innovation. This month’s issue highlights how advances in technology, translational science and clinical practice are reshaping how we understand and manage digestive disease.
This issue also features an Editor’s Choice paper by Huo et al., highlighted on the #gutfrontcover and discussed in the next #gutpodcast (available via gutbmj.podbean.com). The #gutfrontcover is a photo of the Watchtower of the Forbidden City at sunset, Beijing, China, in honour of being the Editor’s choice paper and the great collaborative work by Huo et al. reporting the long-term prognosis of lean MASLD with evidence from three population-based prospective cohorts.
Highlights from this issue include:
Huo et al. present “Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts” via gut.bmj.com/content/75/4/772 (Original research, Hepatology section; Editor’s Choice).
Lean MASLD is often considered lower risk—but this large prospective analysis challenges that assumption. The authors show that individuals without obesity still face significant long-term liver-related and cardiovascular risk. This important work reinforces the need to move beyond BMI when assessing risk and will be highly relevant for everyday clinical practice.
Sheng et al. present “Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy” via gut.bmj.com/content/75/4/733 (Original research, GI cancer section).
Why do targeted therapies stop working? Using spatial transcriptomics, this study reveals how tumour heterogeneity, immune escape and metabolic shifts drive resistance in HER2-positive gastric cancer. A must-read for anyone interested in precision oncology and treatment optimisation.
Grancher et al. present “Does a long time to colonoscopy after a positive faecal immunochemical test result have a deleterious impact on colorectal cancer outcomes? A nationwide cohort study” via gut.bmj.com/content/75/4/748 (Original research, GI cancer section).
Timing matters. This nationwide study shows that delays to colonoscopy after a positive screening test are associated with worse cancer outcomes. The findings provide strong real-world evidence to support faster diagnostic pathways in colorectal cancer screening programmes.
Gupta et al. present “Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers” via gut.bmj.com/content/75/4/725 (Original research, Endoscopy section).
Can we safely push endoscopic therapy further? This study demonstrates that broader use of endoscopic submucosal dissection can achieve excellent oncological outcomes in large Barrett’s neoplasia—potentially reducing the need for surgery.
Pal et al. present “Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?” via gut.bmj.com/content/75/4/681 (Endoscopy news).
A less invasive future? This study explores whether transperineal ultrasound could replace endoscopic ultrasound for staging distal ulcerative colitis, showing promising agreement between techniques and opening the door to more patient-friendly assessment.
Nigam et al. present “Acute upper gastrointestinal bleeding in the UK: 2022 audit update” via gut.bmj.com/content/75/4/760 (Original research, GI bleeding section).
National audit data continue to show encouraging improvements in outcomes for acute upper GI bleeding. Reductions in mortality and rebleeding reflect better organisation of care, earlier intervention and wider uptake of evidence-based practice.
Castells-Nobau et al. present “Gut microbial modulation of 3-hydroxyanthranilic acid and dopaminergic signalling influences attention in obesity” via gut.bmj.com/content/75/4/705 (Original research, Gut microbiota section).
The gut–brain axis in action. This fascinating study links microbial metabolism to dopaminergic signalling and attention, providing mechanistic insight into how the microbiome may influence behaviour in obesity.
Liu et al. present “iPSC-induced multilineage liver organoids, small intestinal organoids and brain organoids sustain gut.bmj.com/content/75/4/787 (Original research, Hepatology section).
A major step forward for translational research, this study shows that human organoid systems can support replication of multiple hepatitis E virus genotypes—offering a powerful new platform for studying infection and testing therapies.
Cui et al. present “Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer” via gut.bmj.com/content/75/4/801 (Original research, Pancreas section).
How does pancreatic cancer evolve? By mapping molecular and immune changes across disease progression, this study provides valuable insight into tumour development and highlights potential opportunities for earlier intervention.
Zhou et al. present “Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities” via gut.bmj.com/content/75/4/815 (Recent advances in clinical practice).
As single therapies fall short, combination approaches are gaining momentum in MASH. This review explores the rationale, challenges and future direction of multi-targeted treatment strategies.
Leung et al. present “Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditions” via gut.bmj.com/content/75/4/685 (Guideline section).
This comprehensive guideline provides clear, practical recommendations for surveillance of gastric premalignant conditions, supporting risk-based approaches to improve early cancer detection.
Damianos et al. present “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration” via gut.bmj.com/content/75/4/826 (Recent advances in basic science).
Barrier dysfunction is central to coeliac disease. This review brings together current understanding of underlying mechanisms and explores emerging therapeutic strategies aimed at restoring intestinal integrity.
In summary…
From redefining risk in liver disease to uncovering mechanisms of cancer resistance and harnessing the microbiome–brain axis, this issue showcases the breadth of modern gastroenterology. Across all sections, a common theme emerges: a shift towards earlier detection, deeper mechanistic insight, and more personalised, less invasive care. -
Gut Journal reposted
Keith Siau
@drkeithsiau
Our state of the art review on upper GI bleeding - showcasing some of the key advances over the last 5 years 💡
📸: fg.bmj.com/content/early/2025/10/22/flgastro-2025-103282.… -
Gut Journal reposted
Dr. Rupa Banerjee
@DrRupaBanerjee1
Unable to make a GRADE recommendation on use of Virtual chromoendoscopy (NBI, FICE & iScan) for colonoscopic surveillance till date. Is there a need for further studies or is HD-DCE (Dye based) set to retain first position for routine clinical practice ?
Gut Journal
@Gut_BMJ
Read the #gutbsgguideline by East et al entitled
"British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease" via
gut.bmj.com/content/75/3/442
@drmorrisgordon @ShahidaDin1 @ProfChrisLamb @anjan_dhar6 @sdolwani @DrBuHayee @BritSocGastro #ibd -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement | Gut gut.bmj.com/content/early/2026/01/21/gutjnl-2025-337374
-
Gut Journal reposted
VCU Stravitz-Sanyal Institute for Liver Disease
@VCU_Liver
NEW #gut_bmj: co-corresponding author @ArunJSanyalVCU and colleagues review combination therapies for #mash, providing a comprehensive framework to optimize individualized management & improve both hepatic and systemic outcomes in patients. #livertwitter gut.bmj.com/content/75/4/815
-
Gut Journal reposted
Wah Yang, MD
@WahYangMD
I am so excited to share our international consensus has been published in the journal Gut (IF 26.2). @iobesitysociety
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement
gut.bmj.com/content/early/2026/01/21/gutjnl-2025-337374 -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🔁📢 REPOST | #fgglobal Webinar — Neurogastroenterology: what clinicians need to know 🧠
Want a practical, clinic-ready update on common neurogastro problems? IBS • functional dyspepsia • gastroparesis (& more)
🎤 Dr Calum Moulton • Prof Alex Ford • Dr Chris Black • Prof Daniel Keszthelyi
🗓️ Thu 26 March 2026 ⏰ 7pm GMT
📝 Register (free) 👉 www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #gastrotwitter #meded #fgglobal
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media @my_UEG @amergastroassn @NASPGHAN @UHSEndoscopy @ESGE_news @amergastroassn @BritSocGastro @ASGEendoscopy @HHCNeuroGI @esnm_eu @RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation
Frontline Gastro
@FrontGastro_BMJ
📌 🎥 #fgglobal Webinar | Neurogastroenterology: What clinicians need to know
Practical, clinic-ready updates on:
IBS • functional dyspepsia • gastroparesis (and more)
🎤 Faculty: Dr Calum Moulton • Prof Alex Ford • Dr Chris Black • Prof Daniel Keszthelyi
🗓️ Thu 26 March 2026 ⏰ 7pm GMT
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #ddw #gastrotwitter #meded
@alex_ford12399 @IBS_Maastricht @DrCJBlack
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @amergastroassn @NASPGHAN @ESGE_news @HHCNeuroGI @esnm_eu
@RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation -
Gut Journal
@Gut_BMJ
Read the #gutbsgguideline by East et al entitled
"British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease" via
gut.bmj.com/content/75/3/442
@drmorrisgordon @ShahidaDin1 @ProfChrisLamb @anjan_dhar6 @sdolwani @DrBuHayee @BritSocGastro #ibd -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Chen et al entitled
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
gut.bmj.com/content/75/3/576
#masld -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al on
"Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma" via
gut.bmj.com/content/75/3/620
#hcc -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Cui et al on
"Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells"
gut.bmj.com/content/75/3/548
#colorectalcancer -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al entitled
"Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure" via
gut.bmj.com/content/75/3/605
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
Read the #gutrecentadvancesinbasicscience paper by Lou et al on
"Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility" via
gut.bmj.com/content/75/3/646
#liverinjury -
Gut Journal
@Gut_BMJ
#gutcover #gutfrontcover
The stunningly beautiful Nanjing Eye Footbridge, Nanjing, Jiangsu Province, China. Read in this issue the great work by Chen et al reporting a two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes via
gut.bmj.com/content/75/3?current-issue=y -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Shen et al entitled
"Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies" via
gut.bmj.com/content/75/3/588
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal
@Gut_BMJ
Watch the new #gutvideo on the published paper by Miyauchi et al entitled
"Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota" via
www.youtube.com/watch?v=PzCWe6lp5SM&t=6s
Paper accessed via
gut.bmj.com/content/75/1/46
#smoking #ibd -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Wang et al entitled
"PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer" via
gut.bmj.com/content/75/3/486
#gastriccancer -
Gut Journal reposted
Sergey Minaev
@sminaev2015
Roseburia inulinivorans increases muscle strength | Gut gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980
-
Gut Journal reposted
Bruno Ramos-Molina, PhD
@Brunorm84
Roseburia inulinivorans increases muscle strength #sarcopenia #aging #microbiota @Gut_BMJ gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980
-
Gut Journal reposted
Pon|食と健康
@PonNutr
原著
Liu, W., Lu, Y., Ng, S. C., Chan, F. K., Sung, J. J., & Yu, J. (2026). Bacterial genomic structural variations in children with autism serve as diagnostic biomarkers. Gut, gutjnl-2025-337280. Advance online publication.
doi.org/10.1136/gutjnl-2025-337280 -
Gut Journal reposted
とうや@企業研究職/食品・栄養 Ph.D
@NzXyZQDOCMpLgz5
筋力向上に寄与する腸内細菌を発見したという論文。
ヒト観察データからRoseburia inulinivoransという細菌が筋力と関連することを見つけ、この菌をマウスへ経口投与すると筋力と筋線維サイズが増加したそうです。アミノ酸代謝に特徴がある細菌とのこと。
Gut誌
gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980 -
Gut Journal reposted
Erwin Loh
@erwinloh
Source: gut.bmj.com/content/early/2026/03/03/gutjnl-2025-336980
-
Gut Journal reposted
Alexander Ford
@alex_ford12399
The final part of my podcast about academic gastroenterology for @FrontGastro_BMJ with @PhilSmithIsBack and @dr_aditi_kumar is now on the FG website.
fgbmj.podbean.com/e/the-life-of-an-academic-in-gastroente…
Happy listening! -
Gut Journal
@Gut_BMJ
Watch the #gutvideo on the paper by Liang et al on
"Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression" via
www.youtube.com/watch?v=Bl0MGX4Cgi4&list=PL80fezoRY4BDr-o…
Access the paper via
gut.bmj.com/content/75/2/367
#hbv #aclf -
Gut Journal
@Gut_BMJ
#gutcommentary by Li et al entitled
"LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis" via
gut.bmj.com/content/75/3/434
#alcohol #hepatitis -
Gut Journal
@Gut_BMJ
Read the first ever published #gutscience paper online now!
Letai et al have published the paper
"Epithelial and stromal remodelling in murine Crohn’s disease-like ileitis" via
gutscience.bmj.com/content/1/1/e000008
#crohnsdisease #ibd @druppygill @BritSocGastro @bmj_company @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
Read the #gutonline #gutrecentadvancesinclinicalpractice paper by Iacucci et al
"Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics" via
gut.bmj.com/content/early/2026/01/26/gutjnl-2025-337171
#crohnsdisease #ai #multiomics #ibd @MariettaIacucci -
Gut Journal
@Gut_BMJ
Read the new #gutblog by Dr Mohamed Shiha @Mo_Shiha and Dr Francesca Manza @mnz_francesca on the paper published in the March issue of @Gut_BMJ entitled
"Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis" via
blogs.bmj.com/gut/2026/02/11/gutblog-global-prevalence-of…
Paper accessed via
gut.bmj.com/content/75/3/502
@shefgastro #ncgws -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Zhong et al on
"Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma" via
gut.bmj.com/content/75/3/563
#pancreaticcancer -
Gut Journal reposted
BMJ Group
@bmj_company
Specific gut bacteria species (R inulinivorans) is linked to muscle strength. This holds promise for treating age-related muscle wasting, say researchers published in @Gut_BMJ
gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-336980 -
Gut Journal reposted
Organoid News
@organoidscience
This @Gut_BMJ study established #ipsc-induced multilineage #organoid infection models, confirming Hepatitis E virus' capacity for pan-tissue infection and revealing potential pathogenic mechanisms in the liver, intestine and nervous system.
📖: gut.bmj.com/content/75/4/787 -
Gut Journal reposted
Antonio García-Hermoso
@a_garciahermoso
💪 Una bacteria intestinal concreta, 🦠 R. inulinivorans, se asocia con una mayor fuerza muscular.
Este hallazgo abre la puerta a nuevas estrategias para combatir la pérdida de masa y fuerza muscular asociada a la edad👵👴➡️🏋️♂️
@borjammt @ruizruizjonatan
BMJ Group
@bmj_company
Specific gut bacteria species (R inulinivorans) is linked to muscle strength. This holds promise for treating age-related muscle wasting, say researchers published in @Gut_BMJ
gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-336980 -
Gut Journal reposted
Medical Xpress
@medical_xpress
Gut microbe Roseburia inulinivorans is linked to greater muscle strength in adults and boosts fast‑twitch muscle fibers in mice, pointing to a potential probiotic strategy against age‑related weakness. doi.org/hbr9rh medicalxpress.com/news/2026-03-specific-gut-bacteria-spec…
-
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
⚠️ Hot AXIOS LAMS recall: BSG interim guidance for T-EUS units.
A practical consensus update on safe next steps, alternatives, and governance for therapeutic EUS services following the urgent recall of selected AXIOS sizes.
Read: doi.org/10.1136/flgastro-2026-103637
#endoscopy #therapeuticeus #patientsafety #fg
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @amergastroassn @NASPGHAN @ESGE_news @BritSocGastro @ASGEendoscopy -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🔎🧠 Don’t miss this upcoming #fgglobal webinar on #neurogastroenterology—designed to bring clinically relevant, practical learning to the forefront.
🎤 Faculty: Dr Calum Moulton • Prof Alex Ford • Dr Chris Black • Prof Daniel Keszthelyi
🗓️ Thu 26 March 2026 ⏰ 7pm GMT
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #ddw #gastrotwitter #meded
@alex_ford12399 @IBS_Maastricht @DrCJBlack
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @amergastroassn @NASPGHAN @ESGE_news @HHCNeuroGI @esnm_eu
@RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation
Frontline Gastro
@FrontGastro_BMJ
📌 🎥 #fgglobal Webinar | Neurogastroenterology: What clinicians need to know
Practical, clinic-ready updates on:
IBS • functional dyspepsia • gastroparesis (and more)
🎤 Faculty: Dr Calum Moulton • Prof Alex Ford • Dr Chris Black • Prof Daniel Keszthelyi
🗓️ Thu 26 March 2026 ⏰ 7pm GMT
✅ Free to join — register here: www.bsg.org.uk/events/fgglobal-webinar-neurogastroenterology
#neurogastroenterology #ddw #gastrotwitter #meded
@alex_ford12399 @IBS_Maastricht @DrCJBlack
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @amergastroassn @NASPGHAN @ESGE_news @HHCNeuroGI @esnm_eu
@RomeGastroPsych @IFFGD @ANMSociety @RomeFoundation -
Gut Journal reposted
Keith Siau
@drkeithsiau
In this @Gut_BMJ case report by @Mo_Shiha, a 72M with transfusion-dependent bleeding from radiation proctopathy (left photo) underwent flexible sigmoidoscopy for treatment with Argon Plasma Coagulation (APC). Despite having a perfectly clean bowel and use of CO2 insufflation, a loud 'bang' was heard echoing in the endoscopy room, as the APC was applied. The patient experienced sudden, severe abdominal pain, and an urgent CT scan revealed a localized perforation and peritoneal free gas (right photo). The diagnosis was a rare colonic gas explosion triggered by APC.
Typically, this devastating complication requires urgent surgery. However, the patient's history of an allogeneic stem cell transplant for leukemia left him with severe bone marrow aplasia, making colonic surgery too risky. He was therefore managed medical with a novel, intensive non-operative approach using antibiotics, parenteral nutrition, and G-CSF.
The patient successfully recovered, was discharged after three weeks, and remained bleeding free at 6 months.
To the authors’ knowledge, this was the first documented instance of a colonic gas explosion successfully treated without surgery.
This is also a reminder that residual stool in the colon can lead to combustible amounts of methane and hydrogen, which can explode when introducing oxygen and heat.
gut.bmj.com/content/70/3/475 -
Gut Journal
@Gut_BMJ
Read the #gutbsgguideline by East et al entitled
"British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease" via
gut.bmj.com/content/75/3/442
@drmorrisgordon @ShahidaDin1 @ProfChrisLamb @anjan_dhar6 @sdolwani @DrBuHayee @BritSocGastro #ibd -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast with Professor Zhi-Gang She from the First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Professor She is interviewed on the paper by Zou et al entitled "Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD" published in paper copy in @Gut_BMJ in February 2026.
Listen to the #gutpodcast here:
▶️ Apple: podcasts.apple.com/us/podcast/targeting-masld-with-new-na…
▶️ Spotify: open.spotify.com/episode/6EYwuRfz00xpw8ysz4QVQD
▶️ Web: gutbmj.podbean.com/e/targeting-masld-with-new-nanoparticles/
Read the paper here:
gut.bmj.com/content/75/2/382
#masld #nanoparticles -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Chen et al entitled
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
gut.bmj.com/content/75/3/576
#masld -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al on
"Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma" via
gut.bmj.com/content/75/3/620
#hcc -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Cui et al on
"Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells"
gut.bmj.com/content/75/3/548
#colorectalcancer -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al entitled
"Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure" via
gut.bmj.com/content/75/3/605
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
Read the #gutrecentadvancesinbasicscience paper by Lou et al on
"Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility" via
gut.bmj.com/content/75/3/646
#liverinjury -
Gut Journal reposted
BSG
@BritSocGastro
We are delighted to share the March 2026 edition of the BSG Gut Highlights! 🙌
This month's abstract summaries include Gut papers focused on pancreas, oesophagus, colon, hepatology, neurogastroenterology, and gut microbiota.
Read them here 👉 www.bsg.org.uk/web-education/bsg-gut-highlights-march-2026
@Gut_BMJ -
Gut Journal reposted
Achintya Singh, MD
@AchintyaSinghMD
RCT comparing G-POEM for gastroparesis in comparison with Sham procedures:
gut.bmj.com/content/71/11/2170
🍯41 patients
🍯Success rate 71% vs 22%
🍯Lowest in post-surgical cases, idiopathic cases
🍯In sham cases, crossing over to G-POEM had 75% success rate -
Gut Journal reposted
STOmics
@ST_Omics
The clinical impact? Higher csCAF levels mean significantly better patient survival. By re-mapping the microenvironment, spatial data provides a blueprint to "reprogram" rather than "eradicate" CAFs. 👇 3/3 🔗 gut.bmj.com/content/early/2026/01/13/gutjnl-2025-335683 #oncology
-
Gut Journal
@Gut_BMJ
#gutcover #gutfrontcover
The stunningly beautiful Nanjing Eye Footbridge, Nanjing, Jiangsu Province, China. Read in this issue the great work by Chen et al reporting a two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes via
gut.bmj.com/content/75/3?current-issue=y -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Shen et al entitled
"Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies" via
gut.bmj.com/content/75/3/588
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
#gutpodcast by Professor Xiaolong Qi from Centre of Liver Disease, Zhongda Hospital, Southeast University, Nanjing, China on the paper
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
▶️ Apple: podcasts.apple.com/us/podcast/managing-type-2-diabetes-pa…
▶️ Spotify: open.spotify.com/episode/47jovabXMnUG6Pjb2UIxL2
▶️ Web: gutbmj.podbean.com/e/managing-type-2-diabetes-patients-wi…
Paper accessed via
gut.bmj.com/content/75/3/576
#masld #t2dm #liverdisease -
Gut Journal reposted
Partha Pal
@ibd_pal
TRIUMPH UC study
Sequels of TRINITY study
gut.bmj.com/content/75/4/681 -
Gut Journal
@Gut_BMJ
Watch the new #gutvideo on the published paper by Miyauchi et al entitled
"Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota" via
www.youtube.com/watch?v=PzCWe6lp5SM&t=6s
Paper accessed via
gut.bmj.com/content/75/1/46
#smoking #ibd -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Wang et al entitled
"PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer" via
gut.bmj.com/content/75/3/486
#gastriccancer -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy | Gut @Gut_BMJ gut.bmj.com/content/75/4/733
-
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🎙️🔥 #fgpodcast (Pt 2/3) is live: The life of an academic in gastroenterology — with Prof Alexander Ford @alex_ford12399
This episode dives into the practical realities of academia in GI:
🧠 choosing questions that matter • 🧾 writing/publishing strategy • 🧑🤝🧑 building the right team • 🧭 navigating “opportunities” (and traps) • ⚖️ protecting time + preventing burnout
🎧 Listen here:
▶️ Apple: podcasts.apple.com/us/podcast/the-life-of-an-academic-in-…
▶️ Spotify: open.spotify.com/episode/5tQm01pPsv2CJ4rAT7Tb1p
▶️ Web: fgbmj.podbean.com/e/the-life-of-an-academic-in-gastroente…
#gastrotwitter #academicmedicine #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @amergastroassn @NASPGHAN @ESGE_news @Gut_BMJ @bmj_latest @BritSocGastro @RomeFoundation @esnm_eu -
Gut Journal
@Gut_BMJ
Watch the #gutvideo on the paper by Liang et al on
"Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression" via
www.youtube.com/watch?v=Bl0MGX4Cgi4&list=PL80fezoRY4BDr-o…
Access the paper via
gut.bmj.com/content/75/2/367
#hbv #aclf -
Gut Journal
@Gut_BMJ
#gutcommentary by Li et al entitled
"LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis" via
gut.bmj.com/content/75/3/434
#alcohol #hepatitis -
Gut Journal
@Gut_BMJ
Read the first ever published #gutscience paper online now!
Letai et al have published the paper
"Epithelial and stromal remodelling in murine Crohn’s disease-like ileitis" via
gutscience.bmj.com/content/1/1/e000008
#crohnsdisease #ibd @druppygill @BritSocGastro @bmj_company @Gut_BMJ @BMJOpen_Gastro @FrontGastro_BMJ -
Gut Journal
@Gut_BMJ
Read the #gutonline #gutrecentadvancesinclinicalpractice paper by Iacucci et al
"Shaping the future of postoperative recurrence in Crohn’s disease: personalised approaches with AI-enabled imaging and multi-omics" via
gut.bmj.com/content/early/2026/01/26/gutjnl-2025-337171
#crohnsdisease #ai #multiomics #ibd @MariettaIacucci -
Gut Journal
@Gut_BMJ
Read the new #gutblog by Dr Mohamed Shiha @Mo_Shiha and Dr Francesca Manza @mnz_francesca on the paper published in the March issue of @Gut_BMJ entitled
"Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis" via
blogs.bmj.com/gut/2026/02/11/gutblog-global-prevalence-of…
Paper accessed via
gut.bmj.com/content/75/3/502
@shefgastro #ncgws -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Zhong et al on
"Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma" via
gut.bmj.com/content/75/3/563
#pancreaticcancer -
Gut Journal reposted
Erman Akkus
@Erman_Akkus
📔Consensus guidance of ICIs in locally advanced rectal cancer
@Gut_BMJ
👉gut.bmj.com/content/early/2026/02/25/gutjnl-2025-336979
#cancer #oncology #rectal #medx @realbowtiedoc @OncoAlert @MyriamChalabi -
Gut Journal reposted
@investigando
@rocatanho
Adiposidad paterna en exceso antes del embarazo se asocia con mayor probabilidad de hepatopatía esteatósica asociada a la disfunción metabólica en los descendientes mediada por el IMC infantil en exceso #parents #masld gut.bmj.com/content/early/2026/02/17/gutjnl-2025-336165
-
Gut Journal
@Gut_BMJ
Listen to the #fgpodcast with our Deputy Editor Professor Alex Ford @alex_ford12399 - this is Part 1 but Parts 2 and 3 are coming soon @FrontGastro_BMJ @BritSocGastro @BMJOpen_Gastro
Frontline Gastro
@FrontGastro_BMJ
🎙️✨ NEW & most anticipated #fgpodcast (Pt 1/3)
📚 The life of an academic in gastroenterology with Prof. Alexander Ford (University of Leeds; Deputy Editor, Gut) @alex_ford12399
🔎 500+ papers • 40,000+ citations
🧭 From non-academic roots → a chance step into research → the mentorship that shaped everything
🎧 Apple: podcasts.apple.com/us/podcast/the-life-of-an-academic-in-…
🎧 Spotify: open.spotify.com/episode/4BgbbtOgnYIJJiGC8ffZ3j
🌐 Web: fgbmj.podbean.com/e/the-life-of-an-academic-in-gastroente…
📝 Paper: fg.bmj.com/content/early/2025/12/04/flgastro-2025-103502
#gastrotwitter #academicmedicine #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @LeedsNhs @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @AmerGastroAssn @Y_ECCO_IBD @RomeFoundation @IFFGD @esnm_eu @ASENEM_ -
Gut Journal reposted
Frontline Gastro
@FrontGastro_BMJ
🎙️✨ NEW & most anticipated #fgpodcast (Pt 1/3)
📚 The life of an academic in gastroenterology with Prof. Alexander Ford (University of Leeds; Deputy Editor, Gut) @alex_ford12399
🔎 500+ papers • 40,000+ citations
🧭 From non-academic roots → a chance step into research → the mentorship that shaped everything
🎧 Apple: podcasts.apple.com/us/podcast/the-life-of-an-academic-in-…
🎧 Spotify: open.spotify.com/episode/4BgbbtOgnYIJJiGC8ffZ3j
🌐 Web: fgbmj.podbean.com/e/the-life-of-an-academic-in-gastroente…
📝 Paper: fg.bmj.com/content/early/2025/12/04/flgastro-2025-103502
#gastrotwitter #academicmedicine #meded
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @LeedsNhs @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media @my_UEG @AmerGastroAssn @Y_ECCO_IBD @RomeFoundation @IFFGD @esnm_eu @ASENEM_ -
Gut Journal
@Gut_BMJ
Read the #gutbsgguideline by East et al entitled
"British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease" via
gut.bmj.com/content/75/3/442
@drmorrisgordon @ShahidaDin1 @ProfChrisLamb @anjan_dhar6 @sdolwani @DrBuHayee @BritSocGastro #ibd -
Gut Journal
@Gut_BMJ
Listen to the latest #gutpodcast with Professor Zhi-Gang She from the First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
Professor She is interviewed on the paper by Zou et al entitled "Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD" published in paper copy in @Gut_BMJ in February 2026.
Listen to the #gutpodcast here:
▶️ Apple: podcasts.apple.com/us/podcast/targeting-masld-with-new-na…
▶️ Spotify: open.spotify.com/episode/6EYwuRfz00xpw8ysz4QVQD
▶️ Web: gutbmj.podbean.com/e/targeting-masld-with-new-nanoparticles/
Read the paper here:
gut.bmj.com/content/75/2/382
#masld #nanoparticles -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Chen et al entitled
"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes" via
gut.bmj.com/content/75/3/576
#masld -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Cui et al on
"Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells"
gut.bmj.com/content/75/3/548
#colorectalcancer -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al on
"Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma" via
gut.bmj.com/content/75/3/620
#hcc -
Gut Journal
@Gut_BMJ
Read the #gutrecentadvancesinbasicscience paper by Lou et al on
"Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility" via
gut.bmj.com/content/75/3/646
#liverinjury -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Xu et al entitled
"Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure" via
gut.bmj.com/content/75/3/605
#hepatitisb #hbv -
Gut Journal
@Gut_BMJ
#gutcover #gutfrontcover
The stunningly beautiful Nanjing Eye Footbridge, Nanjing, Jiangsu Province, China. Read in this issue the great work by Chen et al reporting a two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes via
gut.bmj.com/content/75/3?current-issue=y -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Shen et al entitled
"Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies" via
gut.bmj.com/content/75/3/588
#cholangiocarcinoma -
Gut Journal
@Gut_BMJ
Watch the new #gutvideo on the published paper by Miyauchi et al entitled
"Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota" via
www.youtube.com/watch?v=PzCWe6lp5SM&t=6s
Paper accessed via
gut.bmj.com/content/75/1/46
#smoking #ibd -
Gut Journal
@Gut_BMJ
#gutimage from the paper by Wang et al entitled
"PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer" via
gut.bmj.com/content/75/3/486
#gastriccancer -
Gut Journal reposted
Alexander Ford
@alex_ford12399
I was delighted to be interviewed by @PhilSmithIsBack and @dr_aditi_kumar about my academic career for the @FrontGastro_BMJ podcast.
Part 1 is now out. Happy listening.
fgbmj.podbean.com/e/the-life-of-an-academic-in-gastroente… -
Gut Journal reposted
Kriben Govender
@guthealthgurus
New research in @Gut_BMJ maps how gut bacteria transform a high-fat/red meat diet into cancer promoting secondary bile acids (DCA)🧬 Study shows: blocking this 7α-dehydroxylation pathway ⬇️ tumors.
Microbiome editing is the future of prevention #guthealth #microbiome #coloncancer -
Gut Journal
@Gut_BMJ
Watch the #gutvideo on the paper by Liang et al on
"Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression" via
www.youtube.com/watch?v=Bl0MGX4Cgi4&list=PL80fezoRY4BDr-o…
Access the paper via
gut.bmj.com/content/75/2/367
#hbv #aclf -
Gut Journal
@Gut_BMJ
#gutcommentary by Li et al entitled
"LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis" via
gut.bmj.com/content/75/3/434
#alcohol #hepatitis -
Gut Journal reposted
BMJ Group
@bmj_company
Pre-pregnancy parental overweight/obesity linked to next generation’s heightened fatty liver disease risk, finds research published in @Gut_BMJ
gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-336165 -
Gut Journal reposted
Grace Wong
@wonglaihung
Another wonderful @Gut_BMJ paper under the leadership of @TerryYip12 @VWSWong 👏👏
gut.bmj.com/content/75/3/576
#masld @CUHKMedicine @CUHKGI @JimmyLaiCT @WahKheong -
Gut Journal
@Gut_BMJ
#gutscience is open for submissions now via gutscience.bmj.com
Find out more about our Editor in chief @druppygill and the new basic science journal which is the sister journal to @Gut_BMJ, @FrontGastro_BMJ and @BMJOpen_Gastro - in collaboration between @BritSocGastro and @bmj_group
#gutscience #gutportfolio @emadelomar -
Gut Journal
@Gut_BMJ
#gutabstract from @BonfilsLinea et al on the paper
"Impact of prenatal and postnatal maternal IBD status on offspring’s risk of IBD: a population-based cohort study" via
bmjjournals-chicken.bmj.com/gut/wp-content/uploads/sites/…
Paper via: gut.bmj.com/content/early/2024/07/28/gutjnl-2024-332885
@manasiagrawalmd @JulsgaardMette @PREDICTIBD @DrTineJess @KristineAllin #ibd -
Gut Journal
@Gut_BMJ
#gutcover showing the Charles Dickens Museum, London, UK. Read in this issue the very innovative work of Jevans et al showing, for the first time, how human enteric nervous system progenitor transplantation improves functional responses in Hirschsprung disease patient-derived tissue via gut.bmj.com/content/73/9
@UCLchildhealth @sheffielduni @ConorMcCann_ENS @DRN_Sheffield @a_tsakiridis #hirschsprung -
Gut Journal
@Gut_BMJ
Don't miss out, get the #latest content straight to your inbox⏰ myaccount.bmj.com/myaccount/signup.html?regService=etoc-a…
-
Gut Journal
@Gut_BMJ
Read "Kyoto global consensus report on Helicobacter pylori gastritis" via gut.bmj.com/content/64/9/1353
Rashid Lui 雷諾信
@RashidLui
Should confirm for all
Re: Kyoto global consensus by Sugano et al @Gut_BMJ
I think it's possibly a medicolegal issue if eradication isn't confirmed and patients develop gastric cancer or MALToma many years down the road
www.ncbi.nlm.nih.gov/pmc/articles/PMC4552923/ -
Gut Journal
@Gut_BMJ
The latest #gutpodcast with Professor Peter on "Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice" via soundcloud.com/bmjpodcasts/infants-born-to-mothers-with-i…
Access paper via gut.bmj.com/content/69/1/42 #ibd #microbiome











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































